<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Pharmacological treatment of hypertension in people without prior cerebrovascular disease for the prevention of cognitive impairment and dementia - Cunningham, EL - 2021 | Cochrane Library</title> <meta content="Pharmacological treatment of hypertension in people without prior cerebrovascular disease for the prevention of cognitive impairment and dementia - Cunningham, EL - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004034.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Pharmacological treatment of hypertension in people without prior cerebrovascular disease for the prevention of cognitive impairment and dementia - Cunningham, EL - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004034.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD004034.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Pharmacological treatment of hypertension in people without prior cerebrovascular disease for the prevention of cognitive impairment and dementia" name="citation_title"/> <meta content="Emma L Cunningham" name="citation_author"/> <meta content="Queen's University Belfast" name="citation_author_institution"/> <meta content="Stephen A Todd" name="citation_author"/> <meta content="Western Health and Social Care Trust" name="citation_author_institution"/> <meta content="Peter Passmore" name="citation_author"/> <meta content="Queen's University Belfast" name="citation_author_institution"/> <meta content="Roger Bullock" name="citation_author"/> <meta content="Kingshill Research Centre, Victoria Hospital" name="citation_author_institution"/> <meta content="Bernadette McGuinness" name="citation_author"/> <meta content="Queen's University Belfast" name="citation_author_institution"/> <meta content="b.mcguinness@qub.ac.uk" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD004034.pub4" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/05/24" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004034.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004034.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004034.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Alzheimer Disease [*prevention &amp; control]; Antihypertensive Agents [*therapeutic use]; Cognition Disorders [*prevention &amp; control]; Dementia, Vascular [*prevention &amp; control]; Hypertension [complications, *drug therapy]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004034.pub4&amp;doi=10.1002/14651858.CD004034.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004034.pub4&amp;doi=10.1002/14651858.CD004034.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004034.pub4&amp;doi=10.1002/14651858.CD004034.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004034.pub4&amp;doi=10.1002/14651858.CD004034.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004034.pub4&amp;doi=10.1002/14651858.CD004034.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004034.pub4&amp;doi=10.1002/14651858.CD004034.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004034.pub4&amp;doi=10.1002/14651858.CD004034.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004034.pub4&amp;doi=10.1002/14651858.CD004034.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004034.pub4&amp;doi=10.1002/14651858.CD004034.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004034.pub4&amp;doi=10.1002/14651858.CD004034.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004034.pub4&amp;doi=10.1002/14651858.CD004034.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004034.pub4&amp;doi=10.1002/14651858.CD004034.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004034.pub4&amp;doi=10.1002/14651858.CD004034.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004034.pub4&amp;doi=10.1002/14651858.CD004034.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004034.pub4&amp;doi=10.1002/14651858.CD004034.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004034.pub4&amp;doi=10.1002/14651858.CD004034.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004034.pub4&amp;doi=10.1002/14651858.CD004034.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004034.pub4&amp;doi=10.1002/14651858.CD004034.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004034.pub4&amp;doi=10.1002/14651858.CD004034.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004034.pub4&amp;doi=10.1002/14651858.CD004034.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004034.pub4&amp;doi=10.1002/14651858.CD004034.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004034.pub4&amp;doi=10.1002/14651858.CD004034.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004034.pub4&amp;doi=10.1002/14651858.CD004034.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="IYhCEbRn";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD004034\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD004034\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004034\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004034\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ru","ko","ms","ja","fa","fr","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD004034.pub4",title:"Pharmacological treatment of hypertension in people without prior cerebrovascular disease for the prevention of cognitive impairment and dementia",firstPublishedDate:"May 24, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Dementia and Cognitive Improvement Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=IYhCEbRn&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004034.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004034.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD004034.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD004034.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004034.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD004034.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004034.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD004034.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004034.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD004034.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD004034.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD004034.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD004034.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD004034.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2804 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD004034.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004034.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004034.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004034.pub4/full#CD004034-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004034.pub4/full#CD004034-sec-0095"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004034.pub4/full#CD004034-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004034.pub4/full#CD004034-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004034.pub4/full#CD004034-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004034.pub4/full#CD004034-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004034.pub4/full#CD004034-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004034.pub4/full#CD004034-sec-0086"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD004034.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004034.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004034.pub4/appendices#CD004034-sec-0100"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004034.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004034.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD004034.pub4/media/CDSR/CD004034/table_n/CD004034StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD004034.pub4/media/CDSR/CD004034/table_n/CD004034StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004034.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004034.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004034.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004034.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004034.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD004034.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD004034.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Pharmacological treatment of hypertension in people without prior cerebrovascular disease for the prevention of cognitive impairment and dementia </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004034.pub4/information#CD004034-cr-0004">Emma L Cunningham</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004034.pub4/information#CD004034-cr-0005">Stephen A Todd</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004034.pub4/information#CD004034-cr-0006">Peter Passmore</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004034.pub4/information#CD004034-cr-0007">Roger Bullock</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004034.pub4/information#CD004034-cr-0008"><i class="icon corresponding-author fa fa-envelope"></i>Bernadette McGuinness</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD004034.pub4/information/en#CD004034-sec-0110">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 24 May 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD004034.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD004034.pub4">https://doi.org/10.1002/14651858.CD004034.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD004034-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004034-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004034-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004034-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD004034-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD004034-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD004034-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD004034-abs-0001" lang="en"> <section id="CD004034-sec-0001"> <h3 class="title" id="CD004034-sec-0001">Background</h3> <p>This is an update of a Cochrane Review first published in 2006 (McGuinness 2006), and previously updated in 2009 (McGuinness 2009). Hypertension is a risk factor for dementia. Observational studies suggest antihypertensive treatment is associated with lower incidences of cognitive impairment and dementia. There is already clear evidence to support the treatment of hypertension after stroke. </p> </section> <section id="CD004034-sec-0002"> <h3 class="title" id="CD004034-sec-0002">Objectives</h3> <p>To assess whether pharmacological treatment of hypertension can prevent cognitive impairment or dementia in people who have no history of cerebrovascular disease. </p> </section> <section id="CD004034-sec-0003"> <h3 class="title" id="CD004034-sec-0003">Search methods</h3> <p>We searched the Specialised Register of the Cochrane Dementia and Cognitive Improvement Group, CENTRAL, MEDLINE, Embase, three other databases, as well as many trials registries and grey literature sources, most recently on 7 July 2020. </p> </section> <section id="CD004034-sec-0004"> <h3 class="title" id="CD004034-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) in which pharmacological interventions to treat hypertension were given for at least 12 months. We excluded trials of pharmacological interventions to lower blood pressure in non‐hypertensive participants. We also excluded trials conducted solely in people with stroke. </p> </section> <section id="CD004034-sec-0005"> <h3 class="title" id="CD004034-sec-0005">Data collection and analysis</h3> <p>Two authors independently assessed trial quality and extracted data. We contacted study authors for additional information. We collected information regarding incidence of dementia, cognitive decline, change in blood pressure, adverse effects and quality of life. We assessed the certainty of evidence using GRADE. </p> </section> <section id="CD004034-sec-0006"> <h3 class="title" id="CD004034-sec-0006">Main results</h3> <p>We included 12 studies, totaling 30,412 participants, in this review. Eight studies compared active treatment with placebo. Of the four non‐placebo‐controlled studies, two compared intensive versus standard blood pressure reduction. The two final included studies compared different classes of antihypertensive drug. Study durations varied from one to five years. </p> <p>The combined result of four placebo‐controlled trials that reported incident dementia indicated no evidence of a difference in the risk of dementia between the antihypertensive treatment group and the placebo group (236/7767 versus 259/7660, odds ratio (OR) 0.89, 95% confidence interval (CI) 0.72 to 1.09; very low certainty evidence, downgraded due to study limitations and indirectness). </p> <p>The combined results from five placebo‐controlled trials that reported change in Mini‐Mental State Examination (MMSE) may indicate a modest benefit from antihypertensive treatment (mean difference (MD) 0.20, 95% CI 0.10 to 0.29; very low certainty evidence, downgraded due to study limitations, indirectness and imprecision). </p> <p>The certainty of evidence for both cognitive outcomes was downgraded on the basis of study limitations and indirectness. Study durations were too short, overall, to expect a significant difference in dementia rates between groups. Dementia and cognitive decline were secondary outcomes for most studies. Additional sources of bias include: the use of antihypertensive medication by the placebo group in the placebo‐controlled trials; failure to reach recruitment targets; and early termination of studies on safety grounds. </p> <p>Meta‐analysis of the placebo‐controlled trials reporting results found a mean change in systolic blood pressure of ‐9.25 mmHg (95% CI ‐9.73, ‐8.78) between treatment (n = 8973) and placebo (n = 8820) groups, and a mean change in diastolic blood pressure of ‐2.47 mmHg (95% CI ‐2.70, ‐2.24) between treatment (n = 7700) and placebo (n = 7509) groups (both low certainty evidence downgraded on the basis of study limitations and inconsistency). </p> <p>Three trials ‐ SHEP 1991, LOMIR MCT IL 1996 and MRC 1996 ‐ reported more withdrawals due to adverse events in active treatment groups than placebo groups. Participants on active treatment in Syst Eur 1998 were less likely to discontinue treatment due to side effects, and participants on active treatment in HYVET 2008 reported fewer 'serious adverse events' than in the placebo group. There was no evidence of a difference in withdrawals rates between groups in SCOPE 2003, and results were unclear for Perez Stable 2000 and Zhang 2018. Heterogeneity precluded meta‐analysis. </p> <p>Five of the placebo‐controlled trials provided quality of life (QOL) data. Heterogeneity again precluded meta‐analysis. SHEP 1991, Syst Eur 1998 and HYVET 2008 reported no evidence of a difference in QOL measures between active treatment and placebo groups over time. The SCOPE 2003 sub‐study (Degl'Innocenti 2004) showed a smaller drop in QOL measures in the active treatment compared to the placebo group. LOMIR MCT IL 1996 reported an improvement in a QOL measure at twelve months in one active treatment group and deterioration in another. </p> </section> <section id="CD004034-sec-0007"> <h3 class="title" id="CD004034-sec-0007">Authors' conclusions</h3> <p>High certainty randomised controlled trial evidence regarding the effect of hypertension treatment on dementia and cognitive decline does not yet exist. </p> <p>The studies included in this review provide low certainty evidence (downgraded primarily due to study limitations and indirectness) that pharmacological treatment of hypertension, in people without prior cerebrovascular disease, leads to less cognitive decline compared to controls. This difference is below the level considered clinically significant. The studies included in this review also provide very low certainty evidence that pharmacological treatment of hypertension, in people without prior cerebrovascular disease, prevents dementia. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD004034-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004034-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004034-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004034-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD004034-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD004034-abs-0009">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD004034-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD004034-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD004034-abs-0014">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD004034-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD004034-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD004034-abs-0002" lang="en"> <h3>Treating high blood pressure with medicines to prevent future dementia or problems with memory and thinking </h3> <p><b>Why this review is important</b> </p> <p>Observational studies following participants over many years have suggested that high blood pressure is associated with subsequent dementia or new problems with memory and thinking (cognitive impairment). It is important to establish if treating high blood pressure can reduce the risk of dementia and problems with memory and thinking. There is already clear evidence to support the treatment of high blood pressure after stroke. The evidence for treating high blood pressure in the absence of stroke was not as well established when this review protocol was written. </p> <p><b>Main findings of the review</b> </p> <p>We included 12 trials, with a total of 30,412 participants, in this review. Treating high blood pressure with medicines may reduce the risk of dementia and problems with memory and thinking, but we were unable to confirm this using the data we have available. This may be due to shortcomings in the evidence available. </p> <p>Some participants had side effects from medications, such as falls, that led to them stopping the medications. This is also an important consideration. </p> <p><b>Limitations of the review</b> </p> <p>We were unable to find evidence to confirm that treating high blood pressure with medicines will prevent future dementia or problems with memory and thinking. Based on the evidence available, all we can say is that the methods used in the studies we looked at were not sufficient to answer our study question. In practice, we want to know if treating high blood pressure in mid‐life reduces dementia and problems with memory and thinking in later life. These studies were too short in duration to answer this question. They tended to be designed to investigate heart attack and stroke as outcome measures, with memory and thinking tests added on, which means they were less likely to include the numbers of people with problems with memory and thinking necessary to reliably answer the question. In the studies comparing active medicines and placebo (inactive medicine), many people in the placebo groups ultimately did receive active medicine which further complicated the results. </p> <p>Antihypertensive treatment may prevent new problems with memory and thinking, or dementia, or both, despite the findings of this review. To be more confident in our conclusions, we would need studies that have more distinct treatment and placebo groups, and that treat participants starting at a younger age and with a longer follow‐up. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD004034-sec-0095" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD004034-sec-0095"></div> <h3 class="title" id="CD004034-sec-0096">Implications for practice</h3> <section id="CD004034-sec-0096"> <p>The inclusion of additional studies does not alter the conclusions from the initial review and subsequent update. There is insufficient evidence to recommend pharmacological treatment of hypertension BP to prevent dementia or cognitive decline. </p> <p>There is evidence to support pharmacological treatment of BP to prevent cardiovascular and cerebrovascular morbidity and mortality. People with hypertension are therefore likely to receive pharmacological treatment. It remains unclear what the appropriate BP thresholds are for pharmacological treatment of hypertension in the prevention of cognitive decline or dementia, which agents ‐ if any ‐ confer the greatest cognitive benefit, what the appropriate BP targets should be, and at which points in the life course. </p> </section> <h3 class="title" id="CD004034-sec-0097">Implications for research</h3> <section id="CD004034-sec-0097"> <p>Despite the wealth of evidence from observational studies associating mid‐life hypertension and late‐life cognitive impairment and dementia, and reduction of risk associated with treatment of hypertension, there remains a stubborn lack of RCT evidence to support the hypothesis that treatment of hypertension prevents dementia and cognitive decline. The pervading wisdom is that this reflects the shortcomings of studies to date rather than a rebuttal of the hypothesis. </p> <p>Studies need to include mid‐life participants with decades‐long follow‐up. Studies need to be designed to consider cognition as a primary outcome measure. Appropriate cognitive outcome measures need to be employed. Studies comparing BP targets have been undertaken (<a href="./references#CD004034-bbs2-0001" title="BuseJB , BiggerJT , ByingtonRP , CooperLS , CushmanWC , FriedewaldWT , et al, ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. American Journal of Cardiology2007;99(12A):21i-33i. CushmanWC , Grimm RH Jr, CutlerJA , EvansGW , CapesS , CorsonMA , et al, ACCORD Study Group. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):44i-55i. LaunerLJ , MillerME , WilliamsonJD , LazarRM , GersteinHC , MurrayAM , et al, ACCORD MIND investigators. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurology2011;10(11):969-77. MargolisKL , O'ConnorPJ , MorganTM , BuseJB , CohenRM , CushmanWC , et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care2014;37(6):1721-8. O'ConnorPJ , NarayanKM , AndersonR , FeeneyP , FineL , AliMK , et al. Effect of intensive versus standard blood pressure control on depression and health-related quality of life in type 2 diabetes: the ACCORD trial. Diabetes Care2012;35(7):1479-81. WilliamsonJD , LaunerLJ , BryanRN , CokerLH , LazarRM , GersteinHC , et al, Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Investigators. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Internal Medicine2014;174(3):324-33. WilliamsonJD , MillerME , BryanRN , LazarRM , CokerLH , JohnsonJ , et al, ACCORD Study Group. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. American Journal of Cardiology2007;99(12A):112i-122i. ">ACCORD MIND 2014</a>, <a href="./references#CD004034-bbs2-0010" title="AmbrosiusWT , SinkKM , FoyCG , BerlowitzDR , CheungAK , CushmanWC , FineLJ , Goff DC Jr, JohnsonKC , KilleenAA , LewisCE , OparilS , ReboussinDM , RoccoMV , SnyderJK , WilliamsonJD , Wright JT Jr, WheltonPK , SPRINT Study Research Group. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).. Clinical Trials 2014 Oct;11(5):532-46. BerlowitzDR , FoyCG , KazisLE , BolinLP , ConroyMB , FitzpatrickP , GureTR , KimmelPL , KirchnerK , MoriskyDE , NewmanJ , OlneyC , OparilS , PajewskiNM , PowellJ , RamseyT , SimmonsDL , SnyderJ , SupianoMA , WeinerDE , WhittleJ , SPRINT Research Group. Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes.. The New England Journal of Medicine 2017 Aug 24;377(8):733-744. SPRINT Research Group, Wright JT Jr, WilliamsonJD , WheltonPK , SnyderJK , SinkKM , RoccoMV , ReboussinDM , RahmanM , OparilS , LewisCE , KimmelPL , JohnsonKC , Goff DC Jr, FineLJ , CutlerJA , CushmanWC , CheungAK , Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control.. The New England Journal of Medicine 2015 Nov 26;373(22):2103-16. The SPRINT MIND Investigators for the SPRINT Research Group. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA2019;321(6):553-561. WilliamsonJD , SupianoMA , ApplegateWB , BerlowitzDR , CampbellRC , ChertowGM , FineLJ , HaleyWE , HawfieldAT , IxJH , KitzmanDW , KostisJB , Krousel-WoodMA , LaunerLJ , OparilS , RodriguezCJ , RoumieCL , ShorrRI , SinkKM , WadleyVG , WheltonPK , WhittleJ , WoolardNF , Wright JT Jr, PajewskiNM , SPRINT Research Group. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.. JAMA 2016 Jun 28;315(24):2673-82. ">SPRINT MIND 2019</a>). Future studies will need to compare different classes of antihypertensive drugs. Future studies will also need to include biomarkers of the different dementia‐causing neurodegenerative processes so we can understand the underlying pathophysiology. </p> <p>Trials of BP lowering treatment regimens should therefore be designed to include participants with hypertension in middle age with prolonged follow‐up and assessment of cognition into older age. These trials should be adequately powered to determine, as a primary outcome, whether cognitive impairment and dementia can be prevented. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD004034-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD004034-sec-0008"></div> <div class="table" id="CD004034-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Antihypertensive therapy compared to placebo for patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antihypertensive therapy compared to placebo for people without prior cerebrovascular disease for prevention of cognitive impairment and dementia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants without prior cerebrovascular disease for prevention of cognitive impairment and dementia<br/><b>Setting:</b> community<br/><b>Intervention:</b> antihypertensive therapy<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="middle"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with antihypertensive therapy</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of cases of dementia</p> <p>Range of follow‐up 2 to 5 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.89<br/>(0.72 to 1.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>15,427<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30 per 1000<br/>(25 to 36) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in cognitive score (MMSE)</p> <p>Range of follow‐up 2 to 5 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in MMSE ranged from ‐0.15 to ‐0.08</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in MMSE was 0.20 points higher (0.10 points higher to 0.29 points higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9435<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>VERY LOW<sup>a‐d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in systolic blood pressure level (mmHg)</p> <p>Range of follow‐up 2 to 5 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in systolic blood pressure</p> <p>level (mmHg) ranged from ‐33.5 to ‐15.77</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in systolic blood pressure level (mmHg) was 9.25 points lower (9.73 points lower to 8.78 points lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17,793<br/>(6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>LOW<sup>c,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in diastolic blood pressure level (mmHg)</p> <p>Range of follow‐up 2 to 5 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in diastolic blood pressure level (mmHg) ranged from ‐13.1 to ‐4.21</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in diastolic blood pressure level (mmHg) was</p> <p>2.47 points lower (2.70 points lower to 2.24 points lower)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15,209<br/>(5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>LOW<sup>c,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> <p>Range of follow‐up 2 to 5 years</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign=""> <p>Results varied across studies, with some reporting evidence of more withdrawals due to adverse effects in the antihypertensive therapy group (<a href="./references#CD004034-bbs2-0009" title="ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the Treatment of Isolated Systolic Hypertension on Behavioral Variables. Results From the Systolic Hypertension in the Elderly Program. Arch Intern Med1994;154:2154-2160. Di BariM , PahorM , FranseLV , ShorrRI , WanJY , FerrucciL , et al. Dementia and Disability Outcomes in Large Hypertension Trials: Lessons Learned from the Systolic Hypertension in the Elderly Program (SHEP) Trial. American Journal of Epidemiology2001;153:72-8. SHEP Cooperative Research Group. Prevention of Stroke by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic Hypertension. Final Results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265:3255-64. The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and Design of a Randomized Clinical Trial on Prevention of Stroke in Isolated Systolic Hypertension. Journal of Clinical Epidemiology1988;41:1197-1208. ">SHEP 1991</a>, <a href="./references#CD004034-bbs2-0005" title="YodfatY , Bar-OnD , AmirM , Cristal N. Quality of life in normotensives compared to hypertensive men treated with isradipine or methyldopa as monotherapy or in combination with captopril: the LOMIR-MCT-IL study.. Journal of Human Hypertension 1996 Feb;10(2):117-22. YodfatY , Cristal N. A multicenter, double-blind, randomized, placebo-controlled study of isradipine and methyldopa as monotherapy or in combination with captopril in the treatment of hypertension. The LOMIR-MCT-IH Research Group.. American Journal of Hypertension 1993 Mar;6(3 Pt 2):57S-61S. ">LOMIR MCT IL 1996</a>, <a href="./references#CD004034-bbs2-0006" title="MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. British Medical Journal1992;304(6824):405-12. PrinceMJ , BirdAS , BlizardRA , MannAH . Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. British Medical Journal1996;312(7034):801-5. ">MRC 1996</a>), some reporting evidence of fewer withdrawals in the antihypertensive therapy group (<a href="./references#CD004034-bbs2-0011" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , De LeeuwP , DolleryCT , et al. Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: Objectives, protocol, and organization. Aging Clin Exp Res1991;3:287-302. FletcherAE , BulpittCJ , ThijsL , ToumilehtoJ , AntikainenR , BossiniA , et al. Quality of life on randomised treatment for isolated hypertension: results from the Syst-Eur Trial. Journal of Hypertension2002;20:2069-2079. FletcherAE , BulpittCJ , TuomilehtoJ , BrowneJ , BossiniA , Kawecka-JaszczK , et al. Quality of life of elderly patients with isolated systolic hypertension: baseline data from the Syst-Eur Trial. Journal of Hypertension1988;16:1117-1124. ForetteF , Seux M-L, StaessenJA , ThijsL , Babarskiene M-R, BabeanuS , et al. The Prevention of Dementia With Antihypertensive Treatment. New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study. Archives of Internal Medicine2002;162:2046-2052. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH , BabarskieneMR , et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet1998;352:1347-51. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH . Reduction of dementia by calcium-antagonist-based antihypertensive treatment. European Heart Journal Supplements2000;2:D17-D19. StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Lancet1997;350:757-764. ">Syst Eur 1998</a>, <a href="./references#CD004034-bbs2-0004" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumiterscuD , et al, for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. NEJM2008;358:1887-1898. BulpittC , FletcherA , BeckettN , CoopeJ , Gil-ExtremeraB , ForetteF , et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs &amp; Aging2001;18:151-164. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al, for the HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurology2008;7:683-689. PetersR , BeckettN , McCormackT , FagardR , FletcherA , BulpittC . Treating hypertension in the very elderly-benefits, risks, and future directions, a focus on the hypertension in the very elderly trial. European Heart Journal 2014 Jul;35(26):1712-8. PetersR , BeckettN , NunesM , FletcherA , ForetteF , BulpittC . A substudy protocol of the Hypertension in the Very Elderly Trial assessing cognitive decline and dementia incidence (HYVET-COG): an ongoing randomised, double-blind, placebo-controlled trial. Drugs Aging2006;23:83-92. ">HYVET 2008</a>), and one reporting no evidence of a difference between groups (<a href="./references#CD004034-bbs2-0008" title="Degl'InnocentiA , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , ZanchettiA , WiklundI . Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). Journal of Human Hypertension2004;18(4):239-45. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study of COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. Journal of Hypertension2004;22(8):1605-12. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. Journal of Hypertension2003;21:875-886. PapademetriouV , FarsangC , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , Zanchetti A for the SCOPE Study Group. Stroke Prevention With the Angiotension II Type-1 Receptor Blocker Candesartan in Elderly Patients With Isolated Systolic Hypertension. The Study on Cognition and Prognosis in the Elderly (SCOPE). Journal of the American College of Cardiology2004;44(6):1175-80. SkoogI , LithellH , HanssonL , ElmfeldtD , HofmanA , OlofssonB , et al, for the SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). American Journal of Hypertension2005;18:1052-1059. ">SCOPE 2003</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16,830</p> <p>(6 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>b,c,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heterogeneity precluded meta‐analysis</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> <p>measured via Sickness Impact Profile, PGWB Positive well‐being, and EuroQoL Current Health </p> <p>Range of follow‐up 2 to 5 years</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Two studies reported evidence of a difference between the active treatment and placebo groups (<a href="./references#CD004034-bbs2-0005" title="YodfatY , Bar-OnD , AmirM , Cristal N. Quality of life in normotensives compared to hypertensive men treated with isradipine or methyldopa as monotherapy or in combination with captopril: the LOMIR-MCT-IL study.. Journal of Human Hypertension 1996 Feb;10(2):117-22. YodfatY , Cristal N. A multicenter, double-blind, randomized, placebo-controlled study of isradipine and methyldopa as monotherapy or in combination with captopril in the treatment of hypertension. The LOMIR-MCT-IH Research Group.. American Journal of Hypertension 1993 Mar;6(3 Pt 2):57S-61S. ">LOMIR MCT IL 1996</a>: P = 0.03; <a href="./references#CD004034-bbs2-0008" title="Degl'InnocentiA , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , ZanchettiA , WiklundI . Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). Journal of Human Hypertension2004;18(4):239-45. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study of COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. Journal of Hypertension2004;22(8):1605-12. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. Journal of Hypertension2003;21:875-886. PapademetriouV , FarsangC , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , Zanchetti A for the SCOPE Study Group. Stroke Prevention With the Angiotension II Type-1 Receptor Blocker Candesartan in Elderly Patients With Isolated Systolic Hypertension. The Study on Cognition and Prognosis in the Elderly (SCOPE). Journal of the American College of Cardiology2004;44(6):1175-80. SkoogI , LithellH , HanssonL , ElmfeldtD , HofmanA , OlofssonB , et al, for the SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). American Journal of Hypertension2005;18:1052-1059. ">SCOPE 2003</a>: PGWB Positive well‐being = ‐0.8 vs ‐1.1, P = 0.04, and EuroQoL Current Health = ‐3.1 vs ‐5.3, P = 0.008). </p> <p>Three studies reported no evidence of a difference between groups (<a href="./references#CD004034-bbs2-0009" title="ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the Treatment of Isolated Systolic Hypertension on Behavioral Variables. Results From the Systolic Hypertension in the Elderly Program. Arch Intern Med1994;154:2154-2160. Di BariM , PahorM , FranseLV , ShorrRI , WanJY , FerrucciL , et al. Dementia and Disability Outcomes in Large Hypertension Trials: Lessons Learned from the Systolic Hypertension in the Elderly Program (SHEP) Trial. American Journal of Epidemiology2001;153:72-8. SHEP Cooperative Research Group. Prevention of Stroke by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic Hypertension. Final Results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265:3255-64. The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and Design of a Randomized Clinical Trial on Prevention of Stroke in Isolated Systolic Hypertension. Journal of Clinical Epidemiology1988;41:1197-1208. ">SHEP 1991</a>, <a href="./references#CD004034-bbs2-0011" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , De LeeuwP , DolleryCT , et al. Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: Objectives, protocol, and organization. Aging Clin Exp Res1991;3:287-302. FletcherAE , BulpittCJ , ThijsL , ToumilehtoJ , AntikainenR , BossiniA , et al. Quality of life on randomised treatment for isolated hypertension: results from the Syst-Eur Trial. Journal of Hypertension2002;20:2069-2079. FletcherAE , BulpittCJ , TuomilehtoJ , BrowneJ , BossiniA , Kawecka-JaszczK , et al. Quality of life of elderly patients with isolated systolic hypertension: baseline data from the Syst-Eur Trial. Journal of Hypertension1988;16:1117-1124. ForetteF , Seux M-L, StaessenJA , ThijsL , Babarskiene M-R, BabeanuS , et al. The Prevention of Dementia With Antihypertensive Treatment. New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study. Archives of Internal Medicine2002;162:2046-2052. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH , BabarskieneMR , et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet1998;352:1347-51. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH . Reduction of dementia by calcium-antagonist-based antihypertensive treatment. European Heart Journal Supplements2000;2:D17-D19. StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Lancet1997;350:757-764. ">Syst Eur 1998</a>, <a href="./references#CD004034-bbs2-0004" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumiterscuD , et al, for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. NEJM2008;358:1887-1898. BulpittC , FletcherA , BeckettN , CoopeJ , Gil-ExtremeraB , ForetteF , et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs &amp; Aging2001;18:151-164. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al, for the HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurology2008;7:683-689. PetersR , BeckettN , McCormackT , FagardR , FletcherA , BulpittC . Treating hypertension in the very elderly-benefits, risks, and future directions, a focus on the hypertension in the very elderly trial. European Heart Journal 2014 Jul;35(26):1712-8. PetersR , BeckettN , NunesM , FletcherA , ForetteF , BulpittC . A substudy protocol of the Hypertension in the Very Elderly Trial assessing cognitive decline and dementia incidence (HYVET-COG): an ongoing randomised, double-blind, placebo-controlled trial. Drugs Aging2006;23:83-92. ">HYVET 2008</a>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15,795</p> <p>(5 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>b,c,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heterogeneity precluded meta‐analysis</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded 1 level due to indirectness – studies not powered to detect significant differences in dementia rates or rate of cognitive decline as measured using MMSE between groups. Duration of studies likely too short to detect enough cognitive impairment and dementia in participants of the age studied. Conversely, younger participants may be more likely to benefit long‐term cognitively from prolonged antihypertensive treatment.<br/><sup>b</sup>Downgraded 1 level due to study limitations – likely attrition bias as cognitively impaired and frailer participants more likely to be lost to follow‐up.<br/><sup>c</sup>Downgraded 1 level due to study limitations – proportions of participants in placebo group receiving active treatment, particularly in <a href="./references#CD004034-bbs2-0008" title="Degl'InnocentiA , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , ZanchettiA , WiklundI . Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). Journal of Human Hypertension2004;18(4):239-45. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study of COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. Journal of Hypertension2004;22(8):1605-12. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. Journal of Hypertension2003;21:875-886. PapademetriouV , FarsangC , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , Zanchetti A for the SCOPE Study Group. Stroke Prevention With the Angiotension II Type-1 Receptor Blocker Candesartan in Elderly Patients With Isolated Systolic Hypertension. The Study on Cognition and Prognosis in the Elderly (SCOPE). Journal of the American College of Cardiology2004;44(6):1175-80. SkoogI , LithellH , HanssonL , ElmfeldtD , HofmanA , OlofssonB , et al, for the SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). American Journal of Hypertension2005;18:1052-1059. ">SCOPE 2003</a> and <a href="./references#CD004034-bbs2-0012" title="JiT , ZhaoY , WangJ , CuiY , DuanD , ChaiQ , et al. Effect of low dose statins and apolipoprotein E genotype on cerebral small vessel disease in older hypertensive patients: a subgroup analysis of a randomized clinical trial. J Am Med Dir Assoc2018;19:995-1002. ZhangH , CuiY , ZhaoY , DongY , DuanD , WangJ , ShengL , JiT , ZhouT , HuW , ChenY , SunS , GongG , ChaiQ , LiuZ . Effects of sartans and low-dose statins on cerebral white matter hyperintensities and cognitive function in older patients with hypertension: a randomized, double-blind and placebo-controlled clinical trial. Hypertension research2018;42(5):717-729. ">Zhang 2018</a>, means there is a high risk of contamination bias.<br/><sup>d</sup>Downgraded 1 level due to imprecision – this is below the statistically significant threshold suggested by <a href="./references#CD004034-bbs2-0105" title="PrinceM , AlbaneseE , GuerchetM , PrinaM . World Alzheimer Report 2014. Dementia and Risk Reduction: An Analysis Of Protective And Modifiable Factors. London: Alzheimer's Disease International, September 2014.">Prince 2014</a> and the clinically significant threshold suggested by <a href="./references#CD004034-bbs2-0093" title="LopezOL , BeckerJT , SaxtonJ , SweetRA , KlunkW , DeKoskyST . Alteration of a Clinically Meaningful Outcome in the Natural History of Alzheimer's Disease by Cholinesterase Inhibition. Journal of the American Geriatrics Society2005;53(1):83-7.">Lopez 2005</a> and <a href="./references#CD004034-bbs2-0084" title="JonesR , SheehanB , PhillipsP , JuszczakE , AdamsJ , BaldwinA , et al, DOMINO-AD team. DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT. Trials2009;10:57.">Jones 2009</a>.<br/><sup>e</sup>Downgraded 1 level due to inconsistency ‐ significant heterogeneity. Number of possible reasons, baseline BP varied between studies, different antihypertensive drugs were used, large proportions of participants in placebo groups, especially in <a href="./references#CD004034-bbs2-0008" title="Degl'InnocentiA , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , ZanchettiA , WiklundI . Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). Journal of Human Hypertension2004;18(4):239-45. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study of COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. Journal of Hypertension2004;22(8):1605-12. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. Journal of Hypertension2003;21:875-886. PapademetriouV , FarsangC , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , Zanchetti A for the SCOPE Study Group. Stroke Prevention With the Angiotension II Type-1 Receptor Blocker Candesartan in Elderly Patients With Isolated Systolic Hypertension. The Study on Cognition and Prognosis in the Elderly (SCOPE). Journal of the American College of Cardiology2004;44(6):1175-80. SkoogI , LithellH , HanssonL , ElmfeldtD , HofmanA , OlofssonB , et al, for the SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). American Journal of Hypertension2005;18:1052-1059. ">SCOPE 2003</a> and <a href="./references#CD004034-bbs2-0012" title="JiT , ZhaoY , WangJ , CuiY , DuanD , ChaiQ , et al. Effect of low dose statins and apolipoprotein E genotype on cerebral small vessel disease in older hypertensive patients: a subgroup analysis of a randomized clinical trial. J Am Med Dir Assoc2018;19:995-1002. ZhangH , CuiY , ZhaoY , DongY , DuanD , WangJ , ShengL , JiT , ZhouT , HuW , ChenY , SunS , GongG , ChaiQ , LiuZ . Effects of sartans and low-dose statins on cerebral white matter hyperintensities and cognitive function in older patients with hypertension: a randomized, double-blind and placebo-controlled clinical trial. Hypertension research2018;42(5):717-729. ">Zhang 2018</a>, received active treatment. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD004034-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD004034-sec-0009"></div> <p>This review updates and replaces a previous Cochrane Review, 'Blood pressure (BP) lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia', which was first published in 2006 (<a href="./references#CD004034-bbs2-0133" title="McGuinnessB , ToddS , PassmoreP , BullockR . Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database of Systematic Reviews2006, Issue 2. Art. No: CD004034. Art. No: CD004034. [DOI: CD004034. DOI: 10.1002/14651858.CD004034.pub2]">McGuinness 2006</a>), and updated in 2009 (<a href="./references#CD004034-bbs2-0134" title="McGuinnessB , ToddS , PassmoreP , BullockR . Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database of Systematic Reviews2009, Issue 3. Art. No: CD004034. [DOI: 10.1002/14651858.CD004034.pub3]">McGuinness 2009</a>). These iterations found no convincing evidence that BP lowering prevents the development of dementia or cognitive impairment in hypertensive people with no apparent prior cerebrovascular disease. </p> <section id="CD004034-sec-0010"> <h3 class="title" id="CD004034-sec-0010">Description of the condition</h3> <p>The relationship between BP, cognition and dementia is complex and not yet fully established. Analysis of the epidemiological data must take into account the following methodological issues. Firstly, longitudinal studies can suggest whether a causal relationship exists between BP and cognition or dementia, whereas cross‐sectional studies can not determine causality. Secondly, the definitions of high or low BP and cognitive impairment are heterogeneous across the studies and may limit comparability. The methods used to screen for and to assess cognitive impairment are also heterogeneous. However, the diagnosis of dementia, and its aetiology, do follow established, standardised criteria. Thirdly, studies may vary in controlling for the effect of other vascular risk factors or antihypertensive treatment. Nevertheless, analysis of the available epidemiological data does allow some conclusions to be drawn: (1) elevated BP in mid‐life is associated with cognitive impairment and dementia in later life; (2) treatment of elevated BP in mid‐life would appear to mitigate this risk; and (3) the relationship between BP and cognitive impairment and dementia in later life is more complex. </p> <p>Several longitudinal studies (summarised by <a href="./references#CD004034-bbs2-0081" title="IadecolaC , YaffeK , BillerJ , BratzkeLC , FaraciFM , GorelickPB , et al. American Heart Association Council on Hypertension; Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; and Stroke Council. Hypertension2016;68(6):e67-94.">Iadecola 2016</a> and <a href="./references#CD004034-bbs2-0119" title="WalkerKA , PowerMC , GottesmanRF . Defining the Relationship Between Hypertension, Cognitive Decline, and Dementia: a Review. Current Hypertension Reports 2017 March;19(3):24.">Walker 2017</a>) have reported a consistent relationship between elevated BP in mid‐life (age 40 to 64 years) and cognitive impairment in later life (age 65 years or older) (<a href="./references#CD004034-bbs2-0066" title="EliasMF , WolfPA , AgostinoRBD , CobbJ , WhiteLR . Untreated blood pressure is inversely related to cognitive functioning: the Framingham Study. Journal of Epidemiology1993;138(6):352-64.">Elias 1993</a>; <a href="./references#CD004034-bbs2-0114" title="SwanGE , DeCarliC , MillerBL , ReedT , WolfPA , Jack LM et al. Association of midlife blood pressure to late-life cognitive decline and brain morphology. Neurology1998;51:986-93.">Swan 1998</a>; <a href="./references#CD004034-bbs2-0087" title="KilanderL , NymanH , BobergM , LithellH . The association between low diastolic blood pressure in middle age and cognitive function in old age: a population based study. Age Ageing2000;29:243-248.">Kilander 2000</a>; <a href="./references#CD004034-bbs2-0090" title="LaunerLJ , RossGW , PetrovichH , MasakiK , FoleyD , WhiteLR , et al. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiology of Aging2000;21:49-55.">Launer 2000</a>; <a href="./references#CD004034-bbs2-0067" title="EliasPK , EliasMF , RobbinsMA , BudgeMM . Blood pressure related cognitive decline: does age make a difference?Hypertension2004;44:631-636.">Elias 2004</a>; <a href="./references#CD004034-bbs2-0073" title="GottesmanRF , SchneiderAL , AlbertM , AlonsoA , Bandeen-RocheK , CokerL , et al. Midlife hypertension and 20-year cognitive change: the Atherosclerosis Risk in Communities Neurocognitive Study. JAMA Neurology2014;71(10):1218-27.">Gottesman 2014</a>). This effect was more marked if the high BP was not treated (<a href="./references#CD004034-bbs2-0066" title="EliasMF , WolfPA , AgostinoRBD , CobbJ , WhiteLR . Untreated blood pressure is inversely related to cognitive functioning: the Framingham Study. Journal of Epidemiology1993;138(6):352-64.">Elias 1993</a>; <a href="./references#CD004034-bbs2-0087" title="KilanderL , NymanH , BobergM , LithellH . The association between low diastolic blood pressure in middle age and cognitive function in old age: a population based study. Age Ageing2000;29:243-248.">Kilander 2000</a>; <a href="./references#CD004034-bbs2-0073" title="GottesmanRF , SchneiderAL , AlbertM , AlonsoA , Bandeen-RocheK , CokerL , et al. Midlife hypertension and 20-year cognitive change: the Atherosclerosis Risk in Communities Neurocognitive Study. JAMA Neurology2014;71(10):1218-27.">Gottesman 2014</a>). </p> <p>Several of the same data sets also indicated a relationship between mid‐life hypertension and the incidence of dementia and Alzheimer's disease in later life (<a href="./references#CD004034-bbs2-0090" title="LaunerLJ , RossGW , PetrovichH , MasakiK , FoleyD , WhiteLR , et al. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiology of Aging2000;21:49-55.">Launer 2000</a>; <a href="./references#CD004034-bbs2-0088" title="KivipeltoM , Helkala E-L, LaaksoMP , HänninenT , HallikainenM , AlhainenK , et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ2001;322:1447-51.">Kivipelto 2001</a>; <a href="./references#CD004034-bbs2-0128" title="WuC , ZhouD , WenC , ZhangI , ComoP , QiaoY . Relationship between blood pressure and Alzheimer's disease in Linxian county. Life Science2003;72:1125-33.">Wu 2003</a>; <a href="./references#CD004034-bbs2-0125" title="WhitmerRA , SidneyS , SelbyJ , JohnstonSC , YaffeK . Midlife cardiovascular risk factors and risk of dementia in late life. Neurology2005;64:277-81.">Whitmer 2005</a>). In the Honolulu‐Asia Aging Study, this association was only present in those participants not treated with antihypertensive agents (<a href="./references#CD004034-bbs2-0090" title="LaunerLJ , RossGW , PetrovichH , MasakiK , FoleyD , WhiteLR , et al. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiology of Aging2000;21:49-55.">Launer 2000</a>). One Japanese study reported a relationship of mid‐life high BP to later life vascular dementia but not to Alzheimer's disease (<a href="./references#CD004034-bbs2-0129" title="YamadaM , KasagiF , SasakiH , MaunariN , MimoriY , SuzukiG . Association between dementia and midlife risk factors: the radiation effects research foundation adult health study. Journal of the American Geriatrics Society2003;51:410-4.">Yamada 2003</a>). A systematic review and meta‐analysis of longitudinal studies reported an association between hypertension and both incident and prevalent vascular dementia (<a href="./references#CD004034-bbs2-0112" title="SharpSI , AarslandD , DayS , SønnesynH , Alzheimer's Society Vascular Dementia Systematic Review Group, BallardC . Hypertension is a potential risk factor for vascular dementia: systematic review. International Journal of Geriatric Psychiatry2011;26(7):661-9.">Sharp 2011</a>). </p> <p>The available data regarding later life BP and cognition or dementia are inconsistent (<a href="./references#CD004034-bbs2-0058" title="BirnsJ , KalraL . Cognitive function and hypertension. Journal of Human Hypertension2009;23(2):86-96.">Birns 2009</a>, <a href="./references#CD004034-bbs2-0110" title="RouchL , CestacP , HanonO , CoolC , HelmerC , BouhanickB , et al. Antihypertensive drugs, prevention of cognitive decline and dementia: a systematic review of observational studies, randomized controlled trials and meta-analyses, with discussion of potential mechanisms. CNS Drugs2015;29(2):113-30.">Rouch 2015</a>). Some studies showed no relationship between high BP and cognitive impairment (<a href="./references#CD004034-bbs2-0078" title="HebertLE , ScherrPA , BennetDA , et al. Blood pressure and late-life cognitive function change: a biracial longitudinal population study. Neurology2004;62:2021-2024.">Hebert 2004</a>; <a href="./references#CD004034-bbs2-0115" title="TervoS , KivipeltoM , HänninenT , VanhanenM , HallikainenM , Mannermaa A et al. Incidence and risk factors for mild cognitive impairment: a population based three-year follow-up study of cognitively healthy elderly subjects. Dementia and Geriatric Cognitive Disorders2004;17:196-203.">Tervo 2004</a>; <a href="./references#CD004034-bbs2-0073" title="GottesmanRF , SchneiderAL , AlbertM , AlonsoA , Bandeen-RocheK , CokerL , et al. Midlife hypertension and 20-year cognitive change: the Atherosclerosis Risk in Communities Neurocognitive Study. JAMA Neurology2014;71(10):1218-27.">Gottesman 2014</a>), or dementia (<a href="./references#CD004034-bbs2-0131" title="YoshitakeT , KiyoharaY , KatoI , OhmuraT , IwamotoH , NakayamaK , et al. Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese study: the Hisayama Study. Neurology1995;45:1161-8.">Yoshitake 1995</a>; <a href="./references#CD004034-bbs2-0060" title="BrayneC , GillC , Huppert FA et al. Vascular risks and incident dementia:results from a cohort study of the very old. Dementia and Geriatric Cognitive Disorders1998;9:175-180.">Brayne 1998</a>). Other studies did find a relationship between later life high BP and cognitive decline (<a href="./references#CD004034-bbs2-0066" title="EliasMF , WolfPA , AgostinoRBD , CobbJ , WhiteLR . Untreated blood pressure is inversely related to cognitive functioning: the Framingham Study. Journal of Epidemiology1993;138(6):352-64.">Elias 1993</a>), or dementia (<a href="./references#CD004034-bbs2-0113" title="SkoogI , LernfeltB , LandahlS , PalmertzB , AndreassonLA , NilssonL , et al. 15-year longitudinal study of blood pressure and dementia. Lancet1996;347(9009):1141-5.">Skoog 1996</a>). Low BP in later life has been more consistently associated with cognitive impairment and dementia (<a href="./references#CD004034-bbs2-0074" title="GuoZ , ViitanenM , FratiglioniL , WinbladB . Low blood pressure and dementia in elderly people: the Kungsholmen project. BMJ1996;312:805-808.">Guo 1996</a>; <a href="./references#CD004034-bbs2-0096" title="MorrisMC , ScherrPA , HebertLE , GlynnRJ , BennettDA , EvansDA . Association of incident Alzheimer disease and blood pressure measured from 13 years before to 2 years after diagnosis in a large community study. Archives of Neurology2001;58:1640-6.">Morris 2001</a>; <a href="./references#CD004034-bbs2-0111" title="RuitenbergA , SkoogI , OttA , AevarssonO , WittemanJC , LernfeltB , et al. Blood pressure and risk of dementia: results from the Rotterdam Study and the Gothenburg H-70 Study. Dementia and Geriatric Cognitive Disorders2001;12:33-9.">Ruitenberg 2001</a>; <a href="./references#CD004034-bbs2-0059" title="BohannonAD , FillenbaumGG , PieperCF , HanlonJT , BlazerDG . Relationship of race/ethnicity and blood pressure to change in cognitive function. Journal of the American Geriatrics Society2002;50(3):424-9.">Bohannon 2002</a>; <a href="./references#CD004034-bbs2-0106" title="QiuC , vonStraussE , FastbomJ , WinbladB , FratiglioniL . Low blood pressure and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Archives of Neurology2003;60:223-8.">Qiu 2003</a>; <a href="./references#CD004034-bbs2-0117" title="VergheseJ , LiptonRB , HallCB , KuslanskyG , MatzMJ . Low blood pressure and the risk of dementia in very old individuals. Neurology2003;61:1667-72.">Verghese 2003</a>; <a href="./references#CD004034-bbs2-0078" title="HebertLE , ScherrPA , BennetDA , et al. Blood pressure and late-life cognitive function change: a biracial longitudinal population study. Neurology2004;62:2021-2024.">Hebert 2004</a>; <a href="./references#CD004034-bbs2-0108" title="QiuC , vonStraussE , WinbladB , FratiglioniL . Decline in blood pressure over time and risk of dementia: a longitudinal study from the Kungsholmen Project. Stroke2004;35:1810-5.">Qiu 2004</a>; <a href="./references#CD004034-bbs2-0118" title="WaldsteinSR , GiggeyPP , ThayerJF , ZondermanAB . Nonlinear relations of blood pressure to cognitive function: the Baltimore Longitudinal Study of Aging. Hypertension 2005 Mar;45(3):374-9.">Waldstein 2005</a>). </p> </section> <section id="CD004034-sec-0011"> <h3 class="title" id="CD004034-sec-0011">Description of the intervention</h3> <p>Randomised controlled clinical trial (RCT) evidence has demonstrated a reduction in cardiovascular and cerebrovascular morbidity and mortality associated with treatment of hypertension across the life course (<a href="./references#CD004034-bbs2-0022" title="AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of hypotensive drug treatment in elderly hypertensives: study terminating events in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension. Supplement1985;3(3):S501-11. ">EWPHE 1985</a>, <a href="./references#CD004034-bbs2-0009" title="ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the Treatment of Isolated Systolic Hypertension on Behavioral Variables. Results From the Systolic Hypertension in the Elderly Program. Arch Intern Med1994;154:2154-2160. Di BariM , PahorM , FranseLV , ShorrRI , WanJY , FerrucciL , et al. Dementia and Disability Outcomes in Large Hypertension Trials: Lessons Learned from the Systolic Hypertension in the Elderly Program (SHEP) Trial. American Journal of Epidemiology2001;153:72-8. SHEP Cooperative Research Group. Prevention of Stroke by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic Hypertension. Final Results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265:3255-64. The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and Design of a Randomized Clinical Trial on Prevention of Stroke in Isolated Systolic Hypertension. Journal of Clinical Epidemiology1988;41:1197-1208. ">SHEP 1991</a>, <a href="./references#CD004034-bbs2-0042" title="DahlofB , LindholmLH , HanssonL , ScherstenB , EkbomT , Wester P-O. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP Hypertension). Lancet1991;338:1281-85. ">STOP 1991</a>, <a href="./references#CD004034-bbs2-0006" title="MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. British Medical Journal1992;304(6824):405-12. PrinceMJ , BirdAS , BlizardRA , MannAH . Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. British Medical Journal1996;312(7034):801-5. ">MRC 1996</a>, <a href="./references#CD004034-bbs2-0011" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , De LeeuwP , DolleryCT , et al. Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: Objectives, protocol, and organization. Aging Clin Exp Res1991;3:287-302. FletcherAE , BulpittCJ , ThijsL , ToumilehtoJ , AntikainenR , BossiniA , et al. Quality of life on randomised treatment for isolated hypertension: results from the Syst-Eur Trial. Journal of Hypertension2002;20:2069-2079. FletcherAE , BulpittCJ , TuomilehtoJ , BrowneJ , BossiniA , Kawecka-JaszczK , et al. Quality of life of elderly patients with isolated systolic hypertension: baseline data from the Syst-Eur Trial. Journal of Hypertension1988;16:1117-1124. ForetteF , Seux M-L, StaessenJA , ThijsL , Babarskiene M-R, BabeanuS , et al. The Prevention of Dementia With Antihypertensive Treatment. New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study. Archives of Internal Medicine2002;162:2046-2052. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH , BabarskieneMR , et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet1998;352:1347-51. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH . Reduction of dementia by calcium-antagonist-based antihypertensive treatment. European Heart Journal Supplements2000;2:D17-D19. StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Lancet1997;350:757-764. ">Syst Eur 1998</a>, <a href="./references#CD004034-bbs2-0004" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumiterscuD , et al, for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. NEJM2008;358:1887-1898. BulpittC , FletcherA , BeckettN , CoopeJ , Gil-ExtremeraB , ForetteF , et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs &amp; Aging2001;18:151-164. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al, for the HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurology2008;7:683-689. PetersR , BeckettN , McCormackT , FagardR , FletcherA , BulpittC . Treating hypertension in the very elderly-benefits, risks, and future directions, a focus on the hypertension in the very elderly trial. European Heart Journal 2014 Jul;35(26):1712-8. PetersR , BeckettN , NunesM , FletcherA , ForetteF , BulpittC . A substudy protocol of the Hypertension in the Very Elderly Trial assessing cognitive decline and dementia incidence (HYVET-COG): an ongoing randomised, double-blind, placebo-controlled trial. Drugs Aging2006;23:83-92. ">HYVET 2008</a>, <a href="./references#CD004034-bbs2-0010" title="AmbrosiusWT , SinkKM , FoyCG , BerlowitzDR , CheungAK , CushmanWC , FineLJ , Goff DC Jr, JohnsonKC , KilleenAA , LewisCE , OparilS , ReboussinDM , RoccoMV , SnyderJK , WilliamsonJD , Wright JT Jr, WheltonPK , SPRINT Study Research Group. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).. Clinical Trials 2014 Oct;11(5):532-46. BerlowitzDR , FoyCG , KazisLE , BolinLP , ConroyMB , FitzpatrickP , GureTR , KimmelPL , KirchnerK , MoriskyDE , NewmanJ , OlneyC , OparilS , PajewskiNM , PowellJ , RamseyT , SimmonsDL , SnyderJ , SupianoMA , WeinerDE , WhittleJ , SPRINT Research Group. Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes.. The New England Journal of Medicine 2017 Aug 24;377(8):733-744. SPRINT Research Group, Wright JT Jr, WilliamsonJD , WheltonPK , SnyderJK , SinkKM , RoccoMV , ReboussinDM , RahmanM , OparilS , LewisCE , KimmelPL , JohnsonKC , Goff DC Jr, FineLJ , CutlerJA , CushmanWC , CheungAK , Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control.. The New England Journal of Medicine 2015 Nov 26;373(22):2103-16. The SPRINT MIND Investigators for the SPRINT Research Group. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA2019;321(6):553-561. WilliamsonJD , SupianoMA , ApplegateWB , BerlowitzDR , CampbellRC , ChertowGM , FineLJ , HaleyWE , HawfieldAT , IxJH , KitzmanDW , KostisJB , Krousel-WoodMA , LaunerLJ , OparilS , RodriguezCJ , RoumieCL , ShorrRI , SinkKM , WadleyVG , WheltonPK , WhittleJ , WoolardNF , Wright JT Jr, PajewskiNM , SPRINT Research Group. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.. JAMA 2016 Jun 28;315(24):2673-82. ">SPRINT MIND 2019</a>). Both non‐pharmacological and pharmacological approaches have been shown to be effective. Current guidance in the United Kingdom (UK) recommends encouragement of a healthy diet, regular exercise and reduced alcohol, caffeine and sodium consumption as the first line intervention in people with high BP. UK guidelines recommend pharmacological antihypertensive treatment for people under 80 years old with BP above 140/90 mmHg (or above 150/90 mmHg for those over 80 years) (<a href="./references#CD004034-bbs2-0098" title="National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and management. Guideline2019.">NICE 2019</a>). </p> <p>The 2017 American College of Cardiology (ACC) and American Heart Association (AHA) guidelines and the 2018 European Society of Cardiology (ESC) guidelines recommend a pharmacological antihypertensive treatment threshold of BP over 130/80 mmHg where cardiovascular risk is high, and BP over 140/90 mmHg where cardiovascular risk is low (<a href="./references#CD004034-bbs2-0124" title="WheltonPK , CareyRM , AronowWS , Casey DE Jr, CollinsKJ , Dennison HimmelfarbC , et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2018 Oct 23;138(17):e426-e483.">Whelton 2018</a>; <a href="./references#CD004034-bbs2-0127" title="WilliamsB , ManciaG , SpieringW , Agabiti RoseiE , AziziM , BurnierM , ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal2018;39(33):3021-104.">Williams 2018</a>). The ESC have further age‐specific advice recommending pharmacological treatment of systolic blood pressure (SBP) 140 to 159 mmHg in fit people over 65 years but younger than 80 years where treatment is tolerated. The ACC/AHA recommend a target SBP of below 130 mmHg in fit people over 65 years, and advocate practitioner discretion for people over 65 years with higher levels of comorbidity. The ESC recommends a target SBP of 120 to 129 mmHg for people younger than 65 years, and a target SBP of 130 to 139 mmHg for those older than 65 years and, where tolerated, for those older than 80 years. They recommend a target diastolic blood pressure (DBP) of below 80 mmHg across the board. </p> <p>Recommended first line antihypertensive agents are calcium channel blockers (CCBs) for people aged over 55 years or of African‐Caribbean origin without type 2 diabetes, and angiotensin‐converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for everyone else. Combination therapy with the alternative group and the addition of thiazide‐like diuretics is advocated thereafter (<a href="./references#CD004034-bbs2-0098" title="National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and management. Guideline2019.">NICE 2019</a>). </p> <p>As stated, treatment of high blood pressure has been reported in several observational studies to be protective against cognitive impairment and dementia (<a href="./references#CD004034-bbs2-0075" title="GuoZ , FratiglioniL , ZhuL , FastbornJ , WinbladB , ViitanenM . Occurence and progression of dementia in a community population aged 75 years and older: relationship of antihypertensive medication use. Archives of Neurology1999;56:991-996.">Guo 1999</a>; <a href="./references#CD004034-bbs2-0107" title="QiuC , WinbladB , FastbomJ , FratiglioniL . Combined effects of APOE genotype, blood pressure and antihypertensive drug use on incident AD. Neurology2003;61:655-60.">Qiu 2003a</a>; <a href="./references#CD004034-bbs2-0130" title="YasarS , CorradaM , BrookmeyerR , KawasC . Calcium channel blockers and risk of AD: the Baltimore Longitudinal Study of Aging. Neurobiology of Aging2005;26:157-63.">Yasar 2005</a>; <a href="./references#CD004034-bbs2-0086" title="KhachaturianAS , ZandiPP , LyketsosCG , HaydenKM , SkoogI , NortonMC , et al. Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Archives of Neurology2006;63:686-92.">Khachaturian 2006</a>; <a href="./references#CD004034-bbs2-0073" title="GottesmanRF , SchneiderAL , AlbertM , AlonsoA , Bandeen-RocheK , CokerL , et al. Midlife hypertension and 20-year cognitive change: the Atherosclerosis Risk in Communities Neurocognitive Study. JAMA Neurology2014;71(10):1218-27.">Gottesman 2014</a>). It is unclear whether individual drug classes confer a benefit beyond that of blood pressure lowering, where that association has been found. A systematic review of CCB use and cognitive decline in the elderly did not find evidence to support either a protective or detrimental association between their use in the elderly and subsequent cognitive function (<a href="./references#CD004034-bbs2-0102" title="PetersR , BoothA , PetersJ . A systematic review of calcium channel blocker use and cognitive decline/dementia in the elderly. Journal of Hypertension 2014 Oct;32(10):1945-57.">Peters 2014</a>). A meta‐analysis by <a href="./references#CD004034-bbs2-0091" title="Levi MarpillatN , Macquin-MavierI , TropeanoAI , Bachoud-LeviAC , MaisonP . Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis. Journal of Hypertension2013;31(6):1073-82.">Levi Marpillat 2013</a> suggested ARBs may carry an additional benefit but was not able to draw conclusions. </p> </section> <section id="CD004034-sec-0012"> <h3 class="title" id="CD004034-sec-0012">How the intervention might work</h3> <p>The pathological processes through which hypertension might influence cognitive function are numerous. A position paper on the subject by the American Society of Hypertension suggested that these mechanisms may be divided into five classifications (<a href="./references#CD004034-bbs2-0072" title="GorelickPB , NyenhuisD , MatersonBJ , CalhounDA , ElliottWJ , PhillipsRA , American Society of Hypertension Writing Group. Blood pressure and treatment of persons with hypertension as it relates to cognitive outcomes including executive function. Journal of the American Society of Hypertension : JASH2012;6(5):309-15.">Gorelick 2012</a>): functional (relating to regulation of cerebral blood flow and the blood‐brain‐barrier); structural (relating to increased white matter lesions, cerebral atrophy and the amyloid plaques and neurofibrillary tangles composed of tau that are neuropathological hallmarks of Alzheimer's disease); pharmacological (relating to the role of angiotensin II); stroke‐related (relating to stroke in strategic areas or the neurone loss associated with stroke, or both); and other factors (including the metabolic syndrome and inflammation, age, genetic predisposition and smoking). In vitro, animal and observational studies are ongoing in an effort to better understand these mechanisms. These processes are interrupted by pharmacological interventions proven to reduce blood pressure. Interested readers are also directed towards the more recent scientific statement from the American Heart Association on the impact of hypertension on cognitive function (<a href="./references#CD004034-bbs2-0081" title="IadecolaC , YaffeK , BillerJ , BratzkeLC , FaraciFM , GorelickPB , et al. American Heart Association Council on Hypertension; Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; and Stroke Council. Hypertension2016;68(6):e67-94.">Iadecola 2016</a>). </p> </section> <section id="CD004034-sec-0013"> <h3 class="title" id="CD004034-sec-0013">Why it is important to do this review</h3> <p>This is an update of a Cochrane Review first published in 2006 (<a href="./references#CD004034-bbs2-0133" title="McGuinnessB , ToddS , PassmoreP , BullockR . Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database of Systematic Reviews2006, Issue 2. Art. No: CD004034. Art. No: CD004034. [DOI: CD004034. DOI: 10.1002/14651858.CD004034.pub2]">McGuinness 2006</a>), and previously updated in 2009 (<a href="./references#CD004034-bbs2-0134" title="McGuinnessB , ToddS , PassmoreP , BullockR . Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database of Systematic Reviews2009, Issue 3. Art. No: CD004034. [DOI: 10.1002/14651858.CD004034.pub3]">McGuinness 2009</a>), which found no convincing evidence that BP lowering prevents the development of dementia or cognitive impairment in hypertensive people with no apparent prior cerebrovascular disease. </p> <p>The aim of the original systematic review was to determine the effects of BP lowering on development of cognitive decline and dementia in people with hypertension but no history of stroke or transient ischaemic attack (TIA). Given the burden of both hypertension and dementia, identification of treatments that reduce the rate of cognitive decline or incidence of dementia would be of considerable clinical, public health and societal benefit. </p> <p>This update is important to ensure that relevant data published since the first review and subsequent update are included in feasible meta‐analyses, allowing, where possible, the best possible estimate of the effect of BP lowering on cognitive decline to be obtained. The emergence of landmark trials such as <a href="./references#CD004034-bbs2-0001" title="BuseJB , BiggerJT , ByingtonRP , CooperLS , CushmanWC , FriedewaldWT , et al, ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. American Journal of Cardiology2007;99(12A):21i-33i. CushmanWC , Grimm RH Jr, CutlerJA , EvansGW , CapesS , CorsonMA , et al, ACCORD Study Group. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):44i-55i. LaunerLJ , MillerME , WilliamsonJD , LazarRM , GersteinHC , MurrayAM , et al, ACCORD MIND investigators. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurology2011;10(11):969-77. MargolisKL , O'ConnorPJ , MorganTM , BuseJB , CohenRM , CushmanWC , et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care2014;37(6):1721-8. O'ConnorPJ , NarayanKM , AndersonR , FeeneyP , FineL , AliMK , et al. Effect of intensive versus standard blood pressure control on depression and health-related quality of life in type 2 diabetes: the ACCORD trial. Diabetes Care2012;35(7):1479-81. WilliamsonJD , LaunerLJ , BryanRN , CokerLH , LazarRM , GersteinHC , et al, Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Investigators. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Internal Medicine2014;174(3):324-33. WilliamsonJD , MillerME , BryanRN , LazarRM , CokerLH , JohnsonJ , et al, ACCORD Study Group. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. American Journal of Cardiology2007;99(12A):112i-122i. ">ACCORD MIND 2014</a> and <a href="./references#CD004034-bbs2-0010" title="AmbrosiusWT , SinkKM , FoyCG , BerlowitzDR , CheungAK , CushmanWC , FineLJ , Goff DC Jr, JohnsonKC , KilleenAA , LewisCE , OparilS , ReboussinDM , RoccoMV , SnyderJK , WilliamsonJD , Wright JT Jr, WheltonPK , SPRINT Study Research Group. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).. Clinical Trials 2014 Oct;11(5):532-46. BerlowitzDR , FoyCG , KazisLE , BolinLP , ConroyMB , FitzpatrickP , GureTR , KimmelPL , KirchnerK , MoriskyDE , NewmanJ , OlneyC , OparilS , PajewskiNM , PowellJ , RamseyT , SimmonsDL , SnyderJ , SupianoMA , WeinerDE , WhittleJ , SPRINT Research Group. Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes.. The New England Journal of Medicine 2017 Aug 24;377(8):733-744. SPRINT Research Group, Wright JT Jr, WilliamsonJD , WheltonPK , SnyderJK , SinkKM , RoccoMV , ReboussinDM , RahmanM , OparilS , LewisCE , KimmelPL , JohnsonKC , Goff DC Jr, FineLJ , CutlerJA , CushmanWC , CheungAK , Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control.. The New England Journal of Medicine 2015 Nov 26;373(22):2103-16. The SPRINT MIND Investigators for the SPRINT Research Group. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA2019;321(6):553-561. WilliamsonJD , SupianoMA , ApplegateWB , BerlowitzDR , CampbellRC , ChertowGM , FineLJ , HaleyWE , HawfieldAT , IxJH , KitzmanDW , KostisJB , Krousel-WoodMA , LaunerLJ , OparilS , RodriguezCJ , RoumieCL , ShorrRI , SinkKM , WadleyVG , WheltonPK , WhittleJ , WoolardNF , Wright JT Jr, PajewskiNM , SPRINT Research Group. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.. JAMA 2016 Jun 28;315(24):2673-82. ">SPRINT MIND 2019</a> have strengthened the case for an update. </p> <p>The previous review could have included both pharmacological and non‐pharmacological interventions, but in practice included only double‐blind, placebo‐controlled trials of antihypertensive medications. We have excluded non‐pharmacological interventions which are often complex in nature. These will be dealt with in a separate review. </p> <p>Given the evidence to support treatment of hypertension and the change in guidelines since the initial review was planned, further placebo‐controlled trials would be unethical. For this update, we have therefore broadened the search criteria to include any RCTs in which pharmacological treatment for hypertension was administered for at least 12 months and cognitive outcomes were measured. It now also includes RCTs comparing different antihypertensive drugs or different BP targets. We dropped the requirement that trials had to be double‐blind because we did not think this was essential for head‐to‐head comparisons. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD004034-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD004034-sec-0014"></div> <p>To assess whether pharmacological treatment of hypertension can prevent cognitive impairment or dementia in people who have no history of cerebrovascular disease. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD004034-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD004034-sec-0015"></div> <section id="CD004034-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD004034-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs) in which pharmacological interventions to lower blood pressure (BP) were administered for more than 12 months. We chose 12 months as the minimum trial duration because we considered it infeasible that cognitive effects could be detected in shorter trials. </p> </section> <section id="CD004034-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included people with a diagnosis of hypertension made according to the established criteria for the time. For studies included in the previous reviews, BP readings were at least 160/90 mmHg for entry into essential hypertension studies. Systolic blood pressure (SBP) was 160 to 219 mmHg, and diastolic blood pressure (DBP) was below 90 mmHg for entry into an isolated systolic hypertension study. The most recent National Institute for Health and Care Excellence (NICE) and Joint National Committee on the Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC) 8 guidelines recommend thresholds of 140/90 mmHg and 150/90 mmHg, respectively (<a href="./references#CD004034-bbs2-0098" title="National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and management. Guideline2019.">NICE 2019</a>; <a href="./references#CD004034-bbs2-0083" title="JamesPA , OparilS , CarterBL , CushmanWC , Dennison-HimmelfarbC , HandlerJ , et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA2014;311(5):507-20.">JNC 8</a>). Contemporary guidelines at the time many recent studies were conducted were more stringent, however, with the JNC 7 recommending thresholds of 140/90 mmHg and 130/80 mmHg for diabetics (<a href="./references#CD004034-bbs2-0082" title="ChobanianAV , BakrisGL , BlackHR , CushmanWC , GreenLA , Izzo Jr JL et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA2003;289(19):2560-72.">JNC 7</a>). Therefore, more recent included studies enrolled participants who had lower blood pressures at entry than did the older studies. </p> <p>We excluded studies conducted solely in people with previous cerebrovascular disease as the evidence base for secondary prevention is addressed elsewhere. We did not exclude participants on the basis of prior use of antihypertensive therapy. </p> <p>We had previously excluded studies on the basis that their populations were too young to expect a significant incidence of dementia. Given the emerging evidence of a relationship between vascular risk factors and mid‐life cognition, we have removed this criterion. We reviewed studies previously excluded on the basis of participant age. </p> <p>We excluded studies with a sole focus on people living with dementia, as incidence of dementia is an outcome measure. </p> </section> <section id="CD004034-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included these pharmaceutical agents, or classes of therapy, in this review:</p> <p> <ul id="CD004034-list-0001"> <li> <p>angiotensin‐converting enzyme inhibitors (ACE inhibitors);</p> </li> <li> <p>angiotensin receptor blockers (ARBs);</p> </li> <li> <p>beta adrenergic blockers;</p> </li> <li> <p>combined alpha and beta blockers;</p> </li> <li> <p>calcium channel blockers (CCBs);</p> </li> <li> <p>diuretics;</p> </li> <li> <p>alpha adrenergic blockers;</p> </li> <li> <p>central sympatholytics;</p> </li> <li> <p>direct vasodilators;</p> </li> <li> <p>peripheral adrenergic antagonists; and</p> </li> <li> <p>sympathomimetics.</p> </li> </ul> </p> <p>We included trials giving these medications at any dose for at least 12 months. With the exception of <a href="./references#CD004034-bbs2-0007" title="Pérez-StableEJ , HallidayR , GardinerPS , BaronRB , HauckWW , AcreeM , CoatesTJ . The effects of propranolol on cognitive function and quality of life: a randomized trial among patients with diastolic hypertension.. The American Journal Of Medicine 2000 Apr 1;108(5):359-65. ">Perez Stable 2000</a>, all included studies employed a stepped approach to pharmacological antihypertensive treatment, with dosages increased or drugs added, or both, if BP was above given thresholds at predefined points in the studies. Further details of individual study approaches can be found in the <a href="./references#CD004034-sec-0116" title="">Characteristics of included studies</a> and <a href="#CD004034-tbl-0002">Table 1</a>. </p> <div class="table" id="CD004034-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Study properties</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BP Entry Criteria (mmHg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Baseline BP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Comparison</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study Duration</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Placebo‐controlled RCTs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004034-bbs2-0004" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumiterscuD , et al, for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. NEJM2008;358:1887-1898. BulpittC , FletcherA , BeckettN , CoopeJ , Gil-ExtremeraB , ForetteF , et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs &amp; Aging2001;18:151-164. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al, for the HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurology2008;7:683-689. PetersR , BeckettN , McCormackT , FagardR , FletcherA , BulpittC . Treating hypertension in the very elderly-benefits, risks, and future directions, a focus on the hypertension in the very elderly trial. European Heart Journal 2014 Jul;35(26):1712-8. PetersR , BeckettN , NunesM , FletcherA , ForetteF , BulpittC . A substudy protocol of the Hypertension in the Very Elderly Trial assessing cognitive decline and dementia incidence (HYVET-COG): an ongoing randomised, double-blind, placebo-controlled trial. Drugs Aging2006;23:83-92. ">HYVET 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n=3336</b>, n=1687 Rx group; n=1649 placebo </p> <p>n=1469 completed 2 yr MMSE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SBP 160‐200, DBP &lt; 110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean SBP 173.1 Rx group; 172.9 placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>stepped (diuretic then ACE inhibitor) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 years, 2 year results reported for HYVET‐COG</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004034-bbs2-0007" title="Pérez-StableEJ , HallidayR , GardinerPS , BaronRB , HauckWW , AcreeM , CoatesTJ . The effects of propranolol on cognitive function and quality of life: a randomized trial among patients with diastolic hypertension.. The American Journal Of Medicine 2000 Apr 1;108(5):359-65. ">Perez Stable 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n=312</b>, n=156 each Rx and placebo groups </p> <p>dementia incidence reported for n=102 and n=101 respectively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DBP 90‐104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean BP 140/96 Rx group; 141/96 placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>placebo vs BB also lifestyle intervention factorial design (not included here)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004034-bbs2-0008" title="Degl'InnocentiA , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , ZanchettiA , WiklundI . Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). Journal of Human Hypertension2004;18(4):239-45. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study of COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. Journal of Hypertension2004;22(8):1605-12. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. Journal of Hypertension2003;21:875-886. PapademetriouV , FarsangC , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , Zanchetti A for the SCOPE Study Group. Stroke Prevention With the Angiotension II Type-1 Receptor Blocker Candesartan in Elderly Patients With Isolated Systolic Hypertension. The Study on Cognition and Prognosis in the Elderly (SCOPE). Journal of the American College of Cardiology2004;44(6):1175-80. SkoogI , LithellH , HanssonL , ElmfeldtD , HofmanA , OlofssonB , et al, for the SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). American Journal of Hypertension2005;18:1052-1059. ">SCOPE 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n=4937</b>, n=2477 Rx group; n=2460 placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BP 160‐179/90‐99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean BP 166.0/90.3 Rx group; 166.5/90.4 placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>stepped (ARB then diuretic) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44.6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004034-bbs2-0009" title="ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the Treatment of Isolated Systolic Hypertension on Behavioral Variables. Results From the Systolic Hypertension in the Elderly Program. Arch Intern Med1994;154:2154-2160. Di BariM , PahorM , FranseLV , ShorrRI , WanJY , FerrucciL , et al. Dementia and Disability Outcomes in Large Hypertension Trials: Lessons Learned from the Systolic Hypertension in the Elderly Program (SHEP) Trial. American Journal of Epidemiology2001;153:72-8. SHEP Cooperative Research Group. Prevention of Stroke by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic Hypertension. Final Results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265:3255-64. The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and Design of a Randomized Clinical Trial on Prevention of Stroke in Isolated Systolic Hypertension. Journal of Clinical Epidemiology1988;41:1197-1208. ">SHEP 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n=4736</b>, n=2365 Rx group; n=2371 placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SBP &gt; 160, DBP &lt; 90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean BP 170.5/76.7 Rx group; 170.1/76.4 placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>stepped (diuretic then BB then centrally acting agent) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean follow‐up 4.5 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004034-bbs2-0011" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , De LeeuwP , DolleryCT , et al. Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: Objectives, protocol, and organization. Aging Clin Exp Res1991;3:287-302. FletcherAE , BulpittCJ , ThijsL , ToumilehtoJ , AntikainenR , BossiniA , et al. Quality of life on randomised treatment for isolated hypertension: results from the Syst-Eur Trial. Journal of Hypertension2002;20:2069-2079. FletcherAE , BulpittCJ , TuomilehtoJ , BrowneJ , BossiniA , Kawecka-JaszczK , et al. Quality of life of elderly patients with isolated systolic hypertension: baseline data from the Syst-Eur Trial. Journal of Hypertension1988;16:1117-1124. ForetteF , Seux M-L, StaessenJA , ThijsL , Babarskiene M-R, BabeanuS , et al. The Prevention of Dementia With Antihypertensive Treatment. New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study. Archives of Internal Medicine2002;162:2046-2052. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH , BabarskieneMR , et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet1998;352:1347-51. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH . Reduction of dementia by calcium-antagonist-based antihypertensive treatment. European Heart Journal Supplements2000;2:D17-D19. StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Lancet1997;350:757-764. ">Syst Eur 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n=2418</b>, n=1238 Rx group; n=1180 placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SBP 160‐219, DBP &lt; 95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean BP 173.4/86.0 Rx group; 173.5/86.1 placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>stepped (CCB then ACE inhibitor then diuretic) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median follow‐up 2.0 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004034-bbs2-0005" title="YodfatY , Bar-OnD , AmirM , Cristal N. Quality of life in normotensives compared to hypertensive men treated with isradipine or methyldopa as monotherapy or in combination with captopril: the LOMIR-MCT-IL study.. Journal of Human Hypertension 1996 Feb;10(2):117-22. YodfatY , Cristal N. A multicenter, double-blind, randomized, placebo-controlled study of isradipine and methyldopa as monotherapy or in combination with captopril in the treatment of hypertension. The LOMIR-MCT-IH Research Group.. American Journal of Hypertension 1993 Mar;6(3 Pt 2):57S-61S. ">LOMIR MCT IL 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n=368</b> (n=124; n=120; n=124) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DBP 95‐105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean BP 154.5/99.7; 152.0/99.3; 150.7/99.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>stepped, isradipine vs methyldopa vs placebo, dose doubled then ACE inhibitor added</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004034-bbs2-0006" title="MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. British Medical Journal1992;304(6824):405-12. PrinceMJ , BirdAS , BlizardRA , MannAH . Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. British Medical Journal1996;312(7034):801-5. ">MRC 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n=2651 with n=2567 and <b>n=2584</b> completing PALT and TMT assessments, n=633 diuretic n=640 BB n=1311 placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SBP 160‐209, DBP &lt; 115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean BP diuretic 184.9/90.3; BB 184.2/90.7; placebo 183.5/90.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>stepped, BB vs diuretic vs placebo, then BB dose doubled, other study drug added then CCB added; additional drugs permitted </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004034-bbs2-0012" title="JiT , ZhaoY , WangJ , CuiY , DuanD , ChaiQ , et al. Effect of low dose statins and apolipoprotein E genotype on cerebral small vessel disease in older hypertensive patients: a subgroup analysis of a randomized clinical trial. J Am Med Dir Assoc2018;19:995-1002. ZhangH , CuiY , ZhaoY , DongY , DuanD , WangJ , ShengL , JiT , ZhouT , HuW , ChenY , SunS , GongG , ChaiQ , LiuZ . Effects of sartans and low-dose statins on cerebral white matter hyperintensities and cognitive function in older patients with hypertension: a randomized, double-blind and placebo-controlled clinical trial. Hypertension research2018;42(5):717-729. ">Zhang 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n=732</b> (n=366 both groups) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SBP ≥140 and/or DBP ≥ 90 or self‐reported use of BP lowering meds in previous 2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean 156.1/71.3 ARB; 156.5/71.2 placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>telmisartan vs placebo but all participants also Rx hydrochlorothiazide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean follow‐up 59.8 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Intensive versus standard BP reduction</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004034-bbs2-0001" title="BuseJB , BiggerJT , ByingtonRP , CooperLS , CushmanWC , FriedewaldWT , et al, ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. American Journal of Cardiology2007;99(12A):21i-33i. CushmanWC , Grimm RH Jr, CutlerJA , EvansGW , CapesS , CorsonMA , et al, ACCORD Study Group. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):44i-55i. LaunerLJ , MillerME , WilliamsonJD , LazarRM , GersteinHC , MurrayAM , et al, ACCORD MIND investigators. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurology2011;10(11):969-77. MargolisKL , O'ConnorPJ , MorganTM , BuseJB , CohenRM , CushmanWC , et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care2014;37(6):1721-8. O'ConnorPJ , NarayanKM , AndersonR , FeeneyP , FineL , AliMK , et al. Effect of intensive versus standard blood pressure control on depression and health-related quality of life in type 2 diabetes: the ACCORD trial. Diabetes Care2012;35(7):1479-81. WilliamsonJD , LaunerLJ , BryanRN , CokerLH , LazarRM , GersteinHC , et al, Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Investigators. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Internal Medicine2014;174(3):324-33. WilliamsonJD , MillerME , BryanRN , LazarRM , CokerLH , JohnsonJ , et al, ACCORD Study Group. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. American Journal of Cardiology2007;99(12A):112i-122i. ">ACCORD MIND 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n=1439</b>, n=745 intensive group, n=694 standard group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SBP ≥ 130 on ≥ 2 occasions on no meds, SBP 130‐160 on 0‐3 meds, 161‐170 on 0‐2 meds, 171‐180 on 0‐1 meds </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean 138.8/76.0 intensive group; 139.2/76.3 standard</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 120 vs &lt; 140 mmHg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004034-bbs2-0010" title="AmbrosiusWT , SinkKM , FoyCG , BerlowitzDR , CheungAK , CushmanWC , FineLJ , Goff DC Jr, JohnsonKC , KilleenAA , LewisCE , OparilS , ReboussinDM , RoccoMV , SnyderJK , WilliamsonJD , Wright JT Jr, WheltonPK , SPRINT Study Research Group. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).. Clinical Trials 2014 Oct;11(5):532-46. BerlowitzDR , FoyCG , KazisLE , BolinLP , ConroyMB , FitzpatrickP , GureTR , KimmelPL , KirchnerK , MoriskyDE , NewmanJ , OlneyC , OparilS , PajewskiNM , PowellJ , RamseyT , SimmonsDL , SnyderJ , SupianoMA , WeinerDE , WhittleJ , SPRINT Research Group. Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes.. The New England Journal of Medicine 2017 Aug 24;377(8):733-744. SPRINT Research Group, Wright JT Jr, WilliamsonJD , WheltonPK , SnyderJK , SinkKM , RoccoMV , ReboussinDM , RahmanM , OparilS , LewisCE , KimmelPL , JohnsonKC , Goff DC Jr, FineLJ , CutlerJA , CushmanWC , CheungAK , Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control.. The New England Journal of Medicine 2015 Nov 26;373(22):2103-16. The SPRINT MIND Investigators for the SPRINT Research Group. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA2019;321(6):553-561. WilliamsonJD , SupianoMA , ApplegateWB , BerlowitzDR , CampbellRC , ChertowGM , FineLJ , HaleyWE , HawfieldAT , IxJH , KitzmanDW , KostisJB , Krousel-WoodMA , LaunerLJ , OparilS , RodriguezCJ , RoumieCL , ShorrRI , SinkKM , WadleyVG , WheltonPK , WhittleJ , WoolardNF , Wright JT Jr, PajewskiNM , SPRINT Research Group. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.. JAMA 2016 Jun 28;315(24):2673-82. ">SPRINT MIND 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n=9,361</b>, n=4678 intensive group, n=4683 standard group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SBP 130 ‐ 180 on ≥ 2 occasions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean 139.7/78.2 intensive group; 139.7/78.0 standard</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 120 vs &lt; 140 mmHg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median intervention period 3.34 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Other included studies</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004034-bbs2-0002" title="HajjarI , HartM , ChenYL , MackW , MilbergW , ChuiH , et al. Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: a double-blind randomized clinical trial. Archives of Internal Medicine2012;172(5):442-4. HajjarI , HartM , ChenYL , MackW , NovakV , ChuiH , et al. Antihypertensive therapy and cerebral hemodynamics in executive mild cognitive impairment: results of a pilot randomized clinical trial. Journal of the American Geriatrics Society2013;61(2):194-201. HajjarI , HartM , MackW , LipsitzLA . Aldosterone, cognitive function, and cerebral hemodynamics in hypertension and antihypertensive therapy. American Journal of Hypertension2015;28(3):319-25. HajjarI , HartM , MilbergW , NovakV , LipsitzL . The rationale and design of the antihypertensives and vascular, endothelial, and cognitive function (AVEC) trial in elderly hypertensives with early cognitive impairment: role of the renin angiotensin system inhibition. BMC Geriatrics2009;9:48. ">AVEC 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n=47</b> (n=17; n=17; n=13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 140/90 or on antihypertensives</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean 153/85 ACE inhibitor; 149/81 ARB; 155/83 diuretic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>stepped, ARB vs diuretic vs ACE inhibitor, dose increased then CCB added then BB added</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004034-bbs2-0003" title="SatoN , SaijoY , HasebeN , CAMUI investigators. Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial. International Heart Journal2012;53(4):244-8. SatoN , SaijoY , SasagawaY , MorimotoH , TakeuchiT , SanoH , KoyamaS , TakeharaN , MoritaK , SumitomoK , MaruyamaJ , KikuchiK , HasebeN , CAMUI investigators. Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial: results after 1 year. Journal of Hypertension2013;31(6):1245-55. ">CAMUI 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n=142</b> (n=74 and n=68) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 140/90 or &gt; 130/80 if diabetic or renal disease and already on an ARB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean 156/83 ARB+C; 155/83 ARB+D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>stepped, ARB + CCB vs ARB + diuretic, further ARB added then alpha blocker then BB then antisympathetic agent added </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>RCTs: randomised controlled trials; MMSE: mini mental state examination; SBP: systolic blood pressure; DBP: diastolic blood pressure; Rx: hypertensive treatment group; ACE inhibitor: angiotensin converting enzyme inhibitor; BB: beta‐blocker; ARB: angiotensin receptor blocker; CCB: calcium channel blocker; PALT: paired associate learning test; TMT: trail making test. </p> </div> </div> <p>Previous versions of this review included only placebo‐controlled studies (<a href="./references#CD004034-bbs2-0133" title="McGuinnessB , ToddS , PassmoreP , BullockR . Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database of Systematic Reviews2006, Issue 2. Art. No: CD004034. Art. No: CD004034. [DOI: CD004034. DOI: 10.1002/14651858.CD004034.pub2]">McGuinness 2006</a>; <a href="./references#CD004034-bbs2-0134" title="McGuinnessB , ToddS , PassmoreP , BullockR . Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database of Systematic Reviews2009, Issue 3. Art. No: CD004034. [DOI: 10.1002/14651858.CD004034.pub3]">McGuinness 2009</a>). For this update, Cochrane requested that all RCTs of pharmacological treatment of hypertension be considered. </p> </section> <section id="CD004034-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD004034-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD004034-list-0002"> <li> <p>Incidence of dementia. For the diagnosis of dementia, we accepted standard criteria, such as the American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders (DSM) (<a href="./references#CD004034-bbs2-0055" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd revised edition. Washington DC: APA, 1987.">APA 1987</a>), International Classification of Diseases‐10 (ICD‐10) (<a href="./references#CD004034-bbs2-0126" title="World Health Organisation. The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. Geneva: WHO, 1992.">WHO 1992</a>); National Institute of Neurological and Communicative Disorders and Stroke ‐ Alzheimer's Disease and Related Disorders Association (NINCDS‐ADRDA) (<a href="./references#CD004034-bbs2-0094" title="McKhannG , DrachmanD , FolsteinM , KatzmanR , PriceD , StadlanEM . Clinical Diagnosis of Alzheimer’s Disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology1984;4:939-44.">McKhann 1984</a>), or acceptable equivalents (<a href="./references#CD004034-bbs2-0065" title="DuboisB , FeldmanHH , JacovaC , DekoskyST , Barberger-GateauP , CummingsJ , et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurology2007;6(8):734-46.">Dubois 2007</a>, <a href="./references#CD004034-bbs2-0095" title="McKhannGM , KnopmanDS , ChertkowH , HymanBT , Jack CR Jr, KawasCH , et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's &amp; Dementia2011;7(3):263-9.">McKhann 2011</a>). </p> </li> <li> <p>Cognitive change from baseline. We required cognitive function to have been formally assessed using, for example, the Mini‐Mental State Examination (MMSE) or acceptable alternative. </p> </li> </ul> </p> <p>Mild cognitive impairment was not considered as an outcome measure in either of the previous versions of this review and was not intended to be included in this update. </p> </section> <section id="CD004034-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD004034-list-0003"> <li> <p>Blood pressure level</p> </li> <li> <p>Incidence and severity of adverse effects</p> </li> <li> <p>Quality of life</p> </li> </ul> </p> <p>After termination of the <a href="./references#CD004034-bbs2-0011" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , De LeeuwP , DolleryCT , et al. Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: Objectives, protocol, and organization. Aging Clin Exp Res1991;3:287-302. FletcherAE , BulpittCJ , ThijsL , ToumilehtoJ , AntikainenR , BossiniA , et al. Quality of life on randomised treatment for isolated hypertension: results from the Syst-Eur Trial. Journal of Hypertension2002;20:2069-2079. FletcherAE , BulpittCJ , TuomilehtoJ , BrowneJ , BossiniA , Kawecka-JaszczK , et al. Quality of life of elderly patients with isolated systolic hypertension: baseline data from the Syst-Eur Trial. Journal of Hypertension1988;16:1117-1124. ForetteF , Seux M-L, StaessenJA , ThijsL , Babarskiene M-R, BabeanuS , et al. The Prevention of Dementia With Antihypertensive Treatment. New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study. Archives of Internal Medicine2002;162:2046-2052. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH , BabarskieneMR , et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet1998;352:1347-51. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH . Reduction of dementia by calcium-antagonist-based antihypertensive treatment. European Heart Journal Supplements2000;2:D17-D19. StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Lancet1997;350:757-764. ">Syst Eur 1998</a> trial, any participants exiting double‐blind therapy before the end of the study were followed as open‐label follow‐up until the end of the study and analysed using intention‐to‐treat analyses. In the previous versions of this review (<a href="./references#CD004034-bbs2-0133" title="McGuinnessB , ToddS , PassmoreP , BullockR . Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database of Systematic Reviews2006, Issue 2. Art. No: CD004034. Art. No: CD004034. [DOI: CD004034. DOI: 10.1002/14651858.CD004034.pub2]">McGuinness 2006</a>; <a href="./references#CD004034-bbs2-0134" title="McGuinnessB , ToddS , PassmoreP , BullockR . Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database of Systematic Reviews2009, Issue 3. Art. No: CD004034. [DOI: 10.1002/14651858.CD004034.pub3]">McGuinness 2009</a>), we had included data on the changes in SBP and DBP for the entire <a href="./references#CD004034-bbs2-0011" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , De LeeuwP , DolleryCT , et al. Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: Objectives, protocol, and organization. Aging Clin Exp Res1991;3:287-302. FletcherAE , BulpittCJ , ThijsL , ToumilehtoJ , AntikainenR , BossiniA , et al. Quality of life on randomised treatment for isolated hypertension: results from the Syst-Eur Trial. Journal of Hypertension2002;20:2069-2079. FletcherAE , BulpittCJ , TuomilehtoJ , BrowneJ , BossiniA , Kawecka-JaszczK , et al. Quality of life of elderly patients with isolated systolic hypertension: baseline data from the Syst-Eur Trial. Journal of Hypertension1988;16:1117-1124. ForetteF , Seux M-L, StaessenJA , ThijsL , Babarskiene M-R, BabeanuS , et al. The Prevention of Dementia With Antihypertensive Treatment. New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study. Archives of Internal Medicine2002;162:2046-2052. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH , BabarskieneMR , et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet1998;352:1347-51. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH . Reduction of dementia by calcium-antagonist-based antihypertensive treatment. European Heart Journal Supplements2000;2:D17-D19. StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Lancet1997;350:757-764. ">Syst Eur 1998</a> cohort. For this update, we felt it more appropriate to include only the participants from the cognitive outcome analyses. The updated data are shown in <a href="./references#CD004034-fig-0004" title="">Analysis 3.1</a> and <a href="./references#CD004034-fig-0005" title="">Analysis 3.2</a>. </p> </section> </section> </section> <section id="CD004034-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD004034-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We searched the Cochrane Dementia and Cognitive Improvement Group’s Specialised Register, ALOIS (<a href="https://alois.medsci.ox.ac.uk/" target="_blank">alois.medsci.ox.ac.uk/</a>), on 7 July 2020. ALOIS is maintained by the Information Specialists of the Cochrane Dementia and Cognitive Improvement Group, and contains dementia and cognitive enhancement studies identified from: </p> <p> <ul id="CD004034-list-0004"> <li> <p>quarterly searches of the Cochrane Library’s Central Register of Controlled trials (CENTRAL); </p> </li> <li> <p>monthly searches of a number of major healthcare databases: MEDLINE Ovid, Embase Ovid, CINAHL EBSCO (Cumulative Index to Nursing and Allied Health Literature), PsycINFO Ovid and LILACS (Latin American and Caribbean Health Science Information database); </p> </li> <li> <p>monthly searches of a number of trials registers: metaRegister of Controlled Trials (mRCT); Umin Japan Trial Register; World Heath Organization (WHO) portal (which covers ClinicalTrials.gov, ISRCTN registry (<a href="https://www.isrctn.com/" target="_blank">www.isrctn.com/</a>), Chinese Clinical Trial Registry, German Clinical Trials Register, Iranian Registry of Clinical Trials, the Netherlands National Trials Register, plus others); and </p> </li> <li> <p>monthly searches of a number of grey literature sources, including ISI Web of Knowledge Conference Proceedings. </p> </li> </ul> </p> <p>Additional separate searches were run in each of the above sources to ensure that the most up‐to‐date results were retrieved. The search strategies used for the retrieval of reports of trials can be seen in <a href="./appendices#CD004034-sec-0101">Appendix 1</a>. </p> </section> <section id="CD004034-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We searched conference proceedings in the above searches. We contacted authors for further information as described in the dealing with missing data section below. </p> </section> </section> <section id="CD004034-sec-0026"> <h3 class="title" id="CD004034-sec-0026">Data collection and analysis</h3> <section id="CD004034-sec-0027"> <h4 class="title">Selection of studies</h4> <p>For this update, two review authors, ELC and BMcG, independently screened the search results. Both review authors agreed upon and tested the MeSH terms and search strategy used. The other review authors (PP, ST and RB) acted as adjudicators and reviewed the process. </p> <p>ELC and BMcG independently selected trials for relevance against the defined inclusion criteria. We excluded those trials that did not fulfil the criteria from further analysis. No language restrictions were imposed. We resolved any disagreements through discussion and adjudication. </p> <p>In the case of multiple publications relating to the same study, data are included only once. </p> </section> <section id="CD004034-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>We extracted data on trial characteristics and results from the published reports. The summary statistics required for each trial and each outcome for continuous data were the mean change from baseline, the standard error of the mean change, and the number of participants for each treatment group at each assessment. Where changes from baseline were not reported, the mean, standard deviation, and the number of participants for each treatment group at each time point were extracted. The outcomes measured in clinical trials of dementia and cognitive impairment often arise from ordinal rating scales. Where the rating scales used in the trials had a reasonably large number of categories (more than 10), we treated the data as continuous outcomes arising from a normal distribution. </p> <p>For binary data, we sought the numbers in each treatment group and the numbers experiencing the outcome of interest. We defined the baseline assessment as the latest available assessment prior to randomisation, but no earlier than two months prior. </p> <p>We have incorporated feedback regarding our erroneous interpretation of change in MMSE data from <a href="./references#CD004034-bbs2-0004" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumiterscuD , et al, for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. NEJM2008;358:1887-1898. BulpittC , FletcherA , BeckettN , CoopeJ , Gil-ExtremeraB , ForetteF , et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs &amp; Aging2001;18:151-164. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al, for the HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurology2008;7:683-689. PetersR , BeckettN , McCormackT , FagardR , FletcherA , BulpittC . Treating hypertension in the very elderly-benefits, risks, and future directions, a focus on the hypertension in the very elderly trial. European Heart Journal 2014 Jul;35(26):1712-8. PetersR , BeckettN , NunesM , FletcherA , ForetteF , BulpittC . A substudy protocol of the Hypertension in the Very Elderly Trial assessing cognitive decline and dementia incidence (HYVET-COG): an ongoing randomised, double-blind, placebo-controlled trial. Drugs Aging2006;23:83-92. ">HYVET 2008</a> in the previous update. </p> </section> <section id="CD004034-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed risk of bias in the included studies using Cochrane's tool for assessing risk of bias, applied to the published methods and reports for each study. We assessed selection bias, performance bias, detection bias, attrition bias, reporting bias, and any other sources of bias. Regarding randomisation, we considered studies to be at low risk of bias if robust methods were described and unclear risk if no methods were described. Regarding blinding, we considered studies to be at low risk (of performance and detection bias) if participants and assessors or adjudicators, respectively, were blinded, and high risk if they were not. Regarding attrition bias, we considered reporting of overall follow‐up rates, differential follow‐up rates between study arms, and whether associations were found between baseline characteristics and loss to follow‐up. </p> <p>We used GRADE methods to rate the certainty of evidence (high, moderate, low or very low) behind each effect estimate in the review (<a href="./references#CD004034-bbs2-0077" title="GuyattGH , OxmanAD , SchunemannHJ , TugwellP , KnottnerusA . GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. Journal of Clinical Epidemiology2011;64(4):380-2. [PMID: 21185693]">Guyatt 2011</a>). This rating refers to our level of confidence that the estimate reflects the true effect, taking account of risk of bias in the included studies, inconsistency between studies, imprecision in the effect estimate, indirectness in addressing our review question and the risk of publication bias. We produced a 'Summary of findings' table to show the effect estimate and the quantity and quality of supporting evidence for the following outcomes: incidence of dementia; change in MMSE; change in systolic blood pressure; change in diastolic blood pressure; adverse effects requiring discontinuation of treatment; quality of life measures. </p> </section> <section id="CD004034-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>For continuous outcomes, the measure of the treatment effect was the mean difference (MD) where the pooled trials used the same rating scale or test, and the standardised mean difference (SMD), which was the absolute mean difference divided by the standard deviation, where they used different rating scales or tests. </p> <p>For binary outcomes, such as development of dementia or no dementia, we used the odds ratio (OR) to measure treatment effect. </p> </section> <section id="CD004034-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>This review includes randomised controlled trials only. As a multi‐arm study, we divided up the control group for <a href="./references#CD004034-bbs2-0006" title="MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. British Medical Journal1992;304(6824):405-12. PrinceMJ , BirdAS , BlizardRA , MannAH . Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. British Medical Journal1996;312(7034):801-5. ">MRC 1996</a>. For dichotomous outcomes, we planned to divide up both the number of events and the total number of participants. For continuous outcomes, we planned to divide up only the total number of participants and leave the means and standard deviations unchanged. </p> </section> <section id="CD004034-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We sought data on every participant assessed for each outcome measure. To allow an intention‐to‐treat analysis, we sought the data irrespective of compliance, whether or not the participant was subsequently deemed ineligible, or otherwise excluded from treatment or follow‐up. If intention‐to‐treat data were not available in the publications, we sought 'on‐treatment' data or the data of those who completed the trial and indicated it as such. We contacted authors to request additional information where required. We corresponded with: Peters and colleagues regarding the error in reporting of their <a href="./references#CD004034-bbs2-0004" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumiterscuD , et al, for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. NEJM2008;358:1887-1898. BulpittC , FletcherA , BeckettN , CoopeJ , Gil-ExtremeraB , ForetteF , et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs &amp; Aging2001;18:151-164. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al, for the HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurology2008;7:683-689. PetersR , BeckettN , McCormackT , FagardR , FletcherA , BulpittC . Treating hypertension in the very elderly-benefits, risks, and future directions, a focus on the hypertension in the very elderly trial. European Heart Journal 2014 Jul;35(26):1712-8. PetersR , BeckettN , NunesM , FletcherA , ForetteF , BulpittC . A substudy protocol of the Hypertension in the Very Elderly Trial assessing cognitive decline and dementia incidence (HYVET-COG): an ongoing randomised, double-blind, placebo-controlled trial. Drugs Aging2006;23:83-92. ">HYVET 2008</a> data; Saito and colleagues to clarify the <a href="./references#CD004034-bbs2-0050" title="YamanoS , HoriiM , TakamiT , SakumaM , MorimotoT , OkadaS , et al. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of stroke recurrence and longitudinal progression of white matter lesions and silent brain infarcts on MRI (CEREBRAL study): rationale, design, and methodology. International Journal of Stroke2015;10(3):452-6. ">CEREBRAL</a> study is still ongoing; and Zhang and colleagues to seek additional data (<a href="./references#CD004034-bbs2-0012" title="JiT , ZhaoY , WangJ , CuiY , DuanD , ChaiQ , et al. Effect of low dose statins and apolipoprotein E genotype on cerebral small vessel disease in older hypertensive patients: a subgroup analysis of a randomized clinical trial. J Am Med Dir Assoc2018;19:995-1002. ZhangH , CuiY , ZhaoY , DongY , DuanD , WangJ , ShengL , JiT , ZhouT , HuW , ChenY , SunS , GongG , ChaiQ , LiuZ . Effects of sartans and low-dose statins on cerebral white matter hyperintensities and cognitive function in older patients with hypertension: a randomized, double-blind and placebo-controlled clinical trial. Hypertension research2018;42(5):717-729. ">Zhang 2018</a>). We are grateful to these authors for their co‐operation. We attempted unsuccessfully to correspond with: Williamson and colleagues regarding <a href="./references#CD004034-bbs2-0010" title="AmbrosiusWT , SinkKM , FoyCG , BerlowitzDR , CheungAK , CushmanWC , FineLJ , Goff DC Jr, JohnsonKC , KilleenAA , LewisCE , OparilS , ReboussinDM , RoccoMV , SnyderJK , WilliamsonJD , Wright JT Jr, WheltonPK , SPRINT Study Research Group. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).. Clinical Trials 2014 Oct;11(5):532-46. BerlowitzDR , FoyCG , KazisLE , BolinLP , ConroyMB , FitzpatrickP , GureTR , KimmelPL , KirchnerK , MoriskyDE , NewmanJ , OlneyC , OparilS , PajewskiNM , PowellJ , RamseyT , SimmonsDL , SnyderJ , SupianoMA , WeinerDE , WhittleJ , SPRINT Research Group. Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes.. The New England Journal of Medicine 2017 Aug 24;377(8):733-744. SPRINT Research Group, Wright JT Jr, WilliamsonJD , WheltonPK , SnyderJK , SinkKM , RoccoMV , ReboussinDM , RahmanM , OparilS , LewisCE , KimmelPL , JohnsonKC , Goff DC Jr, FineLJ , CutlerJA , CushmanWC , CheungAK , Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control.. The New England Journal of Medicine 2015 Nov 26;373(22):2103-16. The SPRINT MIND Investigators for the SPRINT Research Group. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA2019;321(6):553-561. WilliamsonJD , SupianoMA , ApplegateWB , BerlowitzDR , CampbellRC , ChertowGM , FineLJ , HaleyWE , HawfieldAT , IxJH , KitzmanDW , KostisJB , Krousel-WoodMA , LaunerLJ , OparilS , RodriguezCJ , RoumieCL , ShorrRI , SinkKM , WadleyVG , WheltonPK , WhittleJ , WoolardNF , Wright JT Jr, PajewskiNM , SPRINT Research Group. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.. JAMA 2016 Jun 28;315(24):2673-82. ">SPRINT MIND 2019</a> results, though these were subsequently published; Wei and colleagues regarding their outcome measures (<a href="./references#CD004034-bbs2-0047" title="WeiY , JinZ , ShenG , ZhaoX , YangW , ZhongY , WangJ . Effects of intensive antihypertensive treatment on Chinese hypertensive patients older than 70 years. Journal Of Clinical Hypertension (Greenwich, Conn)2013;15(6):420-7. ">Wei 2013</a>); and Ma and colleagues regarding cognitive outcomes reported in a conference abstract from 2018 (<a href="./references#CD004034-bbs2-0049" title="MaL , LuP , ZhangY , MengX , FanP , MaL , et al. Effects of antihypertensive therapy on cognitive function and health-related quality of life in high-risk hypertensive patients. Journal of Hypertension. Conference: 27th Scientific Meeting of the International Society of Hypertension, ISH2018;36(Suppl 3):e334-5. MaL , WangW , ZhaoY , ZhangY , DengQ , LiuM , et al. Combination of amlodipine plus angiotensin receptor blocker or diuretics in high-risk hypertensive patients: a 96-week efficacy and safety study. Am J Cardiovasc Drugs2012;12(2):137-42. WangW , MaL , ZhangY , DengQ , LiuM , LiuL . The combination of amlodipine and angiotensin receptor blocker or diuretics in high-risk hypertensive patients: rationale, design and baseline characteristics. J Hum Hypertens2011;25(4):271-7. WangW , MaLY , LiuMB , DengQ , ZhangYQ , LiW , et al, CHIEF Cooperative Group. Effects of amlodipine plus telmisartan or amlodipine plus amiloride regimen on blood pressure control in hypertensive patients: preliminary report of Chinese Hypertension Intervention Efficacy (CHIEF) trial. Zhonghua Xin Xue Guan Bing Za Zhi2009;37(8):701-7. ">CHIEF 2012</a>). </p> </section> <section id="CD004034-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We decided whether or not to synthesise data using a meta‐analysis based on the clinical heterogeneity between trials (including consideration of participants, interventions and outcomes). We performed tests for heterogeneity using a standard Chi<sup>2</sup> statistic and a significance level of P = 0.10, as suggested by Cochrane. We also assessed the impact of heterogeneity on the meta‐analyses using the I<sup>2</sup> statistic. This informed our decision to used random‐effects versus fixed‐effect model. </p> </section> <section id="CD004034-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>We considered whether results for prespecified outcomes published in protocols and methods sections were reported. Where there was a difference between outcome measures as planned in protocols and as reported in published results, we incorporated this into our GRADE assessments. </p> </section> <section id="CD004034-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We planned to undertake an analysis assessing the combined effect of all antihypertensive medications. We conducted meta‐analyses only when we considered the studies to be sufficiently similar clinically. For example, studies comparing placebo and active treatment were amenable to meta‐analysis. It was not possible to pool studies comparing active treatment and placebo, different active treatments and different BP targets in a single meta‐analysis. Where meta‐analyses were feasible, we presented the overall estimate from a fixed‐effect model. If there was significant statistical heterogeneity, we also conducted sensitivity analyses assessing the impact of using a random‐effects model. </p> </section> <section id="CD004034-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We did not plan to undertake any subgroup analyses. We investigated heterogeneity as outlined above. </p> </section> <section id="CD004034-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>We undertook sensitivity analyses to assess the robustness of the results to fixed‐effect versus random‐effects models, and on the inclusion or exclusion of studies of poor quality. </p> </section> <section id="CD004034-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We summarised our findings in the Summary of Findings table (Table 5). We planned to present both primary and secondary outcomes measures where available. We focused on placebo controlled RCTs in keeping with original aim of the review. Certainty of evidence was assessed using the GRADE system and GRADEpro software. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD004034-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD004034-sec-0039"></div> <section id="CD004034-sec-0040"> <h3 class="title">Description of studies</h3> <section id="CD004034-sec-0041"> <h4 class="title">Results of the search</h4> <p>We have undertaken a total of seven searches for this review, including the latest search in July 2020. These are outlined in <a href="#CD004034-fig-0001">Figure 1</a>. In addition to the previously included four studies, describing 15,427 participants, we identified eight new eligible studies, including 14,985 participants, for this update. </p> <div class="figure" id="CD004034-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram for searches December 2014 (212), November 2015 (309), October 2016 (145), August 2017 (220), June 2018 (279), June 2019 (177), July 2020 (259)" data-id="CD004034-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004034.pub4/media/CDSR/CD004034/image_n/nCD004034-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram for searches December 2014 (212), November 2015 (309), October 2016 (145), August 2017 (220), June 2018 (279), June 2019 (177), July 2020 (259) </p> </div> </div> </div> <p>In total, we included 12 randomised controlled trials (RCTs), reporting outcomes for 30,412 participants, in this review. </p> </section> <section id="CD004034-sec-0042"> <h4 class="title">Included studies</h4> <p>Of the eight placebo‐controlled RCTs, two used a diuretic‐based regimen (<a href="./references#CD004034-bbs2-0009" title="ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the Treatment of Isolated Systolic Hypertension on Behavioral Variables. Results From the Systolic Hypertension in the Elderly Program. Arch Intern Med1994;154:2154-2160. Di BariM , PahorM , FranseLV , ShorrRI , WanJY , FerrucciL , et al. Dementia and Disability Outcomes in Large Hypertension Trials: Lessons Learned from the Systolic Hypertension in the Elderly Program (SHEP) Trial. American Journal of Epidemiology2001;153:72-8. SHEP Cooperative Research Group. Prevention of Stroke by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic Hypertension. Final Results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265:3255-64. The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and Design of a Randomized Clinical Trial on Prevention of Stroke in Isolated Systolic Hypertension. Journal of Clinical Epidemiology1988;41:1197-1208. ">SHEP 1991</a>; <a href="./references#CD004034-bbs2-0004" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumiterscuD , et al, for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. NEJM2008;358:1887-1898. BulpittC , FletcherA , BeckettN , CoopeJ , Gil-ExtremeraB , ForetteF , et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs &amp; Aging2001;18:151-164. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al, for the HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurology2008;7:683-689. PetersR , BeckettN , McCormackT , FagardR , FletcherA , BulpittC . Treating hypertension in the very elderly-benefits, risks, and future directions, a focus on the hypertension in the very elderly trial. European Heart Journal 2014 Jul;35(26):1712-8. PetersR , BeckettN , NunesM , FletcherA , ForetteF , BulpittC . A substudy protocol of the Hypertension in the Very Elderly Trial assessing cognitive decline and dementia incidence (HYVET-COG): an ongoing randomised, double-blind, placebo-controlled trial. Drugs Aging2006;23:83-92. ">HYVET 2008</a>), one used an ARB (<a href="./references#CD004034-bbs2-0008" title="Degl'InnocentiA , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , ZanchettiA , WiklundI . Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). Journal of Human Hypertension2004;18(4):239-45. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study of COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. Journal of Hypertension2004;22(8):1605-12. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. Journal of Hypertension2003;21:875-886. PapademetriouV , FarsangC , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , Zanchetti A for the SCOPE Study Group. Stroke Prevention With the Angiotension II Type-1 Receptor Blocker Candesartan in Elderly Patients With Isolated Systolic Hypertension. The Study on Cognition and Prognosis in the Elderly (SCOPE). Journal of the American College of Cardiology2004;44(6):1175-80. SkoogI , LithellH , HanssonL , ElmfeldtD , HofmanA , OlofssonB , et al, for the SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). American Journal of Hypertension2005;18:1052-1059. ">SCOPE 2003</a>), one used a CCB‐based (calcium channel blocker‐based) regimen (<a href="./references#CD004034-bbs2-0011" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , De LeeuwP , DolleryCT , et al. Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: Objectives, protocol, and organization. Aging Clin Exp Res1991;3:287-302. FletcherAE , BulpittCJ , ThijsL , ToumilehtoJ , AntikainenR , BossiniA , et al. Quality of life on randomised treatment for isolated hypertension: results from the Syst-Eur Trial. Journal of Hypertension2002;20:2069-2079. FletcherAE , BulpittCJ , TuomilehtoJ , BrowneJ , BossiniA , Kawecka-JaszczK , et al. Quality of life of elderly patients with isolated systolic hypertension: baseline data from the Syst-Eur Trial. Journal of Hypertension1988;16:1117-1124. ForetteF , Seux M-L, StaessenJA , ThijsL , Babarskiene M-R, BabeanuS , et al. The Prevention of Dementia With Antihypertensive Treatment. New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study. Archives of Internal Medicine2002;162:2046-2052. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH , BabarskieneMR , et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet1998;352:1347-51. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH . Reduction of dementia by calcium-antagonist-based antihypertensive treatment. European Heart Journal Supplements2000;2:D17-D19. StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Lancet1997;350:757-764. ">Syst Eur 1998</a>), and one used a beta‐blocker (BB) regimen (<a href="./references#CD004034-bbs2-0007" title="Pérez-StableEJ , HallidayR , GardinerPS , BaronRB , HauckWW , AcreeM , CoatesTJ . The effects of propranolol on cognitive function and quality of life: a randomized trial among patients with diastolic hypertension.. The American Journal Of Medicine 2000 Apr 1;108(5):359-65. ">Perez Stable 2000</a>). <a href="./references#CD004034-bbs2-0005" title="YodfatY , Bar-OnD , AmirM , Cristal N. Quality of life in normotensives compared to hypertensive men treated with isradipine or methyldopa as monotherapy or in combination with captopril: the LOMIR-MCT-IL study.. Journal of Human Hypertension 1996 Feb;10(2):117-22. YodfatY , Cristal N. A multicenter, double-blind, randomized, placebo-controlled study of isradipine and methyldopa as monotherapy or in combination with captopril in the treatment of hypertension. The LOMIR-MCT-IH Research Group.. American Journal of Hypertension 1993 Mar;6(3 Pt 2):57S-61S. ">LOMIR MCT IL 1996</a> and <a href="./references#CD004034-bbs2-0006" title="MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. British Medical Journal1992;304(6824):405-12. PrinceMJ , BirdAS , BlizardRA , MannAH . Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. British Medical Journal1996;312(7034):801-5. ">MRC 1996</a> had three arms each: two drug arms and one placebo arm. <a href="./references#CD004034-bbs2-0005" title="YodfatY , Bar-OnD , AmirM , Cristal N. Quality of life in normotensives compared to hypertensive men treated with isradipine or methyldopa as monotherapy or in combination with captopril: the LOMIR-MCT-IL study.. Journal of Human Hypertension 1996 Feb;10(2):117-22. YodfatY , Cristal N. A multicenter, double-blind, randomized, placebo-controlled study of isradipine and methyldopa as monotherapy or in combination with captopril in the treatment of hypertension. The LOMIR-MCT-IH Research Group.. American Journal of Hypertension 1993 Mar;6(3 Pt 2):57S-61S. ">LOMIR MCT IL 1996</a> ran parallel isradipine, methyldopa and placebo groups with an ACE inhibitor added if necessary, while <a href="./references#CD004034-bbs2-0006" title="MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. British Medical Journal1992;304(6824):405-12. PrinceMJ , BirdAS , BlizardRA , MannAH . Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. British Medical Journal1996;312(7034):801-5. ">MRC 1996</a> ran parallel diuretic and beta‐blocker‐based groups with matching placebo groups. <a href="./references#CD004034-bbs2-0012" title="JiT , ZhaoY , WangJ , CuiY , DuanD , ChaiQ , et al. Effect of low dose statins and apolipoprotein E genotype on cerebral small vessel disease in older hypertensive patients: a subgroup analysis of a randomized clinical trial. J Am Med Dir Assoc2018;19:995-1002. ZhangH , CuiY , ZhaoY , DongY , DuanD , WangJ , ShengL , JiT , ZhouT , HuW , ChenY , SunS , GongG , ChaiQ , LiuZ . Effects of sartans and low-dose statins on cerebral white matter hyperintensities and cognitive function in older patients with hypertension: a randomized, double-blind and placebo-controlled clinical trial. Hypertension research2018;42(5):717-729. ">Zhang 2018</a> randomised participants using a 2 × 2 factorial design with ARB vs. placebo and statin vs. placebo arms. In addition, all participants were given hydrochlorothiazide. </p> <p>Of the non‐placebo‐controlled studies, two compared intensive versus standard BP reduction (<a href="./references#CD004034-bbs2-0001" title="BuseJB , BiggerJT , ByingtonRP , CooperLS , CushmanWC , FriedewaldWT , et al, ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. American Journal of Cardiology2007;99(12A):21i-33i. CushmanWC , Grimm RH Jr, CutlerJA , EvansGW , CapesS , CorsonMA , et al, ACCORD Study Group. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):44i-55i. LaunerLJ , MillerME , WilliamsonJD , LazarRM , GersteinHC , MurrayAM , et al, ACCORD MIND investigators. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurology2011;10(11):969-77. MargolisKL , O'ConnorPJ , MorganTM , BuseJB , CohenRM , CushmanWC , et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care2014;37(6):1721-8. O'ConnorPJ , NarayanKM , AndersonR , FeeneyP , FineL , AliMK , et al. Effect of intensive versus standard blood pressure control on depression and health-related quality of life in type 2 diabetes: the ACCORD trial. Diabetes Care2012;35(7):1479-81. WilliamsonJD , LaunerLJ , BryanRN , CokerLH , LazarRM , GersteinHC , et al, Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Investigators. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Internal Medicine2014;174(3):324-33. WilliamsonJD , MillerME , BryanRN , LazarRM , CokerLH , JohnsonJ , et al, ACCORD Study Group. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. American Journal of Cardiology2007;99(12A):112i-122i. ">ACCORD MIND 2014</a>; <a href="./references#CD004034-bbs2-0010" title="AmbrosiusWT , SinkKM , FoyCG , BerlowitzDR , CheungAK , CushmanWC , FineLJ , Goff DC Jr, JohnsonKC , KilleenAA , LewisCE , OparilS , ReboussinDM , RoccoMV , SnyderJK , WilliamsonJD , Wright JT Jr, WheltonPK , SPRINT Study Research Group. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).. Clinical Trials 2014 Oct;11(5):532-46. BerlowitzDR , FoyCG , KazisLE , BolinLP , ConroyMB , FitzpatrickP , GureTR , KimmelPL , KirchnerK , MoriskyDE , NewmanJ , OlneyC , OparilS , PajewskiNM , PowellJ , RamseyT , SimmonsDL , SnyderJ , SupianoMA , WeinerDE , WhittleJ , SPRINT Research Group. Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes.. The New England Journal of Medicine 2017 Aug 24;377(8):733-744. SPRINT Research Group, Wright JT Jr, WilliamsonJD , WheltonPK , SnyderJK , SinkKM , RoccoMV , ReboussinDM , RahmanM , OparilS , LewisCE , KimmelPL , JohnsonKC , Goff DC Jr, FineLJ , CutlerJA , CushmanWC , CheungAK , Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control.. The New England Journal of Medicine 2015 Nov 26;373(22):2103-16. The SPRINT MIND Investigators for the SPRINT Research Group. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA2019;321(6):553-561. WilliamsonJD , SupianoMA , ApplegateWB , BerlowitzDR , CampbellRC , ChertowGM , FineLJ , HaleyWE , HawfieldAT , IxJH , KitzmanDW , KostisJB , Krousel-WoodMA , LaunerLJ , OparilS , RodriguezCJ , RoumieCL , ShorrRI , SinkKM , WadleyVG , WheltonPK , WhittleJ , WoolardNF , Wright JT Jr, PajewskiNM , SPRINT Research Group. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.. JAMA 2016 Jun 28;315(24):2673-82. ">SPRINT MIND 2019</a>). Of the two final included studies, <a href="./references#CD004034-bbs2-0002" title="HajjarI , HartM , ChenYL , MackW , MilbergW , ChuiH , et al. Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: a double-blind randomized clinical trial. Archives of Internal Medicine2012;172(5):442-4. HajjarI , HartM , ChenYL , MackW , NovakV , ChuiH , et al. Antihypertensive therapy and cerebral hemodynamics in executive mild cognitive impairment: results of a pilot randomized clinical trial. Journal of the American Geriatrics Society2013;61(2):194-201. HajjarI , HartM , MackW , LipsitzLA . Aldosterone, cognitive function, and cerebral hemodynamics in hypertension and antihypertensive therapy. American Journal of Hypertension2015;28(3):319-25. HajjarI , HartM , MilbergW , NovakV , LipsitzL . The rationale and design of the antihypertensives and vascular, endothelial, and cognitive function (AVEC) trial in elderly hypertensives with early cognitive impairment: role of the renin angiotensin system inhibition. BMC Geriatrics2009;9:48. ">AVEC 2012</a> compared ACE inhibitor, ARB, and diuretic groups, and <a href="./references#CD004034-bbs2-0003" title="SatoN , SaijoY , HasebeN , CAMUI investigators. Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial. International Heart Journal2012;53(4):244-8. SatoN , SaijoY , SasagawaY , MorimotoH , TakeuchiT , SanoH , KoyamaS , TakeharaN , MoritaK , SumitomoK , MaruyamaJ , KikuchiK , HasebeN , CAMUI investigators. Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial: results after 1 year. Journal of Hypertension2013;31(6):1245-55. ">CAMUI 2013</a> compared an ARB plus CCB group with an ARB plus diuretic group. </p> <p>We outline the algorithms for pharmacological management in each trial in <a href="#CD004034-tbl-0002">Table 1</a> with further details available in the <a href="./references#CD004034-sec-0116" title="">Characteristics of included studies</a> table. </p> <p><a href="./references#CD004034-bbs2-0009" title="ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the Treatment of Isolated Systolic Hypertension on Behavioral Variables. Results From the Systolic Hypertension in the Elderly Program. Arch Intern Med1994;154:2154-2160. Di BariM , PahorM , FranseLV , ShorrRI , WanJY , FerrucciL , et al. Dementia and Disability Outcomes in Large Hypertension Trials: Lessons Learned from the Systolic Hypertension in the Elderly Program (SHEP) Trial. American Journal of Epidemiology2001;153:72-8. SHEP Cooperative Research Group. Prevention of Stroke by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic Hypertension. Final Results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265:3255-64. The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and Design of a Randomized Clinical Trial on Prevention of Stroke in Isolated Systolic Hypertension. Journal of Clinical Epidemiology1988;41:1197-1208. ">SHEP 1991</a>, <a href="./references#CD004034-bbs2-0005" title="YodfatY , Bar-OnD , AmirM , Cristal N. Quality of life in normotensives compared to hypertensive men treated with isradipine or methyldopa as monotherapy or in combination with captopril: the LOMIR-MCT-IL study.. Journal of Human Hypertension 1996 Feb;10(2):117-22. YodfatY , Cristal N. A multicenter, double-blind, randomized, placebo-controlled study of isradipine and methyldopa as monotherapy or in combination with captopril in the treatment of hypertension. The LOMIR-MCT-IH Research Group.. American Journal of Hypertension 1993 Mar;6(3 Pt 2):57S-61S. ">LOMIR MCT IL 1996</a>, <a href="./references#CD004034-bbs2-0011" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , De LeeuwP , DolleryCT , et al. Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: Objectives, protocol, and organization. Aging Clin Exp Res1991;3:287-302. FletcherAE , BulpittCJ , ThijsL , ToumilehtoJ , AntikainenR , BossiniA , et al. Quality of life on randomised treatment for isolated hypertension: results from the Syst-Eur Trial. Journal of Hypertension2002;20:2069-2079. FletcherAE , BulpittCJ , TuomilehtoJ , BrowneJ , BossiniA , Kawecka-JaszczK , et al. Quality of life of elderly patients with isolated systolic hypertension: baseline data from the Syst-Eur Trial. Journal of Hypertension1988;16:1117-1124. ForetteF , Seux M-L, StaessenJA , ThijsL , Babarskiene M-R, BabeanuS , et al. The Prevention of Dementia With Antihypertensive Treatment. New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study. Archives of Internal Medicine2002;162:2046-2052. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH , BabarskieneMR , et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet1998;352:1347-51. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH . Reduction of dementia by calcium-antagonist-based antihypertensive treatment. European Heart Journal Supplements2000;2:D17-D19. StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Lancet1997;350:757-764. ">Syst Eur 1998</a>, <a href="./references#CD004034-bbs2-0007" title="Pérez-StableEJ , HallidayR , GardinerPS , BaronRB , HauckWW , AcreeM , CoatesTJ . The effects of propranolol on cognitive function and quality of life: a randomized trial among patients with diastolic hypertension.. The American Journal Of Medicine 2000 Apr 1;108(5):359-65. ">Perez Stable 2000</a>, <a href="./references#CD004034-bbs2-0008" title="Degl'InnocentiA , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , ZanchettiA , WiklundI . Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). Journal of Human Hypertension2004;18(4):239-45. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study of COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. Journal of Hypertension2004;22(8):1605-12. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. Journal of Hypertension2003;21:875-886. PapademetriouV , FarsangC , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , Zanchetti A for the SCOPE Study Group. Stroke Prevention With the Angiotension II Type-1 Receptor Blocker Candesartan in Elderly Patients With Isolated Systolic Hypertension. The Study on Cognition and Prognosis in the Elderly (SCOPE). Journal of the American College of Cardiology2004;44(6):1175-80. SkoogI , LithellH , HanssonL , ElmfeldtD , HofmanA , OlofssonB , et al, for the SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). American Journal of Hypertension2005;18:1052-1059. ">SCOPE 2003</a> and <a href="./references#CD004034-bbs2-0004" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumiterscuD , et al, for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. NEJM2008;358:1887-1898. BulpittC , FletcherA , BeckettN , CoopeJ , Gil-ExtremeraB , ForetteF , et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs &amp; Aging2001;18:151-164. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al, for the HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurology2008;7:683-689. PetersR , BeckettN , McCormackT , FagardR , FletcherA , BulpittC . Treating hypertension in the very elderly-benefits, risks, and future directions, a focus on the hypertension in the very elderly trial. European Heart Journal 2014 Jul;35(26):1712-8. PetersR , BeckettN , NunesM , FletcherA , ForetteF , BulpittC . A substudy protocol of the Hypertension in the Very Elderly Trial assessing cognitive decline and dementia incidence (HYVET-COG): an ongoing randomised, double-blind, placebo-controlled trial. Drugs Aging2006;23:83-92. ">HYVET 2008</a> were double‐blind, placebo‐controlled RCTs. Following the removal of the double‐blind, placebo‐controlled requirement for this update, we have also included <a href="./references#CD004034-bbs2-0006" title="MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. British Medical Journal1992;304(6824):405-12. PrinceMJ , BirdAS , BlizardRA , MannAH . Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. British Medical Journal1996;312(7034):801-5. ">MRC 1996</a> which had a placebo arm but was single‐blind. </p> <p>The remaining five studies have been completed since the last review update. <a href="./references#CD004034-bbs2-0012" title="JiT , ZhaoY , WangJ , CuiY , DuanD , ChaiQ , et al. Effect of low dose statins and apolipoprotein E genotype on cerebral small vessel disease in older hypertensive patients: a subgroup analysis of a randomized clinical trial. J Am Med Dir Assoc2018;19:995-1002. ZhangH , CuiY , ZhaoY , DongY , DuanD , WangJ , ShengL , JiT , ZhouT , HuW , ChenY , SunS , GongG , ChaiQ , LiuZ . Effects of sartans and low-dose statins on cerebral white matter hyperintensities and cognitive function in older patients with hypertension: a randomized, double-blind and placebo-controlled clinical trial. Hypertension research2018;42(5):717-729. ">Zhang 2018</a> was a placebo‐controlled RCT comparing telmisartan to placebo in an elderly hypertensive population with white matter hyperintensity burden as the primary outcome measure. </p> <p>The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial was an open‐label RCT comparing target standard and intensive SBP targets below 140 mmHg and 120 mmHg, respectively, including only participants with type 2 diabetes mellitus. The cognitive sub‐study is <a href="./references#CD004034-bbs2-0001" title="BuseJB , BiggerJT , ByingtonRP , CooperLS , CushmanWC , FriedewaldWT , et al, ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. American Journal of Cardiology2007;99(12A):21i-33i. CushmanWC , Grimm RH Jr, CutlerJA , EvansGW , CapesS , CorsonMA , et al, ACCORD Study Group. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):44i-55i. LaunerLJ , MillerME , WilliamsonJD , LazarRM , GersteinHC , MurrayAM , et al, ACCORD MIND investigators. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurology2011;10(11):969-77. MargolisKL , O'ConnorPJ , MorganTM , BuseJB , CohenRM , CushmanWC , et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care2014;37(6):1721-8. O'ConnorPJ , NarayanKM , AndersonR , FeeneyP , FineL , AliMK , et al. Effect of intensive versus standard blood pressure control on depression and health-related quality of life in type 2 diabetes: the ACCORD trial. Diabetes Care2012;35(7):1479-81. WilliamsonJD , LaunerLJ , BryanRN , CokerLH , LazarRM , GersteinHC , et al, Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Investigators. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Internal Medicine2014;174(3):324-33. WilliamsonJD , MillerME , BryanRN , LazarRM , CokerLH , JohnsonJ , et al, ACCORD Study Group. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. American Journal of Cardiology2007;99(12A):112i-122i. ">ACCORD MIND 2014</a>. The Systolic Blood Pressure Intervention Trial, <a href="./references#CD004034-bbs2-0010" title="AmbrosiusWT , SinkKM , FoyCG , BerlowitzDR , CheungAK , CushmanWC , FineLJ , Goff DC Jr, JohnsonKC , KilleenAA , LewisCE , OparilS , ReboussinDM , RoccoMV , SnyderJK , WilliamsonJD , Wright JT Jr, WheltonPK , SPRINT Study Research Group. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).. Clinical Trials 2014 Oct;11(5):532-46. BerlowitzDR , FoyCG , KazisLE , BolinLP , ConroyMB , FitzpatrickP , GureTR , KimmelPL , KirchnerK , MoriskyDE , NewmanJ , OlneyC , OparilS , PajewskiNM , PowellJ , RamseyT , SimmonsDL , SnyderJ , SupianoMA , WeinerDE , WhittleJ , SPRINT Research Group. Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes.. The New England Journal of Medicine 2017 Aug 24;377(8):733-744. SPRINT Research Group, Wright JT Jr, WilliamsonJD , WheltonPK , SnyderJK , SinkKM , RoccoMV , ReboussinDM , RahmanM , OparilS , LewisCE , KimmelPL , JohnsonKC , Goff DC Jr, FineLJ , CutlerJA , CushmanWC , CheungAK , Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control.. The New England Journal of Medicine 2015 Nov 26;373(22):2103-16. The SPRINT MIND Investigators for the SPRINT Research Group. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA2019;321(6):553-561. WilliamsonJD , SupianoMA , ApplegateWB , BerlowitzDR , CampbellRC , ChertowGM , FineLJ , HaleyWE , HawfieldAT , IxJH , KitzmanDW , KostisJB , Krousel-WoodMA , LaunerLJ , OparilS , RodriguezCJ , RoumieCL , ShorrRI , SinkKM , WadleyVG , WheltonPK , WhittleJ , WoolardNF , Wright JT Jr, PajewskiNM , SPRINT Research Group. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.. JAMA 2016 Jun 28;315(24):2673-82. ">SPRINT MIND 2019</a>, is an open‐label RCT mirroring ACCORD in a non‐diabetic population, comparing target standard and intensive SBP targets below 140 mmHg and 120 mmHg, respectively. </p> <p>The Antihypertensives and Vascular, Endothelial and Cognitive Function trial, <a href="./references#CD004034-bbs2-0002" title="HajjarI , HartM , ChenYL , MackW , MilbergW , ChuiH , et al. Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: a double-blind randomized clinical trial. Archives of Internal Medicine2012;172(5):442-4. HajjarI , HartM , ChenYL , MackW , NovakV , ChuiH , et al. Antihypertensive therapy and cerebral hemodynamics in executive mild cognitive impairment: results of a pilot randomized clinical trial. Journal of the American Geriatrics Society2013;61(2):194-201. HajjarI , HartM , MackW , LipsitzLA . Aldosterone, cognitive function, and cerebral hemodynamics in hypertension and antihypertensive therapy. American Journal of Hypertension2015;28(3):319-25. HajjarI , HartM , MilbergW , NovakV , LipsitzL . The rationale and design of the antihypertensives and vascular, endothelial, and cognitive function (AVEC) trial in elderly hypertensives with early cognitive impairment: role of the renin angiotensin system inhibition. BMC Geriatrics2009;9:48. ">AVEC 2012</a>, is a double‐blind RCT comparing lisinopril, candesartan and hydrochlorothiazide with respect to cognitive outcomes in an elderly, hypertensive population with early cognitive impairment. <a href="./references#CD004034-bbs2-0003" title="SatoN , SaijoY , HasebeN , CAMUI investigators. Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial. International Heart Journal2012;53(4):244-8. SatoN , SaijoY , SasagawaY , MorimotoH , TakeuchiT , SanoH , KoyamaS , TakeharaN , MoritaK , SumitomoK , MaruyamaJ , KikuchiK , HasebeN , CAMUI investigators. Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial: results after 1 year. Journal of Hypertension2013;31(6):1245-55. ">CAMUI 2013</a> was a multicentre, open‐label, non‐placebo‐controlled RCT that administered a combination antihypertensive therapy in the elderly. </p> <section id="CD004034-sec-0043"> <h5 class="title">Sample size</h5> <p>We outline study sample sizes in <a href="#CD004034-tbl-0002">Table 1</a>. <a href="./references#CD004034-bbs2-0006" title="MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. British Medical Journal1992;304(6824):405-12. PrinceMJ , BirdAS , BlizardRA , MannAH . Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. British Medical Journal1996;312(7034):801-5. ">MRC 1996</a>, <a href="./references#CD004034-bbs2-0011" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , De LeeuwP , DolleryCT , et al. Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: Objectives, protocol, and organization. Aging Clin Exp Res1991;3:287-302. FletcherAE , BulpittCJ , ThijsL , ToumilehtoJ , AntikainenR , BossiniA , et al. Quality of life on randomised treatment for isolated hypertension: results from the Syst-Eur Trial. Journal of Hypertension2002;20:2069-2079. FletcherAE , BulpittCJ , TuomilehtoJ , BrowneJ , BossiniA , Kawecka-JaszczK , et al. Quality of life of elderly patients with isolated systolic hypertension: baseline data from the Syst-Eur Trial. Journal of Hypertension1988;16:1117-1124. ForetteF , Seux M-L, StaessenJA , ThijsL , Babarskiene M-R, BabeanuS , et al. The Prevention of Dementia With Antihypertensive Treatment. New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study. Archives of Internal Medicine2002;162:2046-2052. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH , BabarskieneMR , et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet1998;352:1347-51. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH . Reduction of dementia by calcium-antagonist-based antihypertensive treatment. European Heart Journal Supplements2000;2:D17-D19. StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Lancet1997;350:757-764. ">Syst Eur 1998</a>, <a href="./references#CD004034-bbs2-0004" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumiterscuD , et al, for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. NEJM2008;358:1887-1898. BulpittC , FletcherA , BeckettN , CoopeJ , Gil-ExtremeraB , ForetteF , et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs &amp; Aging2001;18:151-164. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al, for the HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurology2008;7:683-689. PetersR , BeckettN , McCormackT , FagardR , FletcherA , BulpittC . Treating hypertension in the very elderly-benefits, risks, and future directions, a focus on the hypertension in the very elderly trial. European Heart Journal 2014 Jul;35(26):1712-8. PetersR , BeckettN , NunesM , FletcherA , ForetteF , BulpittC . A substudy protocol of the Hypertension in the Very Elderly Trial assessing cognitive decline and dementia incidence (HYVET-COG): an ongoing randomised, double-blind, placebo-controlled trial. Drugs Aging2006;23:83-92. ">HYVET 2008</a>, <a href="./references#CD004034-bbs2-0001" title="BuseJB , BiggerJT , ByingtonRP , CooperLS , CushmanWC , FriedewaldWT , et al, ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. American Journal of Cardiology2007;99(12A):21i-33i. CushmanWC , Grimm RH Jr, CutlerJA , EvansGW , CapesS , CorsonMA , et al, ACCORD Study Group. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):44i-55i. LaunerLJ , MillerME , WilliamsonJD , LazarRM , GersteinHC , MurrayAM , et al, ACCORD MIND investigators. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurology2011;10(11):969-77. MargolisKL , O'ConnorPJ , MorganTM , BuseJB , CohenRM , CushmanWC , et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care2014;37(6):1721-8. O'ConnorPJ , NarayanKM , AndersonR , FeeneyP , FineL , AliMK , et al. Effect of intensive versus standard blood pressure control on depression and health-related quality of life in type 2 diabetes: the ACCORD trial. Diabetes Care2012;35(7):1479-81. WilliamsonJD , LaunerLJ , BryanRN , CokerLH , LazarRM , GersteinHC , et al, Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Investigators. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Internal Medicine2014;174(3):324-33. WilliamsonJD , MillerME , BryanRN , LazarRM , CokerLH , JohnsonJ , et al, ACCORD Study Group. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. American Journal of Cardiology2007;99(12A):112i-122i. ">ACCORD MIND 2014</a> and <a href="./references#CD004034-bbs2-0010" title="AmbrosiusWT , SinkKM , FoyCG , BerlowitzDR , CheungAK , CushmanWC , FineLJ , Goff DC Jr, JohnsonKC , KilleenAA , LewisCE , OparilS , ReboussinDM , RoccoMV , SnyderJK , WilliamsonJD , Wright JT Jr, WheltonPK , SPRINT Study Research Group. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).. Clinical Trials 2014 Oct;11(5):532-46. BerlowitzDR , FoyCG , KazisLE , BolinLP , ConroyMB , FitzpatrickP , GureTR , KimmelPL , KirchnerK , MoriskyDE , NewmanJ , OlneyC , OparilS , PajewskiNM , PowellJ , RamseyT , SimmonsDL , SnyderJ , SupianoMA , WeinerDE , WhittleJ , SPRINT Research Group. Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes.. The New England Journal of Medicine 2017 Aug 24;377(8):733-744. SPRINT Research Group, Wright JT Jr, WilliamsonJD , WheltonPK , SnyderJK , SinkKM , RoccoMV , ReboussinDM , RahmanM , OparilS , LewisCE , KimmelPL , JohnsonKC , Goff DC Jr, FineLJ , CutlerJA , CushmanWC , CheungAK , Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control.. The New England Journal of Medicine 2015 Nov 26;373(22):2103-16. The SPRINT MIND Investigators for the SPRINT Research Group. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA2019;321(6):553-561. WilliamsonJD , SupianoMA , ApplegateWB , BerlowitzDR , CampbellRC , ChertowGM , FineLJ , HaleyWE , HawfieldAT , IxJH , KitzmanDW , KostisJB , Krousel-WoodMA , LaunerLJ , OparilS , RodriguezCJ , RoumieCL , ShorrRI , SinkKM , WadleyVG , WheltonPK , WhittleJ , WoolardNF , Wright JT Jr, PajewskiNM , SPRINT Research Group. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.. JAMA 2016 Jun 28;315(24):2673-82. ">SPRINT MIND 2019</a> were all sub‐studies of larger RCTs. </p> </section> <section id="CD004034-sec-0044"> <h5 class="title">Participants</h5> <section id="CD004034-sec-0045"> <h6 class="title">Demographics and baseline cognition</h6> <p>We outline the gender, age, geographical location and, where reported, ethnicity, of participants in <a href="#CD004034-tbl-0003">Table 2</a>. There were more female than male participants overall. Most participants were middle‐aged or older. Study populations were global but predominantly recruited in North America and Europe. Study populations consisted mostly of ambulatory participants recruited from the community or primary care facilities. </p> <div class="table" id="CD004034-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Study demographics</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gender</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Age criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Age</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Geographical area</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Race and ethnicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Educational background</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Baseline cognition</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Placebo‐controlled RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004034-bbs2-0004" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumiterscuD , et al, for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. NEJM2008;358:1887-1898. BulpittC , FletcherA , BeckettN , CoopeJ , Gil-ExtremeraB , ForetteF , et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs &amp; Aging2001;18:151-164. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al, for the HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurology2008;7:683-689. PetersR , BeckettN , McCormackT , FagardR , FletcherA , BulpittC . Treating hypertension in the very elderly-benefits, risks, and future directions, a focus on the hypertension in the very elderly trial. European Heart Journal 2014 Jul;35(26):1712-8. PetersR , BeckettN , NunesM , FletcherA , ForetteF , BulpittC . A substudy protocol of the Hypertension in the Very Elderly Trial assessing cognitive decline and dementia incidence (HYVET-COG): an ongoing randomised, double-blind, placebo-controlled trial. Drugs Aging2006;23:83-92. ">HYVET 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60% female</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 80 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean age 83.5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Eastern Europe (56%),</p> <p>China (40%),</p> <p>Western Europe, Australasia and Tunisia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27% no education</p> <p>28% primary</p> <p>29% secondary</p> <p>12% higher</p> <p>3% further</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median MMSE 26</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004034-bbs2-0007" title="Pérez-StableEJ , HallidayR , GardinerPS , BaronRB , HauckWW , AcreeM , CoatesTJ . The effects of propranolol on cognitive function and quality of life: a randomized trial among patients with diastolic hypertension.. The American Journal Of Medicine 2000 Apr 1;108(5):359-65. ">Perez Stable 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34% female</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18‐59 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean age 46/45 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>California, USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76%/71% white</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean 16 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean (SD) DSST 61 (10)</p> <p>See <a href="./references#CD004034-sec-0116" title="">Characteristics of included studies</a> for other tests </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004034-bbs2-0008" title="Degl'InnocentiA , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , ZanchettiA , WiklundI . Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). Journal of Human Hypertension2004;18(4):239-45. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study of COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. Journal of Hypertension2004;22(8):1605-12. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. Journal of Hypertension2003;21:875-886. PapademetriouV , FarsangC , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , Zanchetti A for the SCOPE Study Group. Stroke Prevention With the Angiotension II Type-1 Receptor Blocker Candesartan in Elderly Patients With Isolated Systolic Hypertension. The Study on Cognition and Prognosis in the Elderly (SCOPE). Journal of the American College of Cardiology2004;44(6):1175-80. SkoogI , LithellH , HanssonL , ElmfeldtD , HofmanA , OlofssonB , et al, for the SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). American Journal of Hypertension2005;18:1052-1059. ">SCOPE 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65% female</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70‐89 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean age 76.4 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primarily Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10% &lt;primary</p> <p>44% primary</p> <p>40% &gt;primary</p> <p>6% university</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean MMSE 28.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004034-bbs2-0009" title="ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the Treatment of Isolated Systolic Hypertension on Behavioral Variables. Results From the Systolic Hypertension in the Elderly Program. Arch Intern Med1994;154:2154-2160. Di BariM , PahorM , FranseLV , ShorrRI , WanJY , FerrucciL , et al. Dementia and Disability Outcomes in Large Hypertension Trials: Lessons Learned from the Systolic Hypertension in the Elderly Program (SHEP) Trial. American Journal of Epidemiology2001;153:72-8. SHEP Cooperative Research Group. Prevention of Stroke by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic Hypertension. Final Results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265:3255-64. The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and Design of a Randomized Clinical Trial on Prevention of Stroke in Isolated Systolic Hypertension. Journal of Clinical Epidemiology1988;41:1197-1208. ">SHEP 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57% female</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 60 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean age 71.6 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exclusively USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86.1% white, 13.9% black, 5% oriental,</p> <p>2% Hispanic, 1% other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean 11.7 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.3% active Rx 0.5% placebo groups 'cognitive impairment scale score of 4 or greater', based on the short‐CARE assessment tool </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004034-bbs2-0011" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , De LeeuwP , DolleryCT , et al. Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: Objectives, protocol, and organization. Aging Clin Exp Res1991;3:287-302. FletcherAE , BulpittCJ , ThijsL , ToumilehtoJ , AntikainenR , BossiniA , et al. Quality of life on randomised treatment for isolated hypertension: results from the Syst-Eur Trial. Journal of Hypertension2002;20:2069-2079. FletcherAE , BulpittCJ , TuomilehtoJ , BrowneJ , BossiniA , Kawecka-JaszczK , et al. Quality of life of elderly patients with isolated systolic hypertension: baseline data from the Syst-Eur Trial. Journal of Hypertension1988;16:1117-1124. ForetteF , Seux M-L, StaessenJA , ThijsL , Babarskiene M-R, BabeanuS , et al. The Prevention of Dementia With Antihypertensive Treatment. New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study. Archives of Internal Medicine2002;162:2046-2052. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH , BabarskieneMR , et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet1998;352:1347-51. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH . Reduction of dementia by calcium-antagonist-based antihypertensive treatment. European Heart Journal Supplements2000;2:D17-D19. StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Lancet1997;350:757-764. ">Syst Eur 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66% female</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 60 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean age 69.9 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exclusively Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean 12.3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median MMSE 29</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004034-bbs2-0005" title="YodfatY , Bar-OnD , AmirM , Cristal N. Quality of life in normotensives compared to hypertensive men treated with isradipine or methyldopa as monotherapy or in combination with captopril: the LOMIR-MCT-IL study.. Journal of Human Hypertension 1996 Feb;10(2):117-22. YodfatY , Cristal N. A multicenter, double-blind, randomized, placebo-controlled study of isradipine and methyldopa as monotherapy or in combination with captopril in the treatment of hypertension. The LOMIR-MCT-IH Research Group.. American Journal of Hypertension 1993 Mar;6(3 Pt 2):57S-61S. ">LOMIR MCT IL 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Solely male</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40‐65 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean age 52 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Israel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean semantic memory score 21.4, 20.8 and 22.3 across groups</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004034-bbs2-0006" title="MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. British Medical Journal1992;304(6824):405-12. PrinceMJ , BirdAS , BlizardRA , MannAH . Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. British Medical Journal1996;312(7034):801-5. ">MRC 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58% female</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65‐74 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean age 70.3/70.4 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean PALT score 17.0 all 3 groups; mean TMT score 59.9, 59.9 and 61.0 across 3 groups</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004034-bbs2-0012" title="JiT , ZhaoY , WangJ , CuiY , DuanD , ChaiQ , et al. Effect of low dose statins and apolipoprotein E genotype on cerebral small vessel disease in older hypertensive patients: a subgroup analysis of a randomized clinical trial. J Am Med Dir Assoc2018;19:995-1002. ZhangH , CuiY , ZhaoY , DongY , DuanD , WangJ , ShengL , JiT , ZhouT , HuW , ChenY , SunS , GongG , ChaiQ , LiuZ . Effects of sartans and low-dose statins on cerebral white matter hyperintensities and cognitive function in older patients with hypertension: a randomized, double-blind and placebo-controlled clinical trial. Hypertension research2018;42(5):717-729. ">Zhang 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48% female</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 60 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean age 70.7 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100% Han Chinese</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean 7 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean (IQR) MMSE 26 (25,28); mean (IQR) DRS 134 (129, 139)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Intensive versus standard BP reduction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004034-bbs2-0001" title="BuseJB , BiggerJT , ByingtonRP , CooperLS , CushmanWC , FriedewaldWT , et al, ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. American Journal of Cardiology2007;99(12A):21i-33i. CushmanWC , Grimm RH Jr, CutlerJA , EvansGW , CapesS , CorsonMA , et al, ACCORD Study Group. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):44i-55i. LaunerLJ , MillerME , WilliamsonJD , LazarRM , GersteinHC , MurrayAM , et al, ACCORD MIND investigators. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurology2011;10(11):969-77. MargolisKL , O'ConnorPJ , MorganTM , BuseJB , CohenRM , CushmanWC , et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care2014;37(6):1721-8. O'ConnorPJ , NarayanKM , AndersonR , FeeneyP , FineL , AliMK , et al. Effect of intensive versus standard blood pressure control on depression and health-related quality of life in type 2 diabetes: the ACCORD trial. Diabetes Care2012;35(7):1479-81. WilliamsonJD , LaunerLJ , BryanRN , CokerLH , LazarRM , GersteinHC , et al, Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Investigators. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Internal Medicine2014;174(3):324-33. WilliamsonJD , MillerME , BryanRN , LazarRM , CokerLH , JohnsonJ , et al, ACCORD Study Group. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. American Journal of Cardiology2007;99(12A):112i-122i. ">ACCORD MIND 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55% female</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 55 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean age 62.3/62.5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>North America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66% white, 22% black, 6% Hispanic, 6% other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14/12% &lt; high school</p> <p>24/28% high school</p> <p>37/35% some college</p> <p>25% ≥ college</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean MMSE 28</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004034-bbs2-0010" title="AmbrosiusWT , SinkKM , FoyCG , BerlowitzDR , CheungAK , CushmanWC , FineLJ , Goff DC Jr, JohnsonKC , KilleenAA , LewisCE , OparilS , ReboussinDM , RoccoMV , SnyderJK , WilliamsonJD , Wright JT Jr, WheltonPK , SPRINT Study Research Group. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).. Clinical Trials 2014 Oct;11(5):532-46. BerlowitzDR , FoyCG , KazisLE , BolinLP , ConroyMB , FitzpatrickP , GureTR , KimmelPL , KirchnerK , MoriskyDE , NewmanJ , OlneyC , OparilS , PajewskiNM , PowellJ , RamseyT , SimmonsDL , SnyderJ , SupianoMA , WeinerDE , WhittleJ , SPRINT Research Group. Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes.. The New England Journal of Medicine 2017 Aug 24;377(8):733-744. SPRINT Research Group, Wright JT Jr, WilliamsonJD , WheltonPK , SnyderJK , SinkKM , RoccoMV , ReboussinDM , RahmanM , OparilS , LewisCE , KimmelPL , JohnsonKC , Goff DC Jr, FineLJ , CutlerJA , CushmanWC , CheungAK , Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control.. The New England Journal of Medicine 2015 Nov 26;373(22):2103-16. The SPRINT MIND Investigators for the SPRINT Research Group. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA2019;321(6):553-561. WilliamsonJD , SupianoMA , ApplegateWB , BerlowitzDR , CampbellRC , ChertowGM , FineLJ , HaleyWE , HawfieldAT , IxJH , KitzmanDW , KostisJB , Krousel-WoodMA , LaunerLJ , OparilS , RodriguezCJ , RoumieCL , ShorrRI , SinkKM , WadleyVG , WheltonPK , WhittleJ , WoolardNF , Wright JT Jr, PajewskiNM , SPRINT Research Group. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.. JAMA 2016 Jun 28;315(24):2673-82. ">SPRINT MIND 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36% female</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 50 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean age 67.9 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58% white,30% black, 10% Hispanic, 2% other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median MoCA 23, range 20‐26; Median logical memory 8; Median digit symbol coding test 51 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Other included studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004034-bbs2-0002" title="HajjarI , HartM , ChenYL , MackW , MilbergW , ChuiH , et al. Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: a double-blind randomized clinical trial. Archives of Internal Medicine2012;172(5):442-4. HajjarI , HartM , ChenYL , MackW , NovakV , ChuiH , et al. Antihypertensive therapy and cerebral hemodynamics in executive mild cognitive impairment: results of a pilot randomized clinical trial. Journal of the American Geriatrics Society2013;61(2):194-201. HajjarI , HartM , MackW , LipsitzLA . Aldosterone, cognitive function, and cerebral hemodynamics in hypertension and antihypertensive therapy. American Journal of Hypertension2015;28(3):319-25. HajjarI , HartM , MilbergW , NovakV , LipsitzL . The rationale and design of the antihypertensives and vascular, endothelial, and cognitive function (AVEC) trial in elderly hypertensives with early cognitive impairment: role of the renin angiotensin system inhibition. BMC Geriatrics2009;9:48. ">AVEC 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57% female</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 60 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean age 72/72/71 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Boston, USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70% White, 23% African American</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19% up to high school, 81% college or more</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean (SD) MMSE 26(2), 26(2), 25(2) across groups</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004034-bbs2-0003" title="SatoN , SaijoY , HasebeN , CAMUI investigators. Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial. International Heart Journal2012;53(4):244-8. SatoN , SaijoY , SasagawaY , MorimotoH , TakeuchiT , SanoH , KoyamaS , TakeharaN , MoritaK , SumitomoK , MaruyamaJ , KikuchiK , HasebeN , CAMUI investigators. Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial: results after 1 year. Journal of Hypertension2013;31(6):1245-55. ">CAMUI 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52% female</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 65 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean age 74.1/74.5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Japan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean (SD) MMSE 27(3) and 26.5(3.2) across groups</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>RCTs: randomised controlled trials; MMSE: mini mental state examination; Rx: hypertensive treatment group; DSST: digit symbol substitution test; short‐CARE: short‐Comprehensive Assessment and Referral Evaluation; PALT: Paired Associate Learning Test; TMT: Trail Making Test; MoCA: Montreal Cognitive Assessment </p> </div> </div> <p>We also outline educational background and baseline cognition, where available, in <a href="#CD004034-tbl-0003">Table 2</a>. </p> </section> <section id="CD004034-sec-0046"> <h6 class="title">Blood pressure (BP) entry criteria</h6> <p>We outline the BP entry criteria for the included studies in <a href="#CD004034-tbl-0002">Table 1</a>, with more complete descriptions in the <a href="./references#CD004034-sec-0116" title="">Characteristics of included studies</a> tables. More recent studies have lower BP eligibility thresholds in line with the evolving guidelines and clinical practice. </p> </section> <section id="CD004034-sec-0047"> <h6 class="title">Interventions</h6> <p>With the exception of <a href="./references#CD004034-bbs2-0007" title="Pérez-StableEJ , HallidayR , GardinerPS , BaronRB , HauckWW , AcreeM , CoatesTJ . The effects of propranolol on cognitive function and quality of life: a randomized trial among patients with diastolic hypertension.. The American Journal Of Medicine 2000 Apr 1;108(5):359-65. ">Perez Stable 2000</a>, all studies employed a stepped approach to pharmacological antihypertensive treatment with dosages increased or drugs added, or both, if BP was above given thresholds at predefined points in the studies. Further details of each study's drug treatment protocol can be found in the <a href="./references#CD004034-sec-0116" title="">Characteristics of included studies</a> tables and <a href="#CD004034-tbl-0002">Table 1</a>. </p> </section> <section id="CD004034-sec-0048"> <h6 class="title">Duration of study</h6> <p>Planned mean length of study follow‐up varied between the studies (one year to five years) and is described in <a href="#CD004034-tbl-0002">Table 1</a>. Three studies ‐ <a href="./references#CD004034-bbs2-0011" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , De LeeuwP , DolleryCT , et al. Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: Objectives, protocol, and organization. Aging Clin Exp Res1991;3:287-302. FletcherAE , BulpittCJ , ThijsL , ToumilehtoJ , AntikainenR , BossiniA , et al. Quality of life on randomised treatment for isolated hypertension: results from the Syst-Eur Trial. Journal of Hypertension2002;20:2069-2079. FletcherAE , BulpittCJ , TuomilehtoJ , BrowneJ , BossiniA , Kawecka-JaszczK , et al. Quality of life of elderly patients with isolated systolic hypertension: baseline data from the Syst-Eur Trial. Journal of Hypertension1988;16:1117-1124. ForetteF , Seux M-L, StaessenJA , ThijsL , Babarskiene M-R, BabeanuS , et al. The Prevention of Dementia With Antihypertensive Treatment. New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study. Archives of Internal Medicine2002;162:2046-2052. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH , BabarskieneMR , et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet1998;352:1347-51. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH . Reduction of dementia by calcium-antagonist-based antihypertensive treatment. European Heart Journal Supplements2000;2:D17-D19. StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Lancet1997;350:757-764. ">Syst Eur 1998</a>, <a href="./references#CD004034-bbs2-0004" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumiterscuD , et al, for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. NEJM2008;358:1887-1898. BulpittC , FletcherA , BeckettN , CoopeJ , Gil-ExtremeraB , ForetteF , et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs &amp; Aging2001;18:151-164. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al, for the HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurology2008;7:683-689. PetersR , BeckettN , McCormackT , FagardR , FletcherA , BulpittC . Treating hypertension in the very elderly-benefits, risks, and future directions, a focus on the hypertension in the very elderly trial. European Heart Journal 2014 Jul;35(26):1712-8. PetersR , BeckettN , NunesM , FletcherA , ForetteF , BulpittC . A substudy protocol of the Hypertension in the Very Elderly Trial assessing cognitive decline and dementia incidence (HYVET-COG): an ongoing randomised, double-blind, placebo-controlled trial. Drugs Aging2006;23:83-92. ">HYVET 2008</a> and <a href="./references#CD004034-bbs2-0010" title="AmbrosiusWT , SinkKM , FoyCG , BerlowitzDR , CheungAK , CushmanWC , FineLJ , Goff DC Jr, JohnsonKC , KilleenAA , LewisCE , OparilS , ReboussinDM , RoccoMV , SnyderJK , WilliamsonJD , Wright JT Jr, WheltonPK , SPRINT Study Research Group. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).. Clinical Trials 2014 Oct;11(5):532-46. BerlowitzDR , FoyCG , KazisLE , BolinLP , ConroyMB , FitzpatrickP , GureTR , KimmelPL , KirchnerK , MoriskyDE , NewmanJ , OlneyC , OparilS , PajewskiNM , PowellJ , RamseyT , SimmonsDL , SnyderJ , SupianoMA , WeinerDE , WhittleJ , SPRINT Research Group. Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes.. The New England Journal of Medicine 2017 Aug 24;377(8):733-744. SPRINT Research Group, Wright JT Jr, WilliamsonJD , WheltonPK , SnyderJK , SinkKM , RoccoMV , ReboussinDM , RahmanM , OparilS , LewisCE , KimmelPL , JohnsonKC , Goff DC Jr, FineLJ , CutlerJA , CushmanWC , CheungAK , Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control.. The New England Journal of Medicine 2015 Nov 26;373(22):2103-16. The SPRINT MIND Investigators for the SPRINT Research Group. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA2019;321(6):553-561. WilliamsonJD , SupianoMA , ApplegateWB , BerlowitzDR , CampbellRC , ChertowGM , FineLJ , HaleyWE , HawfieldAT , IxJH , KitzmanDW , KostisJB , Krousel-WoodMA , LaunerLJ , OparilS , RodriguezCJ , RoumieCL , ShorrRI , SinkKM , WadleyVG , WheltonPK , WhittleJ , WoolardNF , Wright JT Jr, PajewskiNM , SPRINT Research Group. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.. JAMA 2016 Jun 28;315(24):2673-82. ">SPRINT MIND 2019</a> ‐ were stopped early on safety grounds. After termination of the <a href="./references#CD004034-bbs2-0011" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , De LeeuwP , DolleryCT , et al. Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: Objectives, protocol, and organization. Aging Clin Exp Res1991;3:287-302. FletcherAE , BulpittCJ , ThijsL , ToumilehtoJ , AntikainenR , BossiniA , et al. Quality of life on randomised treatment for isolated hypertension: results from the Syst-Eur Trial. Journal of Hypertension2002;20:2069-2079. FletcherAE , BulpittCJ , TuomilehtoJ , BrowneJ , BossiniA , Kawecka-JaszczK , et al. Quality of life of elderly patients with isolated systolic hypertension: baseline data from the Syst-Eur Trial. Journal of Hypertension1988;16:1117-1124. ForetteF , Seux M-L, StaessenJA , ThijsL , Babarskiene M-R, BabeanuS , et al. The Prevention of Dementia With Antihypertensive Treatment. New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study. Archives of Internal Medicine2002;162:2046-2052. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH , BabarskieneMR , et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet1998;352:1347-51. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH . Reduction of dementia by calcium-antagonist-based antihypertensive treatment. European Heart Journal Supplements2000;2:D17-D19. StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Lancet1997;350:757-764. ">Syst Eur 1998</a> trial, any participants exiting double‐blind therapy before the end of the study were followed as open‐label follow‐up until the end of the study and analysed using intention‐to‐treat analyses, the results of which have been incorporated into this review. <a href="./references#CD004034-bbs2-0010" title="AmbrosiusWT , SinkKM , FoyCG , BerlowitzDR , CheungAK , CushmanWC , FineLJ , Goff DC Jr, JohnsonKC , KilleenAA , LewisCE , OparilS , ReboussinDM , RoccoMV , SnyderJK , WilliamsonJD , Wright JT Jr, WheltonPK , SPRINT Study Research Group. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).. Clinical Trials 2014 Oct;11(5):532-46. BerlowitzDR , FoyCG , KazisLE , BolinLP , ConroyMB , FitzpatrickP , GureTR , KimmelPL , KirchnerK , MoriskyDE , NewmanJ , OlneyC , OparilS , PajewskiNM , PowellJ , RamseyT , SimmonsDL , SnyderJ , SupianoMA , WeinerDE , WhittleJ , SPRINT Research Group. Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes.. The New England Journal of Medicine 2017 Aug 24;377(8):733-744. SPRINT Research Group, Wright JT Jr, WilliamsonJD , WheltonPK , SnyderJK , SinkKM , RoccoMV , ReboussinDM , RahmanM , OparilS , LewisCE , KimmelPL , JohnsonKC , Goff DC Jr, FineLJ , CutlerJA , CushmanWC , CheungAK , Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control.. The New England Journal of Medicine 2015 Nov 26;373(22):2103-16. The SPRINT MIND Investigators for the SPRINT Research Group. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA2019;321(6):553-561. WilliamsonJD , SupianoMA , ApplegateWB , BerlowitzDR , CampbellRC , ChertowGM , FineLJ , HaleyWE , HawfieldAT , IxJH , KitzmanDW , KostisJB , Krousel-WoodMA , LaunerLJ , OparilS , RodriguezCJ , RoumieCL , ShorrRI , SinkKM , WadleyVG , WheltonPK , WhittleJ , WoolardNF , Wright JT Jr, PajewskiNM , SPRINT Research Group. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.. JAMA 2016 Jun 28;315(24):2673-82. ">SPRINT MIND 2019</a> had planned for 24‐month and 48‐month cognitive follow‐up with a further assessment at study closeout if that was more than one year from the four‐year follow‐up visit. Participants were recruited between November 2010 and March 2013. The decision was taken to halt the study on safety grounds in August 2015. <a href="./references#CD004034-bbs2-0010" title="AmbrosiusWT , SinkKM , FoyCG , BerlowitzDR , CheungAK , CushmanWC , FineLJ , Goff DC Jr, JohnsonKC , KilleenAA , LewisCE , OparilS , ReboussinDM , RoccoMV , SnyderJK , WilliamsonJD , Wright JT Jr, WheltonPK , SPRINT Study Research Group. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).. Clinical Trials 2014 Oct;11(5):532-46. BerlowitzDR , FoyCG , KazisLE , BolinLP , ConroyMB , FitzpatrickP , GureTR , KimmelPL , KirchnerK , MoriskyDE , NewmanJ , OlneyC , OparilS , PajewskiNM , PowellJ , RamseyT , SimmonsDL , SnyderJ , SupianoMA , WeinerDE , WhittleJ , SPRINT Research Group. Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes.. The New England Journal of Medicine 2017 Aug 24;377(8):733-744. SPRINT Research Group, Wright JT Jr, WilliamsonJD , WheltonPK , SnyderJK , SinkKM , RoccoMV , ReboussinDM , RahmanM , OparilS , LewisCE , KimmelPL , JohnsonKC , Goff DC Jr, FineLJ , CutlerJA , CushmanWC , CheungAK , Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control.. The New England Journal of Medicine 2015 Nov 26;373(22):2103-16. The SPRINT MIND Investigators for the SPRINT Research Group. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA2019;321(6):553-561. WilliamsonJD , SupianoMA , ApplegateWB , BerlowitzDR , CampbellRC , ChertowGM , FineLJ , HaleyWE , HawfieldAT , IxJH , KitzmanDW , KostisJB , Krousel-WoodMA , LaunerLJ , OparilS , RodriguezCJ , RoumieCL , ShorrRI , SinkKM , WadleyVG , WheltonPK , WhittleJ , WoolardNF , Wright JT Jr, PajewskiNM , SPRINT Research Group. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.. JAMA 2016 Jun 28;315(24):2673-82. ">SPRINT MIND 2019</a> reported dementia and mild cognitive impairment (MCI) incidence as ascertained from final extended study visits conducted between October 2017 and July 2018 (median total follow‐up 5.11 years). Limited results were also reported for outcomes ascertained during the study period (median intervention period 3.34 years) and it is those results we report here where possible. <a href="./references#CD004034-bbs2-0001" title="BuseJB , BiggerJT , ByingtonRP , CooperLS , CushmanWC , FriedewaldWT , et al, ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. American Journal of Cardiology2007;99(12A):21i-33i. CushmanWC , Grimm RH Jr, CutlerJA , EvansGW , CapesS , CorsonMA , et al, ACCORD Study Group. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):44i-55i. LaunerLJ , MillerME , WilliamsonJD , LazarRM , GersteinHC , MurrayAM , et al, ACCORD MIND investigators. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurology2011;10(11):969-77. MargolisKL , O'ConnorPJ , MorganTM , BuseJB , CohenRM , CushmanWC , et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care2014;37(6):1721-8. O'ConnorPJ , NarayanKM , AndersonR , FeeneyP , FineL , AliMK , et al. Effect of intensive versus standard blood pressure control on depression and health-related quality of life in type 2 diabetes: the ACCORD trial. Diabetes Care2012;35(7):1479-81. WilliamsonJD , LaunerLJ , BryanRN , CokerLH , LazarRM , GersteinHC , et al, Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Investigators. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Internal Medicine2014;174(3):324-33. WilliamsonJD , MillerME , BryanRN , LazarRM , CokerLH , JohnsonJ , et al, ACCORD Study Group. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. American Journal of Cardiology2007;99(12A):112i-122i. ">ACCORD MIND 2014</a> reported 20‐month and 40‐month follow‐up. The glycaemic control arm of the ACCORD study was terminated early due to concerns regarding increased mortality in the intensive glycaemic control group. </p> </section> </section> <section id="CD004034-sec-0049"> <h5 class="title">Outcomes</h5> <section id="CD004034-sec-0050"> <h6 class="title">Dementia</h6> <p>Five studies measured incidence of dementia (<a href="./references#CD004034-bbs2-0009" title="ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the Treatment of Isolated Systolic Hypertension on Behavioral Variables. Results From the Systolic Hypertension in the Elderly Program. Arch Intern Med1994;154:2154-2160. Di BariM , PahorM , FranseLV , ShorrRI , WanJY , FerrucciL , et al. Dementia and Disability Outcomes in Large Hypertension Trials: Lessons Learned from the Systolic Hypertension in the Elderly Program (SHEP) Trial. American Journal of Epidemiology2001;153:72-8. SHEP Cooperative Research Group. Prevention of Stroke by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic Hypertension. Final Results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265:3255-64. The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and Design of a Randomized Clinical Trial on Prevention of Stroke in Isolated Systolic Hypertension. Journal of Clinical Epidemiology1988;41:1197-1208. ">SHEP 1991</a>, <a href="./references#CD004034-bbs2-0011" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , De LeeuwP , DolleryCT , et al. Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: Objectives, protocol, and organization. Aging Clin Exp Res1991;3:287-302. FletcherAE , BulpittCJ , ThijsL , ToumilehtoJ , AntikainenR , BossiniA , et al. Quality of life on randomised treatment for isolated hypertension: results from the Syst-Eur Trial. Journal of Hypertension2002;20:2069-2079. FletcherAE , BulpittCJ , TuomilehtoJ , BrowneJ , BossiniA , Kawecka-JaszczK , et al. Quality of life of elderly patients with isolated systolic hypertension: baseline data from the Syst-Eur Trial. Journal of Hypertension1988;16:1117-1124. ForetteF , Seux M-L, StaessenJA , ThijsL , Babarskiene M-R, BabeanuS , et al. The Prevention of Dementia With Antihypertensive Treatment. New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study. Archives of Internal Medicine2002;162:2046-2052. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH , BabarskieneMR , et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet1998;352:1347-51. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH . Reduction of dementia by calcium-antagonist-based antihypertensive treatment. European Heart Journal Supplements2000;2:D17-D19. StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Lancet1997;350:757-764. ">Syst Eur 1998</a>, <a href="./references#CD004034-bbs2-0008" title="Degl'InnocentiA , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , ZanchettiA , WiklundI . Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). Journal of Human Hypertension2004;18(4):239-45. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study of COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. Journal of Hypertension2004;22(8):1605-12. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. Journal of Hypertension2003;21:875-886. PapademetriouV , FarsangC , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , Zanchetti A for the SCOPE Study Group. Stroke Prevention With the Angiotension II Type-1 Receptor Blocker Candesartan in Elderly Patients With Isolated Systolic Hypertension. The Study on Cognition and Prognosis in the Elderly (SCOPE). Journal of the American College of Cardiology2004;44(6):1175-80. SkoogI , LithellH , HanssonL , ElmfeldtD , HofmanA , OlofssonB , et al, for the SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). American Journal of Hypertension2005;18:1052-1059. ">SCOPE 2003</a>, <a href="./references#CD004034-bbs2-0004" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumiterscuD , et al, for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. NEJM2008;358:1887-1898. BulpittC , FletcherA , BeckettN , CoopeJ , Gil-ExtremeraB , ForetteF , et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs &amp; Aging2001;18:151-164. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al, for the HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurology2008;7:683-689. PetersR , BeckettN , McCormackT , FagardR , FletcherA , BulpittC . Treating hypertension in the very elderly-benefits, risks, and future directions, a focus on the hypertension in the very elderly trial. European Heart Journal 2014 Jul;35(26):1712-8. PetersR , BeckettN , NunesM , FletcherA , ForetteF , BulpittC . A substudy protocol of the Hypertension in the Very Elderly Trial assessing cognitive decline and dementia incidence (HYVET-COG): an ongoing randomised, double-blind, placebo-controlled trial. Drugs Aging2006;23:83-92. ">HYVET 2008</a>, <a href="./references#CD004034-bbs2-0010" title="AmbrosiusWT , SinkKM , FoyCG , BerlowitzDR , CheungAK , CushmanWC , FineLJ , Goff DC Jr, JohnsonKC , KilleenAA , LewisCE , OparilS , ReboussinDM , RoccoMV , SnyderJK , WilliamsonJD , Wright JT Jr, WheltonPK , SPRINT Study Research Group. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).. Clinical Trials 2014 Oct;11(5):532-46. BerlowitzDR , FoyCG , KazisLE , BolinLP , ConroyMB , FitzpatrickP , GureTR , KimmelPL , KirchnerK , MoriskyDE , NewmanJ , OlneyC , OparilS , PajewskiNM , PowellJ , RamseyT , SimmonsDL , SnyderJ , SupianoMA , WeinerDE , WhittleJ , SPRINT Research Group. Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes.. The New England Journal of Medicine 2017 Aug 24;377(8):733-744. SPRINT Research Group, Wright JT Jr, WilliamsonJD , WheltonPK , SnyderJK , SinkKM , RoccoMV , ReboussinDM , RahmanM , OparilS , LewisCE , KimmelPL , JohnsonKC , Goff DC Jr, FineLJ , CutlerJA , CushmanWC , CheungAK , Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control.. The New England Journal of Medicine 2015 Nov 26;373(22):2103-16. The SPRINT MIND Investigators for the SPRINT Research Group. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA2019;321(6):553-561. WilliamsonJD , SupianoMA , ApplegateWB , BerlowitzDR , CampbellRC , ChertowGM , FineLJ , HaleyWE , HawfieldAT , IxJH , KitzmanDW , KostisJB , Krousel-WoodMA , LaunerLJ , OparilS , RodriguezCJ , RoumieCL , ShorrRI , SinkKM , WadleyVG , WheltonPK , WhittleJ , WoolardNF , Wright JT Jr, PajewskiNM , SPRINT Research Group. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.. JAMA 2016 Jun 28;315(24):2673-82. ">SPRINT MIND 2019</a>). Triggers for (a) further diagnostic evaluation, and (b) the criteria for diagnosis of dementia were: </p> <p> <ul id="CD004034-list-0005"> <li> <p><a href="./references#CD004034-bbs2-0011" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , De LeeuwP , DolleryCT , et al. Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: Objectives, protocol, and organization. Aging Clin Exp Res1991;3:287-302. FletcherAE , BulpittCJ , ThijsL , ToumilehtoJ , AntikainenR , BossiniA , et al. Quality of life on randomised treatment for isolated hypertension: results from the Syst-Eur Trial. Journal of Hypertension2002;20:2069-2079. FletcherAE , BulpittCJ , TuomilehtoJ , BrowneJ , BossiniA , Kawecka-JaszczK , et al. Quality of life of elderly patients with isolated systolic hypertension: baseline data from the Syst-Eur Trial. Journal of Hypertension1988;16:1117-1124. ForetteF , Seux M-L, StaessenJA , ThijsL , Babarskiene M-R, BabeanuS , et al. The Prevention of Dementia With Antihypertensive Treatment. New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study. Archives of Internal Medicine2002;162:2046-2052. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH , BabarskieneMR , et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet1998;352:1347-51. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH . Reduction of dementia by calcium-antagonist-based antihypertensive treatment. European Heart Journal Supplements2000;2:D17-D19. StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Lancet1997;350:757-764. ">Syst Eur 1998</a> ‐ (a) MMSE score below 23 points or symptoms or signs reported by participant or carer or found by doctor; (b) Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised (DSM‐III‐R), with all cases validated by a treatment allocation‐blinded review board; </p> </li> <li> <p><a href="./references#CD004034-bbs2-0008" title="Degl'InnocentiA , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , ZanchettiA , WiklundI . Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). Journal of Human Hypertension2004;18(4):239-45. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study of COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. Journal of Hypertension2004;22(8):1605-12. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. Journal of Hypertension2003;21:875-886. PapademetriouV , FarsangC , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , Zanchetti A for the SCOPE Study Group. Stroke Prevention With the Angiotension II Type-1 Receptor Blocker Candesartan in Elderly Patients With Isolated Systolic Hypertension. The Study on Cognition and Prognosis in the Elderly (SCOPE). Journal of the American College of Cardiology2004;44(6):1175-80. SkoogI , LithellH , HanssonL , ElmfeldtD , HofmanA , OlofssonB , et al, for the SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). American Journal of Hypertension2005;18:1052-1059. ">SCOPE 2003</a> ‐ (a) significant cognitive decline was a reduction by 4 or more points in the MMSE in two consecutive visits in comparison to baseline; (b) International Classification of Diseases‐10 (ICD‐10) criteria, adjudicated by an independent clinical event committee based on information supplied by the local investigator; </p> </li> <li> <p><a href="./references#CD004034-bbs2-0004" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumiterscuD , et al, for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. NEJM2008;358:1887-1898. BulpittC , FletcherA , BeckettN , CoopeJ , Gil-ExtremeraB , ForetteF , et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs &amp; Aging2001;18:151-164. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al, for the HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurology2008;7:683-689. PetersR , BeckettN , McCormackT , FagardR , FletcherA , BulpittC . Treating hypertension in the very elderly-benefits, risks, and future directions, a focus on the hypertension in the very elderly trial. European Heart Journal 2014 Jul;35(26):1712-8. PetersR , BeckettN , NunesM , FletcherA , ForetteF , BulpittC . A substudy protocol of the Hypertension in the Very Elderly Trial assessing cognitive decline and dementia incidence (HYVET-COG): an ongoing randomised, double-blind, placebo-controlled trial. Drugs Aging2006;23:83-92. ">HYVET 2008</a> ‐ (a) decline in MMSE score to below 24 points or fall of more than 3 points in one year; (b) Diagnostic and Statistical Manual of Mental Disorders, Fourth edition (DSM‐IV) (<a href="./references#CD004034-bbs2-0056" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edition. Washington DC: APA, 1994.">APA 1994</a>), with consensus from a treatment allocation‐blinded central committee; </p> </li> <li> <p><a href="./references#CD004034-bbs2-0010" title="AmbrosiusWT , SinkKM , FoyCG , BerlowitzDR , CheungAK , CushmanWC , FineLJ , Goff DC Jr, JohnsonKC , KilleenAA , LewisCE , OparilS , ReboussinDM , RoccoMV , SnyderJK , WilliamsonJD , Wright JT Jr, WheltonPK , SPRINT Study Research Group. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).. Clinical Trials 2014 Oct;11(5):532-46. BerlowitzDR , FoyCG , KazisLE , BolinLP , ConroyMB , FitzpatrickP , GureTR , KimmelPL , KirchnerK , MoriskyDE , NewmanJ , OlneyC , OparilS , PajewskiNM , PowellJ , RamseyT , SimmonsDL , SnyderJ , SupianoMA , WeinerDE , WhittleJ , SPRINT Research Group. Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes.. The New England Journal of Medicine 2017 Aug 24;377(8):733-744. SPRINT Research Group, Wright JT Jr, WilliamsonJD , WheltonPK , SnyderJK , SinkKM , RoccoMV , ReboussinDM , RahmanM , OparilS , LewisCE , KimmelPL , JohnsonKC , Goff DC Jr, FineLJ , CutlerJA , CushmanWC , CheungAK , Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control.. The New England Journal of Medicine 2015 Nov 26;373(22):2103-16. The SPRINT MIND Investigators for the SPRINT Research Group. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA2019;321(6):553-561. WilliamsonJD , SupianoMA , ApplegateWB , BerlowitzDR , CampbellRC , ChertowGM , FineLJ , HaleyWE , HawfieldAT , IxJH , KitzmanDW , KostisJB , Krousel-WoodMA , LaunerLJ , OparilS , RodriguezCJ , RoumieCL , ShorrRI , SinkKM , WadleyVG , WheltonPK , WhittleJ , WoolardNF , Wright JT Jr, PajewskiNM , SPRINT Research Group. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.. JAMA 2016 Jun 28;315(24):2673-82. ">SPRINT MIND 2019</a> ‐ (a) Montreal Cognitive Assessment (MoCA) score below 21 points for white participants with 12 or more years of education, below 19 points for white participants with fewer than 12 years of education or nonwhite participants with 12 or more years of education, or below 17 points for nonwhite participants with fewer than 12 years of education, OR a decrease in MoCA score of 5 or more points led to administration of the Functional Activities Questionnaire to a pre‐identified proxy. A score of more than 0 on the Functional Activities Questionnaire OR 1 or less on the 5‐point delayed recall subtest of the MoCA underwent further testing using an extended cognitive battery (see <a href="./references#CD004034-sec-0116" title="">Characteristics of included studies</a>). A telephone assessment was undertaken where in‐person follow‐up was not possible. In these cases a score of 31 points or less on the Modified Telephone interview for Cognitve Status (instead of a MoCA cut‐off) prompted administration of the Functional Activities Questionnaire. Where a participant had died or could not be contacted, the Dementia Questionnaire was administered to a pre‐specified contact; (b) <a href="./references#CD004034-bbs2-0095" title="McKhannGM , KnopmanDS , ChertkowH , HymanBT , Jack CR Jr, KawasCH , et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's &amp; Dementia2011;7(3):263-9.">McKhann 2011</a> for dementia and <a href="./references#CD004034-bbs2-0053" title="AlbertMS , DeKoskyST , DicksonD , DuboisB , FeldmanHH , FoxNC , et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's &amp; Dementia2011;7(3):270-9.">Albert 2011</a> for mild cognitive impairment (MCI) as adjudicated by an expert multidisciplinary panel blinded to treatment allocation. </p> </li> </ul> </p> <p>In <a href="./references#CD004034-bbs2-0009" title="ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the Treatment of Isolated Systolic Hypertension on Behavioral Variables. Results From the Systolic Hypertension in the Elderly Program. Arch Intern Med1994;154:2154-2160. Di BariM , PahorM , FranseLV , ShorrRI , WanJY , FerrucciL , et al. Dementia and Disability Outcomes in Large Hypertension Trials: Lessons Learned from the Systolic Hypertension in the Elderly Program (SHEP) Trial. American Journal of Epidemiology2001;153:72-8. SHEP Cooperative Research Group. Prevention of Stroke by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic Hypertension. Final Results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265:3255-64. The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and Design of a Randomized Clinical Trial on Prevention of Stroke in Isolated Systolic Hypertension. Journal of Clinical Epidemiology1988;41:1197-1208. ">SHEP 1991</a>, dementia was diagnosed by an expert and confirmed by the central coding panel according to the DSM‐III‐R criteria (<a href="./references#CD004034-bbs2-0055" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd revised edition. Washington DC: APA, 1987.">APA 1987</a>) after referral triggered by score on the short‐Comprehensive Assessment and Referral Evaluation (short‐CARE) at follow‐up. In addition, as reported by Applegate 1994 (see references for <a href="./references#CD004034-bbs2-0009" title="ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the Treatment of Isolated Systolic Hypertension on Behavioral Variables. Results From the Systolic Hypertension in the Elderly Program. Arch Intern Med1994;154:2154-2160. Di BariM , PahorM , FranseLV , ShorrRI , WanJY , FerrucciL , et al. Dementia and Disability Outcomes in Large Hypertension Trials: Lessons Learned from the Systolic Hypertension in the Elderly Program (SHEP) Trial. American Journal of Epidemiology2001;153:72-8. SHEP Cooperative Research Group. Prevention of Stroke by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic Hypertension. Final Results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265:3255-64. The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and Design of a Randomized Clinical Trial on Prevention of Stroke in Isolated Systolic Hypertension. Journal of Clinical Epidemiology1988;41:1197-1208. ">SHEP 1991</a>), a subgroup of six centres undertook additional cognitive assessments comprising the Digit Symbol Subsitution Test, Addition Test, Finding As Test, Boston Naming Test, Delayed Recognition Span Test and the Letter Sets Test. </p> </section> <section id="CD004034-sec-0051"> <h6 class="title">Cognitive decline</h6> <section id="CD004034-sec-0052"> <p><b>Mini‐Mental State Examination</b></p> <p>The most common cognitive test used was the Mini‐Mental State Examination (MMSE) with six studies reporting change in MMSE: <a href="./references#CD004034-bbs2-0008" title="Degl'InnocentiA , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , ZanchettiA , WiklundI . Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). Journal of Human Hypertension2004;18(4):239-45. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study of COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. Journal of Hypertension2004;22(8):1605-12. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. Journal of Hypertension2003;21:875-886. PapademetriouV , FarsangC , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , Zanchetti A for the SCOPE Study Group. Stroke Prevention With the Angiotension II Type-1 Receptor Blocker Candesartan in Elderly Patients With Isolated Systolic Hypertension. The Study on Cognition and Prognosis in the Elderly (SCOPE). Journal of the American College of Cardiology2004;44(6):1175-80. SkoogI , LithellH , HanssonL , ElmfeldtD , HofmanA , OlofssonB , et al, for the SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). American Journal of Hypertension2005;18:1052-1059. ">SCOPE 2003</a> (adjusted change at 44.6 months); <a href="./references#CD004034-bbs2-0011" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , De LeeuwP , DolleryCT , et al. Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: Objectives, protocol, and organization. Aging Clin Exp Res1991;3:287-302. FletcherAE , BulpittCJ , ThijsL , ToumilehtoJ , AntikainenR , BossiniA , et al. Quality of life on randomised treatment for isolated hypertension: results from the Syst-Eur Trial. Journal of Hypertension2002;20:2069-2079. FletcherAE , BulpittCJ , TuomilehtoJ , BrowneJ , BossiniA , Kawecka-JaszczK , et al. Quality of life of elderly patients with isolated systolic hypertension: baseline data from the Syst-Eur Trial. Journal of Hypertension1988;16:1117-1124. ForetteF , Seux M-L, StaessenJA , ThijsL , Babarskiene M-R, BabeanuS , et al. The Prevention of Dementia With Antihypertensive Treatment. New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study. Archives of Internal Medicine2002;162:2046-2052. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH , BabarskieneMR , et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet1998;352:1347-51. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH . Reduction of dementia by calcium-antagonist-based antihypertensive treatment. European Heart Journal Supplements2000;2:D17-D19. StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Lancet1997;350:757-764. ">Syst Eur 1998</a> (mean change at 2 years); <a href="./references#CD004034-bbs2-0004" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumiterscuD , et al, for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. NEJM2008;358:1887-1898. BulpittC , FletcherA , BeckettN , CoopeJ , Gil-ExtremeraB , ForetteF , et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs &amp; Aging2001;18:151-164. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al, for the HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurology2008;7:683-689. PetersR , BeckettN , McCormackT , FagardR , FletcherA , BulpittC . Treating hypertension in the very elderly-benefits, risks, and future directions, a focus on the hypertension in the very elderly trial. European Heart Journal 2014 Jul;35(26):1712-8. PetersR , BeckettN , NunesM , FletcherA , ForetteF , BulpittC . A substudy protocol of the Hypertension in the Very Elderly Trial assessing cognitive decline and dementia incidence (HYVET-COG): an ongoing randomised, double-blind, placebo-controlled trial. Drugs Aging2006;23:83-92. ">HYVET 2008</a> (mean change at 2 years); <a href="./references#CD004034-bbs2-0012" title="JiT , ZhaoY , WangJ , CuiY , DuanD , ChaiQ , et al. Effect of low dose statins and apolipoprotein E genotype on cerebral small vessel disease in older hypertensive patients: a subgroup analysis of a randomized clinical trial. J Am Med Dir Assoc2018;19:995-1002. ZhangH , CuiY , ZhaoY , DongY , DuanD , WangJ , ShengL , JiT , ZhouT , HuW , ChenY , SunS , GongG , ChaiQ , LiuZ . Effects of sartans and low-dose statins on cerebral white matter hyperintensities and cognitive function in older patients with hypertension: a randomized, double-blind and placebo-controlled clinical trial. Hypertension research2018;42(5):717-729. ">Zhang 2018</a> (baseline and 1, 2, 3, 4 and 5 years' mean scores); <a href="./references#CD004034-bbs2-0001" title="BuseJB , BiggerJT , ByingtonRP , CooperLS , CushmanWC , FriedewaldWT , et al, ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. American Journal of Cardiology2007;99(12A):21i-33i. CushmanWC , Grimm RH Jr, CutlerJA , EvansGW , CapesS , CorsonMA , et al, ACCORD Study Group. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):44i-55i. LaunerLJ , MillerME , WilliamsonJD , LazarRM , GersteinHC , MurrayAM , et al, ACCORD MIND investigators. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurology2011;10(11):969-77. MargolisKL , O'ConnorPJ , MorganTM , BuseJB , CohenRM , CushmanWC , et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care2014;37(6):1721-8. O'ConnorPJ , NarayanKM , AndersonR , FeeneyP , FineL , AliMK , et al. Effect of intensive versus standard blood pressure control on depression and health-related quality of life in type 2 diabetes: the ACCORD trial. Diabetes Care2012;35(7):1479-81. WilliamsonJD , LaunerLJ , BryanRN , CokerLH , LazarRM , GersteinHC , et al, Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Investigators. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Internal Medicine2014;174(3):324-33. WilliamsonJD , MillerME , BryanRN , LazarRM , CokerLH , JohnsonJ , et al, ACCORD Study Group. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. American Journal of Cardiology2007;99(12A):112i-122i. ">ACCORD MIND 2014</a> (baseline, 20‐month and 40‐month adjusted mean scores); and <a href="./references#CD004034-bbs2-0003" title="SatoN , SaijoY , HasebeN , CAMUI investigators. Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial. International Heart Journal2012;53(4):244-8. SatoN , SaijoY , SasagawaY , MorimotoH , TakeuchiT , SanoH , KoyamaS , TakeharaN , MoritaK , SumitomoK , MaruyamaJ , KikuchiK , HasebeN , CAMUI investigators. Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial: results after 1 year. Journal of Hypertension2013;31(6):1245-55. ">CAMUI 2013</a> (baseline and 1 year scores). In addition, <a href="./references#CD004034-bbs2-0004" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumiterscuD , et al, for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. NEJM2008;358:1887-1898. BulpittC , FletcherA , BeckettN , CoopeJ , Gil-ExtremeraB , ForetteF , et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs &amp; Aging2001;18:151-164. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al, for the HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurology2008;7:683-689. PetersR , BeckettN , McCormackT , FagardR , FletcherA , BulpittC . Treating hypertension in the very elderly-benefits, risks, and future directions, a focus on the hypertension in the very elderly trial. European Heart Journal 2014 Jul;35(26):1712-8. PetersR , BeckettN , NunesM , FletcherA , ForetteF , BulpittC . A substudy protocol of the Hypertension in the Very Elderly Trial assessing cognitive decline and dementia incidence (HYVET-COG): an ongoing randomised, double-blind, placebo-controlled trial. Drugs Aging2006;23:83-92. ">HYVET 2008</a> and <a href="./references#CD004034-bbs2-0008" title="Degl'InnocentiA , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , ZanchettiA , WiklundI . Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). Journal of Human Hypertension2004;18(4):239-45. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study of COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. Journal of Hypertension2004;22(8):1605-12. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. Journal of Hypertension2003;21:875-886. PapademetriouV , FarsangC , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , Zanchetti A for the SCOPE Study Group. Stroke Prevention With the Angiotension II Type-1 Receptor Blocker Candesartan in Elderly Patients With Isolated Systolic Hypertension. The Study on Cognition and Prognosis in the Elderly (SCOPE). Journal of the American College of Cardiology2004;44(6):1175-80. SkoogI , LithellH , HanssonL , ElmfeldtD , HofmanA , OlofssonB , et al, for the SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). American Journal of Hypertension2005;18:1052-1059. ">SCOPE 2003</a> reported cognitive decline as defined by a fall in MMSE: to less than 24 points, or of more than 3 points in one year (<a href="./references#CD004034-bbs2-0004" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumiterscuD , et al, for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. NEJM2008;358:1887-1898. BulpittC , FletcherA , BeckettN , CoopeJ , Gil-ExtremeraB , ForetteF , et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs &amp; Aging2001;18:151-164. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al, for the HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurology2008;7:683-689. PetersR , BeckettN , McCormackT , FagardR , FletcherA , BulpittC . Treating hypertension in the very elderly-benefits, risks, and future directions, a focus on the hypertension in the very elderly trial. European Heart Journal 2014 Jul;35(26):1712-8. PetersR , BeckettN , NunesM , FletcherA , ForetteF , BulpittC . A substudy protocol of the Hypertension in the Very Elderly Trial assessing cognitive decline and dementia incidence (HYVET-COG): an ongoing randomised, double-blind, placebo-controlled trial. Drugs Aging2006;23:83-92. ">HYVET 2008</a>); or a fall of 4 or more points (<a href="./references#CD004034-bbs2-0008" title="Degl'InnocentiA , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , ZanchettiA , WiklundI . Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). Journal of Human Hypertension2004;18(4):239-45. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study of COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. Journal of Hypertension2004;22(8):1605-12. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. Journal of Hypertension2003;21:875-886. PapademetriouV , FarsangC , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , Zanchetti A for the SCOPE Study Group. Stroke Prevention With the Angiotension II Type-1 Receptor Blocker Candesartan in Elderly Patients With Isolated Systolic Hypertension. The Study on Cognition and Prognosis in the Elderly (SCOPE). Journal of the American College of Cardiology2004;44(6):1175-80. SkoogI , LithellH , HanssonL , ElmfeldtD , HofmanA , OlofssonB , et al, for the SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). American Journal of Hypertension2005;18:1052-1059. ">SCOPE 2003</a>). Of note, <a href="./references#CD004034-bbs2-0004" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumiterscuD , et al, for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. NEJM2008;358:1887-1898. BulpittC , FletcherA , BeckettN , CoopeJ , Gil-ExtremeraB , ForetteF , et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs &amp; Aging2001;18:151-164. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al, for the HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurology2008;7:683-689. PetersR , BeckettN , McCormackT , FagardR , FletcherA , BulpittC . Treating hypertension in the very elderly-benefits, risks, and future directions, a focus on the hypertension in the very elderly trial. European Heart Journal 2014 Jul;35(26):1712-8. PetersR , BeckettN , NunesM , FletcherA , ForetteF , BulpittC . A substudy protocol of the Hypertension in the Very Elderly Trial assessing cognitive decline and dementia incidence (HYVET-COG): an ongoing randomised, double-blind, placebo-controlled trial. Drugs Aging2006;23:83-92. ">HYVET 2008</a> reported MMSE at two years for 1469 of the total 3336 participants. The numbers in each group are not reported in the HYVET COG paper of 2008 but the original HYVET paper in the <i>New England Journal of Medicine</i> notes 2‐year follow‐up blood pressures for 754 participants in the active treatment group and 701 participants in the placebo group, so we have used these numbers here. We are grateful to <a href="./references#CD004034-bbs2-0012" title="JiT , ZhaoY , WangJ , CuiY , DuanD , ChaiQ , et al. Effect of low dose statins and apolipoprotein E genotype on cerebral small vessel disease in older hypertensive patients: a subgroup analysis of a randomized clinical trial. J Am Med Dir Assoc2018;19:995-1002. ZhangH , CuiY , ZhaoY , DongY , DuanD , WangJ , ShengL , JiT , ZhouT , HuW , ChenY , SunS , GongG , ChaiQ , LiuZ . Effects of sartans and low-dose statins on cerebral white matter hyperintensities and cognitive function in older patients with hypertension: a randomized, double-blind and placebo-controlled clinical trial. Hypertension research2018;42(5):717-729. ">Zhang 2018</a> for providing unpublished data regarding change in MMSE and BP over the study period. We have incorporated the 60‐month values in our analyses. <a href="./references#CD004034-bbs2-0002" title="HajjarI , HartM , ChenYL , MackW , MilbergW , ChuiH , et al. Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: a double-blind randomized clinical trial. Archives of Internal Medicine2012;172(5):442-4. HajjarI , HartM , ChenYL , MackW , NovakV , ChuiH , et al. Antihypertensive therapy and cerebral hemodynamics in executive mild cognitive impairment: results of a pilot randomized clinical trial. Journal of the American Geriatrics Society2013;61(2):194-201. HajjarI , HartM , MackW , LipsitzLA . Aldosterone, cognitive function, and cerebral hemodynamics in hypertension and antihypertensive therapy. American Journal of Hypertension2015;28(3):319-25. HajjarI , HartM , MilbergW , NovakV , LipsitzL . The rationale and design of the antihypertensives and vascular, endothelial, and cognitive function (AVEC) trial in elderly hypertensives with early cognitive impairment: role of the renin angiotensin system inhibition. BMC Geriatrics2009;9:48. ">AVEC 2012</a> used MMSE as a screening tool at baseline but did not measure change. </p> </section> <section id="CD004034-sec-0053"> <p><b>Other cognitive measures</b></p> <p><a href="./references#CD004034-bbs2-0005" title="YodfatY , Bar-OnD , AmirM , Cristal N. Quality of life in normotensives compared to hypertensive men treated with isradipine or methyldopa as monotherapy or in combination with captopril: the LOMIR-MCT-IL study.. Journal of Human Hypertension 1996 Feb;10(2):117-22. YodfatY , Cristal N. A multicenter, double-blind, randomized, placebo-controlled study of isradipine and methyldopa as monotherapy or in combination with captopril in the treatment of hypertension. The LOMIR-MCT-IH Research Group.. American Journal of Hypertension 1993 Mar;6(3 Pt 2):57S-61S. ">LOMIR MCT IL 1996</a> measured semantic memory using referenced but non‐specified tools (<a href="./references#CD004034-bbs2-0122" title="WeingartnerH , GrafmanJ , BoutelleW , KayeW , MartinPR . Forms of memory failure. Science 1983 Jul 22;221(4608):380-2.">Weingartner 1983</a>). <a href="./references#CD004034-bbs2-0006" title="MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. British Medical Journal1992;304(6824):405-12. PrinceMJ , BirdAS , BlizardRA , MannAH . Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. British Medical Journal1996;312(7034):801-5. ">MRC 1996</a> reported baseline scores and rate of change over time, adjusted for baseline score, of the Paired Associate Learning Test (PALT) and Trail Making Test A (TMT‐A). A sub‐study of <a href="./references#CD004034-bbs2-0011" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , De LeeuwP , DolleryCT , et al. Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: Objectives, protocol, and organization. Aging Clin Exp Res1991;3:287-302. FletcherAE , BulpittCJ , ThijsL , ToumilehtoJ , AntikainenR , BossiniA , et al. Quality of life on randomised treatment for isolated hypertension: results from the Syst-Eur Trial. Journal of Hypertension2002;20:2069-2079. FletcherAE , BulpittCJ , TuomilehtoJ , BrowneJ , BossiniA , Kawecka-JaszczK , et al. Quality of life of elderly patients with isolated systolic hypertension: baseline data from the Syst-Eur Trial. Journal of Hypertension1988;16:1117-1124. ForetteF , Seux M-L, StaessenJA , ThijsL , Babarskiene M-R, BabeanuS , et al. The Prevention of Dementia With Antihypertensive Treatment. New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study. Archives of Internal Medicine2002;162:2046-2052. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH , BabarskieneMR , et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet1998;352:1347-51. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH . Reduction of dementia by calcium-antagonist-based antihypertensive treatment. European Heart Journal Supplements2000;2:D17-D19. StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Lancet1997;350:757-764. ">Syst Eur 1998</a> used TMT‐A and TMT‐B. <a href="./references#CD004034-bbs2-0007" title="Pérez-StableEJ , HallidayR , GardinerPS , BaronRB , HauckWW , AcreeM , CoatesTJ . The effects of propranolol on cognitive function and quality of life: a randomized trial among patients with diastolic hypertension.. The American Journal Of Medicine 2000 Apr 1;108(5):359-65. ">Perez Stable 2000</a> reported 3‐month and 12‐month change of the Digit Symbol Substitution Test, Stimulus Evaluation/Response Selection Continuous Performance Task and California Verbal Learning Test. In addition to MMSE, <a href="./references#CD004034-bbs2-0012" title="JiT , ZhaoY , WangJ , CuiY , DuanD , ChaiQ , et al. Effect of low dose statins and apolipoprotein E genotype on cerebral small vessel disease in older hypertensive patients: a subgroup analysis of a randomized clinical trial. J Am Med Dir Assoc2018;19:995-1002. ZhangH , CuiY , ZhaoY , DongY , DuanD , WangJ , ShengL , JiT , ZhouT , HuW , ChenY , SunS , GongG , ChaiQ , LiuZ . Effects of sartans and low-dose statins on cerebral white matter hyperintensities and cognitive function in older patients with hypertension: a randomized, double-blind and placebo-controlled clinical trial. Hypertension research2018;42(5):717-729. ">Zhang 2018</a> measured the Mattis Dementia Rating Scale (DRS) at baseline and annual review. In addition to reporting MMSE and DRS scores as continuous variables, Zhang and colleagues considered cognitive impairment as a binary yes/no outcome comprised of 'MMSE score of &lt;=23 points at any annual follow‐up visit or decline by &lt;=3 points between any two annual follow‐up visits and/or DRS score &lt;=123 points at any annual follow‐up visit' (<a href="./references#CD004034-bbs2-0012" title="JiT , ZhaoY , WangJ , CuiY , DuanD , ChaiQ , et al. Effect of low dose statins and apolipoprotein E genotype on cerebral small vessel disease in older hypertensive patients: a subgroup analysis of a randomized clinical trial. J Am Med Dir Assoc2018;19:995-1002. ZhangH , CuiY , ZhaoY , DongY , DuanD , WangJ , ShengL , JiT , ZhouT , HuW , ChenY , SunS , GongG , ChaiQ , LiuZ . Effects of sartans and low-dose statins on cerebral white matter hyperintensities and cognitive function in older patients with hypertension: a randomized, double-blind and placebo-controlled clinical trial. Hypertension research2018;42(5):717-729. ">Zhang 2018</a>). </p> <p>As well as MMSE, <a href="./references#CD004034-bbs2-0001" title="BuseJB , BiggerJT , ByingtonRP , CooperLS , CushmanWC , FriedewaldWT , et al, ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. American Journal of Cardiology2007;99(12A):21i-33i. CushmanWC , Grimm RH Jr, CutlerJA , EvansGW , CapesS , CorsonMA , et al, ACCORD Study Group. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):44i-55i. LaunerLJ , MillerME , WilliamsonJD , LazarRM , GersteinHC , MurrayAM , et al, ACCORD MIND investigators. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurology2011;10(11):969-77. MargolisKL , O'ConnorPJ , MorganTM , BuseJB , CohenRM , CushmanWC , et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care2014;37(6):1721-8. O'ConnorPJ , NarayanKM , AndersonR , FeeneyP , FineL , AliMK , et al. Effect of intensive versus standard blood pressure control on depression and health-related quality of life in type 2 diabetes: the ACCORD trial. Diabetes Care2012;35(7):1479-81. WilliamsonJD , LaunerLJ , BryanRN , CokerLH , LazarRM , GersteinHC , et al, Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Investigators. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Internal Medicine2014;174(3):324-33. WilliamsonJD , MillerME , BryanRN , LazarRM , CokerLH , JohnsonJ , et al, ACCORD Study Group. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. American Journal of Cardiology2007;99(12A):112i-122i. ">ACCORD MIND 2014</a> reported baseline, 20‐month and 40‐month adjusted mean Digit Symbol Substitution Test, Stroop and the Rey Auditory Verbal Learning Test (RAVLT). <a href="./references#CD004034-bbs2-0010" title="AmbrosiusWT , SinkKM , FoyCG , BerlowitzDR , CheungAK , CushmanWC , FineLJ , Goff DC Jr, JohnsonKC , KilleenAA , LewisCE , OparilS , ReboussinDM , RoccoMV , SnyderJK , WilliamsonJD , Wright JT Jr, WheltonPK , SPRINT Study Research Group. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).. Clinical Trials 2014 Oct;11(5):532-46. BerlowitzDR , FoyCG , KazisLE , BolinLP , ConroyMB , FitzpatrickP , GureTR , KimmelPL , KirchnerK , MoriskyDE , NewmanJ , OlneyC , OparilS , PajewskiNM , PowellJ , RamseyT , SimmonsDL , SnyderJ , SupianoMA , WeinerDE , WhittleJ , SPRINT Research Group. Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes.. The New England Journal of Medicine 2017 Aug 24;377(8):733-744. SPRINT Research Group, Wright JT Jr, WilliamsonJD , WheltonPK , SnyderJK , SinkKM , RoccoMV , ReboussinDM , RahmanM , OparilS , LewisCE , KimmelPL , JohnsonKC , Goff DC Jr, FineLJ , CutlerJA , CushmanWC , CheungAK , Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control.. The New England Journal of Medicine 2015 Nov 26;373(22):2103-16. The SPRINT MIND Investigators for the SPRINT Research Group. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA2019;321(6):553-561. WilliamsonJD , SupianoMA , ApplegateWB , BerlowitzDR , CampbellRC , ChertowGM , FineLJ , HaleyWE , HawfieldAT , IxJH , KitzmanDW , KostisJB , Krousel-WoodMA , LaunerLJ , OparilS , RodriguezCJ , RoumieCL , ShorrRI , SinkKM , WadleyVG , WheltonPK , WhittleJ , WoolardNF , Wright JT Jr, PajewskiNM , SPRINT Research Group. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.. JAMA 2016 Jun 28;315(24):2673-82. ">SPRINT MIND 2019</a> reported baseline only MoCA, Logical Memory form II of the Wechsler Memory Scale and Digit Symbol Coding Test of the Wechsler Adult Intelligence Scale tests. In addition to dementia, incidence of mild cognitive impairment, at follow‐up but not as baseline, was reported. </p> <p><a href="./references#CD004034-bbs2-0002" title="HajjarI , HartM , ChenYL , MackW , MilbergW , ChuiH , et al. Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: a double-blind randomized clinical trial. Archives of Internal Medicine2012;172(5):442-4. HajjarI , HartM , ChenYL , MackW , NovakV , ChuiH , et al. Antihypertensive therapy and cerebral hemodynamics in executive mild cognitive impairment: results of a pilot randomized clinical trial. Journal of the American Geriatrics Society2013;61(2):194-201. HajjarI , HartM , MackW , LipsitzLA . Aldosterone, cognitive function, and cerebral hemodynamics in hypertension and antihypertensive therapy. American Journal of Hypertension2015;28(3):319-25. HajjarI , HartM , MilbergW , NovakV , LipsitzL . The rationale and design of the antihypertensives and vascular, endothelial, and cognitive function (AVEC) trial in elderly hypertensives with early cognitive impairment: role of the renin angiotensin system inhibition. BMC Geriatrics2009;9:48. ">AVEC 2012</a> reported change over 12 months as adjusted least square means for the TMT, Digit Span Test (DST) and Hopkins Verbal Learning Test (HVLT). </p> </section> </section> <section id="CD004034-sec-0054"> <h6 class="title">Blood pressure</h6> <p>All studies measured sitting BP on study visits. None of the included studies used ambulatory BP monitoring to generate outcome measurements. </p> </section> <section id="CD004034-sec-0055"> <h6 class="title">Incidence and severity of adverse effects</h6> <p>There was considerable variability in the reporting of adverse effects.</p> <p>Of the placebo‐controlled RCTs, <a href="./references#CD004034-bbs2-0009" title="ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the Treatment of Isolated Systolic Hypertension on Behavioral Variables. Results From the Systolic Hypertension in the Elderly Program. Arch Intern Med1994;154:2154-2160. Di BariM , PahorM , FranseLV , ShorrRI , WanJY , FerrucciL , et al. Dementia and Disability Outcomes in Large Hypertension Trials: Lessons Learned from the Systolic Hypertension in the Elderly Program (SHEP) Trial. American Journal of Epidemiology2001;153:72-8. SHEP Cooperative Research Group. Prevention of Stroke by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic Hypertension. Final Results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265:3255-64. The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and Design of a Randomized Clinical Trial on Prevention of Stroke in Isolated Systolic Hypertension. Journal of Clinical Epidemiology1988;41:1197-1208. ">SHEP 1991</a>, <a href="./references#CD004034-bbs2-0008" title="Degl'InnocentiA , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , ZanchettiA , WiklundI . Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). Journal of Human Hypertension2004;18(4):239-45. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study of COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. Journal of Hypertension2004;22(8):1605-12. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. Journal of Hypertension2003;21:875-886. PapademetriouV , FarsangC , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , Zanchetti A for the SCOPE Study Group. Stroke Prevention With the Angiotension II Type-1 Receptor Blocker Candesartan in Elderly Patients With Isolated Systolic Hypertension. The Study on Cognition and Prognosis in the Elderly (SCOPE). Journal of the American College of Cardiology2004;44(6):1175-80. SkoogI , LithellH , HanssonL , ElmfeldtD , HofmanA , OlofssonB , et al, for the SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). American Journal of Hypertension2005;18:1052-1059. ">SCOPE 2003</a>, <a href="./references#CD004034-bbs2-0005" title="YodfatY , Bar-OnD , AmirM , Cristal N. Quality of life in normotensives compared to hypertensive men treated with isradipine or methyldopa as monotherapy or in combination with captopril: the LOMIR-MCT-IL study.. Journal of Human Hypertension 1996 Feb;10(2):117-22. YodfatY , Cristal N. A multicenter, double-blind, randomized, placebo-controlled study of isradipine and methyldopa as monotherapy or in combination with captopril in the treatment of hypertension. The LOMIR-MCT-IH Research Group.. American Journal of Hypertension 1993 Mar;6(3 Pt 2):57S-61S. ">LOMIR MCT IL 1996</a>, <a href="./references#CD004034-bbs2-0006" title="MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. British Medical Journal1992;304(6824):405-12. PrinceMJ , BirdAS , BlizardRA , MannAH . Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. British Medical Journal1996;312(7034):801-5. ">MRC 1996</a> and <a href="./references#CD004034-bbs2-0011" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , De LeeuwP , DolleryCT , et al. Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: Objectives, protocol, and organization. Aging Clin Exp Res1991;3:287-302. FletcherAE , BulpittCJ , ThijsL , ToumilehtoJ , AntikainenR , BossiniA , et al. Quality of life on randomised treatment for isolated hypertension: results from the Syst-Eur Trial. Journal of Hypertension2002;20:2069-2079. FletcherAE , BulpittCJ , TuomilehtoJ , BrowneJ , BossiniA , Kawecka-JaszczK , et al. Quality of life of elderly patients with isolated systolic hypertension: baseline data from the Syst-Eur Trial. Journal of Hypertension1988;16:1117-1124. ForetteF , Seux M-L, StaessenJA , ThijsL , Babarskiene M-R, BabeanuS , et al. The Prevention of Dementia With Antihypertensive Treatment. New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study. Archives of Internal Medicine2002;162:2046-2052. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH , BabarskieneMR , et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet1998;352:1347-51. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH . Reduction of dementia by calcium-antagonist-based antihypertensive treatment. European Heart Journal Supplements2000;2:D17-D19. StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Lancet1997;350:757-764. ">Syst Eur 1998</a> reported withdrawal for (<a href="./references#CD004034-bbs2-0009" title="ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the Treatment of Isolated Systolic Hypertension on Behavioral Variables. Results From the Systolic Hypertension in the Elderly Program. Arch Intern Med1994;154:2154-2160. Di BariM , PahorM , FranseLV , ShorrRI , WanJY , FerrucciL , et al. Dementia and Disability Outcomes in Large Hypertension Trials: Lessons Learned from the Systolic Hypertension in the Elderly Program (SHEP) Trial. American Journal of Epidemiology2001;153:72-8. SHEP Cooperative Research Group. Prevention of Stroke by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic Hypertension. Final Results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265:3255-64. The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and Design of a Randomized Clinical Trial on Prevention of Stroke in Isolated Systolic Hypertension. Journal of Clinical Epidemiology1988;41:1197-1208. ">SHEP 1991</a>, <a href="./references#CD004034-bbs2-0008" title="Degl'InnocentiA , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , ZanchettiA , WiklundI . Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). Journal of Human Hypertension2004;18(4):239-45. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study of COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. Journal of Hypertension2004;22(8):1605-12. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. Journal of Hypertension2003;21:875-886. PapademetriouV , FarsangC , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , Zanchetti A for the SCOPE Study Group. Stroke Prevention With the Angiotension II Type-1 Receptor Blocker Candesartan in Elderly Patients With Isolated Systolic Hypertension. The Study on Cognition and Prognosis in the Elderly (SCOPE). Journal of the American College of Cardiology2004;44(6):1175-80. SkoogI , LithellH , HanssonL , ElmfeldtD , HofmanA , OlofssonB , et al, for the SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). American Journal of Hypertension2005;18:1052-1059. ">SCOPE 2003</a>, <a href="./references#CD004034-bbs2-0006" title="MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. British Medical Journal1992;304(6824):405-12. PrinceMJ , BirdAS , BlizardRA , MannAH . Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. British Medical Journal1996;312(7034):801-5. ">MRC 1996</a>) or including (<a href="./references#CD004034-bbs2-0005" title="YodfatY , Bar-OnD , AmirM , Cristal N. Quality of life in normotensives compared to hypertensive men treated with isradipine or methyldopa as monotherapy or in combination with captopril: the LOMIR-MCT-IL study.. Journal of Human Hypertension 1996 Feb;10(2):117-22. YodfatY , Cristal N. A multicenter, double-blind, randomized, placebo-controlled study of isradipine and methyldopa as monotherapy or in combination with captopril in the treatment of hypertension. The LOMIR-MCT-IH Research Group.. American Journal of Hypertension 1993 Mar;6(3 Pt 2):57S-61S. ">LOMIR MCT IL 1996</a> and <a href="./references#CD004034-bbs2-0011" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , De LeeuwP , DolleryCT , et al. Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: Objectives, protocol, and organization. Aging Clin Exp Res1991;3:287-302. FletcherAE , BulpittCJ , ThijsL , ToumilehtoJ , AntikainenR , BossiniA , et al. Quality of life on randomised treatment for isolated hypertension: results from the Syst-Eur Trial. Journal of Hypertension2002;20:2069-2079. FletcherAE , BulpittCJ , TuomilehtoJ , BrowneJ , BossiniA , Kawecka-JaszczK , et al. Quality of life of elderly patients with isolated systolic hypertension: baseline data from the Syst-Eur Trial. Journal of Hypertension1988;16:1117-1124. ForetteF , Seux M-L, StaessenJA , ThijsL , Babarskiene M-R, BabeanuS , et al. The Prevention of Dementia With Antihypertensive Treatment. New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study. Archives of Internal Medicine2002;162:2046-2052. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH , BabarskieneMR , et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet1998;352:1347-51. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH . Reduction of dementia by calcium-antagonist-based antihypertensive treatment. European Heart Journal Supplements2000;2:D17-D19. StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Lancet1997;350:757-764. ">Syst Eur 1998</a>) adverse effects. <a href="./references#CD004034-bbs2-0007" title="Pérez-StableEJ , HallidayR , GardinerPS , BaronRB , HauckWW , AcreeM , CoatesTJ . The effects of propranolol on cognitive function and quality of life: a randomized trial among patients with diastolic hypertension.. The American Journal Of Medicine 2000 Apr 1;108(5):359-65. ">Perez Stable 2000</a> reported the numbers in the intervention group not taking the study drug at twelve months but not the reasons for this nor the corresponding number in the placebo group. <a href="./references#CD004034-bbs2-0012" title="JiT , ZhaoY , WangJ , CuiY , DuanD , ChaiQ , et al. Effect of low dose statins and apolipoprotein E genotype on cerebral small vessel disease in older hypertensive patients: a subgroup analysis of a randomized clinical trial. J Am Med Dir Assoc2018;19:995-1002. ZhangH , CuiY , ZhaoY , DongY , DuanD , WangJ , ShengL , JiT , ZhouT , HuW , ChenY , SunS , GongG , ChaiQ , LiuZ . Effects of sartans and low-dose statins on cerebral white matter hyperintensities and cognitive function in older patients with hypertension: a randomized, double-blind and placebo-controlled clinical trial. Hypertension research2018;42(5):717-729. ">Zhang 2018</a> reported study withdrawals over five years but not the reasons for these. Data regarding adverse effects and discontinuation of therapy due to adverse effects were not available for the pre‐specified cognitive sub‐study groups for <a href="./references#CD004034-bbs2-0006" title="MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. British Medical Journal1992;304(6824):405-12. PrinceMJ , BirdAS , BlizardRA , MannAH . Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. British Medical Journal1996;312(7034):801-5. ">MRC 1996</a> and <a href="./references#CD004034-bbs2-0011" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , De LeeuwP , DolleryCT , et al. Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: Objectives, protocol, and organization. Aging Clin Exp Res1991;3:287-302. FletcherAE , BulpittCJ , ThijsL , ToumilehtoJ , AntikainenR , BossiniA , et al. Quality of life on randomised treatment for isolated hypertension: results from the Syst-Eur Trial. Journal of Hypertension2002;20:2069-2079. FletcherAE , BulpittCJ , TuomilehtoJ , BrowneJ , BossiniA , Kawecka-JaszczK , et al. Quality of life of elderly patients with isolated systolic hypertension: baseline data from the Syst-Eur Trial. Journal of Hypertension1988;16:1117-1124. ForetteF , Seux M-L, StaessenJA , ThijsL , Babarskiene M-R, BabeanuS , et al. The Prevention of Dementia With Antihypertensive Treatment. New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study. Archives of Internal Medicine2002;162:2046-2052. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH , BabarskieneMR , et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet1998;352:1347-51. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH . Reduction of dementia by calcium-antagonist-based antihypertensive treatment. European Heart Journal Supplements2000;2:D17-D19. StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Lancet1997;350:757-764. ">Syst Eur 1998</a>, and so we used the results from the overall cohorts. In addition, <a href="./references#CD004034-bbs2-0009" title="ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the Treatment of Isolated Systolic Hypertension on Behavioral Variables. Results From the Systolic Hypertension in the Elderly Program. Arch Intern Med1994;154:2154-2160. Di BariM , PahorM , FranseLV , ShorrRI , WanJY , FerrucciL , et al. Dementia and Disability Outcomes in Large Hypertension Trials: Lessons Learned from the Systolic Hypertension in the Elderly Program (SHEP) Trial. American Journal of Epidemiology2001;153:72-8. SHEP Cooperative Research Group. Prevention of Stroke by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic Hypertension. Final Results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265:3255-64. The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and Design of a Randomized Clinical Trial on Prevention of Stroke in Isolated Systolic Hypertension. Journal of Clinical Epidemiology1988;41:1197-1208. ">SHEP 1991</a> reported 'prevalence of symptoms ever characterised as troublesome or intolerable' and serum clinical chemistry changes. <a href="./references#CD004034-bbs2-0008" title="Degl'InnocentiA , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , ZanchettiA , WiklundI . Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). Journal of Human Hypertension2004;18(4):239-45. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study of COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. Journal of Hypertension2004;22(8):1605-12. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. Journal of Hypertension2003;21:875-886. PapademetriouV , FarsangC , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , Zanchetti A for the SCOPE Study Group. Stroke Prevention With the Angiotension II Type-1 Receptor Blocker Candesartan in Elderly Patients With Isolated Systolic Hypertension. The Study on Cognition and Prognosis in the Elderly (SCOPE). Journal of the American College of Cardiology2004;44(6):1175-80. SkoogI , LithellH , HanssonL , ElmfeldtD , HofmanA , OlofssonB , et al, for the SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). American Journal of Hypertension2005;18:1052-1059. ">SCOPE 2003</a> reported most common adverse effects, adverse effects indicating hypotension and routine clinical chemistry changes. <a href="./references#CD004034-bbs2-0005" title="YodfatY , Bar-OnD , AmirM , Cristal N. Quality of life in normotensives compared to hypertensive men treated with isradipine or methyldopa as monotherapy or in combination with captopril: the LOMIR-MCT-IL study.. Journal of Human Hypertension 1996 Feb;10(2):117-22. YodfatY , Cristal N. A multicenter, double-blind, randomized, placebo-controlled study of isradipine and methyldopa as monotherapy or in combination with captopril in the treatment of hypertension. The LOMIR-MCT-IH Research Group.. American Journal of Hypertension 1993 Mar;6(3 Pt 2):57S-61S. ">LOMIR MCT IL 1996</a> reported most frequently reported adverse symptoms. <a href="./references#CD004034-bbs2-0004" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumiterscuD , et al, for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. NEJM2008;358:1887-1898. BulpittC , FletcherA , BeckettN , CoopeJ , Gil-ExtremeraB , ForetteF , et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs &amp; Aging2001;18:151-164. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al, for the HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurology2008;7:683-689. PetersR , BeckettN , McCormackT , FagardR , FletcherA , BulpittC . Treating hypertension in the very elderly-benefits, risks, and future directions, a focus on the hypertension in the very elderly trial. European Heart Journal 2014 Jul;35(26):1712-8. PetersR , BeckettN , NunesM , FletcherA , ForetteF , BulpittC . A substudy protocol of the Hypertension in the Very Elderly Trial assessing cognitive decline and dementia incidence (HYVET-COG): an ongoing randomised, double-blind, placebo-controlled trial. Drugs Aging2006;23:83-92. ">HYVET 2008</a> reported serious adverse events but not withdrawals due to adverse effects. </p> <p><a href="./references#CD004034-bbs2-0001" title="BuseJB , BiggerJT , ByingtonRP , CooperLS , CushmanWC , FriedewaldWT , et al, ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. American Journal of Cardiology2007;99(12A):21i-33i. CushmanWC , Grimm RH Jr, CutlerJA , EvansGW , CapesS , CorsonMA , et al, ACCORD Study Group. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):44i-55i. LaunerLJ , MillerME , WilliamsonJD , LazarRM , GersteinHC , MurrayAM , et al, ACCORD MIND investigators. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurology2011;10(11):969-77. MargolisKL , O'ConnorPJ , MorganTM , BuseJB , CohenRM , CushmanWC , et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care2014;37(6):1721-8. O'ConnorPJ , NarayanKM , AndersonR , FeeneyP , FineL , AliMK , et al. Effect of intensive versus standard blood pressure control on depression and health-related quality of life in type 2 diabetes: the ACCORD trial. Diabetes Care2012;35(7):1479-81. WilliamsonJD , LaunerLJ , BryanRN , CokerLH , LazarRM , GersteinHC , et al, Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Investigators. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Internal Medicine2014;174(3):324-33. WilliamsonJD , MillerME , BryanRN , LazarRM , CokerLH , JohnsonJ , et al, ACCORD Study Group. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. American Journal of Cardiology2007;99(12A):112i-122i. ">ACCORD MIND 2014</a> reported adverse events for the overall BP trial categorised as serious adverse events (including those attributed to antihypertensive medications), symptoms affecting quality of life, adverse laboratory measures and clinical measures. <a href="./references#CD004034-bbs2-0010" title="AmbrosiusWT , SinkKM , FoyCG , BerlowitzDR , CheungAK , CushmanWC , FineLJ , Goff DC Jr, JohnsonKC , KilleenAA , LewisCE , OparilS , ReboussinDM , RoccoMV , SnyderJK , WilliamsonJD , Wright JT Jr, WheltonPK , SPRINT Study Research Group. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).. Clinical Trials 2014 Oct;11(5):532-46. BerlowitzDR , FoyCG , KazisLE , BolinLP , ConroyMB , FitzpatrickP , GureTR , KimmelPL , KirchnerK , MoriskyDE , NewmanJ , OlneyC , OparilS , PajewskiNM , PowellJ , RamseyT , SimmonsDL , SnyderJ , SupianoMA , WeinerDE , WhittleJ , SPRINT Research Group. Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes.. The New England Journal of Medicine 2017 Aug 24;377(8):733-744. SPRINT Research Group, Wright JT Jr, WilliamsonJD , WheltonPK , SnyderJK , SinkKM , RoccoMV , ReboussinDM , RahmanM , OparilS , LewisCE , KimmelPL , JohnsonKC , Goff DC Jr, FineLJ , CutlerJA , CushmanWC , CheungAK , Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control.. The New England Journal of Medicine 2015 Nov 26;373(22):2103-16. The SPRINT MIND Investigators for the SPRINT Research Group. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA2019;321(6):553-561. WilliamsonJD , SupianoMA , ApplegateWB , BerlowitzDR , CampbellRC , ChertowGM , FineLJ , HaleyWE , HawfieldAT , IxJH , KitzmanDW , KostisJB , Krousel-WoodMA , LaunerLJ , OparilS , RodriguezCJ , RoumieCL , ShorrRI , SinkKM , WadleyVG , WheltonPK , WhittleJ , WoolardNF , Wright JT Jr, PajewskiNM , SPRINT Research Group. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.. JAMA 2016 Jun 28;315(24):2673-82. ">SPRINT MIND 2019</a> reported serious adverse events classified as possibly or definitely related to the intervention. Neither study reported data for adverse events requiring discontinuation of treatment. </p> <p><a href="./references#CD004034-bbs2-0002" title="HajjarI , HartM , ChenYL , MackW , MilbergW , ChuiH , et al. Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: a double-blind randomized clinical trial. Archives of Internal Medicine2012;172(5):442-4. HajjarI , HartM , ChenYL , MackW , NovakV , ChuiH , et al. Antihypertensive therapy and cerebral hemodynamics in executive mild cognitive impairment: results of a pilot randomized clinical trial. Journal of the American Geriatrics Society2013;61(2):194-201. HajjarI , HartM , MackW , LipsitzLA . Aldosterone, cognitive function, and cerebral hemodynamics in hypertension and antihypertensive therapy. American Journal of Hypertension2015;28(3):319-25. HajjarI , HartM , MilbergW , NovakV , LipsitzL . The rationale and design of the antihypertensives and vascular, endothelial, and cognitive function (AVEC) trial in elderly hypertensives with early cognitive impairment: role of the renin angiotensin system inhibition. BMC Geriatrics2009;9:48. ">AVEC 2012</a> reported incidence of the 'most common and serious' adverse events for the three treatment groups and treatment withdrawal due to adverse events. <a href="./references#CD004034-bbs2-0003" title="SatoN , SaijoY , HasebeN , CAMUI investigators. Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial. International Heart Journal2012;53(4):244-8. SatoN , SaijoY , SasagawaY , MorimotoH , TakeuchiT , SanoH , KoyamaS , TakeharaN , MoritaK , SumitomoK , MaruyamaJ , KikuchiK , HasebeN , CAMUI investigators. Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial: results after 1 year. Journal of Hypertension2013;31(6):1245-55. ">CAMUI 2013</a> reported a single withdrawal due to adverse drug effects. </p> </section> <section id="CD004034-sec-0056"> <h6 class="title">Quality of life</h6> <p>Seven trials provided quality of life (QOL) data. <a href="./references#CD004034-bbs2-0009" title="ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the Treatment of Isolated Systolic Hypertension on Behavioral Variables. Results From the Systolic Hypertension in the Elderly Program. Arch Intern Med1994;154:2154-2160. Di BariM , PahorM , FranseLV , ShorrRI , WanJY , FerrucciL , et al. Dementia and Disability Outcomes in Large Hypertension Trials: Lessons Learned from the Systolic Hypertension in the Elderly Program (SHEP) Trial. American Journal of Epidemiology2001;153:72-8. SHEP Cooperative Research Group. Prevention of Stroke by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic Hypertension. Final Results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265:3255-64. The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and Design of a Randomized Clinical Trial on Prevention of Stroke in Isolated Systolic Hypertension. Journal of Clinical Epidemiology1988;41:1197-1208. ">SHEP 1991</a> used the short‐CARE and Social Network Questionnaires and, at the six centres undertaking additional testing, three global quality of life questions. <a href="./references#CD004034-bbs2-0005" title="YodfatY , Bar-OnD , AmirM , Cristal N. Quality of life in normotensives compared to hypertensive men treated with isradipine or methyldopa as monotherapy or in combination with captopril: the LOMIR-MCT-IL study.. Journal of Human Hypertension 1996 Feb;10(2):117-22. YodfatY , Cristal N. A multicenter, double-blind, randomized, placebo-controlled study of isradipine and methyldopa as monotherapy or in combination with captopril in the treatment of hypertension. The LOMIR-MCT-IH Research Group.. American Journal of Hypertension 1993 Mar;6(3 Pt 2):57S-61S. ">LOMIR MCT IL 1996</a> measured QOL using a tailor‐made tool (<a href="./references#CD004034-bbs2-0057" title="Bar-OnD , AmirM . Reexamining the quality of life of hypertensive patients. A new self-structured measure. American Journal of Hypertension1993;6(3 Pt 2):62S-66S.">Bar‐On 1993</a>), in addition to measures of sleep and physical and sexual function (Croog 1986), workplace stress (<a href="./references#CD004034-bbs2-0071" title="FrankenhaeuserM , GardellB . Underload and overload in working life: outline of a multidisciplinary approach. Journal of Human Stress1976;2(3):35-46.">Frankenhaeuser 1976</a>), and an adapted life‐events scale (<a href="./references#CD004034-bbs2-0005" title="YodfatY , Bar-OnD , AmirM , Cristal N. Quality of life in normotensives compared to hypertensive men treated with isradipine or methyldopa as monotherapy or in combination with captopril: the LOMIR-MCT-IL study.. Journal of Human Hypertension 1996 Feb;10(2):117-22. YodfatY , Cristal N. A multicenter, double-blind, randomized, placebo-controlled study of isradipine and methyldopa as monotherapy or in combination with captopril in the treatment of hypertension. The LOMIR-MCT-IH Research Group.. American Journal of Hypertension 1993 Mar;6(3 Pt 2):57S-61S. ">LOMIR MCT IL 1996</a>). A sub‐study of <a href="./references#CD004034-bbs2-0011" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , De LeeuwP , DolleryCT , et al. Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: Objectives, protocol, and organization. Aging Clin Exp Res1991;3:287-302. FletcherAE , BulpittCJ , ThijsL , ToumilehtoJ , AntikainenR , BossiniA , et al. Quality of life on randomised treatment for isolated hypertension: results from the Syst-Eur Trial. Journal of Hypertension2002;20:2069-2079. FletcherAE , BulpittCJ , TuomilehtoJ , BrowneJ , BossiniA , Kawecka-JaszczK , et al. Quality of life of elderly patients with isolated systolic hypertension: baseline data from the Syst-Eur Trial. Journal of Hypertension1988;16:1117-1124. ForetteF , Seux M-L, StaessenJA , ThijsL , Babarskiene M-R, BabeanuS , et al. The Prevention of Dementia With Antihypertensive Treatment. New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study. Archives of Internal Medicine2002;162:2046-2052. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH , BabarskieneMR , et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet1998;352:1347-51. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH . Reduction of dementia by calcium-antagonist-based antihypertensive treatment. European Heart Journal Supplements2000;2:D17-D19. StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Lancet1997;350:757-764. ">Syst Eur 1998</a> used three QOL assessments: Sickness Impact Profile, Brief Assessment Index and a checklist of 32 symptoms associated with hypertension and the side effects of antihypertensive treatment. A <a href="./references#CD004034-bbs2-0008" title="Degl'InnocentiA , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , ZanchettiA , WiklundI . Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). Journal of Human Hypertension2004;18(4):239-45. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study of COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. Journal of Hypertension2004;22(8):1605-12. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. Journal of Hypertension2003;21:875-886. PapademetriouV , FarsangC , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , Zanchetti A for the SCOPE Study Group. Stroke Prevention With the Angiotension II Type-1 Receptor Blocker Candesartan in Elderly Patients With Isolated Systolic Hypertension. The Study on Cognition and Prognosis in the Elderly (SCOPE). Journal of the American College of Cardiology2004;44(6):1175-80. SkoogI , LithellH , HanssonL , ElmfeldtD , HofmanA , OlofssonB , et al, for the SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). American Journal of Hypertension2005;18:1052-1059. ">SCOPE 2003</a> sub‐study, <a href="./references#CD004034-bbs2-0063" title="Degl'InnocentiA , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , et al. Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). Journal of Human Hypertension2004;18(4):239-45.">Degl'Innocenti 2004</a>, reported QOL data using three validated assessments: Psychological General Well‐Being Index (PGWB), Subjective Symptoms Assessment Profile (SSA‐P), and EuroQoL Health Utility Index (EuroQoL). <a href="./references#CD004034-bbs2-0004" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumiterscuD , et al, for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. NEJM2008;358:1887-1898. BulpittC , FletcherA , BeckettN , CoopeJ , Gil-ExtremeraB , ForetteF , et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs &amp; Aging2001;18:151-164. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al, for the HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurology2008;7:683-689. PetersR , BeckettN , McCormackT , FagardR , FletcherA , BulpittC . Treating hypertension in the very elderly-benefits, risks, and future directions, a focus on the hypertension in the very elderly trial. European Heart Journal 2014 Jul;35(26):1712-8. PetersR , BeckettN , NunesM , FletcherA , ForetteF , BulpittC . A substudy protocol of the Hypertension in the Very Elderly Trial assessing cognitive decline and dementia incidence (HYVET-COG): an ongoing randomised, double-blind, placebo-controlled trial. Drugs Aging2006;23:83-92. ">HYVET 2008</a> used 'a quality of life questionnaire including the short‐form (SF) 36 and a list of symptoms associated with hypertension and hypertensive drugs' in a sub‐study of participants. </p> <p><a href="./references#CD004034-bbs2-0001" title="BuseJB , BiggerJT , ByingtonRP , CooperLS , CushmanWC , FriedewaldWT , et al, ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. American Journal of Cardiology2007;99(12A):21i-33i. CushmanWC , Grimm RH Jr, CutlerJA , EvansGW , CapesS , CorsonMA , et al, ACCORD Study Group. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):44i-55i. LaunerLJ , MillerME , WilliamsonJD , LazarRM , GersteinHC , MurrayAM , et al, ACCORD MIND investigators. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurology2011;10(11):969-77. MargolisKL , O'ConnorPJ , MorganTM , BuseJB , CohenRM , CushmanWC , et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care2014;37(6):1721-8. O'ConnorPJ , NarayanKM , AndersonR , FeeneyP , FineL , AliMK , et al. Effect of intensive versus standard blood pressure control on depression and health-related quality of life in type 2 diabetes: the ACCORD trial. Diabetes Care2012;35(7):1479-81. WilliamsonJD , LaunerLJ , BryanRN , CokerLH , LazarRM , GersteinHC , et al, Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Investigators. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Internal Medicine2014;174(3):324-33. WilliamsonJD , MillerME , BryanRN , LazarRM , CokerLH , JohnsonJ , et al, ACCORD Study Group. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. American Journal of Cardiology2007;99(12A):112i-122i. ">ACCORD MIND 2014</a>: the ACCORD BP health‐related quality of life (HRQL) sub‐study reported on 1028 participants who completed baseline and one or more follow‐up QOL evaluations, including the Diabetes Symptoms Distress Checklist; the 36‐Item Short Form Health Survey, Version 2 (SF‐36) (RAND Corporation, Santa Monica, CA); the Patient Health Questionnaire (PHQ) depression measure (Pfizer Inc, New York, NY); the World Health Organization (WHO) Diabetes Treatment Satisfaction Questionnaire (DTSQ); and the EuroQol Feeling Thermometer (EuroQol Group, Rotterdam, Netherlands) (<a href="./references#CD004034-bbs2-0099" title="O'ConnorPJ , NarayanKM , AndersonR , FeeneyP , FineL , AliMK , et al. Effect of intensive versus standard blood pressure control on depression and health-related quality of life in type 2 diabetes: the ACCORD trial. Diabetes Care2012;35(7):1479-81.">O'Connor 2012</a>). Participants in <a href="./references#CD004034-bbs2-0010" title="AmbrosiusWT , SinkKM , FoyCG , BerlowitzDR , CheungAK , CushmanWC , FineLJ , Goff DC Jr, JohnsonKC , KilleenAA , LewisCE , OparilS , ReboussinDM , RoccoMV , SnyderJK , WilliamsonJD , Wright JT Jr, WheltonPK , SPRINT Study Research Group. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).. Clinical Trials 2014 Oct;11(5):532-46. BerlowitzDR , FoyCG , KazisLE , BolinLP , ConroyMB , FitzpatrickP , GureTR , KimmelPL , KirchnerK , MoriskyDE , NewmanJ , OlneyC , OparilS , PajewskiNM , PowellJ , RamseyT , SimmonsDL , SnyderJ , SupianoMA , WeinerDE , WhittleJ , SPRINT Research Group. Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes.. The New England Journal of Medicine 2017 Aug 24;377(8):733-744. SPRINT Research Group, Wright JT Jr, WilliamsonJD , WheltonPK , SnyderJK , SinkKM , RoccoMV , ReboussinDM , RahmanM , OparilS , LewisCE , KimmelPL , JohnsonKC , Goff DC Jr, FineLJ , CutlerJA , CushmanWC , CheungAK , Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control.. The New England Journal of Medicine 2015 Nov 26;373(22):2103-16. The SPRINT MIND Investigators for the SPRINT Research Group. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA2019;321(6):553-561. WilliamsonJD , SupianoMA , ApplegateWB , BerlowitzDR , CampbellRC , ChertowGM , FineLJ , HaleyWE , HawfieldAT , IxJH , KitzmanDW , KostisJB , Krousel-WoodMA , LaunerLJ , OparilS , RodriguezCJ , RoumieCL , ShorrRI , SinkKM , WadleyVG , WheltonPK , WhittleJ , WoolardNF , Wright JT Jr, PajewskiNM , SPRINT Research Group. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.. JAMA 2016 Jun 28;315(24):2673-82. ">SPRINT MIND 2019</a> completed the Veterans RAND 12‐Item Health Survey (VR‐12), the Patient Health Questionnaire (PHQ) depression measure (Pfizer Inc, New York, NY) and a five‐point Likert scale rating patient satisfaction with blood pressure medications and care from very satisfied to very dissatisfied. </p> <p>Five studies did not report QOL measures (<a href="./references#CD004034-bbs2-0006" title="MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. British Medical Journal1992;304(6824):405-12. PrinceMJ , BirdAS , BlizardRA , MannAH . Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. British Medical Journal1996;312(7034):801-5. ">MRC 1996</a>; <a href="./references#CD004034-bbs2-0007" title="Pérez-StableEJ , HallidayR , GardinerPS , BaronRB , HauckWW , AcreeM , CoatesTJ . The effects of propranolol on cognitive function and quality of life: a randomized trial among patients with diastolic hypertension.. The American Journal Of Medicine 2000 Apr 1;108(5):359-65. ">Perez Stable 2000</a>; <a href="./references#CD004034-bbs2-0002" title="HajjarI , HartM , ChenYL , MackW , MilbergW , ChuiH , et al. Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: a double-blind randomized clinical trial. Archives of Internal Medicine2012;172(5):442-4. HajjarI , HartM , ChenYL , MackW , NovakV , ChuiH , et al. Antihypertensive therapy and cerebral hemodynamics in executive mild cognitive impairment: results of a pilot randomized clinical trial. Journal of the American Geriatrics Society2013;61(2):194-201. HajjarI , HartM , MackW , LipsitzLA . Aldosterone, cognitive function, and cerebral hemodynamics in hypertension and antihypertensive therapy. American Journal of Hypertension2015;28(3):319-25. HajjarI , HartM , MilbergW , NovakV , LipsitzL . The rationale and design of the antihypertensives and vascular, endothelial, and cognitive function (AVEC) trial in elderly hypertensives with early cognitive impairment: role of the renin angiotensin system inhibition. BMC Geriatrics2009;9:48. ">AVEC 2012</a>; <a href="./references#CD004034-bbs2-0003" title="SatoN , SaijoY , HasebeN , CAMUI investigators. Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial. International Heart Journal2012;53(4):244-8. SatoN , SaijoY , SasagawaY , MorimotoH , TakeuchiT , SanoH , KoyamaS , TakeharaN , MoritaK , SumitomoK , MaruyamaJ , KikuchiK , HasebeN , CAMUI investigators. Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial: results after 1 year. Journal of Hypertension2013;31(6):1245-55. ">CAMUI 2013</a>; <a href="./references#CD004034-bbs2-0012" title="JiT , ZhaoY , WangJ , CuiY , DuanD , ChaiQ , et al. Effect of low dose statins and apolipoprotein E genotype on cerebral small vessel disease in older hypertensive patients: a subgroup analysis of a randomized clinical trial. J Am Med Dir Assoc2018;19:995-1002. ZhangH , CuiY , ZhaoY , DongY , DuanD , WangJ , ShengL , JiT , ZhouT , HuW , ChenY , SunS , GongG , ChaiQ , LiuZ . Effects of sartans and low-dose statins on cerebral white matter hyperintensities and cognitive function in older patients with hypertension: a randomized, double-blind and placebo-controlled clinical trial. Hypertension research2018;42(5):717-729. ">Zhang 2018</a>). </p> </section> </section> </section> <section id="CD004034-sec-0057"> <h4 class="title">Excluded studies</h4> <p>Three previously excluded studies were included in this update: <a href="./references#CD004034-bbs2-0005" title="YodfatY , Bar-OnD , AmirM , Cristal N. Quality of life in normotensives compared to hypertensive men treated with isradipine or methyldopa as monotherapy or in combination with captopril: the LOMIR-MCT-IL study.. Journal of Human Hypertension 1996 Feb;10(2):117-22. YodfatY , Cristal N. A multicenter, double-blind, randomized, placebo-controlled study of isradipine and methyldopa as monotherapy or in combination with captopril in the treatment of hypertension. The LOMIR-MCT-IH Research Group.. American Journal of Hypertension 1993 Mar;6(3 Pt 2):57S-61S. ">LOMIR MCT IL 1996</a> (participants aged 40 to 65 years), <a href="./references#CD004034-bbs2-0006" title="MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. British Medical Journal1992;304(6824):405-12. PrinceMJ , BirdAS , BlizardRA , MannAH . Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. British Medical Journal1996;312(7034):801-5. ">MRC 1996</a> (single‐blinded), and <a href="./references#CD004034-bbs2-0007" title="Pérez-StableEJ , HallidayR , GardinerPS , BaronRB , HauckWW , AcreeM , CoatesTJ . The effects of propranolol on cognitive function and quality of life: a randomized trial among patients with diastolic hypertension.. The American Journal Of Medicine 2000 Apr 1;108(5):359-65. ">Perez Stable 2000</a> (participants aged 18 to 59 years). </p> <p>Of the excluded studies, we excluded most because they did not report cognitive outcomes; for example, the placebo‐controlled European Working Party on High Blood Pressure in the Elderly (<a href="./references#CD004034-bbs2-0022" title="AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of hypotensive drug treatment in elderly hypertensives: study terminating events in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension. Supplement1985;3(3):S501-11. ">EWPHE 1985</a>) study, <a href="./references#CD004034-bbs2-0042" title="DahlofB , LindholmLH , HanssonL , ScherstenB , EkbomT , Wester P-O. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP Hypertension). Lancet1991;338:1281-85. ">STOP 1991</a>, <a href="./references#CD004034-bbs2-0043" title="LiuL , WangJG , GongL , LiuG , StaessenJA . Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Journal of Hypertension1998;16:1823-1829. ">Syst China 1998</a>, <a href="./references#CD004034-bbs2-0016" title="BlackHR , ElliottWJ , WeberMA , FrishmanWH , StromJA , LiebsonPR , et al. One-Year Study of Felodipine or Placebo for Stage 1 Isolated Systolic Hypertension. Hypertension2001;38:1118-1130. ">Black 2001</a>, <a href="./references#CD004034-bbs2-0014" title="ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Diuretic Versus Alpha-Blocker as First-Step Antihypertensive Therapy. Final Results From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension2003;42:239-246. ">ALLHAT 2003</a>, <a href="./references#CD004034-bbs2-0030" title="Hsieh M-H, ChanP , Sue Y-M, Liu J-C, LiangTH , Huang T-Y, et al. Efficacy and Tolerability of Oral Stevioside in Patients with Mild Essential Hypertension: A Two-Year, Randomised, Placebo-Controlled Study. Clinical Therapeutics2003;25:2797-2808. ">Hsieh 2003</a>, <a href="./references#CD004034-bbs2-0046" title="JuliusS , KjeldsenSE , WeberM , BrunnerHR , EkmanS , HanssonL , et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet2004;363:2022-31. ">VALUE 2004</a> and <a href="./references#CD004034-bbs2-0015" title="DahlofB , SeverPS , PoulterNR , WedelH , BeeversDG , CaulfieldM , et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet2005;366:895-906. ">ASCOT 2005</a>. </p> <p>As the evidence for treating hypertension post‐stroke is now well‐established, we considered a history of cerebrovascular disease an exclusion criterion for this review. Therefore, we excluded the 'Perindopril pROtection aGainst REcurrent Stroke Study' (<a href="./references#CD004034-bbs2-0038" title="The PROGRESS Collaborative Group. Effects of Blood Pressure Lowering With Perindopril and Indapamide Therapy on Dementia and Cognitive Decline in Patients With Cerebrovascular Disease. Arch Intern Med2003;163:1069-75. ">PROGRESS 2003</a>), and the 'Prevention Regimen For Effectively Avoiding Second Strokes' study (<a href="./references#CD004034-bbs2-0037" title="DienerHC , SaccoRL , YusufS , CottonD , OunpuuS , LawtonWA , et al. Effects of aspirin plus extended-release dipyridamoleversus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurology2008;7:875-84. ">PRoFESS 2008</a>), which recruited only participants with a history of transient ischaemic attack (TIA) or stroke. <a href="./references#CD004034-bbs2-0031" title="WhiteWB , WakefieldDB , MoscufoN , GuttmannCRG , KaplanRF , BohannonRW , et al. Effects of Intensive Versus Standard Ambulatory Blood Pressure Control on Cerebrovascular Outcomes in Older People (INFINITY). Circulation2019;140(20):1626-35. ">INFINITY 2019</a> required participants to have a significant white matter hyperintensity burden on MRI at baseline and so was excluded. </p> <p>We also excluded studies that did not require participants to be hypertensive. <a href="./references#CD004034-bbs2-0034" title="AndersonC , TeoK , GaoP , ArimaH , DansA , UngerT , et al, ONTARGET and TRANSCEND Investigators. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurology2011;10(1):43-53. ONTARGET Investigators, YusufS , TeoKK , PogueJ , DyalL , CoplandI , et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. New England Journal of Medicine2008;358(15):1547-59. TeoK , YusufS , SleightP , AndersonC , MookadamF , RamosB , et al, ONTARGET/TRANSCEND Investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. American Heart Journal2004;148(1):52-61. ">ONTARGET 2008</a>, a non‐placebo‐controlled trial, compared an ACE inhibitor, ARB, or both, and <a href="./references#CD004034-bbs2-0045" title="Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, YusufS , TeoK , AndersonC , PogueJ , DyalL , et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patientsintolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet2008;372(9644):1174-83. ">TRANSCEND 2008</a>, a placebo‐controlled RCT, compared an ARB with placebo, with regard to a composite cardiovascular event primary outcome measure, with secondary dementia and cognitive decline outcome measures in a population at high cardiovascular risk. The 'Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation' (<a href="./references#CD004034-bbs2-0013" title="ADVANCE Management Committee. Study rationale and design of ADVANCE: action in diabetes and vascular disease--preterax and diamicron MR controlled evaluation. Diabetologia2001;44(9):1118-20. BattyGD , LiQ , HuxleyR , ZoungasS , TaylorBA , NealB , et al, ADVANCE Collaborative group. Oral disease in relation to future risk of dementia and cognitive decline: prospective cohort study based on the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation (ADVANCE) trial. European Psychiatry2013;28(1):49-52. NinomiyaT , ZoungasS , NealB , WoodwardM , PatelA , PerkovicV , et al, ADVANCE Collaborative Group. Efficacy and safety of routine blood pressure lowering in older patients with diabetes: results from the ADVANCE trial. Journal of Hypertension2010;28(6):1141-9. PatelA , ADVANCE Collaborative Group, MacMahonS , ChalmersJ , NealB , WoodwardM , et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet2007;370(9590):829-40. Van der LeeuwJ , VisserenFL , WoodwardM , ZoungasS , KengneAP , Van der GraafY , et al. Predicting the effects of blood pressure-lowering treatment on major cardiovascular events for individual patients with type 2 diabetes mellitus: results from Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation. Hypertension2015;65(1):115-21. ">ADVANCE 2010</a>) study compared additional antihypertensive agents with placebo in an exclusively diabetic population and included dementia as a secondary outcome but participants were not required to be hypertensive. <a href="./references#CD004034-bbs2-0028" title="BoschJ , O’DonnellM , SwaminathanB , LonnEM , SharmaM , Dagenais G et al, HOPE-3 Investigators. Effects of blood pressure and lipid lowering on cognition: Results from the HOPE-3 study. Neurology2019;92(13):e1435-46. LonnE , BoschJ , PogueJ , AvezumA , ChazovaI , DansA , et al, HOPE-3 Investigators. Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics. The Canadian Journal of Cardiology2016;32(3):311-8. LonnEM , BoschJ , López-JaramilloP , ZhuJ , LiuL , PaisP , et al, HOPE-3 Investigators. Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. The New England Journal of Medicine2016;374(21):2009-20. YusufS , LonnE , PaisP , BoschJ , López-JaramilloP , ZhuJ , et al, HOPE-3 Investigators. Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. The New England Journal Of Medicine2016;374(21):2032-43. ">HOPE 3 2016</a> recruited people in middle age or older with additional cardiovascular risk factors but did not require participants to be hypertensive. The cognitive sub‐study, HOPE 3 2019, included participants aged 70 years and over. </p> <p>The 'Discontinuation of Hypertensive Treatment in Elderly people' (<a href="./references#CD004034-bbs2-0018" title="MoonenJE , Foster-DingleyJC , deRuijterW , van derGrondJ , BertensAS , vanBuchemMA , et al. Effect of Discontinuation of Antihypertensive Treatment in Elderly People on Cognitive Functioning--the DANTE Study Leiden: A Randomized Clinical Trial. JAMA Internal Medicine2015;175(10):1622-30. ">DANTE 2015</a>) study was open‐label and compared the cognitive effects of antihypertensive treatment discontinuation versus continuation in those aged over 75 years with mild cognitive impairment. Discontinuation studies have been considered by another Cochrane Review and are not included in this review (<a href="./references#CD004034-bbs2-0085" title="JongstraS , HarrisonJK , QuinnTJ , RichardE . Antihypertensive withdrawal for the prevention of cognitive decline. The Cochrane database of systematic reviews2016;11:CD011971. [PMID: 27802359]">Jongstra 2016</a>). </p> </section> </section> <section id="CD004034-sec-0058"> <h3 class="title">Risk of bias in included studies</h3> <section id="CD004034-sec-0059"> <h4 class="title">Allocation</h4> <p>Nine of the studies reported a robust method of randomisation (<a href="./references#CD004034-bbs2-0001" title="BuseJB , BiggerJT , ByingtonRP , CooperLS , CushmanWC , FriedewaldWT , et al, ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. American Journal of Cardiology2007;99(12A):21i-33i. CushmanWC , Grimm RH Jr, CutlerJA , EvansGW , CapesS , CorsonMA , et al, ACCORD Study Group. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):44i-55i. LaunerLJ , MillerME , WilliamsonJD , LazarRM , GersteinHC , MurrayAM , et al, ACCORD MIND investigators. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurology2011;10(11):969-77. MargolisKL , O'ConnorPJ , MorganTM , BuseJB , CohenRM , CushmanWC , et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care2014;37(6):1721-8. O'ConnorPJ , NarayanKM , AndersonR , FeeneyP , FineL , AliMK , et al. Effect of intensive versus standard blood pressure control on depression and health-related quality of life in type 2 diabetes: the ACCORD trial. Diabetes Care2012;35(7):1479-81. WilliamsonJD , LaunerLJ , BryanRN , CokerLH , LazarRM , GersteinHC , et al, Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Investigators. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Internal Medicine2014;174(3):324-33. WilliamsonJD , MillerME , BryanRN , LazarRM , CokerLH , JohnsonJ , et al, ACCORD Study Group. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. American Journal of Cardiology2007;99(12A):112i-122i. ">ACCORD MIND 2014</a>; <a href="./references#CD004034-bbs2-0002" title="HajjarI , HartM , ChenYL , MackW , MilbergW , ChuiH , et al. Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: a double-blind randomized clinical trial. Archives of Internal Medicine2012;172(5):442-4. HajjarI , HartM , ChenYL , MackW , NovakV , ChuiH , et al. Antihypertensive therapy and cerebral hemodynamics in executive mild cognitive impairment: results of a pilot randomized clinical trial. Journal of the American Geriatrics Society2013;61(2):194-201. HajjarI , HartM , MackW , LipsitzLA . Aldosterone, cognitive function, and cerebral hemodynamics in hypertension and antihypertensive therapy. American Journal of Hypertension2015;28(3):319-25. HajjarI , HartM , MilbergW , NovakV , LipsitzL . The rationale and design of the antihypertensives and vascular, endothelial, and cognitive function (AVEC) trial in elderly hypertensives with early cognitive impairment: role of the renin angiotensin system inhibition. BMC Geriatrics2009;9:48. ">AVEC 2012</a>; <a href="./references#CD004034-bbs2-0003" title="SatoN , SaijoY , HasebeN , CAMUI investigators. Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial. International Heart Journal2012;53(4):244-8. SatoN , SaijoY , SasagawaY , MorimotoH , TakeuchiT , SanoH , KoyamaS , TakeharaN , MoritaK , SumitomoK , MaruyamaJ , KikuchiK , HasebeN , CAMUI investigators. Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial: results after 1 year. Journal of Hypertension2013;31(6):1245-55. ">CAMUI 2013</a>; <a href="./references#CD004034-bbs2-0004" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumiterscuD , et al, for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. NEJM2008;358:1887-1898. BulpittC , FletcherA , BeckettN , CoopeJ , Gil-ExtremeraB , ForetteF , et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs &amp; Aging2001;18:151-164. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al, for the HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurology2008;7:683-689. PetersR , BeckettN , McCormackT , FagardR , FletcherA , BulpittC . Treating hypertension in the very elderly-benefits, risks, and future directions, a focus on the hypertension in the very elderly trial. European Heart Journal 2014 Jul;35(26):1712-8. PetersR , BeckettN , NunesM , FletcherA , ForetteF , BulpittC . A substudy protocol of the Hypertension in the Very Elderly Trial assessing cognitive decline and dementia incidence (HYVET-COG): an ongoing randomised, double-blind, placebo-controlled trial. Drugs Aging2006;23:83-92. ">HYVET 2008</a>; <a href="./references#CD004034-bbs2-0007" title="Pérez-StableEJ , HallidayR , GardinerPS , BaronRB , HauckWW , AcreeM , CoatesTJ . The effects of propranolol on cognitive function and quality of life: a randomized trial among patients with diastolic hypertension.. The American Journal Of Medicine 2000 Apr 1;108(5):359-65. ">Perez Stable 2000</a>; <a href="./references#CD004034-bbs2-0008" title="Degl'InnocentiA , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , ZanchettiA , WiklundI . Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). Journal of Human Hypertension2004;18(4):239-45. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study of COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. Journal of Hypertension2004;22(8):1605-12. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. Journal of Hypertension2003;21:875-886. PapademetriouV , FarsangC , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , Zanchetti A for the SCOPE Study Group. Stroke Prevention With the Angiotension II Type-1 Receptor Blocker Candesartan in Elderly Patients With Isolated Systolic Hypertension. The Study on Cognition and Prognosis in the Elderly (SCOPE). Journal of the American College of Cardiology2004;44(6):1175-80. SkoogI , LithellH , HanssonL , ElmfeldtD , HofmanA , OlofssonB , et al, for the SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). American Journal of Hypertension2005;18:1052-1059. ">SCOPE 2003</a>; <a href="./references#CD004034-bbs2-0009" title="ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the Treatment of Isolated Systolic Hypertension on Behavioral Variables. Results From the Systolic Hypertension in the Elderly Program. Arch Intern Med1994;154:2154-2160. Di BariM , PahorM , FranseLV , ShorrRI , WanJY , FerrucciL , et al. Dementia and Disability Outcomes in Large Hypertension Trials: Lessons Learned from the Systolic Hypertension in the Elderly Program (SHEP) Trial. American Journal of Epidemiology2001;153:72-8. SHEP Cooperative Research Group. Prevention of Stroke by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic Hypertension. Final Results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265:3255-64. The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and Design of a Randomized Clinical Trial on Prevention of Stroke in Isolated Systolic Hypertension. Journal of Clinical Epidemiology1988;41:1197-1208. ">SHEP 1991</a>; <a href="./references#CD004034-bbs2-0011" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , De LeeuwP , DolleryCT , et al. Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: Objectives, protocol, and organization. Aging Clin Exp Res1991;3:287-302. FletcherAE , BulpittCJ , ThijsL , ToumilehtoJ , AntikainenR , BossiniA , et al. Quality of life on randomised treatment for isolated hypertension: results from the Syst-Eur Trial. Journal of Hypertension2002;20:2069-2079. FletcherAE , BulpittCJ , TuomilehtoJ , BrowneJ , BossiniA , Kawecka-JaszczK , et al. Quality of life of elderly patients with isolated systolic hypertension: baseline data from the Syst-Eur Trial. Journal of Hypertension1988;16:1117-1124. ForetteF , Seux M-L, StaessenJA , ThijsL , Babarskiene M-R, BabeanuS , et al. The Prevention of Dementia With Antihypertensive Treatment. New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study. Archives of Internal Medicine2002;162:2046-2052. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH , BabarskieneMR , et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet1998;352:1347-51. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH . Reduction of dementia by calcium-antagonist-based antihypertensive treatment. European Heart Journal Supplements2000;2:D17-D19. StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Lancet1997;350:757-764. ">Syst Eur 1998</a>; <a href="./references#CD004034-bbs2-0012" title="JiT , ZhaoY , WangJ , CuiY , DuanD , ChaiQ , et al. Effect of low dose statins and apolipoprotein E genotype on cerebral small vessel disease in older hypertensive patients: a subgroup analysis of a randomized clinical trial. J Am Med Dir Assoc2018;19:995-1002. ZhangH , CuiY , ZhaoY , DongY , DuanD , WangJ , ShengL , JiT , ZhouT , HuW , ChenY , SunS , GongG , ChaiQ , LiuZ . Effects of sartans and low-dose statins on cerebral white matter hyperintensities and cognitive function in older patients with hypertension: a randomized, double-blind and placebo-controlled clinical trial. Hypertension research2018;42(5):717-729. ">Zhang 2018</a>). <a href="./references#CD004034-bbs2-0005" title="YodfatY , Bar-OnD , AmirM , Cristal N. Quality of life in normotensives compared to hypertensive men treated with isradipine or methyldopa as monotherapy or in combination with captopril: the LOMIR-MCT-IL study.. Journal of Human Hypertension 1996 Feb;10(2):117-22. YodfatY , Cristal N. A multicenter, double-blind, randomized, placebo-controlled study of isradipine and methyldopa as monotherapy or in combination with captopril in the treatment of hypertension. The LOMIR-MCT-IH Research Group.. American Journal of Hypertension 1993 Mar;6(3 Pt 2):57S-61S. ">LOMIR MCT IL 1996</a> did not describe a method of randomisation. <a href="./references#CD004034-bbs2-0006" title="MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. British Medical Journal1992;304(6824):405-12. PrinceMJ , BirdAS , BlizardRA , MannAH . Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. British Medical Journal1996;312(7034):801-5. ">MRC 1996</a> states randomisation was within stratified blocks but the method of randomisation is unclear. <a href="./references#CD004034-bbs2-0010" title="AmbrosiusWT , SinkKM , FoyCG , BerlowitzDR , CheungAK , CushmanWC , FineLJ , Goff DC Jr, JohnsonKC , KilleenAA , LewisCE , OparilS , ReboussinDM , RoccoMV , SnyderJK , WilliamsonJD , Wright JT Jr, WheltonPK , SPRINT Study Research Group. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).. Clinical Trials 2014 Oct;11(5):532-46. BerlowitzDR , FoyCG , KazisLE , BolinLP , ConroyMB , FitzpatrickP , GureTR , KimmelPL , KirchnerK , MoriskyDE , NewmanJ , OlneyC , OparilS , PajewskiNM , PowellJ , RamseyT , SimmonsDL , SnyderJ , SupianoMA , WeinerDE , WhittleJ , SPRINT Research Group. Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes.. The New England Journal of Medicine 2017 Aug 24;377(8):733-744. SPRINT Research Group, Wright JT Jr, WilliamsonJD , WheltonPK , SnyderJK , SinkKM , RoccoMV , ReboussinDM , RahmanM , OparilS , LewisCE , KimmelPL , JohnsonKC , Goff DC Jr, FineLJ , CutlerJA , CushmanWC , CheungAK , Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control.. The New England Journal of Medicine 2015 Nov 26;373(22):2103-16. The SPRINT MIND Investigators for the SPRINT Research Group. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA2019;321(6):553-561. WilliamsonJD , SupianoMA , ApplegateWB , BerlowitzDR , CampbellRC , ChertowGM , FineLJ , HaleyWE , HawfieldAT , IxJH , KitzmanDW , KostisJB , Krousel-WoodMA , LaunerLJ , OparilS , RodriguezCJ , RoumieCL , ShorrRI , SinkKM , WadleyVG , WheltonPK , WhittleJ , WoolardNF , Wright JT Jr, PajewskiNM , SPRINT Research Group. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.. JAMA 2016 Jun 28;315(24):2673-82. ">SPRINT MIND 2019</a> reported use of 'an internet‐based, web browser randomisation procedure'. </p> </section> <section id="CD004034-sec-0060"> <h4 class="title">Blinding</h4> <p>In contrast to the previous update (<a href="./references#CD004034-bbs2-0134" title="McGuinnessB , ToddS , PassmoreP , BullockR . Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database of Systematic Reviews2009, Issue 3. Art. No: CD004034. [DOI: 10.1002/14651858.CD004034.pub3]">McGuinness 2009</a>), this review included studies that were single‐blind or non‐blinded. In the cases of <a href="./references#CD004034-bbs2-0001" title="BuseJB , BiggerJT , ByingtonRP , CooperLS , CushmanWC , FriedewaldWT , et al, ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. American Journal of Cardiology2007;99(12A):21i-33i. CushmanWC , Grimm RH Jr, CutlerJA , EvansGW , CapesS , CorsonMA , et al, ACCORD Study Group. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):44i-55i. LaunerLJ , MillerME , WilliamsonJD , LazarRM , GersteinHC , MurrayAM , et al, ACCORD MIND investigators. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurology2011;10(11):969-77. MargolisKL , O'ConnorPJ , MorganTM , BuseJB , CohenRM , CushmanWC , et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care2014;37(6):1721-8. O'ConnorPJ , NarayanKM , AndersonR , FeeneyP , FineL , AliMK , et al. Effect of intensive versus standard blood pressure control on depression and health-related quality of life in type 2 diabetes: the ACCORD trial. Diabetes Care2012;35(7):1479-81. WilliamsonJD , LaunerLJ , BryanRN , CokerLH , LazarRM , GersteinHC , et al, Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Investigators. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Internal Medicine2014;174(3):324-33. WilliamsonJD , MillerME , BryanRN , LazarRM , CokerLH , JohnsonJ , et al, ACCORD Study Group. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. American Journal of Cardiology2007;99(12A):112i-122i. ">ACCORD MIND 2014</a> and <a href="./references#CD004034-bbs2-0010" title="AmbrosiusWT , SinkKM , FoyCG , BerlowitzDR , CheungAK , CushmanWC , FineLJ , Goff DC Jr, JohnsonKC , KilleenAA , LewisCE , OparilS , ReboussinDM , RoccoMV , SnyderJK , WilliamsonJD , Wright JT Jr, WheltonPK , SPRINT Study Research Group. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).. Clinical Trials 2014 Oct;11(5):532-46. BerlowitzDR , FoyCG , KazisLE , BolinLP , ConroyMB , FitzpatrickP , GureTR , KimmelPL , KirchnerK , MoriskyDE , NewmanJ , OlneyC , OparilS , PajewskiNM , PowellJ , RamseyT , SimmonsDL , SnyderJ , SupianoMA , WeinerDE , WhittleJ , SPRINT Research Group. Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes.. The New England Journal of Medicine 2017 Aug 24;377(8):733-744. SPRINT Research Group, Wright JT Jr, WilliamsonJD , WheltonPK , SnyderJK , SinkKM , RoccoMV , ReboussinDM , RahmanM , OparilS , LewisCE , KimmelPL , JohnsonKC , Goff DC Jr, FineLJ , CutlerJA , CushmanWC , CheungAK , Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control.. The New England Journal of Medicine 2015 Nov 26;373(22):2103-16. The SPRINT MIND Investigators for the SPRINT Research Group. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA2019;321(6):553-561. WilliamsonJD , SupianoMA , ApplegateWB , BerlowitzDR , CampbellRC , ChertowGM , FineLJ , HaleyWE , HawfieldAT , IxJH , KitzmanDW , KostisJB , Krousel-WoodMA , LaunerLJ , OparilS , RodriguezCJ , RoumieCL , ShorrRI , SinkKM , WadleyVG , WheltonPK , WhittleJ , WoolardNF , Wright JT Jr, PajewskiNM , SPRINT Research Group. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.. JAMA 2016 Jun 28;315(24):2673-82. ">SPRINT MIND 2019</a>, the intensive treatment groups had more visits than the standard treatment groups, which increases the risk of performance bias. The risk of detection bias is theoretically increased in those studies where cognitive tests were administered by unblinded assessors (i.e. <a href="./references#CD004034-bbs2-0006" title="MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. British Medical Journal1992;304(6824):405-12. PrinceMJ , BirdAS , BlizardRA , MannAH . Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. British Medical Journal1996;312(7034):801-5. ">MRC 1996</a>, <a href="./references#CD004034-bbs2-0001" title="BuseJB , BiggerJT , ByingtonRP , CooperLS , CushmanWC , FriedewaldWT , et al, ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. American Journal of Cardiology2007;99(12A):21i-33i. CushmanWC , Grimm RH Jr, CutlerJA , EvansGW , CapesS , CorsonMA , et al, ACCORD Study Group. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):44i-55i. LaunerLJ , MillerME , WilliamsonJD , LazarRM , GersteinHC , MurrayAM , et al, ACCORD MIND investigators. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurology2011;10(11):969-77. MargolisKL , O'ConnorPJ , MorganTM , BuseJB , CohenRM , CushmanWC , et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care2014;37(6):1721-8. O'ConnorPJ , NarayanKM , AndersonR , FeeneyP , FineL , AliMK , et al. Effect of intensive versus standard blood pressure control on depression and health-related quality of life in type 2 diabetes: the ACCORD trial. Diabetes Care2012;35(7):1479-81. WilliamsonJD , LaunerLJ , BryanRN , CokerLH , LazarRM , GersteinHC , et al, Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Investigators. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Internal Medicine2014;174(3):324-33. WilliamsonJD , MillerME , BryanRN , LazarRM , CokerLH , JohnsonJ , et al, ACCORD Study Group. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. American Journal of Cardiology2007;99(12A):112i-122i. ">ACCORD MIND 2014</a> and <a href="./references#CD004034-bbs2-0003" title="SatoN , SaijoY , HasebeN , CAMUI investigators. Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial. International Heart Journal2012;53(4):244-8. SatoN , SaijoY , SasagawaY , MorimotoH , TakeuchiT , SanoH , KoyamaS , TakeharaN , MoritaK , SumitomoK , MaruyamaJ , KikuchiK , HasebeN , CAMUI investigators. Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial: results after 1 year. Journal of Hypertension2013;31(6):1245-55. ">CAMUI 2013</a>). The expert adjudication panel in <a href="./references#CD004034-bbs2-0010" title="AmbrosiusWT , SinkKM , FoyCG , BerlowitzDR , CheungAK , CushmanWC , FineLJ , Goff DC Jr, JohnsonKC , KilleenAA , LewisCE , OparilS , ReboussinDM , RoccoMV , SnyderJK , WilliamsonJD , Wright JT Jr, WheltonPK , SPRINT Study Research Group. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).. Clinical Trials 2014 Oct;11(5):532-46. BerlowitzDR , FoyCG , KazisLE , BolinLP , ConroyMB , FitzpatrickP , GureTR , KimmelPL , KirchnerK , MoriskyDE , NewmanJ , OlneyC , OparilS , PajewskiNM , PowellJ , RamseyT , SimmonsDL , SnyderJ , SupianoMA , WeinerDE , WhittleJ , SPRINT Research Group. Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes.. The New England Journal of Medicine 2017 Aug 24;377(8):733-744. SPRINT Research Group, Wright JT Jr, WilliamsonJD , WheltonPK , SnyderJK , SinkKM , RoccoMV , ReboussinDM , RahmanM , OparilS , LewisCE , KimmelPL , JohnsonKC , Goff DC Jr, FineLJ , CutlerJA , CushmanWC , CheungAK , Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control.. The New England Journal of Medicine 2015 Nov 26;373(22):2103-16. The SPRINT MIND Investigators for the SPRINT Research Group. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA2019;321(6):553-561. WilliamsonJD , SupianoMA , ApplegateWB , BerlowitzDR , CampbellRC , ChertowGM , FineLJ , HaleyWE , HawfieldAT , IxJH , KitzmanDW , KostisJB , Krousel-WoodMA , LaunerLJ , OparilS , RodriguezCJ , RoumieCL , ShorrRI , SinkKM , WadleyVG , WheltonPK , WhittleJ , WoolardNF , Wright JT Jr, PajewskiNM , SPRINT Research Group. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.. JAMA 2016 Jun 28;315(24):2673-82. ">SPRINT MIND 2019</a> was blinded to treatment allocation. </p> </section> <section id="CD004034-sec-0061"> <h4 class="title">Incomplete outcome data</h4> <p>We judged most studies to be at high risk of attrition bias on the basis of lack of reporting or dropout rates associated with older age or worse cognitive function at baseline. Overall loss to follow‐up was similar between study group arms. Less than half of participants in <a href="./references#CD004034-bbs2-0009" title="ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the Treatment of Isolated Systolic Hypertension on Behavioral Variables. Results From the Systolic Hypertension in the Elderly Program. Arch Intern Med1994;154:2154-2160. Di BariM , PahorM , FranseLV , ShorrRI , WanJY , FerrucciL , et al. Dementia and Disability Outcomes in Large Hypertension Trials: Lessons Learned from the Systolic Hypertension in the Elderly Program (SHEP) Trial. American Journal of Epidemiology2001;153:72-8. SHEP Cooperative Research Group. Prevention of Stroke by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic Hypertension. Final Results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265:3255-64. The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and Design of a Randomized Clinical Trial on Prevention of Stroke in Isolated Systolic Hypertension. Journal of Clinical Epidemiology1988;41:1197-1208. ">SHEP 1991</a> and <a href="./references#CD004034-bbs2-0011" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , De LeeuwP , DolleryCT , et al. Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: Objectives, protocol, and organization. Aging Clin Exp Res1991;3:287-302. FletcherAE , BulpittCJ , ThijsL , ToumilehtoJ , AntikainenR , BossiniA , et al. Quality of life on randomised treatment for isolated hypertension: results from the Syst-Eur Trial. Journal of Hypertension2002;20:2069-2079. FletcherAE , BulpittCJ , TuomilehtoJ , BrowneJ , BossiniA , Kawecka-JaszczK , et al. Quality of life of elderly patients with isolated systolic hypertension: baseline data from the Syst-Eur Trial. Journal of Hypertension1988;16:1117-1124. ForetteF , Seux M-L, StaessenJA , ThijsL , Babarskiene M-R, BabeanuS , et al. The Prevention of Dementia With Antihypertensive Treatment. New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study. Archives of Internal Medicine2002;162:2046-2052. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH , BabarskieneMR , et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet1998;352:1347-51. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH . Reduction of dementia by calcium-antagonist-based antihypertensive treatment. European Heart Journal Supplements2000;2:D17-D19. StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Lancet1997;350:757-764. ">Syst Eur 1998</a> completed 5‐year and 4‐year follow‐up, respectively, though numbers were similar across the groups. <a href="./references#CD004034-bbs2-0007" title="Pérez-StableEJ , HallidayR , GardinerPS , BaronRB , HauckWW , AcreeM , CoatesTJ . The effects of propranolol on cognitive function and quality of life: a randomized trial among patients with diastolic hypertension.. The American Journal Of Medicine 2000 Apr 1;108(5):359-65. ">Perez Stable 2000</a> and <a href="./references#CD004034-bbs2-0002" title="HajjarI , HartM , ChenYL , MackW , MilbergW , ChuiH , et al. Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: a double-blind randomized clinical trial. Archives of Internal Medicine2012;172(5):442-4. HajjarI , HartM , ChenYL , MackW , NovakV , ChuiH , et al. Antihypertensive therapy and cerebral hemodynamics in executive mild cognitive impairment: results of a pilot randomized clinical trial. Journal of the American Geriatrics Society2013;61(2):194-201. HajjarI , HartM , MackW , LipsitzLA . Aldosterone, cognitive function, and cerebral hemodynamics in hypertension and antihypertensive therapy. American Journal of Hypertension2015;28(3):319-25. HajjarI , HartM , MilbergW , NovakV , LipsitzL . The rationale and design of the antihypertensives and vascular, endothelial, and cognitive function (AVEC) trial in elderly hypertensives with early cognitive impairment: role of the renin angiotensin system inhibition. BMC Geriatrics2009;9:48. ">AVEC 2012</a> reported 12‐month cognitive outcomes for only two‐thirds of participants without explanation. <a href="./references#CD004034-bbs2-0005" title="YodfatY , Bar-OnD , AmirM , Cristal N. Quality of life in normotensives compared to hypertensive men treated with isradipine or methyldopa as monotherapy or in combination with captopril: the LOMIR-MCT-IL study.. Journal of Human Hypertension 1996 Feb;10(2):117-22. YodfatY , Cristal N. A multicenter, double-blind, randomized, placebo-controlled study of isradipine and methyldopa as monotherapy or in combination with captopril in the treatment of hypertension. The LOMIR-MCT-IH Research Group.. American Journal of Hypertension 1993 Mar;6(3 Pt 2):57S-61S. ">LOMIR MCT IL 1996</a> and <a href="./references#CD004034-bbs2-0003" title="SatoN , SaijoY , HasebeN , CAMUI investigators. Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial. International Heart Journal2012;53(4):244-8. SatoN , SaijoY , SasagawaY , MorimotoH , TakeuchiT , SanoH , KoyamaS , TakeharaN , MoritaK , SumitomoK , MaruyamaJ , KikuchiK , HasebeN , CAMUI investigators. Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial: results after 1 year. Journal of Hypertension2013;31(6):1245-55. ">CAMUI 2013</a> did not explicitly report numbers completing 12‐month cognitive assessments. In <a href="./references#CD004034-bbs2-0006" title="MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. British Medical Journal1992;304(6824):405-12. PrinceMJ , BirdAS , BlizardRA , MannAH . Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. British Medical Journal1996;312(7034):801-5. ">MRC 1996</a>, <a href="./references#CD004034-bbs2-0001" title="BuseJB , BiggerJT , ByingtonRP , CooperLS , CushmanWC , FriedewaldWT , et al, ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. American Journal of Cardiology2007;99(12A):21i-33i. CushmanWC , Grimm RH Jr, CutlerJA , EvansGW , CapesS , CorsonMA , et al, ACCORD Study Group. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):44i-55i. LaunerLJ , MillerME , WilliamsonJD , LazarRM , GersteinHC , MurrayAM , et al, ACCORD MIND investigators. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurology2011;10(11):969-77. MargolisKL , O'ConnorPJ , MorganTM , BuseJB , CohenRM , CushmanWC , et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care2014;37(6):1721-8. O'ConnorPJ , NarayanKM , AndersonR , FeeneyP , FineL , AliMK , et al. Effect of intensive versus standard blood pressure control on depression and health-related quality of life in type 2 diabetes: the ACCORD trial. Diabetes Care2012;35(7):1479-81. WilliamsonJD , LaunerLJ , BryanRN , CokerLH , LazarRM , GersteinHC , et al, Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Investigators. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Internal Medicine2014;174(3):324-33. WilliamsonJD , MillerME , BryanRN , LazarRM , CokerLH , JohnsonJ , et al, ACCORD Study Group. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. American Journal of Cardiology2007;99(12A):112i-122i. ">ACCORD MIND 2014</a> and <a href="./references#CD004034-bbs2-0010" title="AmbrosiusWT , SinkKM , FoyCG , BerlowitzDR , CheungAK , CushmanWC , FineLJ , Goff DC Jr, JohnsonKC , KilleenAA , LewisCE , OparilS , ReboussinDM , RoccoMV , SnyderJK , WilliamsonJD , Wright JT Jr, WheltonPK , SPRINT Study Research Group. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).. Clinical Trials 2014 Oct;11(5):532-46. BerlowitzDR , FoyCG , KazisLE , BolinLP , ConroyMB , FitzpatrickP , GureTR , KimmelPL , KirchnerK , MoriskyDE , NewmanJ , OlneyC , OparilS , PajewskiNM , PowellJ , RamseyT , SimmonsDL , SnyderJ , SupianoMA , WeinerDE , WhittleJ , SPRINT Research Group. Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes.. The New England Journal of Medicine 2017 Aug 24;377(8):733-744. SPRINT Research Group, Wright JT Jr, WilliamsonJD , WheltonPK , SnyderJK , SinkKM , RoccoMV , ReboussinDM , RahmanM , OparilS , LewisCE , KimmelPL , JohnsonKC , Goff DC Jr, FineLJ , CutlerJA , CushmanWC , CheungAK , Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control.. The New England Journal of Medicine 2015 Nov 26;373(22):2103-16. The SPRINT MIND Investigators for the SPRINT Research Group. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA2019;321(6):553-561. WilliamsonJD , SupianoMA , ApplegateWB , BerlowitzDR , CampbellRC , ChertowGM , FineLJ , HaleyWE , HawfieldAT , IxJH , KitzmanDW , KostisJB , Krousel-WoodMA , LaunerLJ , OparilS , RodriguezCJ , RoumieCL , ShorrRI , SinkKM , WadleyVG , WheltonPK , WhittleJ , WoolardNF , Wright JT Jr, PajewskiNM , SPRINT Research Group. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.. JAMA 2016 Jun 28;315(24):2673-82. ">SPRINT MIND 2019</a>, those with lower baseline scores were less likely to be followed up. <a href="./references#CD004034-bbs2-0010" title="AmbrosiusWT , SinkKM , FoyCG , BerlowitzDR , CheungAK , CushmanWC , FineLJ , Goff DC Jr, JohnsonKC , KilleenAA , LewisCE , OparilS , ReboussinDM , RoccoMV , SnyderJK , WilliamsonJD , Wright JT Jr, WheltonPK , SPRINT Study Research Group. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).. Clinical Trials 2014 Oct;11(5):532-46. BerlowitzDR , FoyCG , KazisLE , BolinLP , ConroyMB , FitzpatrickP , GureTR , KimmelPL , KirchnerK , MoriskyDE , NewmanJ , OlneyC , OparilS , PajewskiNM , PowellJ , RamseyT , SimmonsDL , SnyderJ , SupianoMA , WeinerDE , WhittleJ , SPRINT Research Group. Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes.. The New England Journal of Medicine 2017 Aug 24;377(8):733-744. SPRINT Research Group, Wright JT Jr, WilliamsonJD , WheltonPK , SnyderJK , SinkKM , RoccoMV , ReboussinDM , RahmanM , OparilS , LewisCE , KimmelPL , JohnsonKC , Goff DC Jr, FineLJ , CutlerJA , CushmanWC , CheungAK , Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control.. The New England Journal of Medicine 2015 Nov 26;373(22):2103-16. The SPRINT MIND Investigators for the SPRINT Research Group. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA2019;321(6):553-561. WilliamsonJD , SupianoMA , ApplegateWB , BerlowitzDR , CampbellRC , ChertowGM , FineLJ , HaleyWE , HawfieldAT , IxJH , KitzmanDW , KostisJB , Krousel-WoodMA , LaunerLJ , OparilS , RodriguezCJ , RoumieCL , ShorrRI , SinkKM , WadleyVG , WheltonPK , WhittleJ , WoolardNF , Wright JT Jr, PajewskiNM , SPRINT Research Group. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.. JAMA 2016 Jun 28;315(24):2673-82. ">SPRINT MIND 2019</a> showed that more frail participants were also less likely to be followed up. </p> <p>Due to early termination of the trial, only 44% of participants in <a href="./references#CD004034-bbs2-0004" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumiterscuD , et al, for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. NEJM2008;358:1887-1898. BulpittC , FletcherA , BeckettN , CoopeJ , Gil-ExtremeraB , ForetteF , et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs &amp; Aging2001;18:151-164. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al, for the HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurology2008;7:683-689. PetersR , BeckettN , McCormackT , FagardR , FletcherA , BulpittC . Treating hypertension in the very elderly-benefits, risks, and future directions, a focus on the hypertension in the very elderly trial. European Heart Journal 2014 Jul;35(26):1712-8. PetersR , BeckettN , NunesM , FletcherA , ForetteF , BulpittC . A substudy protocol of the Hypertension in the Very Elderly Trial assessing cognitive decline and dementia incidence (HYVET-COG): an ongoing randomised, double-blind, placebo-controlled trial. Drugs Aging2006;23:83-92. ">HYVET 2008</a> completed a 2‐year follow‐up visit. The study was probably too short to exhibit attrition bias. <a href="./references#CD004034-bbs2-0008" title="Degl'InnocentiA , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , ZanchettiA , WiklundI . Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). Journal of Human Hypertension2004;18(4):239-45. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study of COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. Journal of Hypertension2004;22(8):1605-12. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. Journal of Hypertension2003;21:875-886. PapademetriouV , FarsangC , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , Zanchetti A for the SCOPE Study Group. Stroke Prevention With the Angiotension II Type-1 Receptor Blocker Candesartan in Elderly Patients With Isolated Systolic Hypertension. The Study on Cognition and Prognosis in the Elderly (SCOPE). Journal of the American College of Cardiology2004;44(6):1175-80. SkoogI , LithellH , HanssonL , ElmfeldtD , HofmanA , OlofssonB , et al, for the SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). American Journal of Hypertension2005;18:1052-1059. ">SCOPE 2003</a> reported dementia and cognitive decline outcomes for most participants and was therefore also judged to be at low risk of attrition bias. <a href="./references#CD004034-bbs2-0012" title="JiT , ZhaoY , WangJ , CuiY , DuanD , ChaiQ , et al. Effect of low dose statins and apolipoprotein E genotype on cerebral small vessel disease in older hypertensive patients: a subgroup analysis of a randomized clinical trial. J Am Med Dir Assoc2018;19:995-1002. ZhangH , CuiY , ZhaoY , DongY , DuanD , WangJ , ShengL , JiT , ZhouT , HuW , ChenY , SunS , GongG , ChaiQ , LiuZ . Effects of sartans and low-dose statins on cerebral white matter hyperintensities and cognitive function in older patients with hypertension: a randomized, double-blind and placebo-controlled clinical trial. Hypertension research2018;42(5):717-729. ">Zhang 2018</a> reported annual follow‐up rates of over 90%, up to an average follow‐up of 59.8 months. </p> </section> <section id="CD004034-sec-0062"> <h4 class="title">Selective reporting</h4> <p>Several studies reported data for positive findings only, which increases the risk of selective reporting bias. <a href="./references#CD004034-bbs2-0010" title="AmbrosiusWT , SinkKM , FoyCG , BerlowitzDR , CheungAK , CushmanWC , FineLJ , Goff DC Jr, JohnsonKC , KilleenAA , LewisCE , OparilS , ReboussinDM , RoccoMV , SnyderJK , WilliamsonJD , Wright JT Jr, WheltonPK , SPRINT Study Research Group. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).. Clinical Trials 2014 Oct;11(5):532-46. BerlowitzDR , FoyCG , KazisLE , BolinLP , ConroyMB , FitzpatrickP , GureTR , KimmelPL , KirchnerK , MoriskyDE , NewmanJ , OlneyC , OparilS , PajewskiNM , PowellJ , RamseyT , SimmonsDL , SnyderJ , SupianoMA , WeinerDE , WhittleJ , SPRINT Research Group. Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes.. The New England Journal of Medicine 2017 Aug 24;377(8):733-744. SPRINT Research Group, Wright JT Jr, WilliamsonJD , WheltonPK , SnyderJK , SinkKM , RoccoMV , ReboussinDM , RahmanM , OparilS , LewisCE , KimmelPL , JohnsonKC , Goff DC Jr, FineLJ , CutlerJA , CushmanWC , CheungAK , Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control.. The New England Journal of Medicine 2015 Nov 26;373(22):2103-16. The SPRINT MIND Investigators for the SPRINT Research Group. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA2019;321(6):553-561. WilliamsonJD , SupianoMA , ApplegateWB , BerlowitzDR , CampbellRC , ChertowGM , FineLJ , HaleyWE , HawfieldAT , IxJH , KitzmanDW , KostisJB , Krousel-WoodMA , LaunerLJ , OparilS , RodriguezCJ , RoumieCL , ShorrRI , SinkKM , WadleyVG , WheltonPK , WhittleJ , WoolardNF , Wright JT Jr, PajewskiNM , SPRINT Research Group. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.. JAMA 2016 Jun 28;315(24):2673-82. ">SPRINT MIND 2019</a> reported mild cognitive impairment (MCI) as a secondary outcome; however, in the original study protocol, it was described as 'not a primary or secondary outcome'. <a href="./references#CD004034-bbs2-0049" title="MaL , LuP , ZhangY , MengX , FanP , MaL , et al. Effects of antihypertensive therapy on cognitive function and health-related quality of life in high-risk hypertensive patients. Journal of Hypertension. Conference: 27th Scientific Meeting of the International Society of Hypertension, ISH2018;36(Suppl 3):e334-5. MaL , WangW , ZhaoY , ZhangY , DengQ , LiuM , et al. Combination of amlodipine plus angiotensin receptor blocker or diuretics in high-risk hypertensive patients: a 96-week efficacy and safety study. Am J Cardiovasc Drugs2012;12(2):137-42. WangW , MaL , ZhangY , DengQ , LiuM , LiuL . The combination of amlodipine and angiotensin receptor blocker or diuretics in high-risk hypertensive patients: rationale, design and baseline characteristics. J Hum Hypertens2011;25(4):271-7. WangW , MaLY , LiuMB , DengQ , ZhangYQ , LiW , et al, CHIEF Cooperative Group. Effects of amlodipine plus telmisartan or amlodipine plus amiloride regimen on blood pressure control in hypertensive patients: preliminary report of Chinese Hypertension Intervention Efficacy (CHIEF) trial. Zhonghua Xin Xue Guan Bing Za Zhi2009;37(8):701-7. ">CHIEF 2012</a>, a randomised, open‐label, blinded endpoint study comparing CCB plus diuretic and CCB plus ARB in 13,542 hypertensive Chinese participants, measured MMSE at baseline and during follow‐up. A conference abstract from 2018 reports headline results; however, our attempts to contact the authors for further information were unsuccessful. </p> </section> <section id="CD004034-sec-0063"> <h4 class="title">Other potential sources of bias</h4> <p>Dropout rates due to adverse events or lack of treatment effect, or both, did differ across groups and raise the possibility of contamination bias. In the eight placebo‐controlled trials, a proportion of the participants assigned to the placebo group received antihypertensive treatment because their BP exceeded pre‐set 'escape criteria'. Also, a proportion of participants assigned to antihypertensive treatment groups stopped taking their medications due to side effects or because they achieved normal blood pressure off medication. The degree to which participants cross over from one group to another reduces the strength of the results of a study. The percentage of participants assigned to placebo groups who were receiving antihypertensive medication by the end of trials were as follows: <a href="./references#CD004034-bbs2-0009" title="ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the Treatment of Isolated Systolic Hypertension on Behavioral Variables. Results From the Systolic Hypertension in the Elderly Program. Arch Intern Med1994;154:2154-2160. Di BariM , PahorM , FranseLV , ShorrRI , WanJY , FerrucciL , et al. Dementia and Disability Outcomes in Large Hypertension Trials: Lessons Learned from the Systolic Hypertension in the Elderly Program (SHEP) Trial. American Journal of Epidemiology2001;153:72-8. SHEP Cooperative Research Group. Prevention of Stroke by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic Hypertension. Final Results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265:3255-64. The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and Design of a Randomized Clinical Trial on Prevention of Stroke in Isolated Systolic Hypertension. Journal of Clinical Epidemiology1988;41:1197-1208. ">SHEP 1991</a> ‐ 44%; <a href="./references#CD004034-bbs2-0011" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , De LeeuwP , DolleryCT , et al. Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: Objectives, protocol, and organization. Aging Clin Exp Res1991;3:287-302. FletcherAE , BulpittCJ , ThijsL , ToumilehtoJ , AntikainenR , BossiniA , et al. Quality of life on randomised treatment for isolated hypertension: results from the Syst-Eur Trial. Journal of Hypertension2002;20:2069-2079. FletcherAE , BulpittCJ , TuomilehtoJ , BrowneJ , BossiniA , Kawecka-JaszczK , et al. Quality of life of elderly patients with isolated systolic hypertension: baseline data from the Syst-Eur Trial. Journal of Hypertension1988;16:1117-1124. ForetteF , Seux M-L, StaessenJA , ThijsL , Babarskiene M-R, BabeanuS , et al. The Prevention of Dementia With Antihypertensive Treatment. New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study. Archives of Internal Medicine2002;162:2046-2052. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH , BabarskieneMR , et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet1998;352:1347-51. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH . Reduction of dementia by calcium-antagonist-based antihypertensive treatment. European Heart Journal Supplements2000;2:D17-D19. StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Lancet1997;350:757-764. ">Syst Eur 1998</a> ‐ 27%; and <a href="./references#CD004034-bbs2-0008" title="Degl'InnocentiA , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , ZanchettiA , WiklundI . Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). Journal of Human Hypertension2004;18(4):239-45. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study of COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. Journal of Hypertension2004;22(8):1605-12. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. Journal of Hypertension2003;21:875-886. PapademetriouV , FarsangC , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , Zanchetti A for the SCOPE Study Group. Stroke Prevention With the Angiotension II Type-1 Receptor Blocker Candesartan in Elderly Patients With Isolated Systolic Hypertension. The Study on Cognition and Prognosis in the Elderly (SCOPE). Journal of the American College of Cardiology2004;44(6):1175-80. SkoogI , LithellH , HanssonL , ElmfeldtD , HofmanA , OlofssonB , et al, for the SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). American Journal of Hypertension2005;18:1052-1059. ">SCOPE 2003</a> ‐ 84%. In <a href="./references#CD004034-bbs2-0005" title="YodfatY , Bar-OnD , AmirM , Cristal N. Quality of life in normotensives compared to hypertensive men treated with isradipine or methyldopa as monotherapy or in combination with captopril: the LOMIR-MCT-IL study.. Journal of Human Hypertension 1996 Feb;10(2):117-22. YodfatY , Cristal N. A multicenter, double-blind, randomized, placebo-controlled study of isradipine and methyldopa as monotherapy or in combination with captopril in the treatment of hypertension. The LOMIR-MCT-IH Research Group.. American Journal of Hypertension 1993 Mar;6(3 Pt 2):57S-61S. ">LOMIR MCT IL 1996</a>, 27% of participants in the placebo group withdrew. In <a href="./references#CD004034-bbs2-0006" title="MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. British Medical Journal1992;304(6824):405-12. PrinceMJ , BirdAS , BlizardRA , MannAH . Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. British Medical Journal1996;312(7034):801-5. ">MRC 1996</a>, 51% (1309/2584) of participants completed the study in their randomised group, 47% of the placebo group completed the study in their randomised group and without additional antihypertensive therapy (622/1311). In <a href="./references#CD004034-bbs2-0012" title="JiT , ZhaoY , WangJ , CuiY , DuanD , ChaiQ , et al. Effect of low dose statins and apolipoprotein E genotype on cerebral small vessel disease in older hypertensive patients: a subgroup analysis of a randomized clinical trial. J Am Med Dir Assoc2018;19:995-1002. ZhangH , CuiY , ZhaoY , DongY , DuanD , WangJ , ShengL , JiT , ZhouT , HuW , ChenY , SunS , GongG , ChaiQ , LiuZ . Effects of sartans and low-dose statins on cerebral white matter hyperintensities and cognitive function in older patients with hypertension: a randomized, double-blind and placebo-controlled clinical trial. Hypertension research2018;42(5):717-729. ">Zhang 2018</a>, all participants in both groups were commenced on hydrochlorothiazide at the start of the study with the dose increased if required. </p> <p>The percentage of participants assigned to antihypertensive treatment groups who had ceased taking antihypertensive treatment by the end of the trials were as follows: <a href="./references#CD004034-bbs2-0009" title="ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the Treatment of Isolated Systolic Hypertension on Behavioral Variables. Results From the Systolic Hypertension in the Elderly Program. Arch Intern Med1994;154:2154-2160. Di BariM , PahorM , FranseLV , ShorrRI , WanJY , FerrucciL , et al. Dementia and Disability Outcomes in Large Hypertension Trials: Lessons Learned from the Systolic Hypertension in the Elderly Program (SHEP) Trial. American Journal of Epidemiology2001;153:72-8. SHEP Cooperative Research Group. Prevention of Stroke by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic Hypertension. Final Results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265:3255-64. The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and Design of a Randomized Clinical Trial on Prevention of Stroke in Isolated Systolic Hypertension. Journal of Clinical Epidemiology1988;41:1197-1208. ">SHEP 1991</a> ‐ 10%; <a href="./references#CD004034-bbs2-0005" title="YodfatY , Bar-OnD , AmirM , Cristal N. Quality of life in normotensives compared to hypertensive men treated with isradipine or methyldopa as monotherapy or in combination with captopril: the LOMIR-MCT-IL study.. Journal of Human Hypertension 1996 Feb;10(2):117-22. YodfatY , Cristal N. A multicenter, double-blind, randomized, placebo-controlled study of isradipine and methyldopa as monotherapy or in combination with captopril in the treatment of hypertension. The LOMIR-MCT-IH Research Group.. American Journal of Hypertension 1993 Mar;6(3 Pt 2):57S-61S. ">LOMIR MCT IL 1996</a> ‐ 25% (estimated 36/144 as 21 withdrawals in the run‐in phase not described by group and final numbers not reported); <a href="./references#CD004034-bbs2-0011" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , De LeeuwP , DolleryCT , et al. Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: Objectives, protocol, and organization. Aging Clin Exp Res1991;3:287-302. FletcherAE , BulpittCJ , ThijsL , ToumilehtoJ , AntikainenR , BossiniA , et al. Quality of life on randomised treatment for isolated hypertension: results from the Syst-Eur Trial. Journal of Hypertension2002;20:2069-2079. FletcherAE , BulpittCJ , TuomilehtoJ , BrowneJ , BossiniA , Kawecka-JaszczK , et al. Quality of life of elderly patients with isolated systolic hypertension: baseline data from the Syst-Eur Trial. Journal of Hypertension1988;16:1117-1124. ForetteF , Seux M-L, StaessenJA , ThijsL , Babarskiene M-R, BabeanuS , et al. The Prevention of Dementia With Antihypertensive Treatment. New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study. Archives of Internal Medicine2002;162:2046-2052. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH , BabarskieneMR , et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet1998;352:1347-51. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH . Reduction of dementia by calcium-antagonist-based antihypertensive treatment. European Heart Journal Supplements2000;2:D17-D19. StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Lancet1997;350:757-764. ">Syst Eur 1998</a> ‐ 18%; <a href="./references#CD004034-bbs2-0007" title="Pérez-StableEJ , HallidayR , GardinerPS , BaronRB , HauckWW , AcreeM , CoatesTJ . The effects of propranolol on cognitive function and quality of life: a randomized trial among patients with diastolic hypertension.. The American Journal Of Medicine 2000 Apr 1;108(5):359-65. ">Perez Stable 2000</a> ‐ 13%; and <a href="./references#CD004034-bbs2-0008" title="Degl'InnocentiA , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , ZanchettiA , WiklundI . Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). Journal of Human Hypertension2004;18(4):239-45. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study of COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. Journal of Hypertension2004;22(8):1605-12. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. Journal of Hypertension2003;21:875-886. PapademetriouV , FarsangC , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , Zanchetti A for the SCOPE Study Group. Stroke Prevention With the Angiotension II Type-1 Receptor Blocker Candesartan in Elderly Patients With Isolated Systolic Hypertension. The Study on Cognition and Prognosis in the Elderly (SCOPE). Journal of the American College of Cardiology2004;44(6):1175-80. SkoogI , LithellH , HanssonL , ElmfeldtD , HofmanA , OlofssonB , et al, for the SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). American Journal of Hypertension2005;18:1052-1059. ">SCOPE 2003</a> ‐ 0%.The percentage of participants taking initially assigned medication alone, where reported, were as follows: <a href="./references#CD004034-bbs2-0009" title="ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the Treatment of Isolated Systolic Hypertension on Behavioral Variables. Results From the Systolic Hypertension in the Elderly Program. Arch Intern Med1994;154:2154-2160. Di BariM , PahorM , FranseLV , ShorrRI , WanJY , FerrucciL , et al. Dementia and Disability Outcomes in Large Hypertension Trials: Lessons Learned from the Systolic Hypertension in the Elderly Program (SHEP) Trial. American Journal of Epidemiology2001;153:72-8. SHEP Cooperative Research Group. Prevention of Stroke by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic Hypertension. Final Results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265:3255-64. The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and Design of a Randomized Clinical Trial on Prevention of Stroke in Isolated Systolic Hypertension. Journal of Clinical Epidemiology1988;41:1197-1208. ">SHEP 1991</a> ‐ 30%; <a href="./references#CD004034-bbs2-0011" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , De LeeuwP , DolleryCT , et al. Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: Objectives, protocol, and organization. Aging Clin Exp Res1991;3:287-302. FletcherAE , BulpittCJ , ThijsL , ToumilehtoJ , AntikainenR , BossiniA , et al. Quality of life on randomised treatment for isolated hypertension: results from the Syst-Eur Trial. Journal of Hypertension2002;20:2069-2079. FletcherAE , BulpittCJ , TuomilehtoJ , BrowneJ , BossiniA , Kawecka-JaszczK , et al. Quality of life of elderly patients with isolated systolic hypertension: baseline data from the Syst-Eur Trial. Journal of Hypertension1988;16:1117-1124. ForetteF , Seux M-L, StaessenJA , ThijsL , Babarskiene M-R, BabeanuS , et al. The Prevention of Dementia With Antihypertensive Treatment. New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study. Archives of Internal Medicine2002;162:2046-2052. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH , BabarskieneMR , et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet1998;352:1347-51. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH . Reduction of dementia by calcium-antagonist-based antihypertensive treatment. European Heart Journal Supplements2000;2:D17-D19. StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Lancet1997;350:757-764. ">Syst Eur 1998</a> ‐ 30%; and <a href="./references#CD004034-bbs2-0008" title="Degl'InnocentiA , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , ZanchettiA , WiklundI . Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). Journal of Human Hypertension2004;18(4):239-45. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study of COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. Journal of Hypertension2004;22(8):1605-12. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. Journal of Hypertension2003;21:875-886. PapademetriouV , FarsangC , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , Zanchetti A for the SCOPE Study Group. Stroke Prevention With the Angiotension II Type-1 Receptor Blocker Candesartan in Elderly Patients With Isolated Systolic Hypertension. The Study on Cognition and Prognosis in the Elderly (SCOPE). Journal of the American College of Cardiology2004;44(6):1175-80. SkoogI , LithellH , HanssonL , ElmfeldtD , HofmanA , OlofssonB , et al, for the SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). American Journal of Hypertension2005;18:1052-1059. ">SCOPE 2003</a> ‐ 25%. An estimated 20% to 50% of participants in <a href="./references#CD004034-bbs2-0005" title="YodfatY , Bar-OnD , AmirM , Cristal N. Quality of life in normotensives compared to hypertensive men treated with isradipine or methyldopa as monotherapy or in combination with captopril: the LOMIR-MCT-IL study.. Journal of Human Hypertension 1996 Feb;10(2):117-22. YodfatY , Cristal N. A multicenter, double-blind, randomized, placebo-controlled study of isradipine and methyldopa as monotherapy or in combination with captopril in the treatment of hypertension. The LOMIR-MCT-IH Research Group.. American Journal of Hypertension 1993 Mar;6(3 Pt 2):57S-61S. ">LOMIR MCT IL 1996</a> were prescribed captopril in addition to the original study drug but explicit figures were not reported. In <a href="./references#CD004034-bbs2-0004" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumiterscuD , et al, for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. NEJM2008;358:1887-1898. BulpittC , FletcherA , BeckettN , CoopeJ , Gil-ExtremeraB , ForetteF , et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs &amp; Aging2001;18:151-164. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al, for the HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurology2008;7:683-689. PetersR , BeckettN , McCormackT , FagardR , FletcherA , BulpittC . Treating hypertension in the very elderly-benefits, risks, and future directions, a focus on the hypertension in the very elderly trial. European Heart Journal 2014 Jul;35(26):1712-8. PetersR , BeckettN , NunesM , FletcherA , ForetteF , BulpittC . A substudy protocol of the Hypertension in the Very Elderly Trial assessing cognitive decline and dementia incidence (HYVET-COG): an ongoing randomised, double-blind, placebo-controlled trial. Drugs Aging2006;23:83-92. ">HYVET 2008</a>, at the 2‐year follow‐up, 0.8% of the antihypertensive treatment group were not taking one of the three treatment steps specified in the protocol, and 0.6% of the placebo group were not taking one of the matching placebo steps specified in the protocol. We have therefore judged <a href="./references#CD004034-bbs2-0009" title="ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the Treatment of Isolated Systolic Hypertension on Behavioral Variables. Results From the Systolic Hypertension in the Elderly Program. Arch Intern Med1994;154:2154-2160. Di BariM , PahorM , FranseLV , ShorrRI , WanJY , FerrucciL , et al. Dementia and Disability Outcomes in Large Hypertension Trials: Lessons Learned from the Systolic Hypertension in the Elderly Program (SHEP) Trial. American Journal of Epidemiology2001;153:72-8. SHEP Cooperative Research Group. Prevention of Stroke by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic Hypertension. Final Results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265:3255-64. The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and Design of a Randomized Clinical Trial on Prevention of Stroke in Isolated Systolic Hypertension. Journal of Clinical Epidemiology1988;41:1197-1208. ">SHEP 1991</a>, <a href="./references#CD004034-bbs2-0005" title="YodfatY , Bar-OnD , AmirM , Cristal N. Quality of life in normotensives compared to hypertensive men treated with isradipine or methyldopa as monotherapy or in combination with captopril: the LOMIR-MCT-IL study.. Journal of Human Hypertension 1996 Feb;10(2):117-22. YodfatY , Cristal N. A multicenter, double-blind, randomized, placebo-controlled study of isradipine and methyldopa as monotherapy or in combination with captopril in the treatment of hypertension. The LOMIR-MCT-IH Research Group.. American Journal of Hypertension 1993 Mar;6(3 Pt 2):57S-61S. ">LOMIR MCT IL 1996</a>, <a href="./references#CD004034-bbs2-0006" title="MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. British Medical Journal1992;304(6824):405-12. PrinceMJ , BirdAS , BlizardRA , MannAH . Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. British Medical Journal1996;312(7034):801-5. ">MRC 1996</a>, <a href="./references#CD004034-bbs2-0011" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , De LeeuwP , DolleryCT , et al. Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: Objectives, protocol, and organization. Aging Clin Exp Res1991;3:287-302. FletcherAE , BulpittCJ , ThijsL , ToumilehtoJ , AntikainenR , BossiniA , et al. Quality of life on randomised treatment for isolated hypertension: results from the Syst-Eur Trial. Journal of Hypertension2002;20:2069-2079. FletcherAE , BulpittCJ , TuomilehtoJ , BrowneJ , BossiniA , Kawecka-JaszczK , et al. Quality of life of elderly patients with isolated systolic hypertension: baseline data from the Syst-Eur Trial. Journal of Hypertension1988;16:1117-1124. ForetteF , Seux M-L, StaessenJA , ThijsL , Babarskiene M-R, BabeanuS , et al. The Prevention of Dementia With Antihypertensive Treatment. New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study. Archives of Internal Medicine2002;162:2046-2052. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH , BabarskieneMR , et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet1998;352:1347-51. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH . Reduction of dementia by calcium-antagonist-based antihypertensive treatment. European Heart Journal Supplements2000;2:D17-D19. StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Lancet1997;350:757-764. ">Syst Eur 1998</a>, <a href="./references#CD004034-bbs2-0007" title="Pérez-StableEJ , HallidayR , GardinerPS , BaronRB , HauckWW , AcreeM , CoatesTJ . The effects of propranolol on cognitive function and quality of life: a randomized trial among patients with diastolic hypertension.. The American Journal Of Medicine 2000 Apr 1;108(5):359-65. ">Perez Stable 2000</a>, <a href="./references#CD004034-bbs2-0008" title="Degl'InnocentiA , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , ZanchettiA , WiklundI . Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). Journal of Human Hypertension2004;18(4):239-45. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study of COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. Journal of Hypertension2004;22(8):1605-12. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. Journal of Hypertension2003;21:875-886. PapademetriouV , FarsangC , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , Zanchetti A for the SCOPE Study Group. Stroke Prevention With the Angiotension II Type-1 Receptor Blocker Candesartan in Elderly Patients With Isolated Systolic Hypertension. The Study on Cognition and Prognosis in the Elderly (SCOPE). Journal of the American College of Cardiology2004;44(6):1175-80. SkoogI , LithellH , HanssonL , ElmfeldtD , HofmanA , OlofssonB , et al, for the SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). American Journal of Hypertension2005;18:1052-1059. ">SCOPE 2003</a> and <a href="./references#CD004034-bbs2-0012" title="JiT , ZhaoY , WangJ , CuiY , DuanD , ChaiQ , et al. Effect of low dose statins and apolipoprotein E genotype on cerebral small vessel disease in older hypertensive patients: a subgroup analysis of a randomized clinical trial. J Am Med Dir Assoc2018;19:995-1002. ZhangH , CuiY , ZhaoY , DongY , DuanD , WangJ , ShengL , JiT , ZhouT , HuW , ChenY , SunS , GongG , ChaiQ , LiuZ . Effects of sartans and low-dose statins on cerebral white matter hyperintensities and cognitive function in older patients with hypertension: a randomized, double-blind and placebo-controlled clinical trial. Hypertension research2018;42(5):717-729. ">Zhang 2018</a> to be at high risk of contamination bias. This is likely to have led to a systematic underestimate of the effect size. </p> <p><a href="./references#CD004034-bbs2-0010" title="AmbrosiusWT , SinkKM , FoyCG , BerlowitzDR , CheungAK , CushmanWC , FineLJ , Goff DC Jr, JohnsonKC , KilleenAA , LewisCE , OparilS , ReboussinDM , RoccoMV , SnyderJK , WilliamsonJD , Wright JT Jr, WheltonPK , SPRINT Study Research Group. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).. Clinical Trials 2014 Oct;11(5):532-46. BerlowitzDR , FoyCG , KazisLE , BolinLP , ConroyMB , FitzpatrickP , GureTR , KimmelPL , KirchnerK , MoriskyDE , NewmanJ , OlneyC , OparilS , PajewskiNM , PowellJ , RamseyT , SimmonsDL , SnyderJ , SupianoMA , WeinerDE , WhittleJ , SPRINT Research Group. Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes.. The New England Journal of Medicine 2017 Aug 24;377(8):733-744. SPRINT Research Group, Wright JT Jr, WilliamsonJD , WheltonPK , SnyderJK , SinkKM , RoccoMV , ReboussinDM , RahmanM , OparilS , LewisCE , KimmelPL , JohnsonKC , Goff DC Jr, FineLJ , CutlerJA , CushmanWC , CheungAK , Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control.. The New England Journal of Medicine 2015 Nov 26;373(22):2103-16. The SPRINT MIND Investigators for the SPRINT Research Group. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA2019;321(6):553-561. WilliamsonJD , SupianoMA , ApplegateWB , BerlowitzDR , CampbellRC , ChertowGM , FineLJ , HaleyWE , HawfieldAT , IxJH , KitzmanDW , KostisJB , Krousel-WoodMA , LaunerLJ , OparilS , RodriguezCJ , RoumieCL , ShorrRI , SinkKM , WadleyVG , WheltonPK , WhittleJ , WoolardNF , Wright JT Jr, PajewskiNM , SPRINT Research Group. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.. JAMA 2016 Jun 28;315(24):2673-82. ">SPRINT MIND 2019</a> reported headline outcomes from an extended follow‐up visit, two years after the study had been terminated. We have included the results from the in‐study visits here, where possible. </p> <p>The process of identifying cases of dementia in <a href="./references#CD004034-bbs2-0011" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , De LeeuwP , DolleryCT , et al. Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: Objectives, protocol, and organization. Aging Clin Exp Res1991;3:287-302. FletcherAE , BulpittCJ , ThijsL , ToumilehtoJ , AntikainenR , BossiniA , et al. Quality of life on randomised treatment for isolated hypertension: results from the Syst-Eur Trial. Journal of Hypertension2002;20:2069-2079. FletcherAE , BulpittCJ , TuomilehtoJ , BrowneJ , BossiniA , Kawecka-JaszczK , et al. Quality of life of elderly patients with isolated systolic hypertension: baseline data from the Syst-Eur Trial. Journal of Hypertension1988;16:1117-1124. ForetteF , Seux M-L, StaessenJA , ThijsL , Babarskiene M-R, BabeanuS , et al. The Prevention of Dementia With Antihypertensive Treatment. New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study. Archives of Internal Medicine2002;162:2046-2052. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH , BabarskieneMR , et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet1998;352:1347-51. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH . Reduction of dementia by calcium-antagonist-based antihypertensive treatment. European Heart Journal Supplements2000;2:D17-D19. StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Lancet1997;350:757-764. ">Syst Eur 1998</a>, <a href="./references#CD004034-bbs2-0008" title="Degl'InnocentiA , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , ZanchettiA , WiklundI . Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). Journal of Human Hypertension2004;18(4):239-45. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study of COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. Journal of Hypertension2004;22(8):1605-12. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. Journal of Hypertension2003;21:875-886. PapademetriouV , FarsangC , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , Zanchetti A for the SCOPE Study Group. Stroke Prevention With the Angiotension II Type-1 Receptor Blocker Candesartan in Elderly Patients With Isolated Systolic Hypertension. The Study on Cognition and Prognosis in the Elderly (SCOPE). Journal of the American College of Cardiology2004;44(6):1175-80. SkoogI , LithellH , HanssonL , ElmfeldtD , HofmanA , OlofssonB , et al, for the SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). American Journal of Hypertension2005;18:1052-1059. ">SCOPE 2003</a>, <a href="./references#CD004034-bbs2-0004" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumiterscuD , et al, for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. NEJM2008;358:1887-1898. BulpittC , FletcherA , BeckettN , CoopeJ , Gil-ExtremeraB , ForetteF , et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs &amp; Aging2001;18:151-164. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al, for the HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurology2008;7:683-689. PetersR , BeckettN , McCormackT , FagardR , FletcherA , BulpittC . Treating hypertension in the very elderly-benefits, risks, and future directions, a focus on the hypertension in the very elderly trial. European Heart Journal 2014 Jul;35(26):1712-8. PetersR , BeckettN , NunesM , FletcherA , ForetteF , BulpittC . A substudy protocol of the Hypertension in the Very Elderly Trial assessing cognitive decline and dementia incidence (HYVET-COG): an ongoing randomised, double-blind, placebo-controlled trial. Drugs Aging2006;23:83-92. ">HYVET 2008</a> and <a href="./references#CD004034-bbs2-0010" title="AmbrosiusWT , SinkKM , FoyCG , BerlowitzDR , CheungAK , CushmanWC , FineLJ , Goff DC Jr, JohnsonKC , KilleenAA , LewisCE , OparilS , ReboussinDM , RoccoMV , SnyderJK , WilliamsonJD , Wright JT Jr, WheltonPK , SPRINT Study Research Group. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).. Clinical Trials 2014 Oct;11(5):532-46. BerlowitzDR , FoyCG , KazisLE , BolinLP , ConroyMB , FitzpatrickP , GureTR , KimmelPL , KirchnerK , MoriskyDE , NewmanJ , OlneyC , OparilS , PajewskiNM , PowellJ , RamseyT , SimmonsDL , SnyderJ , SupianoMA , WeinerDE , WhittleJ , SPRINT Research Group. Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes.. The New England Journal of Medicine 2017 Aug 24;377(8):733-744. SPRINT Research Group, Wright JT Jr, WilliamsonJD , WheltonPK , SnyderJK , SinkKM , RoccoMV , ReboussinDM , RahmanM , OparilS , LewisCE , KimmelPL , JohnsonKC , Goff DC Jr, FineLJ , CutlerJA , CushmanWC , CheungAK , Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control.. The New England Journal of Medicine 2015 Nov 26;373(22):2103-16. The SPRINT MIND Investigators for the SPRINT Research Group. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA2019;321(6):553-561. WilliamsonJD , SupianoMA , ApplegateWB , BerlowitzDR , CampbellRC , ChertowGM , FineLJ , HaleyWE , HawfieldAT , IxJH , KitzmanDW , KostisJB , Krousel-WoodMA , LaunerLJ , OparilS , RodriguezCJ , RoumieCL , ShorrRI , SinkKM , WadleyVG , WheltonPK , WhittleJ , WoolardNF , Wright JT Jr, PajewskiNM , SPRINT Research Group. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.. JAMA 2016 Jun 28;315(24):2673-82. ">SPRINT MIND 2019</a> may have led to a systematic underestimation of the effect by relying on screening tests such as MMSE, which are known to lack sensitivity (<a href="./references#CD004034-bbs2-0061" title="CreavinST , WisniewskiS , Noel‐StorrAH , TrevelyanCM , HamptonT , RaymentD , et al. Mini‐Mental State Examination (MMSE) for the detection of dementia in clinically unevaluated people aged 65 and over in community and primary care populations. Cochrane Database of Systematic Reviews2016, Issue 1. Art. No: CD011145. [DOI: 10.1002/14651858.CD011145.pub2]">Creavin 2016</a>), and in the case of <a href="./references#CD004034-bbs2-0010" title="AmbrosiusWT , SinkKM , FoyCG , BerlowitzDR , CheungAK , CushmanWC , FineLJ , Goff DC Jr, JohnsonKC , KilleenAA , LewisCE , OparilS , ReboussinDM , RoccoMV , SnyderJK , WilliamsonJD , Wright JT Jr, WheltonPK , SPRINT Study Research Group. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).. Clinical Trials 2014 Oct;11(5):532-46. BerlowitzDR , FoyCG , KazisLE , BolinLP , ConroyMB , FitzpatrickP , GureTR , KimmelPL , KirchnerK , MoriskyDE , NewmanJ , OlneyC , OparilS , PajewskiNM , PowellJ , RamseyT , SimmonsDL , SnyderJ , SupianoMA , WeinerDE , WhittleJ , SPRINT Research Group. Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes.. The New England Journal of Medicine 2017 Aug 24;377(8):733-744. SPRINT Research Group, Wright JT Jr, WilliamsonJD , WheltonPK , SnyderJK , SinkKM , RoccoMV , ReboussinDM , RahmanM , OparilS , LewisCE , KimmelPL , JohnsonKC , Goff DC Jr, FineLJ , CutlerJA , CushmanWC , CheungAK , Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control.. The New England Journal of Medicine 2015 Nov 26;373(22):2103-16. The SPRINT MIND Investigators for the SPRINT Research Group. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA2019;321(6):553-561. WilliamsonJD , SupianoMA , ApplegateWB , BerlowitzDR , CampbellRC , ChertowGM , FineLJ , HaleyWE , HawfieldAT , IxJH , KitzmanDW , KostisJB , Krousel-WoodMA , LaunerLJ , OparilS , RodriguezCJ , RoumieCL , ShorrRI , SinkKM , WadleyVG , WheltonPK , WhittleJ , WoolardNF , Wright JT Jr, PajewskiNM , SPRINT Research Group. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.. JAMA 2016 Jun 28;315(24):2673-82. ">SPRINT MIND 2019</a>, a MoCA score below that shown to be most sensitive (<a href="./references#CD004034-bbs2-0062" title="DavisDH , CreavinST , YipJL , Noel‐StorrAH , BrayneC , CullumS . Montreal Cognitive Assessment for the diagnosis of Alzheimer’s disease and other dementias. Cochrane Database of Systematic Reviews2015, Issue 10. Art. No: CD010775. [DOI: 10.1002/14651858.CD010775.pub2]">Davis 2015</a>). </p> </section> </section> <section id="CD004034-sec-0064"> <h3 class="title" id="CD004034-sec-0064">Effects of interventions</h3> <p>See: <a href="./full#CD004034-tbl-0001"><b>Summary of findings 1</b> Antihypertensive therapy compared to placebo for patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia</a> </p> <section id="CD004034-sec-0065"> <h4 class="title">Comparison 1: Antihypertensive therapy compared to placebo</h4> <section id="CD004034-sec-0066"> <h5 class="title">Incidence of dementia</h5> <p>Incidence of dementia was a secondary outcome in five of the included trials (<a href="./references#CD004034-bbs2-0009" title="ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the Treatment of Isolated Systolic Hypertension on Behavioral Variables. Results From the Systolic Hypertension in the Elderly Program. Arch Intern Med1994;154:2154-2160. Di BariM , PahorM , FranseLV , ShorrRI , WanJY , FerrucciL , et al. Dementia and Disability Outcomes in Large Hypertension Trials: Lessons Learned from the Systolic Hypertension in the Elderly Program (SHEP) Trial. American Journal of Epidemiology2001;153:72-8. SHEP Cooperative Research Group. Prevention of Stroke by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic Hypertension. Final Results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265:3255-64. The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and Design of a Randomized Clinical Trial on Prevention of Stroke in Isolated Systolic Hypertension. Journal of Clinical Epidemiology1988;41:1197-1208. ">SHEP 1991</a>; <a href="./references#CD004034-bbs2-0011" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , De LeeuwP , DolleryCT , et al. Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: Objectives, protocol, and organization. Aging Clin Exp Res1991;3:287-302. FletcherAE , BulpittCJ , ThijsL , ToumilehtoJ , AntikainenR , BossiniA , et al. Quality of life on randomised treatment for isolated hypertension: results from the Syst-Eur Trial. Journal of Hypertension2002;20:2069-2079. FletcherAE , BulpittCJ , TuomilehtoJ , BrowneJ , BossiniA , Kawecka-JaszczK , et al. Quality of life of elderly patients with isolated systolic hypertension: baseline data from the Syst-Eur Trial. Journal of Hypertension1988;16:1117-1124. ForetteF , Seux M-L, StaessenJA , ThijsL , Babarskiene M-R, BabeanuS , et al. The Prevention of Dementia With Antihypertensive Treatment. New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study. Archives of Internal Medicine2002;162:2046-2052. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH , BabarskieneMR , et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet1998;352:1347-51. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH . Reduction of dementia by calcium-antagonist-based antihypertensive treatment. European Heart Journal Supplements2000;2:D17-D19. StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Lancet1997;350:757-764. ">Syst Eur 1998</a>; <a href="./references#CD004034-bbs2-0008" title="Degl'InnocentiA , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , ZanchettiA , WiklundI . Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). Journal of Human Hypertension2004;18(4):239-45. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study of COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. Journal of Hypertension2004;22(8):1605-12. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. Journal of Hypertension2003;21:875-886. PapademetriouV , FarsangC , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , Zanchetti A for the SCOPE Study Group. Stroke Prevention With the Angiotension II Type-1 Receptor Blocker Candesartan in Elderly Patients With Isolated Systolic Hypertension. The Study on Cognition and Prognosis in the Elderly (SCOPE). Journal of the American College of Cardiology2004;44(6):1175-80. SkoogI , LithellH , HanssonL , ElmfeldtD , HofmanA , OlofssonB , et al, for the SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). American Journal of Hypertension2005;18:1052-1059. ">SCOPE 2003</a>; <a href="./references#CD004034-bbs2-0004" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumiterscuD , et al, for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. NEJM2008;358:1887-1898. BulpittC , FletcherA , BeckettN , CoopeJ , Gil-ExtremeraB , ForetteF , et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs &amp; Aging2001;18:151-164. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al, for the HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurology2008;7:683-689. PetersR , BeckettN , McCormackT , FagardR , FletcherA , BulpittC . Treating hypertension in the very elderly-benefits, risks, and future directions, a focus on the hypertension in the very elderly trial. European Heart Journal 2014 Jul;35(26):1712-8. PetersR , BeckettN , NunesM , FletcherA , ForetteF , BulpittC . A substudy protocol of the Hypertension in the Very Elderly Trial assessing cognitive decline and dementia incidence (HYVET-COG): an ongoing randomised, double-blind, placebo-controlled trial. Drugs Aging2006;23:83-92. ">HYVET 2008</a>; <a href="./references#CD004034-bbs2-0010" title="AmbrosiusWT , SinkKM , FoyCG , BerlowitzDR , CheungAK , CushmanWC , FineLJ , Goff DC Jr, JohnsonKC , KilleenAA , LewisCE , OparilS , ReboussinDM , RoccoMV , SnyderJK , WilliamsonJD , Wright JT Jr, WheltonPK , SPRINT Study Research Group. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).. Clinical Trials 2014 Oct;11(5):532-46. BerlowitzDR , FoyCG , KazisLE , BolinLP , ConroyMB , FitzpatrickP , GureTR , KimmelPL , KirchnerK , MoriskyDE , NewmanJ , OlneyC , OparilS , PajewskiNM , PowellJ , RamseyT , SimmonsDL , SnyderJ , SupianoMA , WeinerDE , WhittleJ , SPRINT Research Group. Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes.. The New England Journal of Medicine 2017 Aug 24;377(8):733-744. SPRINT Research Group, Wright JT Jr, WilliamsonJD , WheltonPK , SnyderJK , SinkKM , RoccoMV , ReboussinDM , RahmanM , OparilS , LewisCE , KimmelPL , JohnsonKC , Goff DC Jr, FineLJ , CutlerJA , CushmanWC , CheungAK , Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control.. The New England Journal of Medicine 2015 Nov 26;373(22):2103-16. The SPRINT MIND Investigators for the SPRINT Research Group. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA2019;321(6):553-561. WilliamsonJD , SupianoMA , ApplegateWB , BerlowitzDR , CampbellRC , ChertowGM , FineLJ , HaleyWE , HawfieldAT , IxJH , KitzmanDW , KostisJB , Krousel-WoodMA , LaunerLJ , OparilS , RodriguezCJ , RoumieCL , ShorrRI , SinkKM , WadleyVG , WheltonPK , WhittleJ , WoolardNF , Wright JT Jr, PajewskiNM , SPRINT Research Group. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.. JAMA 2016 Jun 28;315(24):2673-82. ">SPRINT MIND 2019</a>). The combined results of the four placebo‐controlled trials suggest that antihypertensive treatment results in little to no difference in dementia incidence (OR = 0.89, 95% CI 0.72 to 1.09; 4 trials, 15,427 participants; <a href="./references#CD004034-fig-0002" title="">Analysis 1.1</a>). We considered this to be very low certainty evidence, downgraded due to study limitations and indirectness. The incidence of dementia was lower in the antihypertensive group but there was uncertainty regarding the size and direction of effect. </p> <p>Of the individual studies, only <a href="./references#CD004034-bbs2-0011" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , De LeeuwP , DolleryCT , et al. Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: Objectives, protocol, and organization. Aging Clin Exp Res1991;3:287-302. FletcherAE , BulpittCJ , ThijsL , ToumilehtoJ , AntikainenR , BossiniA , et al. Quality of life on randomised treatment for isolated hypertension: results from the Syst-Eur Trial. Journal of Hypertension2002;20:2069-2079. FletcherAE , BulpittCJ , TuomilehtoJ , BrowneJ , BossiniA , Kawecka-JaszczK , et al. Quality of life of elderly patients with isolated systolic hypertension: baseline data from the Syst-Eur Trial. Journal of Hypertension1988;16:1117-1124. ForetteF , Seux M-L, StaessenJA , ThijsL , Babarskiene M-R, BabeanuS , et al. The Prevention of Dementia With Antihypertensive Treatment. New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study. Archives of Internal Medicine2002;162:2046-2052. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH , BabarskieneMR , et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet1998;352:1347-51. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH . Reduction of dementia by calcium-antagonist-based antihypertensive treatment. European Heart Journal Supplements2000;2:D17-D19. StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Lancet1997;350:757-764. ">Syst Eur 1998</a> reported a significant benefit of the intervention. There were 21 cases of incident dementia in the placebo group and 11 in the antihypertensive group. The numbers of patient years were 2737 and 2885, respectively. Active treatment reduced the rate of dementia by 50% (95% CI 0 to 76) from 7.7 to 3.8 cases per 1000 patient‐years (P = 0.05). However, when the numbers of participants in the antihypertensive (1238) and placebo groups (1180) are considered, consistent with analysis of the other included studies, the benefit with antihypertensive treatment is no longer significant (OR 0.49, 95% CI 0.24 to 1.03; <a href="./references#CD004034-fig-0002" title="">Analysis 1.1</a>). </p> <p>We conducted a sensitivity analysis excluding <a href="./references#CD004034-bbs2-0008" title="Degl'InnocentiA , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , ZanchettiA , WiklundI . Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). Journal of Human Hypertension2004;18(4):239-45. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study of COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. Journal of Hypertension2004;22(8):1605-12. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. Journal of Hypertension2003;21:875-886. PapademetriouV , FarsangC , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , Zanchetti A for the SCOPE Study Group. Stroke Prevention With the Angiotension II Type-1 Receptor Blocker Candesartan in Elderly Patients With Isolated Systolic Hypertension. The Study on Cognition and Prognosis in the Elderly (SCOPE). Journal of the American College of Cardiology2004;44(6):1175-80. SkoogI , LithellH , HanssonL , ElmfeldtD , HofmanA , OlofssonB , et al, for the SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). American Journal of Hypertension2005;18:1052-1059. ">SCOPE 2003</a> (due to the very high rate of antihypertensive use in the placebo group), but evidence still suggested that antihypertensive treatment results in little to no difference in dementia incidence. </p> </section> <section id="CD004034-sec-0067"> <h5 class="title">Cognitive change from baseline</h5> <p><a href="./references#CD004034-bbs2-0011" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , De LeeuwP , DolleryCT , et al. Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: Objectives, protocol, and organization. Aging Clin Exp Res1991;3:287-302. FletcherAE , BulpittCJ , ThijsL , ToumilehtoJ , AntikainenR , BossiniA , et al. Quality of life on randomised treatment for isolated hypertension: results from the Syst-Eur Trial. Journal of Hypertension2002;20:2069-2079. FletcherAE , BulpittCJ , TuomilehtoJ , BrowneJ , BossiniA , Kawecka-JaszczK , et al. Quality of life of elderly patients with isolated systolic hypertension: baseline data from the Syst-Eur Trial. Journal of Hypertension1988;16:1117-1124. ForetteF , Seux M-L, StaessenJA , ThijsL , Babarskiene M-R, BabeanuS , et al. The Prevention of Dementia With Antihypertensive Treatment. New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study. Archives of Internal Medicine2002;162:2046-2052. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH , BabarskieneMR , et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet1998;352:1347-51. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH . Reduction of dementia by calcium-antagonist-based antihypertensive treatment. European Heart Journal Supplements2000;2:D17-D19. StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Lancet1997;350:757-764. ">Syst Eur 1998</a>, <a href="./references#CD004034-bbs2-0008" title="Degl'InnocentiA , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , ZanchettiA , WiklundI . Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). Journal of Human Hypertension2004;18(4):239-45. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study of COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. Journal of Hypertension2004;22(8):1605-12. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. Journal of Hypertension2003;21:875-886. PapademetriouV , FarsangC , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , Zanchetti A for the SCOPE Study Group. Stroke Prevention With the Angiotension II Type-1 Receptor Blocker Candesartan in Elderly Patients With Isolated Systolic Hypertension. The Study on Cognition and Prognosis in the Elderly (SCOPE). Journal of the American College of Cardiology2004;44(6):1175-80. SkoogI , LithellH , HanssonL , ElmfeldtD , HofmanA , OlofssonB , et al, for the SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). American Journal of Hypertension2005;18:1052-1059. ">SCOPE 2003</a>, <a href="./references#CD004034-bbs2-0004" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumiterscuD , et al, for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. NEJM2008;358:1887-1898. BulpittC , FletcherA , BeckettN , CoopeJ , Gil-ExtremeraB , ForetteF , et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs &amp; Aging2001;18:151-164. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al, for the HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurology2008;7:683-689. PetersR , BeckettN , McCormackT , FagardR , FletcherA , BulpittC . Treating hypertension in the very elderly-benefits, risks, and future directions, a focus on the hypertension in the very elderly trial. European Heart Journal 2014 Jul;35(26):1712-8. PetersR , BeckettN , NunesM , FletcherA , ForetteF , BulpittC . A substudy protocol of the Hypertension in the Very Elderly Trial assessing cognitive decline and dementia incidence (HYVET-COG): an ongoing randomised, double-blind, placebo-controlled trial. Drugs Aging2006;23:83-92. ">HYVET 2008</a> and <a href="./references#CD004034-bbs2-0012" title="JiT , ZhaoY , WangJ , CuiY , DuanD , ChaiQ , et al. Effect of low dose statins and apolipoprotein E genotype on cerebral small vessel disease in older hypertensive patients: a subgroup analysis of a randomized clinical trial. J Am Med Dir Assoc2018;19:995-1002. ZhangH , CuiY , ZhaoY , DongY , DuanD , WangJ , ShengL , JiT , ZhouT , HuW , ChenY , SunS , GongG , ChaiQ , LiuZ . Effects of sartans and low-dose statins on cerebral white matter hyperintensities and cognitive function in older patients with hypertension: a randomized, double-blind and placebo-controlled clinical trial. Hypertension research2018;42(5):717-729. ">Zhang 2018</a> compared antihypertensive treatment to placebo and provided data on cognitive change from baseline. The combined results from these four trials, which reported change in MMSE, showed that MMSE was 0.20 points higher (indicating better cognitive function) in the active treatment group (MD 0.20, 95% CI 0.10 to 0.29; 4 studies, 9335 participants; very low certainty of evidence downgraded due to study limitations, indirectness and imprecision; <a href="./references#CD004034-fig-0003" title="">Analysis 2.1</a>). However, the magnitude of the effect is below that considered statistically significant by convention, as described in the 2014 World Alzheimer's Report (<a href="./references#CD004034-bbs2-0105" title="PrinceM , AlbaneseE , GuerchetM , PrinaM . World Alzheimer Report 2014. Dementia and Risk Reduction: An Analysis Of Protective And Modifiable Factors. London: Alzheimer's Disease International, September 2014.">Prince 2014</a>), as well as that considered minimally clinically significant in the literature (<a href="./references#CD004034-bbs2-0093" title="LopezOL , BeckerJT , SaxtonJ , SweetRA , KlunkW , DeKoskyST . Alteration of a Clinically Meaningful Outcome in the Natural History of Alzheimer's Disease by Cholinesterase Inhibition. Journal of the American Geriatrics Society2005;53(1):83-7.">Lopez 2005</a>; <a href="./references#CD004034-bbs2-0084" title="JonesR , SheehanB , PhillipsP , JuszczakE , AdamsJ , BaldwinA , et al, DOMINO-AD team. DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT. Trials2009;10:57.">Jones 2009</a>; <a href="./references#CD004034-bbs2-0079" title="HowardR , McShaneR , LindesayJ , RitchieC , BaldwinA , BarberR , et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. New England Journal of Medicine2012;366(10):893-903.">Howard 2012</a>; <a href="./references#CD004034-bbs2-0054" title="AndrewsJS , DesaiU , KirsonNY , ZichlinML , BallDE , MatthewsBR . Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials. Alzheimer's &amp; Dementia2019;5:354-363.">Andrews 2019</a>). </p> <p>We conducted a sensitivity analysis excluding <a href="./references#CD004034-bbs2-0008" title="Degl'InnocentiA , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , ZanchettiA , WiklundI . Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). Journal of Human Hypertension2004;18(4):239-45. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study of COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. Journal of Hypertension2004;22(8):1605-12. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. Journal of Hypertension2003;21:875-886. PapademetriouV , FarsangC , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , Zanchetti A for the SCOPE Study Group. Stroke Prevention With the Angiotension II Type-1 Receptor Blocker Candesartan in Elderly Patients With Isolated Systolic Hypertension. The Study on Cognition and Prognosis in the Elderly (SCOPE). Journal of the American College of Cardiology2004;44(6):1175-80. SkoogI , LithellH , HanssonL , ElmfeldtD , HofmanA , OlofssonB , et al, for the SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). American Journal of Hypertension2005;18:1052-1059. ">SCOPE 2003</a> and <a href="./references#CD004034-bbs2-0012" title="JiT , ZhaoY , WangJ , CuiY , DuanD , ChaiQ , et al. Effect of low dose statins and apolipoprotein E genotype on cerebral small vessel disease in older hypertensive patients: a subgroup analysis of a randomized clinical trial. J Am Med Dir Assoc2018;19:995-1002. ZhangH , CuiY , ZhaoY , DongY , DuanD , WangJ , ShengL , JiT , ZhouT , HuW , ChenY , SunS , GongG , ChaiQ , LiuZ . Effects of sartans and low-dose statins on cerebral white matter hyperintensities and cognitive function in older patients with hypertension: a randomized, double-blind and placebo-controlled clinical trial. Hypertension research2018;42(5):717-729. ">Zhang 2018</a> (due to the very high rate of antihypertensive use in the placebo group), which in fact further reduced the statistical significance of the difference in MMSE decline between the intervention and placebo groups (MD ‐0.01, 95% CI ‐0.16 to 0.14; 2 studies, 3873 participants; very low certainty of evidence downgraded due to study limitations, indirectness and imprecision). </p> <p>A subgroup of <a href="./references#CD004034-bbs2-0009" title="ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the Treatment of Isolated Systolic Hypertension on Behavioral Variables. Results From the Systolic Hypertension in the Elderly Program. Arch Intern Med1994;154:2154-2160. Di BariM , PahorM , FranseLV , ShorrRI , WanJY , FerrucciL , et al. Dementia and Disability Outcomes in Large Hypertension Trials: Lessons Learned from the Systolic Hypertension in the Elderly Program (SHEP) Trial. American Journal of Epidemiology2001;153:72-8. SHEP Cooperative Research Group. Prevention of Stroke by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic Hypertension. Final Results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265:3255-64. The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and Design of a Randomized Clinical Trial on Prevention of Stroke in Isolated Systolic Hypertension. Journal of Clinical Epidemiology1988;41:1197-1208. ">SHEP 1991</a> (n = 798 hypertensive treatment and n = 766 placebo) completed baseline and follow‐up cognitive testing using the digit symbol substitution test (DSST), addition test, finding A's test, Boston naming test, letter sets test and delayed recognition span test. No differences were found in mean changes in cognitive tests between the groups. </p> <p><a href="./references#CD004034-bbs2-0006" title="MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. British Medical Journal1992;304(6824):405-12. PrinceMJ , BirdAS , BlizardRA , MannAH . Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. British Medical Journal1996;312(7034):801-5. ">MRC 1996</a>, comparing beta‐blocker (n = 640), diuretic (n = 633) and placebo (n = 1311) groups, reported adjusted (for age, sex and baseline intelligence, cognitive and depression scores) PALT (Paired Associate Learning Test) and TMT‐A (Trail Making Test‐A) coefficients where these were calculated as 'the slope of the regression lines derived by regressing the cognitive test scores on time for each subject.... assigning time values of 1,2,3,4, and 5 to cognitive tests scores at entry and 1,9,21 and 54 months respectively' (<a href="./references#CD004034-bbs2-0006" title="MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. British Medical Journal1992;304(6824):405-12. PrinceMJ , BirdAS , BlizardRA , MannAH . Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. British Medical Journal1996;312(7034):801-5. ">MRC 1996</a>). No difference was found between treatment and placebo groups on intention‐to‐treat or per protocol analyses. Change in overall mean TMT‐A and PALT scores were reported for the whole cohort only. </p> <p><a href="./references#CD004034-bbs2-0005" title="YodfatY , Bar-OnD , AmirM , Cristal N. Quality of life in normotensives compared to hypertensive men treated with isradipine or methyldopa as monotherapy or in combination with captopril: the LOMIR-MCT-IL study.. Journal of Human Hypertension 1996 Feb;10(2):117-22. YodfatY , Cristal N. A multicenter, double-blind, randomized, placebo-controlled study of isradipine and methyldopa as monotherapy or in combination with captopril in the treatment of hypertension. The LOMIR-MCT-IH Research Group.. American Journal of Hypertension 1993 Mar;6(3 Pt 2):57S-61S. ">LOMIR MCT IL 1996</a> reported that after twelve months 'patients treated with the combination of isradipine and captopril showed a statistically significant improvement from baseline in semantic memory (p&lt;0.001) ... the methyldopa group treated as monotherapy or with captopril showed a negative change from baseline in semantic memory'. Results for the placebo group were only represented graphically and appeared to show a deterioration in semantic memory over the twelve months. </p> <p><a href="./references#CD004034-bbs2-0007" title="Pérez-StableEJ , HallidayR , GardinerPS , BaronRB , HauckWW , AcreeM , CoatesTJ . The effects of propranolol on cognitive function and quality of life: a randomized trial among patients with diastolic hypertension.. The American Journal Of Medicine 2000 Apr 1;108(5):359-65. ">Perez Stable 2000</a> reported cognitive performance at twelve months for propranolol and placebo groups for all four cognitive tests used. No statistically significant differences were found between propranolol and placebo groups at twelve months. </p> </section> <section id="CD004034-sec-0068"> <h5 class="title">Change in systolic blood pressure (SBP)</h5> <p>The combined results from six trials reporting change in SBP indicated evidence suggesting antihypertensive treatment reduces SBP (MD ‐9.25 mmHg, 95% CI ‐9.73 to ‐8.78; 6 studies, 17,793 participants; low certainty of evidence downgraded on the basis of study limitations and inconsistency; <a href="./references#CD004034-fig-0004" title="">Analysis 3.1</a>) (<a href="./references#CD004034-bbs2-0009" title="ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the Treatment of Isolated Systolic Hypertension on Behavioral Variables. Results From the Systolic Hypertension in the Elderly Program. Arch Intern Med1994;154:2154-2160. Di BariM , PahorM , FranseLV , ShorrRI , WanJY , FerrucciL , et al. Dementia and Disability Outcomes in Large Hypertension Trials: Lessons Learned from the Systolic Hypertension in the Elderly Program (SHEP) Trial. American Journal of Epidemiology2001;153:72-8. SHEP Cooperative Research Group. Prevention of Stroke by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic Hypertension. Final Results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265:3255-64. The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and Design of a Randomized Clinical Trial on Prevention of Stroke in Isolated Systolic Hypertension. Journal of Clinical Epidemiology1988;41:1197-1208. ">SHEP 1991</a>; <a href="./references#CD004034-bbs2-0006" title="MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. British Medical Journal1992;304(6824):405-12. PrinceMJ , BirdAS , BlizardRA , MannAH . Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. British Medical Journal1996;312(7034):801-5. ">MRC 1996</a>, <a href="./references#CD004034-bbs2-0011" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , De LeeuwP , DolleryCT , et al. Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: Objectives, protocol, and organization. Aging Clin Exp Res1991;3:287-302. FletcherAE , BulpittCJ , ThijsL , ToumilehtoJ , AntikainenR , BossiniA , et al. Quality of life on randomised treatment for isolated hypertension: results from the Syst-Eur Trial. Journal of Hypertension2002;20:2069-2079. FletcherAE , BulpittCJ , TuomilehtoJ , BrowneJ , BossiniA , Kawecka-JaszczK , et al. Quality of life of elderly patients with isolated systolic hypertension: baseline data from the Syst-Eur Trial. Journal of Hypertension1988;16:1117-1124. ForetteF , Seux M-L, StaessenJA , ThijsL , Babarskiene M-R, BabeanuS , et al. The Prevention of Dementia With Antihypertensive Treatment. New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study. Archives of Internal Medicine2002;162:2046-2052. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH , BabarskieneMR , et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet1998;352:1347-51. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH . Reduction of dementia by calcium-antagonist-based antihypertensive treatment. European Heart Journal Supplements2000;2:D17-D19. StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Lancet1997;350:757-764. ">Syst Eur 1998</a>; <a href="./references#CD004034-bbs2-0008" title="Degl'InnocentiA , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , ZanchettiA , WiklundI . Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). Journal of Human Hypertension2004;18(4):239-45. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study of COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. Journal of Hypertension2004;22(8):1605-12. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. Journal of Hypertension2003;21:875-886. PapademetriouV , FarsangC , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , Zanchetti A for the SCOPE Study Group. Stroke Prevention With the Angiotension II Type-1 Receptor Blocker Candesartan in Elderly Patients With Isolated Systolic Hypertension. The Study on Cognition and Prognosis in the Elderly (SCOPE). Journal of the American College of Cardiology2004;44(6):1175-80. SkoogI , LithellH , HanssonL , ElmfeldtD , HofmanA , OlofssonB , et al, for the SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). American Journal of Hypertension2005;18:1052-1059. ">SCOPE 2003</a>; <a href="./references#CD004034-bbs2-0004" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumiterscuD , et al, for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. NEJM2008;358:1887-1898. BulpittC , FletcherA , BeckettN , CoopeJ , Gil-ExtremeraB , ForetteF , et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs &amp; Aging2001;18:151-164. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al, for the HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurology2008;7:683-689. PetersR , BeckettN , McCormackT , FagardR , FletcherA , BulpittC . Treating hypertension in the very elderly-benefits, risks, and future directions, a focus on the hypertension in the very elderly trial. European Heart Journal 2014 Jul;35(26):1712-8. PetersR , BeckettN , NunesM , FletcherA , ForetteF , BulpittC . A substudy protocol of the Hypertension in the Very Elderly Trial assessing cognitive decline and dementia incidence (HYVET-COG): an ongoing randomised, double-blind, placebo-controlled trial. Drugs Aging2006;23:83-92. ">HYVET 2008</a>; <a href="./references#CD004034-bbs2-0012" title="JiT , ZhaoY , WangJ , CuiY , DuanD , ChaiQ , et al. Effect of low dose statins and apolipoprotein E genotype on cerebral small vessel disease in older hypertensive patients: a subgroup analysis of a randomized clinical trial. J Am Med Dir Assoc2018;19:995-1002. ZhangH , CuiY , ZhaoY , DongY , DuanD , WangJ , ShengL , JiT , ZhouT , HuW , ChenY , SunS , GongG , ChaiQ , LiuZ . Effects of sartans and low-dose statins on cerebral white matter hyperintensities and cognitive function in older patients with hypertension: a randomized, double-blind and placebo-controlled clinical trial. Hypertension research2018;42(5):717-729. ">Zhang 2018</a>). Intention‐to‐treat analysis figures were used. The low numbers who ended the study in the randomised group should be noted. All included studies indicated a significant benefit of treatment. Given the presence of heterogeneity, we undertook a sensitivity analysis comparing fixed‐effect versus random‐effects models, which gave the same evidence. </p> <p>Reporting of results varied. <a href="./references#CD004034-bbs2-0006" title="MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. British Medical Journal1992;304(6824):405-12. PrinceMJ , BirdAS , BlizardRA , MannAH . Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. British Medical Journal1996;312(7034):801-5. ">MRC 1996</a>, <a href="./references#CD004034-bbs2-0011" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , De LeeuwP , DolleryCT , et al. Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: Objectives, protocol, and organization. Aging Clin Exp Res1991;3:287-302. FletcherAE , BulpittCJ , ThijsL , ToumilehtoJ , AntikainenR , BossiniA , et al. Quality of life on randomised treatment for isolated hypertension: results from the Syst-Eur Trial. Journal of Hypertension2002;20:2069-2079. FletcherAE , BulpittCJ , TuomilehtoJ , BrowneJ , BossiniA , Kawecka-JaszczK , et al. Quality of life of elderly patients with isolated systolic hypertension: baseline data from the Syst-Eur Trial. Journal of Hypertension1988;16:1117-1124. ForetteF , Seux M-L, StaessenJA , ThijsL , Babarskiene M-R, BabeanuS , et al. The Prevention of Dementia With Antihypertensive Treatment. New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study. Archives of Internal Medicine2002;162:2046-2052. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH , BabarskieneMR , et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet1998;352:1347-51. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH . Reduction of dementia by calcium-antagonist-based antihypertensive treatment. European Heart Journal Supplements2000;2:D17-D19. StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Lancet1997;350:757-764. ">Syst Eur 1998</a> and <a href="./references#CD004034-bbs2-0004" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumiterscuD , et al, for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. NEJM2008;358:1887-1898. BulpittC , FletcherA , BeckettN , CoopeJ , Gil-ExtremeraB , ForetteF , et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs &amp; Aging2001;18:151-164. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al, for the HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurology2008;7:683-689. PetersR , BeckettN , McCormackT , FagardR , FletcherA , BulpittC . Treating hypertension in the very elderly-benefits, risks, and future directions, a focus on the hypertension in the very elderly trial. European Heart Journal 2014 Jul;35(26):1712-8. PetersR , BeckettN , NunesM , FletcherA , ForetteF , BulpittC . A substudy protocol of the Hypertension in the Very Elderly Trial assessing cognitive decline and dementia incidence (HYVET-COG): an ongoing randomised, double-blind, placebo-controlled trial. Drugs Aging2006;23:83-92. ">HYVET 2008</a> reported change in BP only, not final values. <a href="./references#CD004034-bbs2-0009" title="ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the Treatment of Isolated Systolic Hypertension on Behavioral Variables. Results From the Systolic Hypertension in the Elderly Program. Arch Intern Med1994;154:2154-2160. Di BariM , PahorM , FranseLV , ShorrRI , WanJY , FerrucciL , et al. Dementia and Disability Outcomes in Large Hypertension Trials: Lessons Learned from the Systolic Hypertension in the Elderly Program (SHEP) Trial. American Journal of Epidemiology2001;153:72-8. SHEP Cooperative Research Group. Prevention of Stroke by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic Hypertension. Final Results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265:3255-64. The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and Design of a Randomized Clinical Trial on Prevention of Stroke in Isolated Systolic Hypertension. Journal of Clinical Epidemiology1988;41:1197-1208. ">SHEP 1991</a> provided yearly systolic and diastolic blood pressure measures for active treatment and placebo groups for five years along with difference between active treatment group and placebo. <a href="./references#CD004034-bbs2-0005" title="YodfatY , Bar-OnD , AmirM , Cristal N. Quality of life in normotensives compared to hypertensive men treated with isradipine or methyldopa as monotherapy or in combination with captopril: the LOMIR-MCT-IL study.. Journal of Human Hypertension 1996 Feb;10(2):117-22. YodfatY , Cristal N. A multicenter, double-blind, randomized, placebo-controlled study of isradipine and methyldopa as monotherapy or in combination with captopril in the treatment of hypertension. The LOMIR-MCT-IH Research Group.. American Journal of Hypertension 1993 Mar;6(3 Pt 2):57S-61S. ">LOMIR MCT IL 1996</a> reported baseline SBP and DBP across groups; twelve month BP and change in BP were not reported. <a href="./references#CD004034-bbs2-0007" title="Pérez-StableEJ , HallidayR , GardinerPS , BaronRB , HauckWW , AcreeM , CoatesTJ . The effects of propranolol on cognitive function and quality of life: a randomized trial among patients with diastolic hypertension.. The American Journal Of Medicine 2000 Apr 1;108(5):359-65. ">Perez Stable 2000</a> reported baseline and twelve month SBP and DBP only and did not report change. <a href="./references#CD004034-bbs2-0008" title="Degl'InnocentiA , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , ZanchettiA , WiklundI . Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). Journal of Human Hypertension2004;18(4):239-45. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study of COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. Journal of Hypertension2004;22(8):1605-12. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. Journal of Hypertension2003;21:875-886. PapademetriouV , FarsangC , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , Zanchetti A for the SCOPE Study Group. Stroke Prevention With the Angiotension II Type-1 Receptor Blocker Candesartan in Elderly Patients With Isolated Systolic Hypertension. The Study on Cognition and Prognosis in the Elderly (SCOPE). Journal of the American College of Cardiology2004;44(6):1175-80. SkoogI , LithellH , HanssonL , ElmfeldtD , HofmanA , OlofssonB , et al, for the SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). American Journal of Hypertension2005;18:1052-1059. ">SCOPE 2003</a> reported baseline, final and adjusted (for country and baseline BP) change in BP for the two groups. <a href="./references#CD004034-bbs2-0012" title="JiT , ZhaoY , WangJ , CuiY , DuanD , ChaiQ , et al. Effect of low dose statins and apolipoprotein E genotype on cerebral small vessel disease in older hypertensive patients: a subgroup analysis of a randomized clinical trial. J Am Med Dir Assoc2018;19:995-1002. ZhangH , CuiY , ZhaoY , DongY , DuanD , WangJ , ShengL , JiT , ZhouT , HuW , ChenY , SunS , GongG , ChaiQ , LiuZ . Effects of sartans and low-dose statins on cerebral white matter hyperintensities and cognitive function in older patients with hypertension: a randomized, double-blind and placebo-controlled clinical trial. Hypertension research2018;42(5):717-729. ">Zhang 2018</a> reported baseline and annual mean SBP for each group and provided us with unpublished data describing change when requested. </p> </section> <section id="CD004034-sec-0069"> <h5 class="title">Change in diastolic blood pressure (DBP)</h5> <p>The combined results from five trials reporting change in DBP level indicated evidence suggesting antihypertensive treatment reduces DBP (MD ‐2.47 mmHg, 95% CI ‐2.70 to ‐2.24; 5 studies, 15,209 participants; low certainty of evidence downgraded on the basis of study limitations and inconsistency; <a href="./references#CD004034-fig-0005" title="">Analysis 3.2</a>) (<a href="./references#CD004034-bbs2-0009" title="ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the Treatment of Isolated Systolic Hypertension on Behavioral Variables. Results From the Systolic Hypertension in the Elderly Program. Arch Intern Med1994;154:2154-2160. Di BariM , PahorM , FranseLV , ShorrRI , WanJY , FerrucciL , et al. Dementia and Disability Outcomes in Large Hypertension Trials: Lessons Learned from the Systolic Hypertension in the Elderly Program (SHEP) Trial. American Journal of Epidemiology2001;153:72-8. SHEP Cooperative Research Group. Prevention of Stroke by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic Hypertension. Final Results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265:3255-64. The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and Design of a Randomized Clinical Trial on Prevention of Stroke in Isolated Systolic Hypertension. Journal of Clinical Epidemiology1988;41:1197-1208. ">SHEP 1991</a>; <a href="./references#CD004034-bbs2-0011" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , De LeeuwP , DolleryCT , et al. Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: Objectives, protocol, and organization. Aging Clin Exp Res1991;3:287-302. FletcherAE , BulpittCJ , ThijsL , ToumilehtoJ , AntikainenR , BossiniA , et al. Quality of life on randomised treatment for isolated hypertension: results from the Syst-Eur Trial. Journal of Hypertension2002;20:2069-2079. FletcherAE , BulpittCJ , TuomilehtoJ , BrowneJ , BossiniA , Kawecka-JaszczK , et al. Quality of life of elderly patients with isolated systolic hypertension: baseline data from the Syst-Eur Trial. Journal of Hypertension1988;16:1117-1124. ForetteF , Seux M-L, StaessenJA , ThijsL , Babarskiene M-R, BabeanuS , et al. The Prevention of Dementia With Antihypertensive Treatment. New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study. Archives of Internal Medicine2002;162:2046-2052. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH , BabarskieneMR , et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet1998;352:1347-51. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH . Reduction of dementia by calcium-antagonist-based antihypertensive treatment. European Heart Journal Supplements2000;2:D17-D19. StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Lancet1997;350:757-764. ">Syst Eur 1998</a>; <a href="./references#CD004034-bbs2-0008" title="Degl'InnocentiA , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , ZanchettiA , WiklundI . Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). Journal of Human Hypertension2004;18(4):239-45. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study of COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. Journal of Hypertension2004;22(8):1605-12. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. Journal of Hypertension2003;21:875-886. PapademetriouV , FarsangC , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , Zanchetti A for the SCOPE Study Group. Stroke Prevention With the Angiotension II Type-1 Receptor Blocker Candesartan in Elderly Patients With Isolated Systolic Hypertension. The Study on Cognition and Prognosis in the Elderly (SCOPE). Journal of the American College of Cardiology2004;44(6):1175-80. SkoogI , LithellH , HanssonL , ElmfeldtD , HofmanA , OlofssonB , et al, for the SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). American Journal of Hypertension2005;18:1052-1059. ">SCOPE 2003</a>; <a href="./references#CD004034-bbs2-0004" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumiterscuD , et al, for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. NEJM2008;358:1887-1898. BulpittC , FletcherA , BeckettN , CoopeJ , Gil-ExtremeraB , ForetteF , et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs &amp; Aging2001;18:151-164. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al, for the HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurology2008;7:683-689. PetersR , BeckettN , McCormackT , FagardR , FletcherA , BulpittC . Treating hypertension in the very elderly-benefits, risks, and future directions, a focus on the hypertension in the very elderly trial. European Heart Journal 2014 Jul;35(26):1712-8. PetersR , BeckettN , NunesM , FletcherA , ForetteF , BulpittC . A substudy protocol of the Hypertension in the Very Elderly Trial assessing cognitive decline and dementia incidence (HYVET-COG): an ongoing randomised, double-blind, placebo-controlled trial. Drugs Aging2006;23:83-92. ">HYVET 2008</a>, <a href="./references#CD004034-bbs2-0012" title="JiT , ZhaoY , WangJ , CuiY , DuanD , ChaiQ , et al. Effect of low dose statins and apolipoprotein E genotype on cerebral small vessel disease in older hypertensive patients: a subgroup analysis of a randomized clinical trial. J Am Med Dir Assoc2018;19:995-1002. ZhangH , CuiY , ZhaoY , DongY , DuanD , WangJ , ShengL , JiT , ZhouT , HuW , ChenY , SunS , GongG , ChaiQ , LiuZ . Effects of sartans and low-dose statins on cerebral white matter hyperintensities and cognitive function in older patients with hypertension: a randomized, double-blind and placebo-controlled clinical trial. Hypertension research2018;42(5):717-729. ">Zhang 2018</a>). All included studies indicated a significant benefit of treatment although <a href="./references#CD004034-bbs2-0011" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , De LeeuwP , DolleryCT , et al. Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: Objectives, protocol, and organization. Aging Clin Exp Res1991;3:287-302. FletcherAE , BulpittCJ , ThijsL , ToumilehtoJ , AntikainenR , BossiniA , et al. Quality of life on randomised treatment for isolated hypertension: results from the Syst-Eur Trial. Journal of Hypertension2002;20:2069-2079. FletcherAE , BulpittCJ , TuomilehtoJ , BrowneJ , BossiniA , Kawecka-JaszczK , et al. Quality of life of elderly patients with isolated systolic hypertension: baseline data from the Syst-Eur Trial. Journal of Hypertension1988;16:1117-1124. ForetteF , Seux M-L, StaessenJA , ThijsL , Babarskiene M-R, BabeanuS , et al. The Prevention of Dementia With Antihypertensive Treatment. New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study. Archives of Internal Medicine2002;162:2046-2052. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH , BabarskieneMR , et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet1998;352:1347-51. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH . Reduction of dementia by calcium-antagonist-based antihypertensive treatment. European Heart Journal Supplements2000;2:D17-D19. StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Lancet1997;350:757-764. ">Syst Eur 1998</a> included participants with isolated systolic hypertension only. Given the presence of heterogeneity, we undertook a sensitivity analysis comparing fixed‐effect versus random‐effects models, which gave the same evidence. As above, <a href="./references#CD004034-bbs2-0005" title="YodfatY , Bar-OnD , AmirM , Cristal N. Quality of life in normotensives compared to hypertensive men treated with isradipine or methyldopa as monotherapy or in combination with captopril: the LOMIR-MCT-IL study.. Journal of Human Hypertension 1996 Feb;10(2):117-22. YodfatY , Cristal N. A multicenter, double-blind, randomized, placebo-controlled study of isradipine and methyldopa as monotherapy or in combination with captopril in the treatment of hypertension. The LOMIR-MCT-IH Research Group.. American Journal of Hypertension 1993 Mar;6(3 Pt 2):57S-61S. ">LOMIR MCT IL 1996</a> did not report change in DBP. <a href="./references#CD004034-bbs2-0006" title="MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. British Medical Journal1992;304(6824):405-12. PrinceMJ , BirdAS , BlizardRA , MannAH . Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. British Medical Journal1996;312(7034):801-5. ">MRC 1996</a>, comparing beta‐blocker (n = 640), diuretic (n = 633) and placebo (n = 1311) groups, did not report change in DBP. A previous report from the authors of <a href="./references#CD004034-bbs2-0007" title="Pérez-StableEJ , HallidayR , GardinerPS , BaronRB , HauckWW , AcreeM , CoatesTJ . The effects of propranolol on cognitive function and quality of life: a randomized trial among patients with diastolic hypertension.. The American Journal Of Medicine 2000 Apr 1;108(5):359-65. ">Perez Stable 2000</a> reported a mean decrease in DBP of 7.7 mmHg in the propranolol only group and 5.9 mmHg in the placebo only group. </p> </section> <section id="CD004034-sec-0070"> <h5 class="title">Incidence and severity of adverse effects</h5> <p>In <a href="./references#CD004034-bbs2-0009" title="ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the Treatment of Isolated Systolic Hypertension on Behavioral Variables. Results From the Systolic Hypertension in the Elderly Program. Arch Intern Med1994;154:2154-2160. Di BariM , PahorM , FranseLV , ShorrRI , WanJY , FerrucciL , et al. Dementia and Disability Outcomes in Large Hypertension Trials: Lessons Learned from the Systolic Hypertension in the Elderly Program (SHEP) Trial. American Journal of Epidemiology2001;153:72-8. SHEP Cooperative Research Group. Prevention of Stroke by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic Hypertension. Final Results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265:3255-64. The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and Design of a Randomized Clinical Trial on Prevention of Stroke in Isolated Systolic Hypertension. Journal of Clinical Epidemiology1988;41:1197-1208. ">SHEP 1991</a>, significantly more participants on active treatment withdrew due to adverse events (OR 1.98, 95% CI 1.63 to 2.42). <a href="./references#CD004034-bbs2-0005" title="YodfatY , Bar-OnD , AmirM , Cristal N. Quality of life in normotensives compared to hypertensive men treated with isradipine or methyldopa as monotherapy or in combination with captopril: the LOMIR-MCT-IL study.. Journal of Human Hypertension 1996 Feb;10(2):117-22. YodfatY , Cristal N. A multicenter, double-blind, randomized, placebo-controlled study of isradipine and methyldopa as monotherapy or in combination with captopril in the treatment of hypertension. The LOMIR-MCT-IH Research Group.. American Journal of Hypertension 1993 Mar;6(3 Pt 2):57S-61S. ">LOMIR MCT IL 1996</a> reported a statistically significant increase in sleep and sexual disorders and withdrawals due to side effects in the methyldopa compared to the isradipine and placebo groups. The overall <a href="./references#CD004034-bbs2-0006" title="MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. British Medical Journal1992;304(6824):405-12. PrinceMJ , BirdAS , BlizardRA , MannAH . Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. British Medical Journal1996;312(7034):801-5. ">MRC 1996</a> study reported a significantly higher rate of withdrawals due to major side effects in the beta‐blocker (333/1102) compared to the diuretic (160/1081) and placebo groups (82/2213). <a href="./references#CD004034-bbs2-0011" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , De LeeuwP , DolleryCT , et al. Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: Objectives, protocol, and organization. Aging Clin Exp Res1991;3:287-302. FletcherAE , BulpittCJ , ThijsL , ToumilehtoJ , AntikainenR , BossiniA , et al. Quality of life on randomised treatment for isolated hypertension: results from the Syst-Eur Trial. Journal of Hypertension2002;20:2069-2079. FletcherAE , BulpittCJ , TuomilehtoJ , BrowneJ , BossiniA , Kawecka-JaszczK , et al. Quality of life of elderly patients with isolated systolic hypertension: baseline data from the Syst-Eur Trial. Journal of Hypertension1988;16:1117-1124. ForetteF , Seux M-L, StaessenJA , ThijsL , Babarskiene M-R, BabeanuS , et al. The Prevention of Dementia With Antihypertensive Treatment. New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study. Archives of Internal Medicine2002;162:2046-2052. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH , BabarskieneMR , et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet1998;352:1347-51. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH . Reduction of dementia by calcium-antagonist-based antihypertensive treatment. European Heart Journal Supplements2000;2:D17-D19. StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Lancet1997;350:757-764. ">Syst Eur 1998</a> reached significance, with participants on active treatment less likely to discontinue treatment due to side effects (OR 0.42, 95% CI 0.33 to 0.54). <a href="./references#CD004034-bbs2-0007" title="Pérez-StableEJ , HallidayR , GardinerPS , BaronRB , HauckWW , AcreeM , CoatesTJ . The effects of propranolol on cognitive function and quality of life: a randomized trial among patients with diastolic hypertension.. The American Journal Of Medicine 2000 Apr 1;108(5):359-65. ">Perez Stable 2000</a> reported that 20/156 participants in the propranolol group were not taking the study drug at 12‐month follow‐up but did not specify reasons for this. Discontinuation of treatment in the placebo group was not reported. No significant difference between the active treatment and placebo groups in adverse events requiring discontinuation of treatment was found in <a href="./references#CD004034-bbs2-0008" title="Degl'InnocentiA , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , ZanchettiA , WiklundI . Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). Journal of Human Hypertension2004;18(4):239-45. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study of COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. Journal of Hypertension2004;22(8):1605-12. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. Journal of Hypertension2003;21:875-886. PapademetriouV , FarsangC , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , Zanchetti A for the SCOPE Study Group. Stroke Prevention With the Angiotension II Type-1 Receptor Blocker Candesartan in Elderly Patients With Isolated Systolic Hypertension. The Study on Cognition and Prognosis in the Elderly (SCOPE). Journal of the American College of Cardiology2004;44(6):1175-80. SkoogI , LithellH , HanssonL , ElmfeldtD , HofmanA , OlofssonB , et al, for the SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). American Journal of Hypertension2005;18:1052-1059. ">SCOPE 2003</a>, possibly because of the large proportion of participants in the placebo group who commenced active treatment during the study. <a href="./references#CD004034-bbs2-0004" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumiterscuD , et al, for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. NEJM2008;358:1887-1898. BulpittC , FletcherA , BeckettN , CoopeJ , Gil-ExtremeraB , ForetteF , et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs &amp; Aging2001;18:151-164. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al, for the HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurology2008;7:683-689. PetersR , BeckettN , McCormackT , FagardR , FletcherA , BulpittC . Treating hypertension in the very elderly-benefits, risks, and future directions, a focus on the hypertension in the very elderly trial. European Heart Journal 2014 Jul;35(26):1712-8. PetersR , BeckettN , NunesM , FletcherA , ForetteF , BulpittC . A substudy protocol of the Hypertension in the Very Elderly Trial assessing cognitive decline and dementia incidence (HYVET-COG): an ongoing randomised, double-blind, placebo-controlled trial. Drugs Aging2006;23:83-92. ">HYVET 2008</a> reported fewer 'serious adverse events' in the active treatment group than in the placebo group (358 versus 448, P <i>=</i> 0.001). <a href="./references#CD004034-bbs2-0012" title="JiT , ZhaoY , WangJ , CuiY , DuanD , ChaiQ , et al. Effect of low dose statins and apolipoprotein E genotype on cerebral small vessel disease in older hypertensive patients: a subgroup analysis of a randomized clinical trial. J Am Med Dir Assoc2018;19:995-1002. ZhangH , CuiY , ZhaoY , DongY , DuanD , WangJ , ShengL , JiT , ZhouT , HuW , ChenY , SunS , GongG , ChaiQ , LiuZ . Effects of sartans and low-dose statins on cerebral white matter hyperintensities and cognitive function in older patients with hypertension: a randomized, double-blind and placebo-controlled clinical trial. Hypertension research2018;42(5):717-729. ">Zhang 2018</a> reported 31 deaths, 16 withdrawals and 5 losses to follow‐up for their study population of 732 participants over five years. Reasons for study withdrawal were not reported. Hetergeneity precluded meta‐analysis. </p> </section> <section id="CD004034-sec-0071"> <h5 class="title">Quality of life (QOL)</h5> <p><a href="./references#CD004034-bbs2-0009" title="ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the Treatment of Isolated Systolic Hypertension on Behavioral Variables. Results From the Systolic Hypertension in the Elderly Program. Arch Intern Med1994;154:2154-2160. Di BariM , PahorM , FranseLV , ShorrRI , WanJY , FerrucciL , et al. Dementia and Disability Outcomes in Large Hypertension Trials: Lessons Learned from the Systolic Hypertension in the Elderly Program (SHEP) Trial. American Journal of Epidemiology2001;153:72-8. SHEP Cooperative Research Group. Prevention of Stroke by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic Hypertension. Final Results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265:3255-64. The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and Design of a Randomized Clinical Trial on Prevention of Stroke in Isolated Systolic Hypertension. Journal of Clinical Epidemiology1988;41:1197-1208. ">SHEP 1991</a> reported no significant differences between active treatment and placebo groups in any of the three global quality of life questions at baseline or final visit for those in that subgroup. Similarly, the sub‐study of <a href="./references#CD004034-bbs2-0011" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , De LeeuwP , DolleryCT , et al. Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: Objectives, protocol, and organization. Aging Clin Exp Res1991;3:287-302. FletcherAE , BulpittCJ , ThijsL , ToumilehtoJ , AntikainenR , BossiniA , et al. Quality of life on randomised treatment for isolated hypertension: results from the Syst-Eur Trial. Journal of Hypertension2002;20:2069-2079. FletcherAE , BulpittCJ , TuomilehtoJ , BrowneJ , BossiniA , Kawecka-JaszczK , et al. Quality of life of elderly patients with isolated systolic hypertension: baseline data from the Syst-Eur Trial. Journal of Hypertension1988;16:1117-1124. ForetteF , Seux M-L, StaessenJA , ThijsL , Babarskiene M-R, BabeanuS , et al. The Prevention of Dementia With Antihypertensive Treatment. New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study. Archives of Internal Medicine2002;162:2046-2052. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH , BabarskieneMR , et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet1998;352:1347-51. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH . Reduction of dementia by calcium-antagonist-based antihypertensive treatment. European Heart Journal Supplements2000;2:D17-D19. StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Lancet1997;350:757-764. ">Syst Eur 1998</a> showed no significant difference in change in Sickness Impact Profile at two years between active treatment and placebo groups. The <a href="./references#CD004034-bbs2-0008" title="Degl'InnocentiA , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , ZanchettiA , WiklundI . Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). Journal of Human Hypertension2004;18(4):239-45. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study of COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. Journal of Hypertension2004;22(8):1605-12. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. Journal of Hypertension2003;21:875-886. PapademetriouV , FarsangC , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , Zanchetti A for the SCOPE Study Group. Stroke Prevention With the Angiotension II Type-1 Receptor Blocker Candesartan in Elderly Patients With Isolated Systolic Hypertension. The Study on Cognition and Prognosis in the Elderly (SCOPE). Journal of the American College of Cardiology2004;44(6):1175-80. SkoogI , LithellH , HanssonL , ElmfeldtD , HofmanA , OlofssonB , et al, for the SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). American Journal of Hypertension2005;18:1052-1059. ">SCOPE 2003</a> sub‐study, <a href="./references#CD004034-bbs2-0063" title="Degl'InnocentiA , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , et al. Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). Journal of Human Hypertension2004;18(4):239-45.">Degl'Innocenti 2004</a>, showed significant differences in change in QOL measures between the active treatment and placebo groups including Psychological General Well‐Being (PGWB) Index Positive well‐being (‐0.8 versus ‐1.1, P = 0.04) and EuroQoL Current Health (‐3.1 versus ‐5.3, P = 0.008). <a href="./references#CD004034-bbs2-0005" title="YodfatY , Bar-OnD , AmirM , Cristal N. Quality of life in normotensives compared to hypertensive men treated with isradipine or methyldopa as monotherapy or in combination with captopril: the LOMIR-MCT-IL study.. Journal of Human Hypertension 1996 Feb;10(2):117-22. YodfatY , Cristal N. A multicenter, double-blind, randomized, placebo-controlled study of isradipine and methyldopa as monotherapy or in combination with captopril in the treatment of hypertension. The LOMIR-MCT-IH Research Group.. American Journal of Hypertension 1993 Mar;6(3 Pt 2):57S-61S. ">LOMIR MCT IL 1996</a> reported a statistically significant (P = 0.03) improvement in a subjective measure of QOL at twelve months in the isradipine and captopril combined therapy group. The methyldopa monotherapy group showed a deterioration in subjective QOL at twelve months but statistical significance was not reported. <a href="./references#CD004034-bbs2-0004" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumiterscuD , et al, for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. NEJM2008;358:1887-1898. BulpittC , FletcherA , BeckettN , CoopeJ , Gil-ExtremeraB , ForetteF , et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs &amp; Aging2001;18:151-164. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al, for the HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurology2008;7:683-689. PetersR , BeckettN , McCormackT , FagardR , FletcherA , BulpittC . Treating hypertension in the very elderly-benefits, risks, and future directions, a focus on the hypertension in the very elderly trial. European Heart Journal 2014 Jul;35(26):1712-8. PetersR , BeckettN , NunesM , FletcherA , ForetteF , BulpittC . A substudy protocol of the Hypertension in the Very Elderly Trial assessing cognitive decline and dementia incidence (HYVET-COG): an ongoing randomised, double-blind, placebo-controlled trial. Drugs Aging2006;23:83-92. ">HYVET 2008</a> reported no difference in SF‐36 scores between active treatment and placebo groups over time. <a href="./references#CD004034-bbs2-0006" title="MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. British Medical Journal1992;304(6824):405-12. PrinceMJ , BirdAS , BlizardRA , MannAH . Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. British Medical Journal1996;312(7034):801-5. ">MRC 1996</a>, <a href="./references#CD004034-bbs2-0007" title="Pérez-StableEJ , HallidayR , GardinerPS , BaronRB , HauckWW , AcreeM , CoatesTJ . The effects of propranolol on cognitive function and quality of life: a randomized trial among patients with diastolic hypertension.. The American Journal Of Medicine 2000 Apr 1;108(5):359-65. ">Perez Stable 2000</a> and <a href="./references#CD004034-bbs2-0012" title="JiT , ZhaoY , WangJ , CuiY , DuanD , ChaiQ , et al. Effect of low dose statins and apolipoprotein E genotype on cerebral small vessel disease in older hypertensive patients: a subgroup analysis of a randomized clinical trial. J Am Med Dir Assoc2018;19:995-1002. ZhangH , CuiY , ZhaoY , DongY , DuanD , WangJ , ShengL , JiT , ZhouT , HuW , ChenY , SunS , GongG , ChaiQ , LiuZ . Effects of sartans and low-dose statins on cerebral white matter hyperintensities and cognitive function in older patients with hypertension: a randomized, double-blind and placebo-controlled clinical trial. Hypertension research2018;42(5):717-729. ">Zhang 2018</a> did not report QOL measures. </p> </section> </section> <section id="CD004034-sec-0072"> <h4 class="title">Comparison 2: intensive versus standard blood pressure reduction</h4> <section id="CD004034-sec-0073"> <h5 class="title">Incidence of dementia</h5> <p><a href="./references#CD004034-bbs2-0010" title="AmbrosiusWT , SinkKM , FoyCG , BerlowitzDR , CheungAK , CushmanWC , FineLJ , Goff DC Jr, JohnsonKC , KilleenAA , LewisCE , OparilS , ReboussinDM , RoccoMV , SnyderJK , WilliamsonJD , Wright JT Jr, WheltonPK , SPRINT Study Research Group. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).. Clinical Trials 2014 Oct;11(5):532-46. BerlowitzDR , FoyCG , KazisLE , BolinLP , ConroyMB , FitzpatrickP , GureTR , KimmelPL , KirchnerK , MoriskyDE , NewmanJ , OlneyC , OparilS , PajewskiNM , PowellJ , RamseyT , SimmonsDL , SnyderJ , SupianoMA , WeinerDE , WhittleJ , SPRINT Research Group. Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes.. The New England Journal of Medicine 2017 Aug 24;377(8):733-744. SPRINT Research Group, Wright JT Jr, WilliamsonJD , WheltonPK , SnyderJK , SinkKM , RoccoMV , ReboussinDM , RahmanM , OparilS , LewisCE , KimmelPL , JohnsonKC , Goff DC Jr, FineLJ , CutlerJA , CushmanWC , CheungAK , Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control.. The New England Journal of Medicine 2015 Nov 26;373(22):2103-16. The SPRINT MIND Investigators for the SPRINT Research Group. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA2019;321(6):553-561. WilliamsonJD , SupianoMA , ApplegateWB , BerlowitzDR , CampbellRC , ChertowGM , FineLJ , HaleyWE , HawfieldAT , IxJH , KitzmanDW , KostisJB , Krousel-WoodMA , LaunerLJ , OparilS , RodriguezCJ , RoumieCL , ShorrRI , SinkKM , WadleyVG , WheltonPK , WhittleJ , WoolardNF , Wright JT Jr, PajewskiNM , SPRINT Research Group. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.. JAMA 2016 Jun 28;315(24):2673-82. ">SPRINT MIND 2019</a> did not show a significant difference in dementia incidence between standard and intensive treatment groups (HR 0.93 (95% CI 0.73‐1.18), P = 0.54). </p> </section> <section id="CD004034-sec-0074"> <h5 class="title">Cognitive change from baseline</h5> <p><a href="./references#CD004034-bbs2-0001" title="BuseJB , BiggerJT , ByingtonRP , CooperLS , CushmanWC , FriedewaldWT , et al, ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. American Journal of Cardiology2007;99(12A):21i-33i. CushmanWC , Grimm RH Jr, CutlerJA , EvansGW , CapesS , CorsonMA , et al, ACCORD Study Group. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):44i-55i. LaunerLJ , MillerME , WilliamsonJD , LazarRM , GersteinHC , MurrayAM , et al, ACCORD MIND investigators. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurology2011;10(11):969-77. MargolisKL , O'ConnorPJ , MorganTM , BuseJB , CohenRM , CushmanWC , et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care2014;37(6):1721-8. O'ConnorPJ , NarayanKM , AndersonR , FeeneyP , FineL , AliMK , et al. Effect of intensive versus standard blood pressure control on depression and health-related quality of life in type 2 diabetes: the ACCORD trial. Diabetes Care2012;35(7):1479-81. WilliamsonJD , LaunerLJ , BryanRN , CokerLH , LazarRM , GersteinHC , et al, Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Investigators. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Internal Medicine2014;174(3):324-33. WilliamsonJD , MillerME , BryanRN , LazarRM , CokerLH , JohnsonJ , et al, ACCORD Study Group. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. American Journal of Cardiology2007;99(12A):112i-122i. ">ACCORD MIND 2014</a>, comparing standard versus intensive BP control, reported baseline, 20‐ and 40‐month performance in MMSE, digit symbol substitution test (DSST), Rey Auditory Verbal Learning Test (RAVLT) and Stroop, and 40‐month change, adjusted for baseline score of the relevant measure. No significant difference was noted between groups for any of the tests. Change in adjusted mean MMSE over 40 months in the intensive (n = 690) and standard (n = 659) groups were ‐0.25 (CI ‐0.42 to ‐0.08) and ‐0.30 (CI ‐0.48 to ‐0.13), respectively. <a href="./references#CD004034-bbs2-0010" title="AmbrosiusWT , SinkKM , FoyCG , BerlowitzDR , CheungAK , CushmanWC , FineLJ , Goff DC Jr, JohnsonKC , KilleenAA , LewisCE , OparilS , ReboussinDM , RoccoMV , SnyderJK , WilliamsonJD , Wright JT Jr, WheltonPK , SPRINT Study Research Group. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).. Clinical Trials 2014 Oct;11(5):532-46. BerlowitzDR , FoyCG , KazisLE , BolinLP , ConroyMB , FitzpatrickP , GureTR , KimmelPL , KirchnerK , MoriskyDE , NewmanJ , OlneyC , OparilS , PajewskiNM , PowellJ , RamseyT , SimmonsDL , SnyderJ , SupianoMA , WeinerDE , WhittleJ , SPRINT Research Group. Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes.. The New England Journal of Medicine 2017 Aug 24;377(8):733-744. SPRINT Research Group, Wright JT Jr, WilliamsonJD , WheltonPK , SnyderJK , SinkKM , RoccoMV , ReboussinDM , RahmanM , OparilS , LewisCE , KimmelPL , JohnsonKC , Goff DC Jr, FineLJ , CutlerJA , CushmanWC , CheungAK , Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control.. The New England Journal of Medicine 2015 Nov 26;373(22):2103-16. The SPRINT MIND Investigators for the SPRINT Research Group. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA2019;321(6):553-561. WilliamsonJD , SupianoMA , ApplegateWB , BerlowitzDR , CampbellRC , ChertowGM , FineLJ , HaleyWE , HawfieldAT , IxJH , KitzmanDW , KostisJB , Krousel-WoodMA , LaunerLJ , OparilS , RodriguezCJ , RoumieCL , ShorrRI , SinkKM , WadleyVG , WheltonPK , WhittleJ , WoolardNF , Wright JT Jr, PajewskiNM , SPRINT Research Group. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.. JAMA 2016 Jun 28;315(24):2673-82. ">SPRINT MIND 2019</a> reported baseline but not follow‐up cognitive assessment data. </p> </section> <section id="CD004034-sec-0075"> <h5 class="title">Change in systolic blood pressure (SBP)</h5> <p><a href="./references#CD004034-bbs2-0001" title="BuseJB , BiggerJT , ByingtonRP , CooperLS , CushmanWC , FriedewaldWT , et al, ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. American Journal of Cardiology2007;99(12A):21i-33i. CushmanWC , Grimm RH Jr, CutlerJA , EvansGW , CapesS , CorsonMA , et al, ACCORD Study Group. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):44i-55i. LaunerLJ , MillerME , WilliamsonJD , LazarRM , GersteinHC , MurrayAM , et al, ACCORD MIND investigators. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurology2011;10(11):969-77. MargolisKL , O'ConnorPJ , MorganTM , BuseJB , CohenRM , CushmanWC , et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care2014;37(6):1721-8. O'ConnorPJ , NarayanKM , AndersonR , FeeneyP , FineL , AliMK , et al. Effect of intensive versus standard blood pressure control on depression and health-related quality of life in type 2 diabetes: the ACCORD trial. Diabetes Care2012;35(7):1479-81. WilliamsonJD , LaunerLJ , BryanRN , CokerLH , LazarRM , GersteinHC , et al, Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Investigators. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Internal Medicine2014;174(3):324-33. WilliamsonJD , MillerME , BryanRN , LazarRM , CokerLH , JohnsonJ , et al, ACCORD Study Group. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. American Journal of Cardiology2007;99(12A):112i-122i. ">ACCORD MIND 2014</a>, comparing standard versus intensive BP control, reported baseline and 40‐month SBP as mean (SD) as outlined in the data analyses tables. At 40 months, mean SBP was 133.2 (14.8) versus 119.0 (14.7) mmHg respectively. <a href="./references#CD004034-bbs2-0010" title="AmbrosiusWT , SinkKM , FoyCG , BerlowitzDR , CheungAK , CushmanWC , FineLJ , Goff DC Jr, JohnsonKC , KilleenAA , LewisCE , OparilS , ReboussinDM , RoccoMV , SnyderJK , WilliamsonJD , Wright JT Jr, WheltonPK , SPRINT Study Research Group. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).. Clinical Trials 2014 Oct;11(5):532-46. BerlowitzDR , FoyCG , KazisLE , BolinLP , ConroyMB , FitzpatrickP , GureTR , KimmelPL , KirchnerK , MoriskyDE , NewmanJ , OlneyC , OparilS , PajewskiNM , PowellJ , RamseyT , SimmonsDL , SnyderJ , SupianoMA , WeinerDE , WhittleJ , SPRINT Research Group. Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes.. The New England Journal of Medicine 2017 Aug 24;377(8):733-744. SPRINT Research Group, Wright JT Jr, WilliamsonJD , WheltonPK , SnyderJK , SinkKM , RoccoMV , ReboussinDM , RahmanM , OparilS , LewisCE , KimmelPL , JohnsonKC , Goff DC Jr, FineLJ , CutlerJA , CushmanWC , CheungAK , Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control.. The New England Journal of Medicine 2015 Nov 26;373(22):2103-16. The SPRINT MIND Investigators for the SPRINT Research Group. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA2019;321(6):553-561. WilliamsonJD , SupianoMA , ApplegateWB , BerlowitzDR , CampbellRC , ChertowGM , FineLJ , HaleyWE , HawfieldAT , IxJH , KitzmanDW , KostisJB , Krousel-WoodMA , LaunerLJ , OparilS , RodriguezCJ , RoumieCL , ShorrRI , SinkKM , WadleyVG , WheltonPK , WhittleJ , WoolardNF , Wright JT Jr, PajewskiNM , SPRINT Research Group. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.. JAMA 2016 Jun 28;315(24):2673-82. ">SPRINT MIND 2019</a>, when it was halted in August 2015, reported mean SBP in the standard and intensive treatment groups of 134.8 mmHg (95% CI 134.1 to 135.6 mmHg) and 121.6 mmHg (95% CI 120.8 to 122.3 mmHg), respectively. </p> </section> <section id="CD004034-sec-0076"> <h5 class="title">Change in diastolic blood pressure (DBP)</h5> <p><a href="./references#CD004034-bbs2-0001" title="BuseJB , BiggerJT , ByingtonRP , CooperLS , CushmanWC , FriedewaldWT , et al, ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. American Journal of Cardiology2007;99(12A):21i-33i. CushmanWC , Grimm RH Jr, CutlerJA , EvansGW , CapesS , CorsonMA , et al, ACCORD Study Group. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):44i-55i. LaunerLJ , MillerME , WilliamsonJD , LazarRM , GersteinHC , MurrayAM , et al, ACCORD MIND investigators. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurology2011;10(11):969-77. MargolisKL , O'ConnorPJ , MorganTM , BuseJB , CohenRM , CushmanWC , et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care2014;37(6):1721-8. O'ConnorPJ , NarayanKM , AndersonR , FeeneyP , FineL , AliMK , et al. Effect of intensive versus standard blood pressure control on depression and health-related quality of life in type 2 diabetes: the ACCORD trial. Diabetes Care2012;35(7):1479-81. WilliamsonJD , LaunerLJ , BryanRN , CokerLH , LazarRM , GersteinHC , et al, Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Investigators. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Internal Medicine2014;174(3):324-33. WilliamsonJD , MillerME , BryanRN , LazarRM , CokerLH , JohnsonJ , et al, ACCORD Study Group. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. American Journal of Cardiology2007;99(12A):112i-122i. ">ACCORD MIND 2014</a>, comparing standard versus intensive BP control, reported baseline and 40‐month DBP as mean (SD), as outlined in the data analyses tables. At 40 months, mean DBP was 64.0 (10.1) versus 30.2 (9.9) mmHg. <a href="./references#CD004034-bbs2-0010" title="AmbrosiusWT , SinkKM , FoyCG , BerlowitzDR , CheungAK , CushmanWC , FineLJ , Goff DC Jr, JohnsonKC , KilleenAA , LewisCE , OparilS , ReboussinDM , RoccoMV , SnyderJK , WilliamsonJD , Wright JT Jr, WheltonPK , SPRINT Study Research Group. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).. Clinical Trials 2014 Oct;11(5):532-46. BerlowitzDR , FoyCG , KazisLE , BolinLP , ConroyMB , FitzpatrickP , GureTR , KimmelPL , KirchnerK , MoriskyDE , NewmanJ , OlneyC , OparilS , PajewskiNM , PowellJ , RamseyT , SimmonsDL , SnyderJ , SupianoMA , WeinerDE , WhittleJ , SPRINT Research Group. Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes.. The New England Journal of Medicine 2017 Aug 24;377(8):733-744. SPRINT Research Group, Wright JT Jr, WilliamsonJD , WheltonPK , SnyderJK , SinkKM , RoccoMV , ReboussinDM , RahmanM , OparilS , LewisCE , KimmelPL , JohnsonKC , Goff DC Jr, FineLJ , CutlerJA , CushmanWC , CheungAK , Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control.. The New England Journal of Medicine 2015 Nov 26;373(22):2103-16. The SPRINT MIND Investigators for the SPRINT Research Group. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA2019;321(6):553-561. WilliamsonJD , SupianoMA , ApplegateWB , BerlowitzDR , CampbellRC , ChertowGM , FineLJ , HaleyWE , HawfieldAT , IxJH , KitzmanDW , KostisJB , Krousel-WoodMA , LaunerLJ , OparilS , RodriguezCJ , RoumieCL , ShorrRI , SinkKM , WadleyVG , WheltonPK , WhittleJ , WoolardNF , Wright JT Jr, PajewskiNM , SPRINT Research Group. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.. JAMA 2016 Jun 28;315(24):2673-82. ">SPRINT MIND 2019</a> did not report change in DBP. </p> </section> <section id="CD004034-sec-0077"> <h5 class="title">Incidence and severity of adverse effects</h5> <p><a href="./references#CD004034-bbs2-0001" title="BuseJB , BiggerJT , ByingtonRP , CooperLS , CushmanWC , FriedewaldWT , et al, ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. American Journal of Cardiology2007;99(12A):21i-33i. CushmanWC , Grimm RH Jr, CutlerJA , EvansGW , CapesS , CorsonMA , et al, ACCORD Study Group. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):44i-55i. LaunerLJ , MillerME , WilliamsonJD , LazarRM , GersteinHC , MurrayAM , et al, ACCORD MIND investigators. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurology2011;10(11):969-77. MargolisKL , O'ConnorPJ , MorganTM , BuseJB , CohenRM , CushmanWC , et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care2014;37(6):1721-8. O'ConnorPJ , NarayanKM , AndersonR , FeeneyP , FineL , AliMK , et al. Effect of intensive versus standard blood pressure control on depression and health-related quality of life in type 2 diabetes: the ACCORD trial. Diabetes Care2012;35(7):1479-81. WilliamsonJD , LaunerLJ , BryanRN , CokerLH , LazarRM , GersteinHC , et al, Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Investigators. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Internal Medicine2014;174(3):324-33. WilliamsonJD , MillerME , BryanRN , LazarRM , CokerLH , JohnsonJ , et al, ACCORD Study Group. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. American Journal of Cardiology2007;99(12A):112i-122i. ">ACCORD MIND 2014</a> reported significantly more (P &lt; 0.001) serious adverse events attributed to antihypertensive medications in the intensive treatment arm (77/2362, 3.3%) than those in the standard treatment arm (30/2371,1.3%). <a href="./references#CD004034-bbs2-0010" title="AmbrosiusWT , SinkKM , FoyCG , BerlowitzDR , CheungAK , CushmanWC , FineLJ , Goff DC Jr, JohnsonKC , KilleenAA , LewisCE , OparilS , ReboussinDM , RoccoMV , SnyderJK , WilliamsonJD , Wright JT Jr, WheltonPK , SPRINT Study Research Group. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).. Clinical Trials 2014 Oct;11(5):532-46. BerlowitzDR , FoyCG , KazisLE , BolinLP , ConroyMB , FitzpatrickP , GureTR , KimmelPL , KirchnerK , MoriskyDE , NewmanJ , OlneyC , OparilS , PajewskiNM , PowellJ , RamseyT , SimmonsDL , SnyderJ , SupianoMA , WeinerDE , WhittleJ , SPRINT Research Group. Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes.. The New England Journal of Medicine 2017 Aug 24;377(8):733-744. SPRINT Research Group, Wright JT Jr, WilliamsonJD , WheltonPK , SnyderJK , SinkKM , RoccoMV , ReboussinDM , RahmanM , OparilS , LewisCE , KimmelPL , JohnsonKC , Goff DC Jr, FineLJ , CutlerJA , CushmanWC , CheungAK , Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control.. The New England Journal of Medicine 2015 Nov 26;373(22):2103-16. The SPRINT MIND Investigators for the SPRINT Research Group. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA2019;321(6):553-561. WilliamsonJD , SupianoMA , ApplegateWB , BerlowitzDR , CampbellRC , ChertowGM , FineLJ , HaleyWE , HawfieldAT , IxJH , KitzmanDW , KostisJB , Krousel-WoodMA , LaunerLJ , OparilS , RodriguezCJ , RoumieCL , ShorrRI , SinkKM , WadleyVG , WheltonPK , WhittleJ , WoolardNF , Wright JT Jr, PajewskiNM , SPRINT Research Group. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.. JAMA 2016 Jun 28;315(24):2673-82. ">SPRINT MIND 2019</a> reported serious adverse events classified as possibly or definitely related to the intervention for 118 participants (2.5%) in the standard treatment group and 220 participants (4.7%) in the intensive treatment group (hazard ratio (HR) 1.88, P &lt; 0.001). </p> </section> <section id="CD004034-sec-0078"> <h5 class="title">Quality of life (QOL)</h5> <p>The ACCORD BP HRQL sub‐study of <a href="./references#CD004034-bbs2-0001" title="BuseJB , BiggerJT , ByingtonRP , CooperLS , CushmanWC , FriedewaldWT , et al, ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. American Journal of Cardiology2007;99(12A):21i-33i. CushmanWC , Grimm RH Jr, CutlerJA , EvansGW , CapesS , CorsonMA , et al, ACCORD Study Group. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):44i-55i. LaunerLJ , MillerME , WilliamsonJD , LazarRM , GersteinHC , MurrayAM , et al, ACCORD MIND investigators. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurology2011;10(11):969-77. MargolisKL , O'ConnorPJ , MorganTM , BuseJB , CohenRM , CushmanWC , et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care2014;37(6):1721-8. O'ConnorPJ , NarayanKM , AndersonR , FeeneyP , FineL , AliMK , et al. Effect of intensive versus standard blood pressure control on depression and health-related quality of life in type 2 diabetes: the ACCORD trial. Diabetes Care2012;35(7):1479-81. WilliamsonJD , LaunerLJ , BryanRN , CokerLH , LazarRM , GersteinHC , et al, Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Investigators. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Internal Medicine2014;174(3):324-33. WilliamsonJD , MillerME , BryanRN , LazarRM , CokerLH , JohnsonJ , et al, ACCORD Study Group. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. American Journal of Cardiology2007;99(12A):112i-122i. ">ACCORD MIND 2014</a> reported no significant differences in five out of six QOL measures. Those assigned to intensive BP control had statistically, but not clinically, significant worsening of physical component scores of SF‐36 (‐0.8 versus ‐0.2, P = 0.02). The <a href="./references#CD004034-bbs2-0010" title="AmbrosiusWT , SinkKM , FoyCG , BerlowitzDR , CheungAK , CushmanWC , FineLJ , Goff DC Jr, JohnsonKC , KilleenAA , LewisCE , OparilS , ReboussinDM , RoccoMV , SnyderJK , WilliamsonJD , Wright JT Jr, WheltonPK , SPRINT Study Research Group. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).. Clinical Trials 2014 Oct;11(5):532-46. BerlowitzDR , FoyCG , KazisLE , BolinLP , ConroyMB , FitzpatrickP , GureTR , KimmelPL , KirchnerK , MoriskyDE , NewmanJ , OlneyC , OparilS , PajewskiNM , PowellJ , RamseyT , SimmonsDL , SnyderJ , SupianoMA , WeinerDE , WhittleJ , SPRINT Research Group. Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes.. The New England Journal of Medicine 2017 Aug 24;377(8):733-744. SPRINT Research Group, Wright JT Jr, WilliamsonJD , WheltonPK , SnyderJK , SinkKM , RoccoMV , ReboussinDM , RahmanM , OparilS , LewisCE , KimmelPL , JohnsonKC , Goff DC Jr, FineLJ , CutlerJA , CushmanWC , CheungAK , Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control.. The New England Journal of Medicine 2015 Nov 26;373(22):2103-16. The SPRINT MIND Investigators for the SPRINT Research Group. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA2019;321(6):553-561. WilliamsonJD , SupianoMA , ApplegateWB , BerlowitzDR , CampbellRC , ChertowGM , FineLJ , HaleyWE , HawfieldAT , IxJH , KitzmanDW , KostisJB , Krousel-WoodMA , LaunerLJ , OparilS , RodriguezCJ , RoumieCL , ShorrRI , SinkKM , WadleyVG , WheltonPK , WhittleJ , WoolardNF , Wright JT Jr, PajewskiNM , SPRINT Research Group. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.. JAMA 2016 Jun 28;315(24):2673-82. ">SPRINT MIND 2019</a> group reported, in 2017, no significant difference in QOL measures between treatment groups. </p> </section> </section> <section id="CD004034-sec-0079"> <h4 class="title">Comparison 3: non‐placebo‐controlled RCTs</h4> <section id="CD004034-sec-0080"> <h5 class="title">Incidence of dementia</h5> <p>Neither <a href="./references#CD004034-bbs2-0002" title="HajjarI , HartM , ChenYL , MackW , MilbergW , ChuiH , et al. Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: a double-blind randomized clinical trial. Archives of Internal Medicine2012;172(5):442-4. HajjarI , HartM , ChenYL , MackW , NovakV , ChuiH , et al. Antihypertensive therapy and cerebral hemodynamics in executive mild cognitive impairment: results of a pilot randomized clinical trial. Journal of the American Geriatrics Society2013;61(2):194-201. HajjarI , HartM , MackW , LipsitzLA . Aldosterone, cognitive function, and cerebral hemodynamics in hypertension and antihypertensive therapy. American Journal of Hypertension2015;28(3):319-25. HajjarI , HartM , MilbergW , NovakV , LipsitzL . The rationale and design of the antihypertensives and vascular, endothelial, and cognitive function (AVEC) trial in elderly hypertensives with early cognitive impairment: role of the renin angiotensin system inhibition. BMC Geriatrics2009;9:48. ">AVEC 2012</a> nor <a href="./references#CD004034-bbs2-0003" title="SatoN , SaijoY , HasebeN , CAMUI investigators. Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial. International Heart Journal2012;53(4):244-8. SatoN , SaijoY , SasagawaY , MorimotoH , TakeuchiT , SanoH , KoyamaS , TakeharaN , MoritaK , SumitomoK , MaruyamaJ , KikuchiK , HasebeN , CAMUI investigators. Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial: results after 1 year. Journal of Hypertension2013;31(6):1245-55. ">CAMUI 2013</a> reported incidence of dementia. </p> </section> <section id="CD004034-sec-0081"> <h5 class="title">Cognitive change from baseline</h5> <p><a href="./references#CD004034-bbs2-0002" title="HajjarI , HartM , ChenYL , MackW , MilbergW , ChuiH , et al. Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: a double-blind randomized clinical trial. Archives of Internal Medicine2012;172(5):442-4. HajjarI , HartM , ChenYL , MackW , NovakV , ChuiH , et al. Antihypertensive therapy and cerebral hemodynamics in executive mild cognitive impairment: results of a pilot randomized clinical trial. Journal of the American Geriatrics Society2013;61(2):194-201. HajjarI , HartM , MackW , LipsitzLA . Aldosterone, cognitive function, and cerebral hemodynamics in hypertension and antihypertensive therapy. American Journal of Hypertension2015;28(3):319-25. HajjarI , HartM , MilbergW , NovakV , LipsitzL . The rationale and design of the antihypertensives and vascular, endothelial, and cognitive function (AVEC) trial in elderly hypertensives with early cognitive impairment: role of the renin angiotensin system inhibition. BMC Geriatrics2009;9:48. ">AVEC 2012</a>, comparing ARB, diuretic and ACE inhibitor groups, reported change in Trail Making Test (TMT), Hopkins Verbal Learning Test (HVLT) and Digit Span Test (DST) over 12 months as least square means adjusted for baseline age and MMSE. Data were incompletely reported in the 2013 paper, as follows: 12‐month least square mean decrease in time taken to complete TMT‐B of 17.1 seconds in ARB group (n = 17), 4.2 seconds in diuretic group (n = 13) and an increase of 14.4 seconds in the ACE inhibitor group (n = 17) (between group P = 0.008); improvement in recognition portion of HVLT in ARB group (P = 0.03); no group difference in immediate and delayed recall portions of HVLT and DST. Data were shown in figures but not reported in a 2012 report. Data were not extrapolated from the figures for these analyses. </p> <p><a href="./references#CD004034-bbs2-0003" title="SatoN , SaijoY , HasebeN , CAMUI investigators. Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial. International Heart Journal2012;53(4):244-8. SatoN , SaijoY , SasagawaY , MorimotoH , TakeuchiT , SanoH , KoyamaS , TakeharaN , MoritaK , SumitomoK , MaruyamaJ , KikuchiK , HasebeN , CAMUI investigators. Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial: results after 1 year. Journal of Hypertension2013;31(6):1245-55. ">CAMUI 2013</a>, comparing ARB plus CCB and ARB plus diuretic combinations, reported no significant difference in MMSE values at baseline and one year in either group, or between groups. Mean MMSE at baseline and one year for the ARB plus CCB group (n = 68) were 27.0 and 26.6 points, respectively, and for the ARB plus diuretic group (n = 74), 26.5 and 26.5 points, respectively. Group means only were reported for final MMSE. </p> </section> <section id="CD004034-sec-0082"> <h5 class="title">Change in systolic blood pressure (SBP)</h5> <p><a href="./references#CD004034-bbs2-0002" title="HajjarI , HartM , ChenYL , MackW , MilbergW , ChuiH , et al. Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: a double-blind randomized clinical trial. Archives of Internal Medicine2012;172(5):442-4. HajjarI , HartM , ChenYL , MackW , NovakV , ChuiH , et al. Antihypertensive therapy and cerebral hemodynamics in executive mild cognitive impairment: results of a pilot randomized clinical trial. Journal of the American Geriatrics Society2013;61(2):194-201. HajjarI , HartM , MackW , LipsitzLA . Aldosterone, cognitive function, and cerebral hemodynamics in hypertension and antihypertensive therapy. American Journal of Hypertension2015;28(3):319-25. HajjarI , HartM , MilbergW , NovakV , LipsitzL . The rationale and design of the antihypertensives and vascular, endothelial, and cognitive function (AVEC) trial in elderly hypertensives with early cognitive impairment: role of the renin angiotensin system inhibition. BMC Geriatrics2009;9:48. ">AVEC 2012</a>, comparing ARB (n = 17), diuretic (n = 13) and ACE inhibitor (n = 17) groups, reported baseline, 6‐ and 12‐month age‐adjusted least square mean (SE) SBP for the three groups, and also change in SBP over 12 months as mean reduction with standard errors for each of the three groups: ARB 26 (5) mmHg, diuretic 25 (6) mmHg and ACE inhibitor 27 (5) mmHg, as shown in the data analyses tables. These were reported as not significantly different between groups (P = 0.93). </p> <p><a href="./references#CD004034-bbs2-0003" title="SatoN , SaijoY , HasebeN , CAMUI investigators. Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial. International Heart Journal2012;53(4):244-8. SatoN , SaijoY , SasagawaY , MorimotoH , TakeuchiT , SanoH , KoyamaS , TakeharaN , MoritaK , SumitomoK , MaruyamaJ , KikuchiK , HasebeN , CAMUI investigators. Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial: results after 1 year. Journal of Hypertension2013;31(6):1245-55. ">CAMUI 2013</a>, comparing ARB plus CCB and ARB plus diuretic combinations, reported as a figure baseline, 3‐, 6‐, and 12‐month SBP for both groups. Mean and SD data were reported explicitly only for baseline, 3‐ and 6‐month BP data, with 6‐month SBP of 132 (13) in the ARB plus CCB group (n = 68) and 133 (16) in the ARB plus diuretic group (n = 74) (P = 0.575). </p> </section> <section id="CD004034-sec-0083"> <h5 class="title">Change in diastolic blood pressure (DBP)</h5> <p><a href="./references#CD004034-bbs2-0002" title="HajjarI , HartM , ChenYL , MackW , MilbergW , ChuiH , et al. Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: a double-blind randomized clinical trial. Archives of Internal Medicine2012;172(5):442-4. HajjarI , HartM , ChenYL , MackW , NovakV , ChuiH , et al. Antihypertensive therapy and cerebral hemodynamics in executive mild cognitive impairment: results of a pilot randomized clinical trial. Journal of the American Geriatrics Society2013;61(2):194-201. HajjarI , HartM , MackW , LipsitzLA . Aldosterone, cognitive function, and cerebral hemodynamics in hypertension and antihypertensive therapy. American Journal of Hypertension2015;28(3):319-25. HajjarI , HartM , MilbergW , NovakV , LipsitzL . The rationale and design of the antihypertensives and vascular, endothelial, and cognitive function (AVEC) trial in elderly hypertensives with early cognitive impairment: role of the renin angiotensin system inhibition. BMC Geriatrics2009;9:48. ">AVEC 2012</a>, comparing ARB (n = 17), diuretic (n = 13) and ACE inhibitor (n = 17) groups, reported baseline, 6‐ and 12‐month age‐adjusted least square mean (SE) DBP for the three groups. <a href="./references#CD004034-bbs2-0003" title="SatoN , SaijoY , HasebeN , CAMUI investigators. Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial. International Heart Journal2012;53(4):244-8. SatoN , SaijoY , SasagawaY , MorimotoH , TakeuchiT , SanoH , KoyamaS , TakeharaN , MoritaK , SumitomoK , MaruyamaJ , KikuchiK , HasebeN , CAMUI investigators. Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial: results after 1 year. Journal of Hypertension2013;31(6):1245-55. ">CAMUI 2013</a>, comparing ARB plus CCB and ARB plus diuretic combinations, reported as a figure baseline, 3‐, 6‐ and 12‐month DBP for both groups. Mean and standard deviation data were reported explicitly only for baseline, 3‐ and 6‐month BP data, with 6‐month DBP of 72 (9) in the ARB plus CCB group (n = 68) and 73 (11) in the ARB plus diuretic group (n = 74) (P = 0.791). </p> </section> <section id="CD004034-sec-0084"> <h5 class="title">Incidence and severity of adverse effects</h5> <p><a href="./references#CD004034-bbs2-0002" title="HajjarI , HartM , ChenYL , MackW , MilbergW , ChuiH , et al. Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: a double-blind randomized clinical trial. Archives of Internal Medicine2012;172(5):442-4. HajjarI , HartM , ChenYL , MackW , NovakV , ChuiH , et al. Antihypertensive therapy and cerebral hemodynamics in executive mild cognitive impairment: results of a pilot randomized clinical trial. Journal of the American Geriatrics Society2013;61(2):194-201. HajjarI , HartM , MackW , LipsitzLA . Aldosterone, cognitive function, and cerebral hemodynamics in hypertension and antihypertensive therapy. American Journal of Hypertension2015;28(3):319-25. HajjarI , HartM , MilbergW , NovakV , LipsitzL . The rationale and design of the antihypertensives and vascular, endothelial, and cognitive function (AVEC) trial in elderly hypertensives with early cognitive impairment: role of the renin angiotensin system inhibition. BMC Geriatrics2009;9:48. ">AVEC 2012</a>, comparing ARB (n = 17), diuretic (n = 13) and ACE inhibitor (n = 17) groups, reported incidence of the 'most common and serious' adverse events for the three treatment groups with no significant difference between the groups. One participant withdrew due to adverse events from each of the ACE inhibitor and ARB groups. <a href="./references#CD004034-bbs2-0003" title="SatoN , SaijoY , HasebeN , CAMUI investigators. Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial. International Heart Journal2012;53(4):244-8. SatoN , SaijoY , SasagawaY , MorimotoH , TakeuchiT , SanoH , KoyamaS , TakeharaN , MoritaK , SumitomoK , MaruyamaJ , KikuchiK , HasebeN , CAMUI investigators. Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial: results after 1 year. Journal of Hypertension2013;31(6):1245-55. ">CAMUI 2013</a> reported no participants withdrawn from the ARB plus CCB group (n = 68) due to adverse events, and one participant withdrawn from ARB plus diuretic group (n = 74) (due to uric acid elevation). </p> </section> <section id="CD004034-sec-0085"> <h5 class="title">Quality of life (QOL)</h5> <p>Neither <a href="./references#CD004034-bbs2-0002" title="HajjarI , HartM , ChenYL , MackW , MilbergW , ChuiH , et al. Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: a double-blind randomized clinical trial. Archives of Internal Medicine2012;172(5):442-4. HajjarI , HartM , ChenYL , MackW , NovakV , ChuiH , et al. Antihypertensive therapy and cerebral hemodynamics in executive mild cognitive impairment: results of a pilot randomized clinical trial. Journal of the American Geriatrics Society2013;61(2):194-201. HajjarI , HartM , MackW , LipsitzLA . Aldosterone, cognitive function, and cerebral hemodynamics in hypertension and antihypertensive therapy. American Journal of Hypertension2015;28(3):319-25. HajjarI , HartM , MilbergW , NovakV , LipsitzL . The rationale and design of the antihypertensives and vascular, endothelial, and cognitive function (AVEC) trial in elderly hypertensives with early cognitive impairment: role of the renin angiotensin system inhibition. BMC Geriatrics2009;9:48. ">AVEC 2012</a> nor <a href="./references#CD004034-bbs2-0003" title="SatoN , SaijoY , HasebeN , CAMUI investigators. Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial. International Heart Journal2012;53(4):244-8. SatoN , SaijoY , SasagawaY , MorimotoH , TakeuchiT , SanoH , KoyamaS , TakeharaN , MoritaK , SumitomoK , MaruyamaJ , KikuchiK , HasebeN , CAMUI investigators. Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial: results after 1 year. Journal of Hypertension2013;31(6):1245-55. ">CAMUI 2013</a> reported QOL measures. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD004034-sec-0086" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD004034-sec-0086"></div> <section id="CD004034-sec-0087"> <h3 class="title" id="CD004034-sec-0087">Summary of main results</h3> <p>The studies included in this systematic review do not provide evidence that pharmacological treatment of hypertension reduces cognitive impairment or dementia. Firm conclusions cannot be drawn, however, due to the certainty of the evidence available, as summarised in the 'Summary of findings' table. </p> <p>Regarding our secondary outcomes, we found evidence, as expected, that pharmacological treatment of hypertension reduces blood pressure. We found evidence that pharmacological treatment of blood pressure causes adverse events but not convincing evidence that this leads to discontinuation of treatment. We were unable to draw conclusions regarding quality of life measures. </p> </section> <section id="CD004034-sec-0088"> <h3 class="title" id="CD004034-sec-0088">Overall completeness and applicability of evidence</h3> <p>This review identified 12 studies which address the updated review question of whether pharmacological treatment of hypertension prevents cognitive decline or dementia. However, these studies were not sufficient to answer the review question. </p> <p>The shift towards lower BP targets is due to the accumulating evidence supporting stricter control of BP to prevent cardiovascular morbidity and mortality (<a href="./references#CD004034-bbs2-0124" title="WheltonPK , CareyRM , AronowWS , Casey DE Jr, CollinsKJ , Dennison HimmelfarbC , et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2018 Oct 23;138(17):e426-e483.">Whelton 2018</a>; <a href="./references#CD004034-bbs2-0127" title="WilliamsB , ManciaG , SpieringW , Agabiti RoseiE , AziziM , BurnierM , ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal2018;39(33):3021-104.">Williams 2018</a>; <a href="./references#CD004034-bbs2-0098" title="National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and management. Guideline2019.">NICE 2019</a>). The context in which we continue to test the hypothesis that treatment of BP ‐ in addition to reducing cardiovascular events ‐ will reduce dementia and cognitive decline, is therefore further constrained. </p> <p>In order to answer our research question of whether pharmacological treatment of hypertension reduces dementia and cognitive decline, we need to consider whether to treat, which agent to treat with and at which BP target to aim. The inclusion of <a href="./references#CD004034-bbs2-0001" title="BuseJB , BiggerJT , ByingtonRP , CooperLS , CushmanWC , FriedewaldWT , et al, ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. American Journal of Cardiology2007;99(12A):21i-33i. CushmanWC , Grimm RH Jr, CutlerJA , EvansGW , CapesS , CorsonMA , et al, ACCORD Study Group. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):44i-55i. LaunerLJ , MillerME , WilliamsonJD , LazarRM , GersteinHC , MurrayAM , et al, ACCORD MIND investigators. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurology2011;10(11):969-77. MargolisKL , O'ConnorPJ , MorganTM , BuseJB , CohenRM , CushmanWC , et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care2014;37(6):1721-8. O'ConnorPJ , NarayanKM , AndersonR , FeeneyP , FineL , AliMK , et al. Effect of intensive versus standard blood pressure control on depression and health-related quality of life in type 2 diabetes: the ACCORD trial. Diabetes Care2012;35(7):1479-81. WilliamsonJD , LaunerLJ , BryanRN , CokerLH , LazarRM , GersteinHC , et al, Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Investigators. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Internal Medicine2014;174(3):324-33. WilliamsonJD , MillerME , BryanRN , LazarRM , CokerLH , JohnsonJ , et al, ACCORD Study Group. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. American Journal of Cardiology2007;99(12A):112i-122i. ">ACCORD MIND 2014</a> and <a href="./references#CD004034-bbs2-0010" title="AmbrosiusWT , SinkKM , FoyCG , BerlowitzDR , CheungAK , CushmanWC , FineLJ , Goff DC Jr, JohnsonKC , KilleenAA , LewisCE , OparilS , ReboussinDM , RoccoMV , SnyderJK , WilliamsonJD , Wright JT Jr, WheltonPK , SPRINT Study Research Group. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).. Clinical Trials 2014 Oct;11(5):532-46. BerlowitzDR , FoyCG , KazisLE , BolinLP , ConroyMB , FitzpatrickP , GureTR , KimmelPL , KirchnerK , MoriskyDE , NewmanJ , OlneyC , OparilS , PajewskiNM , PowellJ , RamseyT , SimmonsDL , SnyderJ , SupianoMA , WeinerDE , WhittleJ , SPRINT Research Group. Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes.. The New England Journal of Medicine 2017 Aug 24;377(8):733-744. SPRINT Research Group, Wright JT Jr, WilliamsonJD , WheltonPK , SnyderJK , SinkKM , RoccoMV , ReboussinDM , RahmanM , OparilS , LewisCE , KimmelPL , JohnsonKC , Goff DC Jr, FineLJ , CutlerJA , CushmanWC , CheungAK , Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control.. The New England Journal of Medicine 2015 Nov 26;373(22):2103-16. The SPRINT MIND Investigators for the SPRINT Research Group. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA2019;321(6):553-561. WilliamsonJD , SupianoMA , ApplegateWB , BerlowitzDR , CampbellRC , ChertowGM , FineLJ , HaleyWE , HawfieldAT , IxJH , KitzmanDW , KostisJB , Krousel-WoodMA , LaunerLJ , OparilS , RodriguezCJ , RoumieCL , ShorrRI , SinkKM , WadleyVG , WheltonPK , WhittleJ , WoolardNF , Wright JT Jr, PajewskiNM , SPRINT Research Group. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.. JAMA 2016 Jun 28;315(24):2673-82. ">SPRINT MIND 2019</a> in this review increases the relevance of the evidence to the research question but does not provide evidence that intensive BP management reduces dementia or cognitive decline. </p> <p>Included studies with the longest durations are unlikely to have sufficient follow‐up periods to provide evidence of cognitive benefit from pharmacological antihypertensive treatment, if it does indeed exist. The shorter, more recent trials certainly do not afford such an opportunity. The testing of pathophysiological hypotheses in the shorter studies of <a href="./references#CD004034-bbs2-0002" title="HajjarI , HartM , ChenYL , MackW , MilbergW , ChuiH , et al. Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: a double-blind randomized clinical trial. Archives of Internal Medicine2012;172(5):442-4. HajjarI , HartM , ChenYL , MackW , NovakV , ChuiH , et al. Antihypertensive therapy and cerebral hemodynamics in executive mild cognitive impairment: results of a pilot randomized clinical trial. Journal of the American Geriatrics Society2013;61(2):194-201. HajjarI , HartM , MackW , LipsitzLA . Aldosterone, cognitive function, and cerebral hemodynamics in hypertension and antihypertensive therapy. American Journal of Hypertension2015;28(3):319-25. HajjarI , HartM , MilbergW , NovakV , LipsitzL . The rationale and design of the antihypertensives and vascular, endothelial, and cognitive function (AVEC) trial in elderly hypertensives with early cognitive impairment: role of the renin angiotensin system inhibition. BMC Geriatrics2009;9:48. ">AVEC 2012</a> explain why these brief durations of follow‐up were undertaken. </p> <p>The utilisation of drug combinations within and across studies means conclusions regarding individual drug classes cannot be drawn, especially with the small numbers of participants in the newly included studies. In <a href="./references#CD004034-bbs2-0011" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , De LeeuwP , DolleryCT , et al. Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: Objectives, protocol, and organization. Aging Clin Exp Res1991;3:287-302. FletcherAE , BulpittCJ , ThijsL , ToumilehtoJ , AntikainenR , BossiniA , et al. Quality of life on randomised treatment for isolated hypertension: results from the Syst-Eur Trial. Journal of Hypertension2002;20:2069-2079. FletcherAE , BulpittCJ , TuomilehtoJ , BrowneJ , BossiniA , Kawecka-JaszczK , et al. Quality of life of elderly patients with isolated systolic hypertension: baseline data from the Syst-Eur Trial. Journal of Hypertension1988;16:1117-1124. ForetteF , Seux M-L, StaessenJA , ThijsL , Babarskiene M-R, BabeanuS , et al. The Prevention of Dementia With Antihypertensive Treatment. New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study. Archives of Internal Medicine2002;162:2046-2052. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH , BabarskieneMR , et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet1998;352:1347-51. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH . Reduction of dementia by calcium-antagonist-based antihypertensive treatment. European Heart Journal Supplements2000;2:D17-D19. StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Lancet1997;350:757-764. ">Syst Eur 1998</a>, it was speculated that dementia prevention was facilitated by the neuroprotective role of the CCB nitrendipine. One meta‐analysis suggests differential effects between dihydropyridine calcium channel blockers (CCBs) and diuretics, on the one hand, and inhibitors of the renin‐angiotensin system, on the other (<a href="./references#CD004034-bbs2-0120" title="WangJG , StaessenJA , Birkenhäger, WH. Antihypertensive treatment and prevention of stroke and dementia. Seminars in Cerebrovascular Diseases and Stroke2003;3:155-64.">Wang 2003</a>). Potential different class effects have been considered elsewhere (<a href="./references#CD004034-bbs2-0091" title="Levi MarpillatN , Macquin-MavierI , TropeanoAI , Bachoud-LeviAC , MaisonP . Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis. Journal of Hypertension2013;31(6):1073-82.">Levi Marpillat 2013</a>; <a href="./references#CD004034-bbs2-0102" title="PetersR , BoothA , PetersJ . A systematic review of calcium channel blocker use and cognitive decline/dementia in the elderly. Journal of Hypertension 2014 Oct;32(10):1945-57.">Peters 2014</a>; <a href="./references#CD004034-bbs2-0103" title="PetersR . INVESTIGATION OF ANTIHYPERTENSIVE CLASS EFFECTS ON DEMENTIA AND COGNITIVE DECLINE: A COLLABORATIVE META-ANALYSIS OF PARTICIPANT DATA. Alzheimers &amp; Dementia: The Journal of the Alzheimer's Associaiton July 2018;14(7):Supplement, Page P1388.">Peters 2018</a>), and further work is ongoing. </p> <p>It is important to note that cardiovascular, including cerebrovascular, outcomes were the primary endpoints in the majority of the included studies in this review, with dementia and cognitive function as secondary outcomes. The earlier trials were terminated once benefits for the primary endpoints were shown. It is therefore possible that beneficial effects on cognition were not observed prior to the cardiovascular benefits becoming apparent. </p> <p>For these reasons, the studies identified are not sufficient to answer the research question. </p> <p>RCTs have provided evidence to support the active treatment of hypertension, even in the very elderly. Interestingly, a retrospective analysis has shown no interaction effect between frailty and the effect of antihypertensive treatment in HYVET (<a href="./references#CD004034-bbs2-0121" title="WarwickJ , FalaschettiE , RockwoodK , MitnitskiA , ThijsL , BeckettN , et al. No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: an investigation of the impact of frailty upon treatment effect in the HYpertension in the Very Elderly Trial (HYVET) study, a double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over. BMC Medicine2015;13:78.">Warwick 2015</a>). Given the shift towards age‐specific BP thresholds and targets, as evidenced by the ESC guidelines, it is imperative that studies include participants across age ranges. The included studies did cover a relatively broad age range. </p> <p>Placebo‐controlled trials, at least at the BP thresholds used in the older RCTs, are no longer directly relevant and the expansion of our inclusion criteria reflects this. We excluded studies without specific BP entry criteria, which may have excluded potentially relevant studies such as <a href="./references#CD004034-bbs2-0034" title="AndersonC , TeoK , GaoP , ArimaH , DansA , UngerT , et al, ONTARGET and TRANSCEND Investigators. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurology2011;10(1):43-53. ONTARGET Investigators, YusufS , TeoKK , PogueJ , DyalL , CoplandI , et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. New England Journal of Medicine2008;358(15):1547-59. TeoK , YusufS , SleightP , AndersonC , MookadamF , RamosB , et al, ONTARGET/TRANSCEND Investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. American Heart Journal2004;148(1):52-61. ">ONTARGET 2008</a>, <a href="./references#CD004034-bbs2-0045" title="Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, YusufS , TeoK , AndersonC , PogueJ , DyalL , et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patientsintolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet2008;372(9644):1174-83. ">TRANSCEND 2008</a>, <a href="./references#CD004034-bbs2-0013" title="ADVANCE Management Committee. Study rationale and design of ADVANCE: action in diabetes and vascular disease--preterax and diamicron MR controlled evaluation. Diabetologia2001;44(9):1118-20. BattyGD , LiQ , HuxleyR , ZoungasS , TaylorBA , NealB , et al, ADVANCE Collaborative group. Oral disease in relation to future risk of dementia and cognitive decline: prospective cohort study based on the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation (ADVANCE) trial. European Psychiatry2013;28(1):49-52. NinomiyaT , ZoungasS , NealB , WoodwardM , PatelA , PerkovicV , et al, ADVANCE Collaborative Group. Efficacy and safety of routine blood pressure lowering in older patients with diabetes: results from the ADVANCE trial. Journal of Hypertension2010;28(6):1141-9. PatelA , ADVANCE Collaborative Group, MacMahonS , ChalmersJ , NealB , WoodwardM , et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet2007;370(9590):829-40. Van der LeeuwJ , VisserenFL , WoodwardM , ZoungasS , KengneAP , Van der GraafY , et al. Predicting the effects of blood pressure-lowering treatment on major cardiovascular events for individual patients with type 2 diabetes mellitus: results from Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation. Hypertension2015;65(1):115-21. ">ADVANCE 2010</a> and the recently published cognitive sub‐study of <a href="./references#CD004034-bbs2-0028" title="BoschJ , O’DonnellM , SwaminathanB , LonnEM , SharmaM , Dagenais G et al, HOPE-3 Investigators. Effects of blood pressure and lipid lowering on cognition: Results from the HOPE-3 study. Neurology2019;92(13):e1435-46. LonnE , BoschJ , PogueJ , AvezumA , ChazovaI , DansA , et al, HOPE-3 Investigators. Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics. The Canadian Journal of Cardiology2016;32(3):311-8. LonnEM , BoschJ , López-JaramilloP , ZhuJ , LiuL , PaisP , et al, HOPE-3 Investigators. Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. The New England Journal of Medicine2016;374(21):2009-20. YusufS , LonnE , PaisP , BoschJ , López-JaramilloP , ZhuJ , et al, HOPE-3 Investigators. Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. The New England Journal Of Medicine2016;374(21):2032-43. ">HOPE 3 2016</a>. </p> <p><a href="./references#CD004034-bbs2-0001" title="BuseJB , BiggerJT , ByingtonRP , CooperLS , CushmanWC , FriedewaldWT , et al, ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. American Journal of Cardiology2007;99(12A):21i-33i. CushmanWC , Grimm RH Jr, CutlerJA , EvansGW , CapesS , CorsonMA , et al, ACCORD Study Group. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):44i-55i. LaunerLJ , MillerME , WilliamsonJD , LazarRM , GersteinHC , MurrayAM , et al, ACCORD MIND investigators. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurology2011;10(11):969-77. MargolisKL , O'ConnorPJ , MorganTM , BuseJB , CohenRM , CushmanWC , et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care2014;37(6):1721-8. O'ConnorPJ , NarayanKM , AndersonR , FeeneyP , FineL , AliMK , et al. Effect of intensive versus standard blood pressure control on depression and health-related quality of life in type 2 diabetes: the ACCORD trial. Diabetes Care2012;35(7):1479-81. WilliamsonJD , LaunerLJ , BryanRN , CokerLH , LazarRM , GersteinHC , et al, Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Investigators. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Internal Medicine2014;174(3):324-33. WilliamsonJD , MillerME , BryanRN , LazarRM , CokerLH , JohnsonJ , et al, ACCORD Study Group. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. American Journal of Cardiology2007;99(12A):112i-122i. ">ACCORD MIND 2014</a> recruited only diabetics. <a href="./references#CD004034-bbs2-0005" title="YodfatY , Bar-OnD , AmirM , Cristal N. Quality of life in normotensives compared to hypertensive men treated with isradipine or methyldopa as monotherapy or in combination with captopril: the LOMIR-MCT-IL study.. Journal of Human Hypertension 1996 Feb;10(2):117-22. YodfatY , Cristal N. A multicenter, double-blind, randomized, placebo-controlled study of isradipine and methyldopa as monotherapy or in combination with captopril in the treatment of hypertension. The LOMIR-MCT-IH Research Group.. American Journal of Hypertension 1993 Mar;6(3 Pt 2):57S-61S. ">LOMIR MCT IL 1996</a> and <a href="./references#CD004034-bbs2-0007" title="Pérez-StableEJ , HallidayR , GardinerPS , BaronRB , HauckWW , AcreeM , CoatesTJ . The effects of propranolol on cognitive function and quality of life: a randomized trial among patients with diastolic hypertension.. The American Journal Of Medicine 2000 Apr 1;108(5):359-65. ">Perez Stable 2000</a> recruited participants with diastolic dysfunction. Included studies all used office BP measurements; continuous BP monitoring is assumed to be similar but may affect validity. </p> <section id="CD004034-sec-0089"> <h4 class="title">Open‐label extension studies</h4> <p>Only those cognitive outcomes measured during the study period were analysed and reported in <a href="./references#CD004034-bbs2-0004" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumiterscuD , et al, for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. NEJM2008;358:1887-1898. BulpittC , FletcherA , BeckettN , CoopeJ , Gil-ExtremeraB , ForetteF , et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs &amp; Aging2001;18:151-164. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al, for the HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurology2008;7:683-689. PetersR , BeckettN , McCormackT , FagardR , FletcherA , BulpittC . Treating hypertension in the very elderly-benefits, risks, and future directions, a focus on the hypertension in the very elderly trial. European Heart Journal 2014 Jul;35(26):1712-8. PetersR , BeckettN , NunesM , FletcherA , ForetteF , BulpittC . A substudy protocol of the Hypertension in the Very Elderly Trial assessing cognitive decline and dementia incidence (HYVET-COG): an ongoing randomised, double-blind, placebo-controlled trial. Drugs Aging2006;23:83-92. ">HYVET 2008</a>. <a href="./references#CD004034-bbs2-0011" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , De LeeuwP , DolleryCT , et al. Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: Objectives, protocol, and organization. Aging Clin Exp Res1991;3:287-302. FletcherAE , BulpittCJ , ThijsL , ToumilehtoJ , AntikainenR , BossiniA , et al. Quality of life on randomised treatment for isolated hypertension: results from the Syst-Eur Trial. Journal of Hypertension2002;20:2069-2079. FletcherAE , BulpittCJ , TuomilehtoJ , BrowneJ , BossiniA , Kawecka-JaszczK , et al. Quality of life of elderly patients with isolated systolic hypertension: baseline data from the Syst-Eur Trial. Journal of Hypertension1988;16:1117-1124. ForetteF , Seux M-L, StaessenJA , ThijsL , Babarskiene M-R, BabeanuS , et al. The Prevention of Dementia With Antihypertensive Treatment. New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study. Archives of Internal Medicine2002;162:2046-2052. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH , BabarskieneMR , et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet1998;352:1347-51. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH . Reduction of dementia by calcium-antagonist-based antihypertensive treatment. European Heart Journal Supplements2000;2:D17-D19. StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Lancet1997;350:757-764. ">Syst Eur 1998</a> reported both the per protocol analysis, including only data collected while participants were on double‐blind treatment, and intention‐to‐treat analysis, including data collected during the study period but while some participants were on open‐label treatment (median follow‐up two years). It is the latter results which are included in this review. A further open‐label, active treatment follow‐up study in the same population based on the original active study medication was later completed (<a href="./references#CD004034-bbs2-0070" title="ForetteF , Seux M-L, StaessenJA , ThijsL , Babarskiene M-R, BabeanuS , et al. The prevention of dementia with antihypertensive treatment. New evidence from the Systolic Hypertension in Europe (Syst-Eur) Study. Archives of Internal Medicine2002;162:2046-2052.">Forette 2002</a>). The median follow‐up was 3.9 years. From the placebo group, 80.5% of participants ended up on antihypertensive medication due to blood pressure level. Throughout follow‐up, systolic/diastolic blood pressure was 7.0/3.2 mmHg higher in the 1417 participants on placebo than in the 1485 participants originally randomised to antihypertensive treatment. Compared with the controls, long‐term antihypertensive therapy reduced the risk of dementia by 55% from 7.4 to 3.3 cases per 1000 patient‐years (43 versus 21 cases, P &lt; 0.001). There was no significant change in MMSE between placebo and antihypertensive treatment groups. </p> <p>Subsequent to publication of <a href="./references#CD004034-bbs2-0001" title="BuseJB , BiggerJT , ByingtonRP , CooperLS , CushmanWC , FriedewaldWT , et al, ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. American Journal of Cardiology2007;99(12A):21i-33i. CushmanWC , Grimm RH Jr, CutlerJA , EvansGW , CapesS , CorsonMA , et al, ACCORD Study Group. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):44i-55i. LaunerLJ , MillerME , WilliamsonJD , LazarRM , GersteinHC , MurrayAM , et al, ACCORD MIND investigators. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurology2011;10(11):969-77. MargolisKL , O'ConnorPJ , MorganTM , BuseJB , CohenRM , CushmanWC , et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care2014;37(6):1721-8. O'ConnorPJ , NarayanKM , AndersonR , FeeneyP , FineL , AliMK , et al. Effect of intensive versus standard blood pressure control on depression and health-related quality of life in type 2 diabetes: the ACCORD trial. Diabetes Care2012;35(7):1479-81. WilliamsonJD , LaunerLJ , BryanRN , CokerLH , LazarRM , GersteinHC , et al, Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Investigators. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Internal Medicine2014;174(3):324-33. WilliamsonJD , MillerME , BryanRN , LazarRM , CokerLH , JohnsonJ , et al, ACCORD Study Group. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. American Journal of Cardiology2007;99(12A):112i-122i. ">ACCORD MIND 2014</a>, results of an open‐label observational extension study, ACCORDION MIND (<a href="./references#CD004034-bbs2-0097" title="MurrayAM , HsuFC , WilliamsonJD , BryanRN , GersteinHC , SullivanMD , et al, Action to Control Cardiovascular Risk in Diabetes Follow-On Memory in Diabetes (ACCORDION MIND) Investigators. ACCORDION MIND: results of the observational extension of the ACCORD MIND randomised trial.. Diabetologia2017;60(1):69-80.">Murray 2017</a>), were published showing no difference in cognitive outcomes between the intensive and standard groups at 80 months. There was significant loss to follow‐up, and the differences in BP seen between the intensive and standard BP groups during the study were not maintained. </p> <p>At the end of the <a href="./references#CD004034-bbs2-0010" title="AmbrosiusWT , SinkKM , FoyCG , BerlowitzDR , CheungAK , CushmanWC , FineLJ , Goff DC Jr, JohnsonKC , KilleenAA , LewisCE , OparilS , ReboussinDM , RoccoMV , SnyderJK , WilliamsonJD , Wright JT Jr, WheltonPK , SPRINT Study Research Group. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).. Clinical Trials 2014 Oct;11(5):532-46. BerlowitzDR , FoyCG , KazisLE , BolinLP , ConroyMB , FitzpatrickP , GureTR , KimmelPL , KirchnerK , MoriskyDE , NewmanJ , OlneyC , OparilS , PajewskiNM , PowellJ , RamseyT , SimmonsDL , SnyderJ , SupianoMA , WeinerDE , WhittleJ , SPRINT Research Group. Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes.. The New England Journal of Medicine 2017 Aug 24;377(8):733-744. SPRINT Research Group, Wright JT Jr, WilliamsonJD , WheltonPK , SnyderJK , SinkKM , RoccoMV , ReboussinDM , RahmanM , OparilS , LewisCE , KimmelPL , JohnsonKC , Goff DC Jr, FineLJ , CutlerJA , CushmanWC , CheungAK , Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control.. The New England Journal of Medicine 2015 Nov 26;373(22):2103-16. The SPRINT MIND Investigators for the SPRINT Research Group. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA2019;321(6):553-561. WilliamsonJD , SupianoMA , ApplegateWB , BerlowitzDR , CampbellRC , ChertowGM , FineLJ , HaleyWE , HawfieldAT , IxJH , KitzmanDW , KostisJB , Krousel-WoodMA , LaunerLJ , OparilS , RodriguezCJ , RoumieCL , ShorrRI , SinkKM , WadleyVG , WheltonPK , WhittleJ , WoolardNF , Wright JT Jr, PajewskiNM , SPRINT Research Group. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.. JAMA 2016 Jun 28;315(24):2673-82. ">SPRINT MIND 2019</a> study phase in August 2015, the mean SBP in the intensive and standard groups were 121.6 mmHg (95% CI 120.8 to 122.3 mmHg) and 134.8 mmHg (95% CI 134.1 to 135.6 mmHg), respectively, with a mean difference of 13.3 mmHg (95% CI 12.3 to 14.3 mmHg) between groups. During the extended study visits in 2017 to 2018, the between‐group mean difference had reduced to 6.4 mmHg (95% CI 4.2 mmHg to 8.5 mmHg) which the investigators attributed largely to the increase in SBP in the previously intensively treated group to 129.2 mmHg (95% CI 127.7 mmHg to 130.7 mmHg). </p> </section> <section id="CD004034-sec-0090"> <h4 class="title">Outcome measures</h4> <p>As discussed by <a href="./references#CD004034-bbs2-0081" title="IadecolaC , YaffeK , BillerJ , BratzkeLC , FaraciFM , GorelickPB , et al. American Heart Association Council on Hypertension; Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; and Stroke Council. Hypertension2016;68(6):e67-94.">Iadecola 2016</a> and <a href="./references#CD004034-bbs2-0068" title="EliasMF , TorresRV , DaveyA . Clinical trials of blood pressure lowering and antihypertensive medication: is cognitive measurement state-of-the-art?American Journal of Hypertension2018;31(6):631-642.">Elias 2018</a>, cognitive outcome measures used in studies to date, especially those with younger participants and shorter study durations, are likely inadequate, and have contributed to under powering of studies. More thorough cognitive assessments and outcomes, focused on the most relevant domains ‐ for example, executive function ‐ will in time address these problems. </p> </section> <section id="CD004034-sec-0091"> <h4 class="title">Non‐pharmacological interventions</h4> <p>In keeping with the original review (<a href="./references#CD004034-bbs2-0133" title="McGuinnessB , ToddS , PassmoreP , BullockR . Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database of Systematic Reviews2006, Issue 2. Art. No: CD004034. Art. No: CD004034. [DOI: CD004034. DOI: 10.1002/14651858.CD004034.pub2]">McGuinness 2006</a>) and update (<a href="./references#CD004034-bbs2-0134" title="McGuinnessB , ToddS , PassmoreP , BullockR . Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database of Systematic Reviews2009, Issue 3. Art. No: CD004034. [DOI: 10.1002/14651858.CD004034.pub3]">McGuinness 2009</a>), non‐pharmacological studies were not included in this update. Interest is now moving to more complex interventions, targeting multiple vascular risk factors and combining pharmacological and behavioural elements. These require different review methods and will be covered in a new Cochrane Review. </p> </section> </section> <section id="CD004034-sec-0092"> <h3 class="title" id="CD004034-sec-0092">Quality of the evidence</h3> <p>We identified 12 studies including 30,412 participants. The body of evidence identified in this review does not allow robust conclusions to be drawn regarding whether pharmacological treatment of hypertension prevents dementia and cognitive impairment. </p> <p>Our concerns regarding indirectness for the dementia and cognitive impairment outcomes were due to relatively short studies ‐ several of which did not report dementia incidence ‐ being included in a review asking a question regarding pharmacological antihypertensive treatment, which tends, in practice, to be a long‐term undertaking. The participants in the included studies were, on average, older than those in whom treatment of hypertension has been associated with later cognitive benefit in observational studies (<a href="./references#CD004034-bbs2-0119" title="WalkerKA , PowerMC , GottesmanRF . Defining the Relationship Between Hypertension, Cognitive Decline, and Dementia: a Review. Current Hypertension Reports 2017 March;19(3):24.">Walker 2017</a>). The window for successfully treating hypertension with a view to preventing cognitive decline and dementia may have already passed by the time these participants were enrolled in the studies. In addition, we have combined studies employing different antihypertensive agents, although as outlined above emerging evidence would seem to suggest that certain agents may have disease‐modifying benefits over others. For nine of the included studies, cognition was a secondary endpoint. Only <a href="./references#CD004034-bbs2-0001" title="BuseJB , BiggerJT , ByingtonRP , CooperLS , CushmanWC , FriedewaldWT , et al, ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. American Journal of Cardiology2007;99(12A):21i-33i. CushmanWC , Grimm RH Jr, CutlerJA , EvansGW , CapesS , CorsonMA , et al, ACCORD Study Group. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):44i-55i. LaunerLJ , MillerME , WilliamsonJD , LazarRM , GersteinHC , MurrayAM , et al, ACCORD MIND investigators. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurology2011;10(11):969-77. MargolisKL , O'ConnorPJ , MorganTM , BuseJB , CohenRM , CushmanWC , et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care2014;37(6):1721-8. O'ConnorPJ , NarayanKM , AndersonR , FeeneyP , FineL , AliMK , et al. Effect of intensive versus standard blood pressure control on depression and health-related quality of life in type 2 diabetes: the ACCORD trial. Diabetes Care2012;35(7):1479-81. WilliamsonJD , LaunerLJ , BryanRN , CokerLH , LazarRM , GersteinHC , et al, Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Investigators. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Internal Medicine2014;174(3):324-33. WilliamsonJD , MillerME , BryanRN , LazarRM , CokerLH , JohnsonJ , et al, ACCORD Study Group. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. American Journal of Cardiology2007;99(12A):112i-122i. ">ACCORD MIND 2014</a>, <a href="./references#CD004034-bbs2-0011" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , De LeeuwP , DolleryCT , et al. Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: Objectives, protocol, and organization. Aging Clin Exp Res1991;3:287-302. FletcherAE , BulpittCJ , ThijsL , ToumilehtoJ , AntikainenR , BossiniA , et al. Quality of life on randomised treatment for isolated hypertension: results from the Syst-Eur Trial. Journal of Hypertension2002;20:2069-2079. FletcherAE , BulpittCJ , TuomilehtoJ , BrowneJ , BossiniA , Kawecka-JaszczK , et al. Quality of life of elderly patients with isolated systolic hypertension: baseline data from the Syst-Eur Trial. Journal of Hypertension1988;16:1117-1124. ForetteF , Seux M-L, StaessenJA , ThijsL , Babarskiene M-R, BabeanuS , et al. The Prevention of Dementia With Antihypertensive Treatment. New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study. Archives of Internal Medicine2002;162:2046-2052. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH , BabarskieneMR , et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet1998;352:1347-51. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH . Reduction of dementia by calcium-antagonist-based antihypertensive treatment. European Heart Journal Supplements2000;2:D17-D19. StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Lancet1997;350:757-764. ">Syst Eur 1998</a> and <a href="./references#CD004034-bbs2-0004" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumiterscuD , et al, for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. NEJM2008;358:1887-1898. BulpittC , FletcherA , BeckettN , CoopeJ , Gil-ExtremeraB , ForetteF , et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs &amp; Aging2001;18:151-164. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al, for the HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurology2008;7:683-689. PetersR , BeckettN , McCormackT , FagardR , FletcherA , BulpittC . Treating hypertension in the very elderly-benefits, risks, and future directions, a focus on the hypertension in the very elderly trial. European Heart Journal 2014 Jul;35(26):1712-8. PetersR , BeckettN , NunesM , FletcherA , ForetteF , BulpittC . A substudy protocol of the Hypertension in the Very Elderly Trial assessing cognitive decline and dementia incidence (HYVET-COG): an ongoing randomised, double-blind, placebo-controlled trial. Drugs Aging2006;23:83-92. ">HYVET 2008</a> were powered at the outset to detect a significant difference in cognitive decline between the groups. Cardiovascular endpoints continue to be the main outcome measure for hypertension studies and continue to be the endpoints on which treatment guidelines are based (<a href="./references#CD004034-bbs2-0109" title="ReboussinDM , AllenNB , GriswoldME , GuallarE , HongY , LacklandDT , et al. Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation2018;138(17):e595-616.">Reboussin 2018</a>, <a href="./references#CD004034-bbs2-0127" title="WilliamsB , ManciaG , SpieringW , Agabiti RoseiE , AziziM , BurnierM , ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal2018;39(33):3021-104.">Williams 2018</a>). This increases the risk of indirectness in the studies where cognitive outcomes measures are add‐ons. </p> <p>The heterogeneity of the study methods and the results give rise to concern regarding inconsistency for the dementia and cognitive impairment outcomes. In particular, the varying durations of the wider range of studies included in this updated review are of concern. </p> <p>We have deemed the included studies to be at a serious risk of bias overall for all outcomes. This is primarily due to attrition and contamination bias. </p> <p>The loss to follow‐up of participants who did not complete follow‐up cognitive assessments increases the risk of attrition bias. As <a href="./references#CD004034-bbs2-0006" title="MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. British Medical Journal1992;304(6824):405-12. PrinceMJ , BirdAS , BlizardRA , MannAH . Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. British Medical Journal1996;312(7034):801-5. ">MRC 1996</a>, <a href="./references#CD004034-bbs2-0001" title="BuseJB , BiggerJT , ByingtonRP , CooperLS , CushmanWC , FriedewaldWT , et al, ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. American Journal of Cardiology2007;99(12A):21i-33i. CushmanWC , Grimm RH Jr, CutlerJA , EvansGW , CapesS , CorsonMA , et al, ACCORD Study Group. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):44i-55i. LaunerLJ , MillerME , WilliamsonJD , LazarRM , GersteinHC , MurrayAM , et al, ACCORD MIND investigators. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurology2011;10(11):969-77. MargolisKL , O'ConnorPJ , MorganTM , BuseJB , CohenRM , CushmanWC , et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care2014;37(6):1721-8. O'ConnorPJ , NarayanKM , AndersonR , FeeneyP , FineL , AliMK , et al. Effect of intensive versus standard blood pressure control on depression and health-related quality of life in type 2 diabetes: the ACCORD trial. Diabetes Care2012;35(7):1479-81. WilliamsonJD , LaunerLJ , BryanRN , CokerLH , LazarRM , GersteinHC , et al, Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Investigators. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Internal Medicine2014;174(3):324-33. WilliamsonJD , MillerME , BryanRN , LazarRM , CokerLH , JohnsonJ , et al, ACCORD Study Group. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. American Journal of Cardiology2007;99(12A):112i-122i. ">ACCORD MIND 2014</a> and <a href="./references#CD004034-bbs2-0010" title="AmbrosiusWT , SinkKM , FoyCG , BerlowitzDR , CheungAK , CushmanWC , FineLJ , Goff DC Jr, JohnsonKC , KilleenAA , LewisCE , OparilS , ReboussinDM , RoccoMV , SnyderJK , WilliamsonJD , Wright JT Jr, WheltonPK , SPRINT Study Research Group. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).. Clinical Trials 2014 Oct;11(5):532-46. BerlowitzDR , FoyCG , KazisLE , BolinLP , ConroyMB , FitzpatrickP , GureTR , KimmelPL , KirchnerK , MoriskyDE , NewmanJ , OlneyC , OparilS , PajewskiNM , PowellJ , RamseyT , SimmonsDL , SnyderJ , SupianoMA , WeinerDE , WhittleJ , SPRINT Research Group. Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes.. The New England Journal of Medicine 2017 Aug 24;377(8):733-744. SPRINT Research Group, Wright JT Jr, WilliamsonJD , WheltonPK , SnyderJK , SinkKM , RoccoMV , ReboussinDM , RahmanM , OparilS , LewisCE , KimmelPL , JohnsonKC , Goff DC Jr, FineLJ , CutlerJA , CushmanWC , CheungAK , Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control.. The New England Journal of Medicine 2015 Nov 26;373(22):2103-16. The SPRINT MIND Investigators for the SPRINT Research Group. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA2019;321(6):553-561. WilliamsonJD , SupianoMA , ApplegateWB , BerlowitzDR , CampbellRC , ChertowGM , FineLJ , HaleyWE , HawfieldAT , IxJH , KitzmanDW , KostisJB , Krousel-WoodMA , LaunerLJ , OparilS , RodriguezCJ , RoumieCL , ShorrRI , SinkKM , WadleyVG , WheltonPK , WhittleJ , WoolardNF , Wright JT Jr, PajewskiNM , SPRINT Research Group. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.. JAMA 2016 Jun 28;315(24):2673-82. ">SPRINT MIND 2019</a> show, these participants may not be randomly lost to follow‐up. A follow‐up study to <a href="./references#CD004034-bbs2-0009" title="ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the Treatment of Isolated Systolic Hypertension on Behavioral Variables. Results From the Systolic Hypertension in the Elderly Program. Arch Intern Med1994;154:2154-2160. Di BariM , PahorM , FranseLV , ShorrRI , WanJY , FerrucciL , et al. Dementia and Disability Outcomes in Large Hypertension Trials: Lessons Learned from the Systolic Hypertension in the Elderly Program (SHEP) Trial. American Journal of Epidemiology2001;153:72-8. SHEP Cooperative Research Group. Prevention of Stroke by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic Hypertension. Final Results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265:3255-64. The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and Design of a Randomized Clinical Trial on Prevention of Stroke in Isolated Systolic Hypertension. Journal of Clinical Epidemiology1988;41:1197-1208. ">SHEP 1991</a>, carried out by <a href="./references#CD004034-bbs2-0064" title="Di BariM , PahorM , FranseLV , ShorrRI , WanJY , FerrucciL , et al. Dementia and disability outcomes in large hypertension trials: lessons learned from the Systolic Hypertension in the Elderly Program (SHEP) trial. American Journal of Epidemiology2001;153(1):72-8.">Di Bari 2001</a>, aimed to evaluate whether assessment of cognitive and functional outcomes was biased by differential dropout. Characteristics of participants who did or did not participate in follow‐up cognitive assessments were compared. Assignment to placebo group and the occurrence of cardiovascular events independently predicted missed assessments. When 20% to 30% of the participants who missed the assessment were assumed to be cognitively impaired, assignment to antihypertensive treatment reduced the risk of cognitive impairment. The authors concluded that, in <a href="./references#CD004034-bbs2-0009" title="ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the Treatment of Isolated Systolic Hypertension on Behavioral Variables. Results From the Systolic Hypertension in the Elderly Program. Arch Intern Med1994;154:2154-2160. Di BariM , PahorM , FranseLV , ShorrRI , WanJY , FerrucciL , et al. Dementia and Disability Outcomes in Large Hypertension Trials: Lessons Learned from the Systolic Hypertension in the Elderly Program (SHEP) Trial. American Journal of Epidemiology2001;153:72-8. SHEP Cooperative Research Group. Prevention of Stroke by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic Hypertension. Final Results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265:3255-64. The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and Design of a Randomized Clinical Trial on Prevention of Stroke in Isolated Systolic Hypertension. Journal of Clinical Epidemiology1988;41:1197-1208. ">SHEP 1991</a>, the cognitive evaluations were biased toward the null effect by differential dropout. This might have obscured the appraisal of a protective effect of treatment on the incidence of cognitive decline in older hypertensive adults. It is also important to note that <a href="./references#CD004034-bbs2-0004" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumiterscuD , et al, for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. NEJM2008;358:1887-1898. BulpittC , FletcherA , BeckettN , CoopeJ , Gil-ExtremeraB , ForetteF , et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs &amp; Aging2001;18:151-164. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al, for the HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurology2008;7:683-689. PetersR , BeckettN , McCormackT , FagardR , FletcherA , BulpittC . Treating hypertension in the very elderly-benefits, risks, and future directions, a focus on the hypertension in the very elderly trial. European Heart Journal 2014 Jul;35(26):1712-8. PetersR , BeckettN , NunesM , FletcherA , ForetteF , BulpittC . A substudy protocol of the Hypertension in the Very Elderly Trial assessing cognitive decline and dementia incidence (HYVET-COG): an ongoing randomised, double-blind, placebo-controlled trial. Drugs Aging2006;23:83-92. ">HYVET 2008</a> and <a href="./references#CD004034-bbs2-0011" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , De LeeuwP , DolleryCT , et al. Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: Objectives, protocol, and organization. Aging Clin Exp Res1991;3:287-302. FletcherAE , BulpittCJ , ThijsL , ToumilehtoJ , AntikainenR , BossiniA , et al. Quality of life on randomised treatment for isolated hypertension: results from the Syst-Eur Trial. Journal of Hypertension2002;20:2069-2079. FletcherAE , BulpittCJ , TuomilehtoJ , BrowneJ , BossiniA , Kawecka-JaszczK , et al. Quality of life of elderly patients with isolated systolic hypertension: baseline data from the Syst-Eur Trial. Journal of Hypertension1988;16:1117-1124. ForetteF , Seux M-L, StaessenJA , ThijsL , Babarskiene M-R, BabeanuS , et al. The Prevention of Dementia With Antihypertensive Treatment. New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study. Archives of Internal Medicine2002;162:2046-2052. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH , BabarskieneMR , et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet1998;352:1347-51. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH . Reduction of dementia by calcium-antagonist-based antihypertensive treatment. European Heart Journal Supplements2000;2:D17-D19. StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Lancet1997;350:757-764. ">Syst Eur 1998</a> were halted early on safety grounds. </p> <p>The treatment of participants in placebo groups with antihypertensive agents was necessitated by the changing ethical requirements as a result of emerging evidence in the earlier studies. In addition, those randomised to a specific treatment group often went on to require additional antihypertensive agents from a different class. A large proportion of participants included in this review ended studies on a different treatment to which they had been initially randomised (see <a href="#CD004034-sec-0029">Assessment of risk of bias in included studies</a> section above). The high proportions of the placebo group in <a href="./references#CD004034-bbs2-0008" title="Degl'InnocentiA , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , ZanchettiA , WiklundI . Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). Journal of Human Hypertension2004;18(4):239-45. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study of COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. Journal of Hypertension2004;22(8):1605-12. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. Journal of Hypertension2003;21:875-886. PapademetriouV , FarsangC , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , Zanchetti A for the SCOPE Study Group. Stroke Prevention With the Angiotension II Type-1 Receptor Blocker Candesartan in Elderly Patients With Isolated Systolic Hypertension. The Study on Cognition and Prognosis in the Elderly (SCOPE). Journal of the American College of Cardiology2004;44(6):1175-80. SkoogI , LithellH , HanssonL , ElmfeldtD , HofmanA , OlofssonB , et al, for the SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). American Journal of Hypertension2005;18:1052-1059. ">SCOPE 2003</a> and <a href="./references#CD004034-bbs2-0012" title="JiT , ZhaoY , WangJ , CuiY , DuanD , ChaiQ , et al. Effect of low dose statins and apolipoprotein E genotype on cerebral small vessel disease in older hypertensive patients: a subgroup analysis of a randomized clinical trial. J Am Med Dir Assoc2018;19:995-1002. ZhangH , CuiY , ZhaoY , DongY , DuanD , WangJ , ShengL , JiT , ZhouT , HuW , ChenY , SunS , GongG , ChaiQ , LiuZ . Effects of sartans and low-dose statins on cerebral white matter hyperintensities and cognitive function in older patients with hypertension: a randomized, double-blind and placebo-controlled clinical trial. Hypertension research2018;42(5):717-729. ">Zhang 2018</a> are a particular cause for concern. Our sensitivity analysis removing SCOPE from the dementia outcome analysis made no difference. Removing both studies from the change in MMSE analysis served only to slightly reduce the statistical significance of the difference in MMSE detected between the groups. </p> </section> <section id="CD004034-sec-0093"> <h3 class="title" id="CD004034-sec-0093">Potential biases in the review process</h3> <p>We used well‐described, stringent search criteria and methods for this review. Two authors (ELC and BMcG) independently reviewed search results and any disagreements were settled by consensus (ELC, BMcG, ST and PP). We reviewed the high number of systematic reviews addressing similar questions and no additional studies were identified, increasing the likelihood that we identified all relevant studies. </p> <p>It is possible that our study selection has introduced bias. We chose to include only studies of participants with hypertension, as diagnosed using published criteria. We excluded studies which did not have BP entry criteria (<a href="./references#CD004034-bbs2-0013" title="ADVANCE Management Committee. Study rationale and design of ADVANCE: action in diabetes and vascular disease--preterax and diamicron MR controlled evaluation. Diabetologia2001;44(9):1118-20. BattyGD , LiQ , HuxleyR , ZoungasS , TaylorBA , NealB , et al, ADVANCE Collaborative group. Oral disease in relation to future risk of dementia and cognitive decline: prospective cohort study based on the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation (ADVANCE) trial. European Psychiatry2013;28(1):49-52. NinomiyaT , ZoungasS , NealB , WoodwardM , PatelA , PerkovicV , et al, ADVANCE Collaborative Group. Efficacy and safety of routine blood pressure lowering in older patients with diabetes: results from the ADVANCE trial. Journal of Hypertension2010;28(6):1141-9. PatelA , ADVANCE Collaborative Group, MacMahonS , ChalmersJ , NealB , WoodwardM , et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet2007;370(9590):829-40. Van der LeeuwJ , VisserenFL , WoodwardM , ZoungasS , KengneAP , Van der GraafY , et al. Predicting the effects of blood pressure-lowering treatment on major cardiovascular events for individual patients with type 2 diabetes mellitus: results from Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation. Hypertension2015;65(1):115-21. ">ADVANCE 2010</a>, <a href="./references#CD004034-bbs2-0034" title="AndersonC , TeoK , GaoP , ArimaH , DansA , UngerT , et al, ONTARGET and TRANSCEND Investigators. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurology2011;10(1):43-53. ONTARGET Investigators, YusufS , TeoKK , PogueJ , DyalL , CoplandI , et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. New England Journal of Medicine2008;358(15):1547-59. TeoK , YusufS , SleightP , AndersonC , MookadamF , RamosB , et al, ONTARGET/TRANSCEND Investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. American Heart Journal2004;148(1):52-61. ">ONTARGET 2008</a>, <a href="./references#CD004034-bbs2-0045" title="Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, YusufS , TeoK , AndersonC , PogueJ , DyalL , et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patientsintolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet2008;372(9644):1174-83. ">TRANSCEND 2008</a> and <a href="./references#CD004034-bbs2-0028" title="BoschJ , O’DonnellM , SwaminathanB , LonnEM , SharmaM , Dagenais G et al, HOPE-3 Investigators. Effects of blood pressure and lipid lowering on cognition: Results from the HOPE-3 study. Neurology2019;92(13):e1435-46. LonnE , BoschJ , PogueJ , AvezumA , ChazovaI , DansA , et al, HOPE-3 Investigators. Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics. The Canadian Journal of Cardiology2016;32(3):311-8. LonnEM , BoschJ , López-JaramilloP , ZhuJ , LiuL , PaisP , et al, HOPE-3 Investigators. Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. The New England Journal of Medicine2016;374(21):2009-20. YusufS , LonnE , PaisP , BoschJ , López-JaramilloP , ZhuJ , et al, HOPE-3 Investigators. Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. The New England Journal Of Medicine2016;374(21):2032-43. ">HOPE 3 2016</a>). We feel these are appropriate criteria for this review. They do introduce the risk that we have excluded studies that are relevant to our study question. The reasons for exclusion of these studies from the current meta‐analysis, according to the prespecified criteria in the Methods, may be found in the <a href="./references#CD004034-sec-0117" title="">Characteristics of excluded studies</a> section. </p> <p>We attempted to contact the authors of the <a href="./references#CD004034-bbs2-0049" title="MaL , LuP , ZhangY , MengX , FanP , MaL , et al. Effects of antihypertensive therapy on cognitive function and health-related quality of life in high-risk hypertensive patients. Journal of Hypertension. Conference: 27th Scientific Meeting of the International Society of Hypertension, ISH2018;36(Suppl 3):e334-5. MaL , WangW , ZhaoY , ZhangY , DengQ , LiuM , et al. Combination of amlodipine plus angiotensin receptor blocker or diuretics in high-risk hypertensive patients: a 96-week efficacy and safety study. Am J Cardiovasc Drugs2012;12(2):137-42. WangW , MaL , ZhangY , DengQ , LiuM , LiuL . The combination of amlodipine and angiotensin receptor blocker or diuretics in high-risk hypertensive patients: rationale, design and baseline characteristics. J Hum Hypertens2011;25(4):271-7. WangW , MaLY , LiuMB , DengQ , ZhangYQ , LiW , et al, CHIEF Cooperative Group. Effects of amlodipine plus telmisartan or amlodipine plus amiloride regimen on blood pressure control in hypertensive patients: preliminary report of Chinese Hypertension Intervention Efficacy (CHIEF) trial. Zhonghua Xin Xue Guan Bing Za Zhi2009;37(8):701-7. ">CHIEF 2012</a> study but were unsuccessful. </p> </section> <section id="CD004034-sec-0094"> <h3 class="title" id="CD004034-sec-0094">Agreements and disagreements with other studies or reviews</h3> <p>Several systematic reviews and meta‐analyses have considered related questions.</p> <p><a href="./references#CD004034-bbs2-0101" title="ParsonsC , MuradMH , AndersenS , MookadamF , LabonteH . The effect of antihypertensive treatment on the incidence of stroke and cognitive decline in the elderly: a meta-analysis. Future Cardiology2016;12(2):237-48.">Parsons 2016</a> systematically reviewed placebo‐controlled RCTs of antihypertensive treatment with a mean participant age of 65 years or older. Their meta‐analysis contained the same four RCTs as our 2009 review. </p> <p><a href="./references#CD004034-bbs2-0123" title="WeissJ , FreemanM , LowA , FuR , KerfootA , PaynterR , et al. Benefits and Harms of Intensive Blood Pressure Treatment in Adults Aged 60 Years or Older: A Systematic Review and Meta-analysis. Annals of Internal Medicine2017;166(6):419-29.">Weiss 2017</a> systematically reviewed studies considering intensive blood pressure treatment with a mean participant age of at least 60 years. They described results from <a href="./references#CD004034-bbs2-0008" title="Degl'InnocentiA , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , ZanchettiA , WiklundI . Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). Journal of Human Hypertension2004;18(4):239-45. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study of COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. Journal of Hypertension2004;22(8):1605-12. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. Journal of Hypertension2003;21:875-886. PapademetriouV , FarsangC , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , Zanchetti A for the SCOPE Study Group. Stroke Prevention With the Angiotension II Type-1 Receptor Blocker Candesartan in Elderly Patients With Isolated Systolic Hypertension. The Study on Cognition and Prognosis in the Elderly (SCOPE). Journal of the American College of Cardiology2004;44(6):1175-80. SkoogI , LithellH , HanssonL , ElmfeldtD , HofmanA , OlofssonB , et al, for the SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). American Journal of Hypertension2005;18:1052-1059. ">SCOPE 2003</a>, <a href="./references#CD004034-bbs2-0009" title="ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the Treatment of Isolated Systolic Hypertension on Behavioral Variables. Results From the Systolic Hypertension in the Elderly Program. Arch Intern Med1994;154:2154-2160. Di BariM , PahorM , FranseLV , ShorrRI , WanJY , FerrucciL , et al. Dementia and Disability Outcomes in Large Hypertension Trials: Lessons Learned from the Systolic Hypertension in the Elderly Program (SHEP) Trial. American Journal of Epidemiology2001;153:72-8. SHEP Cooperative Research Group. Prevention of Stroke by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic Hypertension. Final Results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265:3255-64. The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and Design of a Randomized Clinical Trial on Prevention of Stroke in Isolated Systolic Hypertension. Journal of Clinical Epidemiology1988;41:1197-1208. ">SHEP 1991</a>, <a href="./references#CD004034-bbs2-0011" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , De LeeuwP , DolleryCT , et al. Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: Objectives, protocol, and organization. Aging Clin Exp Res1991;3:287-302. FletcherAE , BulpittCJ , ThijsL , ToumilehtoJ , AntikainenR , BossiniA , et al. Quality of life on randomised treatment for isolated hypertension: results from the Syst-Eur Trial. Journal of Hypertension2002;20:2069-2079. FletcherAE , BulpittCJ , TuomilehtoJ , BrowneJ , BossiniA , Kawecka-JaszczK , et al. Quality of life of elderly patients with isolated systolic hypertension: baseline data from the Syst-Eur Trial. Journal of Hypertension1988;16:1117-1124. ForetteF , Seux M-L, StaessenJA , ThijsL , Babarskiene M-R, BabeanuS , et al. The Prevention of Dementia With Antihypertensive Treatment. New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study. Archives of Internal Medicine2002;162:2046-2052. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH , BabarskieneMR , et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet1998;352:1347-51. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH . Reduction of dementia by calcium-antagonist-based antihypertensive treatment. European Heart Journal Supplements2000;2:D17-D19. StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Lancet1997;350:757-764. ">Syst Eur 1998</a>, <a href="./references#CD004034-bbs2-0004" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumiterscuD , et al, for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. NEJM2008;358:1887-1898. BulpittC , FletcherA , BeckettN , CoopeJ , Gil-ExtremeraB , ForetteF , et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs &amp; Aging2001;18:151-164. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al, for the HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurology2008;7:683-689. PetersR , BeckettN , McCormackT , FagardR , FletcherA , BulpittC . Treating hypertension in the very elderly-benefits, risks, and future directions, a focus on the hypertension in the very elderly trial. European Heart Journal 2014 Jul;35(26):1712-8. PetersR , BeckettN , NunesM , FletcherA , ForetteF , BulpittC . A substudy protocol of the Hypertension in the Very Elderly Trial assessing cognitive decline and dementia incidence (HYVET-COG): an ongoing randomised, double-blind, placebo-controlled trial. Drugs Aging2006;23:83-92. ">HYVET 2008</a>, <a href="./references#CD004034-bbs2-0006" title="MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. British Medical Journal1992;304(6824):405-12. PrinceMJ , BirdAS , BlizardRA , MannAH . Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. British Medical Journal1996;312(7034):801-5. ">MRC 1996</a>, <a href="./references#CD004034-bbs2-0001" title="BuseJB , BiggerJT , ByingtonRP , CooperLS , CushmanWC , FriedewaldWT , et al, ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. American Journal of Cardiology2007;99(12A):21i-33i. CushmanWC , Grimm RH Jr, CutlerJA , EvansGW , CapesS , CorsonMA , et al, ACCORD Study Group. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):44i-55i. LaunerLJ , MillerME , WilliamsonJD , LazarRM , GersteinHC , MurrayAM , et al, ACCORD MIND investigators. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurology2011;10(11):969-77. MargolisKL , O'ConnorPJ , MorganTM , BuseJB , CohenRM , CushmanWC , et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care2014;37(6):1721-8. O'ConnorPJ , NarayanKM , AndersonR , FeeneyP , FineL , AliMK , et al. Effect of intensive versus standard blood pressure control on depression and health-related quality of life in type 2 diabetes: the ACCORD trial. Diabetes Care2012;35(7):1479-81. WilliamsonJD , LaunerLJ , BryanRN , CokerLH , LazarRM , GersteinHC , et al, Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Investigators. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Internal Medicine2014;174(3):324-33. WilliamsonJD , MillerME , BryanRN , LazarRM , CokerLH , JohnsonJ , et al, ACCORD Study Group. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. American Journal of Cardiology2007;99(12A):112i-122i. ">ACCORD MIND 2014</a> and <a href="./references#CD004034-bbs2-0038" title="The PROGRESS Collaborative Group. Effects of Blood Pressure Lowering With Perindopril and Indapamide Therapy on Dementia and Cognitive Decline in Patients With Cerebrovascular Disease. Arch Intern Med2003;163:1069-75. ">PROGRESS 2003</a>. Their only meta‐analysis incorporated <a href="./references#CD004034-bbs2-0001" title="BuseJB , BiggerJT , ByingtonRP , CooperLS , CushmanWC , FriedewaldWT , et al, ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. American Journal of Cardiology2007;99(12A):21i-33i. CushmanWC , Grimm RH Jr, CutlerJA , EvansGW , CapesS , CorsonMA , et al, ACCORD Study Group. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):44i-55i. LaunerLJ , MillerME , WilliamsonJD , LazarRM , GersteinHC , MurrayAM , et al, ACCORD MIND investigators. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurology2011;10(11):969-77. MargolisKL , O'ConnorPJ , MorganTM , BuseJB , CohenRM , CushmanWC , et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care2014;37(6):1721-8. O'ConnorPJ , NarayanKM , AndersonR , FeeneyP , FineL , AliMK , et al. Effect of intensive versus standard blood pressure control on depression and health-related quality of life in type 2 diabetes: the ACCORD trial. Diabetes Care2012;35(7):1479-81. WilliamsonJD , LaunerLJ , BryanRN , CokerLH , LazarRM , GersteinHC , et al, Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Investigators. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Internal Medicine2014;174(3):324-33. WilliamsonJD , MillerME , BryanRN , LazarRM , CokerLH , JohnsonJ , et al, ACCORD Study Group. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. American Journal of Cardiology2007;99(12A):112i-122i. ">ACCORD MIND 2014</a> and three observational studies and found that, in those studies combined, using antihypertensives to achieve moderate BP control had no effect on rates of incident dementia (OR 0.89, 95% CI 0.74 to 1.07). </p> <p><a href="./references#CD004034-bbs2-0069" title="FinkHA , JutkowitzE , McCartenJR , HemmyLS , ButlerM , DavilaH , et al. Pharmacologic interventions to prevent cognitive decline, mild cognitive impairment, and clinical Alzheimer-type dementia: a systematic review. Annals of Internal Medicine2018;168(1):39-51.">Fink 2018</a> conducted a wide‐ranging systematic review of the literature and considered studies in three groups – comparing the effects of pharmacological antihypertensive treatments versus placebo, intensive versus standard pharmacological antihypertensive approaches, and different pharmacological antihypertensive treatments on the outcomes of dementia, mild cognitive impairment (MCI) and cognitive domain‐specific tests. <a href="./references#CD004034-bbs2-0069" title="FinkHA , JutkowitzE , McCartenJR , HemmyLS , ButlerM , DavilaH , et al. Pharmacologic interventions to prevent cognitive decline, mild cognitive impairment, and clinical Alzheimer-type dementia: a systematic review. Annals of Internal Medicine2018;168(1):39-51.">Fink 2018</a> included shorter studies than we included, with a minimum required duration of six months (<a href="./references#CD004034-bbs2-0041" title="StarrJM , WhalleyLJ , DearyIJ . The effects of antihypertensive treatment on cognitive function: results from the HOPE study. Journal of the American Geriatrics Society1996;44(4):411-5. StarrJM , WhalleyLJ . Hypertensive Old People in Edinburgh (HOPE) Study: electrocardiographic changes after captopril or bendrofluazide treatment. Age and Ageing1993;22(5):343-8. ">Starr 1996</a>; <a href="./references#CD004034-bbs2-0024" title="FogariR , MugelliniA , ZoppiA , DerosaG , PasottiC , FogariE , et al. Influence of losartan and atenolol on memory function in very elderly hypertensive patients. Journal Of Human Hypertension2003;17(11):781-5. ">Fogari 2003</a>; <a href="./references#CD004034-bbs2-0025" title="FogariR , MugelliniA , ZoppiA , LazzariP , DestroM , RinaldiA , et al. Effect of telmisartan/hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients. Journal Of Human Hypertension2006;20(3):177-85. ">Fogari 2006</a>; <a href="./references#CD004034-bbs2-0026" title="GoldsteinG , MatersonBJ , CushmanWC , RedaDJ , FreisED , RamirezEA , et al. Treatment of hypertension in the elderly: II. Cognitive and behavioral function. Results of a Department of Veterans Affairs Cooperative Study. Hypertension1990;15(4):361-9. MatersonBJ , CushmanWC , GoldsteinG , RedaDJ , FreisED , RamirezEA , et al. Treatment of hypertension in the elderly: I. Blood pressure and clinical changes. Results of a Department of Veterans Affairs Cooperative Study. Hypertension1990;15(4):348-60. ">Goldstein 1990</a>), studies without BP entry criteria (<a href="./references#CD004034-bbs2-0013" title="ADVANCE Management Committee. Study rationale and design of ADVANCE: action in diabetes and vascular disease--preterax and diamicron MR controlled evaluation. Diabetologia2001;44(9):1118-20. BattyGD , LiQ , HuxleyR , ZoungasS , TaylorBA , NealB , et al, ADVANCE Collaborative group. Oral disease in relation to future risk of dementia and cognitive decline: prospective cohort study based on the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation (ADVANCE) trial. European Psychiatry2013;28(1):49-52. NinomiyaT , ZoungasS , NealB , WoodwardM , PatelA , PerkovicV , et al, ADVANCE Collaborative Group. Efficacy and safety of routine blood pressure lowering in older patients with diabetes: results from the ADVANCE trial. Journal of Hypertension2010;28(6):1141-9. PatelA , ADVANCE Collaborative Group, MacMahonS , ChalmersJ , NealB , WoodwardM , et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet2007;370(9590):829-40. Van der LeeuwJ , VisserenFL , WoodwardM , ZoungasS , KengneAP , Van der GraafY , et al. Predicting the effects of blood pressure-lowering treatment on major cardiovascular events for individual patients with type 2 diabetes mellitus: results from Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation. Hypertension2015;65(1):115-21. ">ADVANCE 2010</a>; <a href="./references#CD004034-bbs2-0034" title="AndersonC , TeoK , GaoP , ArimaH , DansA , UngerT , et al, ONTARGET and TRANSCEND Investigators. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurology2011;10(1):43-53. ONTARGET Investigators, YusufS , TeoKK , PogueJ , DyalL , CoplandI , et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. New England Journal of Medicine2008;358(15):1547-59. TeoK , YusufS , SleightP , AndersonC , MookadamF , RamosB , et al, ONTARGET/TRANSCEND Investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. American Heart Journal2004;148(1):52-61. ">ONTARGET 2008</a>; <a href="./references#CD004034-bbs2-0045" title="Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, YusufS , TeoK , AndersonC , PogueJ , DyalL , et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patientsintolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet2008;372(9644):1174-83. ">TRANSCEND 2008</a>), and a study in which the majority of participants were likely to have dementia at the outset (<a href="./references#CD004034-bbs2-0044" title="TedescoMA , RattiG , MennellaS , ManzoG , GriecoM , RainoneAC , et al. Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients. American Journal Of Hypertension1999;12((11 Pt 1)):1130-4. ">Tedesco 1999</a>). They concluded that 'low‐strength evidence in adults with normal cognition showed that antihypertensive treatment versus placebo does not reduce risk for dementia, and moderate strength evidence showed no difference between these treatments on global cognitive screening tests' and otherwise presented narrative conclusions. </p> <p><a href="./references#CD004034-bbs2-0089" title="LarssonSC , MarkusHS . Does Treating Vascular Risk Factors Prevent Dementia and Alzheimer's Disease? A Systematic Review and Meta-Analysis. Journal of Alzheimer's disease2018;64(2):657-68.">Larsson 2018</a> conducted a systematic review and meta‐analysis of RCTs and prospective studies of antihypertensive drug treatment with dementia as an outcome measure. They combined <a href="./references#CD004034-bbs2-0008" title="Degl'InnocentiA , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , ZanchettiA , WiklundI . Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). Journal of Human Hypertension2004;18(4):239-45. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study of COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. Journal of Hypertension2004;22(8):1605-12. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. Journal of Hypertension2003;21:875-886. PapademetriouV , FarsangC , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , Zanchetti A for the SCOPE Study Group. Stroke Prevention With the Angiotension II Type-1 Receptor Blocker Candesartan in Elderly Patients With Isolated Systolic Hypertension. The Study on Cognition and Prognosis in the Elderly (SCOPE). Journal of the American College of Cardiology2004;44(6):1175-80. SkoogI , LithellH , HanssonL , ElmfeldtD , HofmanA , OlofssonB , et al, for the SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). American Journal of Hypertension2005;18:1052-1059. ">SCOPE 2003</a>, <a href="./references#CD004034-bbs2-0009" title="ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the Treatment of Isolated Systolic Hypertension on Behavioral Variables. Results From the Systolic Hypertension in the Elderly Program. Arch Intern Med1994;154:2154-2160. Di BariM , PahorM , FranseLV , ShorrRI , WanJY , FerrucciL , et al. Dementia and Disability Outcomes in Large Hypertension Trials: Lessons Learned from the Systolic Hypertension in the Elderly Program (SHEP) Trial. American Journal of Epidemiology2001;153:72-8. SHEP Cooperative Research Group. Prevention of Stroke by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic Hypertension. Final Results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265:3255-64. The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and Design of a Randomized Clinical Trial on Prevention of Stroke in Isolated Systolic Hypertension. Journal of Clinical Epidemiology1988;41:1197-1208. ">SHEP 1991</a>, <a href="./references#CD004034-bbs2-0011" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , De LeeuwP , DolleryCT , et al. Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: Objectives, protocol, and organization. Aging Clin Exp Res1991;3:287-302. FletcherAE , BulpittCJ , ThijsL , ToumilehtoJ , AntikainenR , BossiniA , et al. Quality of life on randomised treatment for isolated hypertension: results from the Syst-Eur Trial. Journal of Hypertension2002;20:2069-2079. FletcherAE , BulpittCJ , TuomilehtoJ , BrowneJ , BossiniA , Kawecka-JaszczK , et al. Quality of life of elderly patients with isolated systolic hypertension: baseline data from the Syst-Eur Trial. Journal of Hypertension1988;16:1117-1124. ForetteF , Seux M-L, StaessenJA , ThijsL , Babarskiene M-R, BabeanuS , et al. The Prevention of Dementia With Antihypertensive Treatment. New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study. Archives of Internal Medicine2002;162:2046-2052. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH , BabarskieneMR , et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet1998;352:1347-51. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH . Reduction of dementia by calcium-antagonist-based antihypertensive treatment. European Heart Journal Supplements2000;2:D17-D19. StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Lancet1997;350:757-764. ">Syst Eur 1998</a>, <a href="./references#CD004034-bbs2-0004" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumiterscuD , et al, for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. NEJM2008;358:1887-1898. BulpittC , FletcherA , BeckettN , CoopeJ , Gil-ExtremeraB , ForetteF , et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs &amp; Aging2001;18:151-164. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al, for the HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurology2008;7:683-689. PetersR , BeckettN , McCormackT , FagardR , FletcherA , BulpittC . Treating hypertension in the very elderly-benefits, risks, and future directions, a focus on the hypertension in the very elderly trial. European Heart Journal 2014 Jul;35(26):1712-8. PetersR , BeckettN , NunesM , FletcherA , ForetteF , BulpittC . A substudy protocol of the Hypertension in the Very Elderly Trial assessing cognitive decline and dementia incidence (HYVET-COG): an ongoing randomised, double-blind, placebo-controlled trial. Drugs Aging2006;23:83-92. ">HYVET 2008</a>, and <a href="./references#CD004034-bbs2-0038" title="The PROGRESS Collaborative Group. Effects of Blood Pressure Lowering With Perindopril and Indapamide Therapy on Dementia and Cognitive Decline in Patients With Cerebrovascular Disease. Arch Intern Med2003;163:1069-75. ">PROGRESS 2003</a> in an analysis and reported a non‐significant relative risk of dementia of 0.84 (95% CI 0.69 to 1.02) for active treatment compared to placebo. </p> <p><a href="./references#CD004034-bbs2-0116" title="Van MiddelaarT , Van VughtLA , Van GoolWA , SimonsEM , Van Den Born B-JH, Van CharanteEP , et al. Blood pressure-lowering interventions to prevent dementia: a systematic review and meta-analysis. Journal of Hypertension2018;36(9):1780-7.">Van Middelaar 2018</a> systematically reviewed studies of BP lowering by both pharmacological and non‐pharmacological means, measuring dementia incidence. They included <a href="./references#CD004034-bbs2-0008" title="Degl'InnocentiA , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , ZanchettiA , WiklundI . Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). Journal of Human Hypertension2004;18(4):239-45. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study of COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. Journal of Hypertension2004;22(8):1605-12. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. Journal of Hypertension2003;21:875-886. PapademetriouV , FarsangC , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , Zanchetti A for the SCOPE Study Group. Stroke Prevention With the Angiotension II Type-1 Receptor Blocker Candesartan in Elderly Patients With Isolated Systolic Hypertension. The Study on Cognition and Prognosis in the Elderly (SCOPE). Journal of the American College of Cardiology2004;44(6):1175-80. SkoogI , LithellH , HanssonL , ElmfeldtD , HofmanA , OlofssonB , et al, for the SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). American Journal of Hypertension2005;18:1052-1059. ">SCOPE 2003</a>, <a href="./references#CD004034-bbs2-0009" title="ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the Treatment of Isolated Systolic Hypertension on Behavioral Variables. Results From the Systolic Hypertension in the Elderly Program. Arch Intern Med1994;154:2154-2160. Di BariM , PahorM , FranseLV , ShorrRI , WanJY , FerrucciL , et al. Dementia and Disability Outcomes in Large Hypertension Trials: Lessons Learned from the Systolic Hypertension in the Elderly Program (SHEP) Trial. American Journal of Epidemiology2001;153:72-8. SHEP Cooperative Research Group. Prevention of Stroke by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic Hypertension. Final Results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265:3255-64. The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and Design of a Randomized Clinical Trial on Prevention of Stroke in Isolated Systolic Hypertension. Journal of Clinical Epidemiology1988;41:1197-1208. ">SHEP 1991</a>, <a href="./references#CD004034-bbs2-0011" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , De LeeuwP , DolleryCT , et al. Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: Objectives, protocol, and organization. Aging Clin Exp Res1991;3:287-302. FletcherAE , BulpittCJ , ThijsL , ToumilehtoJ , AntikainenR , BossiniA , et al. Quality of life on randomised treatment for isolated hypertension: results from the Syst-Eur Trial. Journal of Hypertension2002;20:2069-2079. FletcherAE , BulpittCJ , TuomilehtoJ , BrowneJ , BossiniA , Kawecka-JaszczK , et al. Quality of life of elderly patients with isolated systolic hypertension: baseline data from the Syst-Eur Trial. Journal of Hypertension1988;16:1117-1124. ForetteF , Seux M-L, StaessenJA , ThijsL , Babarskiene M-R, BabeanuS , et al. The Prevention of Dementia With Antihypertensive Treatment. New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study. Archives of Internal Medicine2002;162:2046-2052. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH , BabarskieneMR , et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet1998;352:1347-51. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH . Reduction of dementia by calcium-antagonist-based antihypertensive treatment. European Heart Journal Supplements2000;2:D17-D19. StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Lancet1997;350:757-764. ">Syst Eur 1998</a>, <a href="./references#CD004034-bbs2-0004" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumiterscuD , et al, for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. NEJM2008;358:1887-1898. BulpittC , FletcherA , BeckettN , CoopeJ , Gil-ExtremeraB , ForetteF , et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs &amp; Aging2001;18:151-164. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al, for the HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurology2008;7:683-689. PetersR , BeckettN , McCormackT , FagardR , FletcherA , BulpittC . Treating hypertension in the very elderly-benefits, risks, and future directions, a focus on the hypertension in the very elderly trial. European Heart Journal 2014 Jul;35(26):1712-8. PetersR , BeckettN , NunesM , FletcherA , ForetteF , BulpittC . A substudy protocol of the Hypertension in the Very Elderly Trial assessing cognitive decline and dementia incidence (HYVET-COG): an ongoing randomised, double-blind, placebo-controlled trial. Drugs Aging2006;23:83-92. ">HYVET 2008</a>, studies of secondary stroke prevention (<a href="./references#CD004034-bbs2-0038" title="The PROGRESS Collaborative Group. Effects of Blood Pressure Lowering With Perindopril and Indapamide Therapy on Dementia and Cognitive Decline in Patients With Cerebrovascular Disease. Arch Intern Med2003;163:1069-75. ">PROGRESS 2003</a> and <a href="./references#CD004034-bbs2-0037" title="DienerHC , SaccoRL , YusufS , CottonD , OunpuuS , LawtonWA , et al. Effects of aspirin plus extended-release dipyridamoleversus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurology2008;7:875-84. ">PRoFESS 2008</a>), studies without a BP entry criteria (<a href="./references#CD004034-bbs2-0013" title="ADVANCE Management Committee. Study rationale and design of ADVANCE: action in diabetes and vascular disease--preterax and diamicron MR controlled evaluation. Diabetologia2001;44(9):1118-20. BattyGD , LiQ , HuxleyR , ZoungasS , TaylorBA , NealB , et al, ADVANCE Collaborative group. Oral disease in relation to future risk of dementia and cognitive decline: prospective cohort study based on the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation (ADVANCE) trial. European Psychiatry2013;28(1):49-52. NinomiyaT , ZoungasS , NealB , WoodwardM , PatelA , PerkovicV , et al, ADVANCE Collaborative Group. Efficacy and safety of routine blood pressure lowering in older patients with diabetes: results from the ADVANCE trial. Journal of Hypertension2010;28(6):1141-9. PatelA , ADVANCE Collaborative Group, MacMahonS , ChalmersJ , NealB , WoodwardM , et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet2007;370(9590):829-40. Van der LeeuwJ , VisserenFL , WoodwardM , ZoungasS , KengneAP , Van der GraafY , et al. Predicting the effects of blood pressure-lowering treatment on major cardiovascular events for individual patients with type 2 diabetes mellitus: results from Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation. Hypertension2015;65(1):115-21. ">ADVANCE 2010</a>) and multicomponent interventions (<a href="./references#CD004034-bbs2-0035" title="Moll van CharanteEP , RichardE , EurelingsLS , vanDalenJW , LigthartSA , vanBusselEF , et al. Effectiveness of a 6-year multidomain vascular care intervention to prevent dementia (preDIVA): a cluster-randomised controlled trial. Lancet2016;388(10046):797-805. ">PreDIVA 2016</a> and <a href="./references#CD004034-bbs2-0092" title="EspelandMA , LuchsingerJA , BakerLD , NeibergR , KahnSE , Arnold SE et al. Effect of a long-term intensive lifestyle intervention on prevalence of cognitive impairment. Neurology2017;88(21):2026-35.">Look AHEAD 2017</a>) and reported a pooled risk ratio of 0.93 (95% CI 0.84 to 1.02) for intervention compared to control. </p> <p><a href="./references#CD004034-bbs2-0068" title="EliasMF , TorresRV , DaveyA . Clinical trials of blood pressure lowering and antihypertensive medication: is cognitive measurement state-of-the-art?American Journal of Hypertension2018;31(6):631-642.">Elias 2018</a> considered placebo‐controlled RCTs of antihypertensive medication use that included cognitive outcomes in their quest to examine the quality of cognitive outcomes assessment in these trials. </p> <p><a href="./references#CD004034-bbs2-0104" title="PetersR , WarwickJ , AnsteyKJ , AndersonCS . Blood pressure and dementia: What the SPRINT-MIND trial adds and what we still need to know. Neurology2019;92(21):1017-8.">Peters 2019</a> combined data from eight RCTs of antihypertensive therapy that measured dementia incidence (<a href="./references#CD004034-bbs2-0009" title="ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the Treatment of Isolated Systolic Hypertension on Behavioral Variables. Results From the Systolic Hypertension in the Elderly Program. Arch Intern Med1994;154:2154-2160. Di BariM , PahorM , FranseLV , ShorrRI , WanJY , FerrucciL , et al. Dementia and Disability Outcomes in Large Hypertension Trials: Lessons Learned from the Systolic Hypertension in the Elderly Program (SHEP) Trial. American Journal of Epidemiology2001;153:72-8. SHEP Cooperative Research Group. Prevention of Stroke by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic Hypertension. Final Results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265:3255-64. The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and Design of a Randomized Clinical Trial on Prevention of Stroke in Isolated Systolic Hypertension. Journal of Clinical Epidemiology1988;41:1197-1208. ">SHEP 1991</a>, <a href="./references#CD004034-bbs2-0008" title="Degl'InnocentiA , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , ZanchettiA , WiklundI . Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). Journal of Human Hypertension2004;18(4):239-45. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study of COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. Journal of Hypertension2004;22(8):1605-12. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. Journal of Hypertension2003;21:875-886. PapademetriouV , FarsangC , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , Zanchetti A for the SCOPE Study Group. Stroke Prevention With the Angiotension II Type-1 Receptor Blocker Candesartan in Elderly Patients With Isolated Systolic Hypertension. The Study on Cognition and Prognosis in the Elderly (SCOPE). Journal of the American College of Cardiology2004;44(6):1175-80. SkoogI , LithellH , HanssonL , ElmfeldtD , HofmanA , OlofssonB , et al, for the SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). American Journal of Hypertension2005;18:1052-1059. ">SCOPE 2003</a>, <a href="./references#CD004034-bbs2-0004" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumiterscuD , et al, for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. NEJM2008;358:1887-1898. BulpittC , FletcherA , BeckettN , CoopeJ , Gil-ExtremeraB , ForetteF , et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs &amp; Aging2001;18:151-164. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al, for the HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurology2008;7:683-689. PetersR , BeckettN , McCormackT , FagardR , FletcherA , BulpittC . Treating hypertension in the very elderly-benefits, risks, and future directions, a focus on the hypertension in the very elderly trial. European Heart Journal 2014 Jul;35(26):1712-8. PetersR , BeckettN , NunesM , FletcherA , ForetteF , BulpittC . A substudy protocol of the Hypertension in the Very Elderly Trial assessing cognitive decline and dementia incidence (HYVET-COG): an ongoing randomised, double-blind, placebo-controlled trial. Drugs Aging2006;23:83-92. ">HYVET 2008</a>, <a href="./references#CD004034-bbs2-0038" title="The PROGRESS Collaborative Group. Effects of Blood Pressure Lowering With Perindopril and Indapamide Therapy on Dementia and Cognitive Decline in Patients With Cerebrovascular Disease. Arch Intern Med2003;163:1069-75. ">PROGRESS 2003</a>, <a href="./references#CD004034-bbs2-0037" title="DienerHC , SaccoRL , YusufS , CottonD , OunpuuS , LawtonWA , et al. Effects of aspirin plus extended-release dipyridamoleversus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurology2008;7:875-84. ">PRoFESS 2008</a>, <a href="./references#CD004034-bbs2-0013" title="ADVANCE Management Committee. Study rationale and design of ADVANCE: action in diabetes and vascular disease--preterax and diamicron MR controlled evaluation. Diabetologia2001;44(9):1118-20. BattyGD , LiQ , HuxleyR , ZoungasS , TaylorBA , NealB , et al, ADVANCE Collaborative group. Oral disease in relation to future risk of dementia and cognitive decline: prospective cohort study based on the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation (ADVANCE) trial. European Psychiatry2013;28(1):49-52. NinomiyaT , ZoungasS , NealB , WoodwardM , PatelA , PerkovicV , et al, ADVANCE Collaborative Group. Efficacy and safety of routine blood pressure lowering in older patients with diabetes: results from the ADVANCE trial. Journal of Hypertension2010;28(6):1141-9. PatelA , ADVANCE Collaborative Group, MacMahonS , ChalmersJ , NealB , WoodwardM , et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet2007;370(9590):829-40. Van der LeeuwJ , VisserenFL , WoodwardM , ZoungasS , KengneAP , Van der GraafY , et al. Predicting the effects of blood pressure-lowering treatment on major cardiovascular events for individual patients with type 2 diabetes mellitus: results from Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation. Hypertension2015;65(1):115-21. ">ADVANCE 2010</a> and <a href="./references#CD004034-bbs2-0010" title="AmbrosiusWT , SinkKM , FoyCG , BerlowitzDR , CheungAK , CushmanWC , FineLJ , Goff DC Jr, JohnsonKC , KilleenAA , LewisCE , OparilS , ReboussinDM , RoccoMV , SnyderJK , WilliamsonJD , Wright JT Jr, WheltonPK , SPRINT Study Research Group. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).. Clinical Trials 2014 Oct;11(5):532-46. BerlowitzDR , FoyCG , KazisLE , BolinLP , ConroyMB , FitzpatrickP , GureTR , KimmelPL , KirchnerK , MoriskyDE , NewmanJ , OlneyC , OparilS , PajewskiNM , PowellJ , RamseyT , SimmonsDL , SnyderJ , SupianoMA , WeinerDE , WhittleJ , SPRINT Research Group. Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes.. The New England Journal of Medicine 2017 Aug 24;377(8):733-744. SPRINT Research Group, Wright JT Jr, WilliamsonJD , WheltonPK , SnyderJK , SinkKM , RoccoMV , ReboussinDM , RahmanM , OparilS , LewisCE , KimmelPL , JohnsonKC , Goff DC Jr, FineLJ , CutlerJA , CushmanWC , CheungAK , Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control.. The New England Journal of Medicine 2015 Nov 26;373(22):2103-16. The SPRINT MIND Investigators for the SPRINT Research Group. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA2019;321(6):553-561. WilliamsonJD , SupianoMA , ApplegateWB , BerlowitzDR , CampbellRC , ChertowGM , FineLJ , HaleyWE , HawfieldAT , IxJH , KitzmanDW , KostisJB , Krousel-WoodMA , LaunerLJ , OparilS , RodriguezCJ , RoumieCL , ShorrRI , SinkKM , WadleyVG , WheltonPK , WhittleJ , WoolardNF , Wright JT Jr, PajewskiNM , SPRINT Research Group. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.. JAMA 2016 Jun 28;315(24):2673-82. ">SPRINT MIND 2019</a>), and reported a relative risk reduction of dementia of 0.93 (95% CI 0.86 to 1.00) associated with antihypertensive treatment. </p> <p>Most recently, Hughes and colleagues have systematically reviewed RCTs of antihypertensive agents of 1000 or more participants and lasting at least one year, that measured dementia incidence or change in cognitive scores, or both (<a href="./references#CD004034-bbs2-0080" title="HughesD , JudgeC , MurphyR , LoughlinE , CostelloM , WhiteleyW , et al. Association of blood pressure lowering with incident dementia or cognitive impairment: a systematic review and meta-analysis. JAMA2020;323(19):1934-1944.">Hughes 2020</a>). They included <a href="./references#CD004034-bbs2-0009" title="ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the Treatment of Isolated Systolic Hypertension on Behavioral Variables. Results From the Systolic Hypertension in the Elderly Program. Arch Intern Med1994;154:2154-2160. Di BariM , PahorM , FranseLV , ShorrRI , WanJY , FerrucciL , et al. Dementia and Disability Outcomes in Large Hypertension Trials: Lessons Learned from the Systolic Hypertension in the Elderly Program (SHEP) Trial. American Journal of Epidemiology2001;153:72-8. SHEP Cooperative Research Group. Prevention of Stroke by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic Hypertension. Final Results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265:3255-64. The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and Design of a Randomized Clinical Trial on Prevention of Stroke in Isolated Systolic Hypertension. Journal of Clinical Epidemiology1988;41:1197-1208. ">SHEP 1991</a>, <a href="./references#CD004034-bbs2-0006" title="MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. British Medical Journal1992;304(6824):405-12. PrinceMJ , BirdAS , BlizardRA , MannAH . Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. British Medical Journal1996;312(7034):801-5. ">MRC 1996</a>, <a href="./references#CD004034-bbs2-0011" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , De LeeuwP , DolleryCT , et al. Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: Objectives, protocol, and organization. Aging Clin Exp Res1991;3:287-302. FletcherAE , BulpittCJ , ThijsL , ToumilehtoJ , AntikainenR , BossiniA , et al. Quality of life on randomised treatment for isolated hypertension: results from the Syst-Eur Trial. Journal of Hypertension2002;20:2069-2079. FletcherAE , BulpittCJ , TuomilehtoJ , BrowneJ , BossiniA , Kawecka-JaszczK , et al. Quality of life of elderly patients with isolated systolic hypertension: baseline data from the Syst-Eur Trial. Journal of Hypertension1988;16:1117-1124. ForetteF , Seux M-L, StaessenJA , ThijsL , Babarskiene M-R, BabeanuS , et al. The Prevention of Dementia With Antihypertensive Treatment. New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study. Archives of Internal Medicine2002;162:2046-2052. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH , BabarskieneMR , et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet1998;352:1347-51. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH . Reduction of dementia by calcium-antagonist-based antihypertensive treatment. European Heart Journal Supplements2000;2:D17-D19. StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Lancet1997;350:757-764. ">Syst Eur 1998</a>, <a href="./references#CD004034-bbs2-0038" title="The PROGRESS Collaborative Group. Effects of Blood Pressure Lowering With Perindopril and Indapamide Therapy on Dementia and Cognitive Decline in Patients With Cerebrovascular Disease. Arch Intern Med2003;163:1069-75. ">PROGRESS 2003</a>, <a href="./references#CD004034-bbs2-0008" title="Degl'InnocentiA , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , ZanchettiA , WiklundI . Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). Journal of Human Hypertension2004;18(4):239-45. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study of COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. Journal of Hypertension2004;22(8):1605-12. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. Journal of Hypertension2003;21:875-886. PapademetriouV , FarsangC , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , Zanchetti A for the SCOPE Study Group. Stroke Prevention With the Angiotension II Type-1 Receptor Blocker Candesartan in Elderly Patients With Isolated Systolic Hypertension. The Study on Cognition and Prognosis in the Elderly (SCOPE). Journal of the American College of Cardiology2004;44(6):1175-80. SkoogI , LithellH , HanssonL , ElmfeldtD , HofmanA , OlofssonB , et al, for the SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). American Journal of Hypertension2005;18:1052-1059. ">SCOPE 2003</a>, <a href="./references#CD004034-bbs2-0004" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumiterscuD , et al, for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. NEJM2008;358:1887-1898. BulpittC , FletcherA , BeckettN , CoopeJ , Gil-ExtremeraB , ForetteF , et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs &amp; Aging2001;18:151-164. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al, for the HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurology2008;7:683-689. PetersR , BeckettN , McCormackT , FagardR , FletcherA , BulpittC . Treating hypertension in the very elderly-benefits, risks, and future directions, a focus on the hypertension in the very elderly trial. European Heart Journal 2014 Jul;35(26):1712-8. PetersR , BeckettN , NunesM , FletcherA , ForetteF , BulpittC . A substudy protocol of the Hypertension in the Very Elderly Trial assessing cognitive decline and dementia incidence (HYVET-COG): an ongoing randomised, double-blind, placebo-controlled trial. Drugs Aging2006;23:83-92. ">HYVET 2008</a>, <a href="./references#CD004034-bbs2-0037" title="DienerHC , SaccoRL , YusufS , CottonD , OunpuuS , LawtonWA , et al. Effects of aspirin plus extended-release dipyridamoleversus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurology2008;7:875-84. ">PRoFESS 2008</a>, <a href="./references#CD004034-bbs2-0013" title="ADVANCE Management Committee. Study rationale and design of ADVANCE: action in diabetes and vascular disease--preterax and diamicron MR controlled evaluation. Diabetologia2001;44(9):1118-20. BattyGD , LiQ , HuxleyR , ZoungasS , TaylorBA , NealB , et al, ADVANCE Collaborative group. Oral disease in relation to future risk of dementia and cognitive decline: prospective cohort study based on the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation (ADVANCE) trial. European Psychiatry2013;28(1):49-52. NinomiyaT , ZoungasS , NealB , WoodwardM , PatelA , PerkovicV , et al, ADVANCE Collaborative Group. Efficacy and safety of routine blood pressure lowering in older patients with diabetes: results from the ADVANCE trial. Journal of Hypertension2010;28(6):1141-9. PatelA , ADVANCE Collaborative Group, MacMahonS , ChalmersJ , NealB , WoodwardM , et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet2007;370(9590):829-40. Van der LeeuwJ , VisserenFL , WoodwardM , ZoungasS , KengneAP , Van der GraafY , et al. Predicting the effects of blood pressure-lowering treatment on major cardiovascular events for individual patients with type 2 diabetes mellitus: results from Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation. Hypertension2015;65(1):115-21. ">ADVANCE 2010</a>, <a href="./references#CD004034-bbs2-0034" title="AndersonC , TeoK , GaoP , ArimaH , DansA , UngerT , et al, ONTARGET and TRANSCEND Investigators. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurology2011;10(1):43-53. ONTARGET Investigators, YusufS , TeoKK , PogueJ , DyalL , CoplandI , et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. New England Journal of Medicine2008;358(15):1547-59. TeoK , YusufS , SleightP , AndersonC , MookadamF , RamosB , et al, ONTARGET/TRANSCEND Investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. American Heart Journal2004;148(1):52-61. ">ONTARGET 2008</a>, <a href="./references#CD004034-bbs2-0045" title="Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, YusufS , TeoK , AndersonC , PogueJ , DyalL , et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patientsintolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet2008;372(9644):1174-83. ">TRANSCEND 2008</a>, <a href="./references#CD004034-bbs2-0001" title="BuseJB , BiggerJT , ByingtonRP , CooperLS , CushmanWC , FriedewaldWT , et al, ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. American Journal of Cardiology2007;99(12A):21i-33i. CushmanWC , Grimm RH Jr, CutlerJA , EvansGW , CapesS , CorsonMA , et al, ACCORD Study Group. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):44i-55i. LaunerLJ , MillerME , WilliamsonJD , LazarRM , GersteinHC , MurrayAM , et al, ACCORD MIND investigators. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurology2011;10(11):969-77. MargolisKL , O'ConnorPJ , MorganTM , BuseJB , CohenRM , CushmanWC , et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care2014;37(6):1721-8. O'ConnorPJ , NarayanKM , AndersonR , FeeneyP , FineL , AliMK , et al. Effect of intensive versus standard blood pressure control on depression and health-related quality of life in type 2 diabetes: the ACCORD trial. Diabetes Care2012;35(7):1479-81. WilliamsonJD , LaunerLJ , BryanRN , CokerLH , LazarRM , GersteinHC , et al, Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Investigators. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Internal Medicine2014;174(3):324-33. WilliamsonJD , MillerME , BryanRN , LazarRM , CokerLH , JohnsonJ , et al, ACCORD Study Group. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. American Journal of Cardiology2007;99(12A):112i-122i. ">ACCORD MIND 2014</a>, <a href="./references#CD004034-bbs2-0040" title="PearceLA , McClureLA , AndersonDC , JacovaC , SharmaM , HartRG , et al. Effects of long-term blood pressure lowering and dual antiplatelet therapy on cognition in patients with recent lacunar stroke: Secondary Prevention of Small Subcortical Strokes (SPS3) trial. Lancet Neurology2014;13(12):1177-85. ">SPS3 2014</a>, <a href="./references#CD004034-bbs2-0010" title="AmbrosiusWT , SinkKM , FoyCG , BerlowitzDR , CheungAK , CushmanWC , FineLJ , Goff DC Jr, JohnsonKC , KilleenAA , LewisCE , OparilS , ReboussinDM , RoccoMV , SnyderJK , WilliamsonJD , Wright JT Jr, WheltonPK , SPRINT Study Research Group. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).. Clinical Trials 2014 Oct;11(5):532-46. BerlowitzDR , FoyCG , KazisLE , BolinLP , ConroyMB , FitzpatrickP , GureTR , KimmelPL , KirchnerK , MoriskyDE , NewmanJ , OlneyC , OparilS , PajewskiNM , PowellJ , RamseyT , SimmonsDL , SnyderJ , SupianoMA , WeinerDE , WhittleJ , SPRINT Research Group. Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes.. The New England Journal of Medicine 2017 Aug 24;377(8):733-744. SPRINT Research Group, Wright JT Jr, WilliamsonJD , WheltonPK , SnyderJK , SinkKM , RoccoMV , ReboussinDM , RahmanM , OparilS , LewisCE , KimmelPL , JohnsonKC , Goff DC Jr, FineLJ , CutlerJA , CushmanWC , CheungAK , Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control.. The New England Journal of Medicine 2015 Nov 26;373(22):2103-16. The SPRINT MIND Investigators for the SPRINT Research Group. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA2019;321(6):553-561. WilliamsonJD , SupianoMA , ApplegateWB , BerlowitzDR , CampbellRC , ChertowGM , FineLJ , HaleyWE , HawfieldAT , IxJH , KitzmanDW , KostisJB , Krousel-WoodMA , LaunerLJ , OparilS , RodriguezCJ , RoumieCL , ShorrRI , SinkKM , WadleyVG , WheltonPK , WhittleJ , WoolardNF , Wright JT Jr, PajewskiNM , SPRINT Research Group. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.. JAMA 2016 Jun 28;315(24):2673-82. ">SPRINT MIND 2019</a>, and <a href="./references#CD004034-bbs2-0028" title="BoschJ , O’DonnellM , SwaminathanB , LonnEM , SharmaM , Dagenais G et al, HOPE-3 Investigators. Effects of blood pressure and lipid lowering on cognition: Results from the HOPE-3 study. Neurology2019;92(13):e1435-46. LonnE , BoschJ , PogueJ , AvezumA , ChazovaI , DansA , et al, HOPE-3 Investigators. Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics. The Canadian Journal of Cardiology2016;32(3):311-8. LonnEM , BoschJ , López-JaramilloP , ZhuJ , LiuL , PaisP , et al, HOPE-3 Investigators. Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. The New England Journal of Medicine2016;374(21):2009-20. YusufS , LonnE , PaisP , BoschJ , López-JaramilloP , ZhuJ , et al, HOPE-3 Investigators. Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. The New England Journal Of Medicine2016;374(21):2032-43. ">HOPE 3 2016</a>. Meta analysis of 12 studies (excluding <a href="./references#CD004034-bbs2-0006" title="MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. British Medical Journal1992;304(6824):405-12. PrinceMJ , BirdAS , BlizardRA , MannAH . Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. British Medical Journal1996;312(7034):801-5. ">MRC 1996</a> and <a href="./references#CD004034-bbs2-0001" title="BuseJB , BiggerJT , ByingtonRP , CooperLS , CushmanWC , FriedewaldWT , et al, ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. American Journal of Cardiology2007;99(12A):21i-33i. CushmanWC , Grimm RH Jr, CutlerJA , EvansGW , CapesS , CorsonMA , et al, ACCORD Study Group. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):44i-55i. LaunerLJ , MillerME , WilliamsonJD , LazarRM , GersteinHC , MurrayAM , et al, ACCORD MIND investigators. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurology2011;10(11):969-77. MargolisKL , O'ConnorPJ , MorganTM , BuseJB , CohenRM , CushmanWC , et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care2014;37(6):1721-8. O'ConnorPJ , NarayanKM , AndersonR , FeeneyP , FineL , AliMK , et al. Effect of intensive versus standard blood pressure control on depression and health-related quality of life in type 2 diabetes: the ACCORD trial. Diabetes Care2012;35(7):1479-81. WilliamsonJD , LaunerLJ , BryanRN , CokerLH , LazarRM , GersteinHC , et al, Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Investigators. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Internal Medicine2014;174(3):324-33. WilliamsonJD , MillerME , BryanRN , LazarRM , CokerLH , JohnsonJ , et al, ACCORD Study Group. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. American Journal of Cardiology2007;99(12A):112i-122i. ">ACCORD MIND 2014</a>) found a reduced risk of dementia or cognitive impairment (7.0% versus 7.5%; OR 0.93, 95% CI 0.88 to 0.98; absolute risk reduction 0.39%, 95% CI 0.09% to 0.68%). Meta‐analysis of eight studies (<a href="./references#CD004034-bbs2-0038" title="The PROGRESS Collaborative Group. Effects of Blood Pressure Lowering With Perindopril and Indapamide Therapy on Dementia and Cognitive Decline in Patients With Cerebrovascular Disease. Arch Intern Med2003;163:1069-75. ">PROGRESS 2003</a>, <a href="./references#CD004034-bbs2-0008" title="Degl'InnocentiA , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , ZanchettiA , WiklundI . Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). Journal of Human Hypertension2004;18(4):239-45. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study of COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. Journal of Hypertension2004;22(8):1605-12. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. Journal of Hypertension2003;21:875-886. PapademetriouV , FarsangC , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , Zanchetti A for the SCOPE Study Group. Stroke Prevention With the Angiotension II Type-1 Receptor Blocker Candesartan in Elderly Patients With Isolated Systolic Hypertension. The Study on Cognition and Prognosis in the Elderly (SCOPE). Journal of the American College of Cardiology2004;44(6):1175-80. SkoogI , LithellH , HanssonL , ElmfeldtD , HofmanA , OlofssonB , et al, for the SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). American Journal of Hypertension2005;18:1052-1059. ">SCOPE 2003</a>, <a href="./references#CD004034-bbs2-0004" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumiterscuD , et al, for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. NEJM2008;358:1887-1898. BulpittC , FletcherA , BeckettN , CoopeJ , Gil-ExtremeraB , ForetteF , et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs &amp; Aging2001;18:151-164. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al, for the HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurology2008;7:683-689. PetersR , BeckettN , McCormackT , FagardR , FletcherA , BulpittC . Treating hypertension in the very elderly-benefits, risks, and future directions, a focus on the hypertension in the very elderly trial. European Heart Journal 2014 Jul;35(26):1712-8. PetersR , BeckettN , NunesM , FletcherA , ForetteF , BulpittC . A substudy protocol of the Hypertension in the Very Elderly Trial assessing cognitive decline and dementia incidence (HYVET-COG): an ongoing randomised, double-blind, placebo-controlled trial. Drugs Aging2006;23:83-92. ">HYVET 2008</a>, <a href="./references#CD004034-bbs2-0037" title="DienerHC , SaccoRL , YusufS , CottonD , OunpuuS , LawtonWA , et al. Effects of aspirin plus extended-release dipyridamoleversus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurology2008;7:875-84. ">PRoFESS 2008</a>, <a href="./references#CD004034-bbs2-0045" title="Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, YusufS , TeoK , AndersonC , PogueJ , DyalL , et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patientsintolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet2008;372(9644):1174-83. ">TRANSCEND 2008</a>, <a href="./references#CD004034-bbs2-0034" title="AndersonC , TeoK , GaoP , ArimaH , DansA , UngerT , et al, ONTARGET and TRANSCEND Investigators. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurology2011;10(1):43-53. ONTARGET Investigators, YusufS , TeoKK , PogueJ , DyalL , CoplandI , et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. New England Journal of Medicine2008;358(15):1547-59. TeoK , YusufS , SleightP , AndersonC , MookadamF , RamosB , et al, ONTARGET/TRANSCEND Investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. American Heart Journal2004;148(1):52-61. ">ONTARGET 2008</a> (2 arms), <a href="./references#CD004034-bbs2-0010" title="AmbrosiusWT , SinkKM , FoyCG , BerlowitzDR , CheungAK , CushmanWC , FineLJ , Goff DC Jr, JohnsonKC , KilleenAA , LewisCE , OparilS , ReboussinDM , RoccoMV , SnyderJK , WilliamsonJD , Wright JT Jr, WheltonPK , SPRINT Study Research Group. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).. Clinical Trials 2014 Oct;11(5):532-46. BerlowitzDR , FoyCG , KazisLE , BolinLP , ConroyMB , FitzpatrickP , GureTR , KimmelPL , KirchnerK , MoriskyDE , NewmanJ , OlneyC , OparilS , PajewskiNM , PowellJ , RamseyT , SimmonsDL , SnyderJ , SupianoMA , WeinerDE , WhittleJ , SPRINT Research Group. Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes.. The New England Journal of Medicine 2017 Aug 24;377(8):733-744. SPRINT Research Group, Wright JT Jr, WilliamsonJD , WheltonPK , SnyderJK , SinkKM , RoccoMV , ReboussinDM , RahmanM , OparilS , LewisCE , KimmelPL , JohnsonKC , Goff DC Jr, FineLJ , CutlerJA , CushmanWC , CheungAK , Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control.. The New England Journal of Medicine 2015 Nov 26;373(22):2103-16. The SPRINT MIND Investigators for the SPRINT Research Group. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA2019;321(6):553-561. WilliamsonJD , SupianoMA , ApplegateWB , BerlowitzDR , CampbellRC , ChertowGM , FineLJ , HaleyWE , HawfieldAT , IxJH , KitzmanDW , KostisJB , Krousel-WoodMA , LaunerLJ , OparilS , RodriguezCJ , RoumieCL , ShorrRI , SinkKM , WadleyVG , WheltonPK , WhittleJ , WoolardNF , Wright JT Jr, PajewskiNM , SPRINT Research Group. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.. JAMA 2016 Jun 28;315(24):2673-82. ">SPRINT MIND 2019</a> and <a href="./references#CD004034-bbs2-0028" title="BoschJ , O’DonnellM , SwaminathanB , LonnEM , SharmaM , Dagenais G et al, HOPE-3 Investigators. Effects of blood pressure and lipid lowering on cognition: Results from the HOPE-3 study. Neurology2019;92(13):e1435-46. LonnE , BoschJ , PogueJ , AvezumA , ChazovaI , DansA , et al, HOPE-3 Investigators. Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics. The Canadian Journal of Cardiology2016;32(3):311-8. LonnEM , BoschJ , López-JaramilloP , ZhuJ , LiuL , PaisP , et al, HOPE-3 Investigators. Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. The New England Journal of Medicine2016;374(21):2009-20. YusufS , LonnE , PaisP , BoschJ , López-JaramilloP , ZhuJ , et al, HOPE-3 Investigators. Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. The New England Journal Of Medicine2016;374(21):2032-43. ">HOPE 3 2016</a>) showed a reduced risk of cognitive decline (20.2% versus 21.1%; OR 0.93, 95% CI 0.88 to 0.99; absolute risk reduction 0.71%, 95% CI 0.19% to 1.2%). </p> <p>Gupta and colleagues systematically reviewed RCTs of antihypertensive treatment to reduce cognitive decline but did not require participants to be hypertensive or free of dementia (<a href="./references#CD004034-bbs2-0076" title="GuptaA , PerdomoS , BillingerS , BeddhuS , BurnsJ , GronsethG . Treatment of hypertension reduces cognitive decline in older adults: a systematic review and meta-analysis. BMJ Open2020;10(11):e038971.">Gupta 2020</a>). They did require mean or median participant age to be 60 years or older, and the comparison group to be no intervention, placebo standard of care or a higher BP goal and at least one year follow‐up. They included nine RCTs with 34,994 participants: <a href="./references#CD004034-bbs2-0009" title="ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the Treatment of Isolated Systolic Hypertension on Behavioral Variables. Results From the Systolic Hypertension in the Elderly Program. Arch Intern Med1994;154:2154-2160. Di BariM , PahorM , FranseLV , ShorrRI , WanJY , FerrucciL , et al. Dementia and Disability Outcomes in Large Hypertension Trials: Lessons Learned from the Systolic Hypertension in the Elderly Program (SHEP) Trial. American Journal of Epidemiology2001;153:72-8. SHEP Cooperative Research Group. Prevention of Stroke by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic Hypertension. Final Results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265:3255-64. The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and Design of a Randomized Clinical Trial on Prevention of Stroke in Isolated Systolic Hypertension. Journal of Clinical Epidemiology1988;41:1197-1208. ">SHEP 1991</a>, <a href="./references#CD004034-bbs2-0006" title="MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. British Medical Journal1992;304(6824):405-12. PrinceMJ , BirdAS , BlizardRA , MannAH . Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. British Medical Journal1996;312(7034):801-5. ">MRC 1996</a>, <a href="./references#CD004034-bbs2-0011" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , De LeeuwP , DolleryCT , et al. Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: Objectives, protocol, and organization. Aging Clin Exp Res1991;3:287-302. FletcherAE , BulpittCJ , ThijsL , ToumilehtoJ , AntikainenR , BossiniA , et al. Quality of life on randomised treatment for isolated hypertension: results from the Syst-Eur Trial. Journal of Hypertension2002;20:2069-2079. FletcherAE , BulpittCJ , TuomilehtoJ , BrowneJ , BossiniA , Kawecka-JaszczK , et al. Quality of life of elderly patients with isolated systolic hypertension: baseline data from the Syst-Eur Trial. Journal of Hypertension1988;16:1117-1124. ForetteF , Seux M-L, StaessenJA , ThijsL , Babarskiene M-R, BabeanuS , et al. The Prevention of Dementia With Antihypertensive Treatment. New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study. Archives of Internal Medicine2002;162:2046-2052. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH , BabarskieneMR , et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet1998;352:1347-51. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH . Reduction of dementia by calcium-antagonist-based antihypertensive treatment. European Heart Journal Supplements2000;2:D17-D19. StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Lancet1997;350:757-764. ">Syst Eur 1998</a>, <a href="./references#CD004034-bbs2-0008" title="Degl'InnocentiA , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , ZanchettiA , WiklundI . Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). Journal of Human Hypertension2004;18(4):239-45. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study of COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. Journal of Hypertension2004;22(8):1605-12. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. Journal of Hypertension2003;21:875-886. PapademetriouV , FarsangC , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , Zanchetti A for the SCOPE Study Group. Stroke Prevention With the Angiotension II Type-1 Receptor Blocker Candesartan in Elderly Patients With Isolated Systolic Hypertension. The Study on Cognition and Prognosis in the Elderly (SCOPE). Journal of the American College of Cardiology2004;44(6):1175-80. SkoogI , LithellH , HanssonL , ElmfeldtD , HofmanA , OlofssonB , et al, for the SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). American Journal of Hypertension2005;18:1052-1059. ">SCOPE 2003</a>, <a href="./references#CD004034-bbs2-0100" title="PantoniL , delSerT , SoglianAG , AmigoniS , SpadariG , BinelliD , et al. Efficacy and Safety of Nimodipine in Subcortical Vascular Dementia. Stroke2005;36:619-24.">Pantoni 2005</a>, <a href="./references#CD004034-bbs2-0004" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumiterscuD , et al, for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. NEJM2008;358:1887-1898. BulpittC , FletcherA , BeckettN , CoopeJ , Gil-ExtremeraB , ForetteF , et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs &amp; Aging2001;18:151-164. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al, for the HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurology2008;7:683-689. PetersR , BeckettN , McCormackT , FagardR , FletcherA , BulpittC . Treating hypertension in the very elderly-benefits, risks, and future directions, a focus on the hypertension in the very elderly trial. European Heart Journal 2014 Jul;35(26):1712-8. PetersR , BeckettN , NunesM , FletcherA , ForetteF , BulpittC . A substudy protocol of the Hypertension in the Very Elderly Trial assessing cognitive decline and dementia incidence (HYVET-COG): an ongoing randomised, double-blind, placebo-controlled trial. Drugs Aging2006;23:83-92. ">HYVET 2008</a>, <a href="./references#CD004034-bbs2-0045" title="Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, YusufS , TeoK , AndersonC , PogueJ , DyalL , et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patientsintolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet2008;372(9644):1174-83. ">TRANSCEND 2008</a>, <a href="./references#CD004034-bbs2-0001" title="BuseJB , BiggerJT , ByingtonRP , CooperLS , CushmanWC , FriedewaldWT , et al, ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. American Journal of Cardiology2007;99(12A):21i-33i. CushmanWC , Grimm RH Jr, CutlerJA , EvansGW , CapesS , CorsonMA , et al, ACCORD Study Group. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):44i-55i. LaunerLJ , MillerME , WilliamsonJD , LazarRM , GersteinHC , MurrayAM , et al, ACCORD MIND investigators. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurology2011;10(11):969-77. MargolisKL , O'ConnorPJ , MorganTM , BuseJB , CohenRM , CushmanWC , et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care2014;37(6):1721-8. O'ConnorPJ , NarayanKM , AndersonR , FeeneyP , FineL , AliMK , et al. Effect of intensive versus standard blood pressure control on depression and health-related quality of life in type 2 diabetes: the ACCORD trial. Diabetes Care2012;35(7):1479-81. WilliamsonJD , LaunerLJ , BryanRN , CokerLH , LazarRM , GersteinHC , et al, Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Investigators. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Internal Medicine2014;174(3):324-33. WilliamsonJD , MillerME , BryanRN , LazarRM , CokerLH , JohnsonJ , et al, ACCORD Study Group. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. American Journal of Cardiology2007;99(12A):112i-122i. ">ACCORD MIND 2014</a> and <a href="./references#CD004034-bbs2-0010" title="AmbrosiusWT , SinkKM , FoyCG , BerlowitzDR , CheungAK , CushmanWC , FineLJ , Goff DC Jr, JohnsonKC , KilleenAA , LewisCE , OparilS , ReboussinDM , RoccoMV , SnyderJK , WilliamsonJD , Wright JT Jr, WheltonPK , SPRINT Study Research Group. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).. Clinical Trials 2014 Oct;11(5):532-46. BerlowitzDR , FoyCG , KazisLE , BolinLP , ConroyMB , FitzpatrickP , GureTR , KimmelPL , KirchnerK , MoriskyDE , NewmanJ , OlneyC , OparilS , PajewskiNM , PowellJ , RamseyT , SimmonsDL , SnyderJ , SupianoMA , WeinerDE , WhittleJ , SPRINT Research Group. Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes.. The New England Journal of Medicine 2017 Aug 24;377(8):733-744. SPRINT Research Group, Wright JT Jr, WilliamsonJD , WheltonPK , SnyderJK , SinkKM , RoccoMV , ReboussinDM , RahmanM , OparilS , LewisCE , KimmelPL , JohnsonKC , Goff DC Jr, FineLJ , CutlerJA , CushmanWC , CheungAK , Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control.. The New England Journal of Medicine 2015 Nov 26;373(22):2103-16. The SPRINT MIND Investigators for the SPRINT Research Group. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA2019;321(6):553-561. WilliamsonJD , SupianoMA , ApplegateWB , BerlowitzDR , CampbellRC , ChertowGM , FineLJ , HaleyWE , HawfieldAT , IxJH , KitzmanDW , KostisJB , Krousel-WoodMA , LaunerLJ , OparilS , RodriguezCJ , RoumieCL , ShorrRI , SinkKM , WadleyVG , WheltonPK , WhittleJ , WoolardNF , Wright JT Jr, PajewskiNM , SPRINT Research Group. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.. JAMA 2016 Jun 28;315(24):2673-82. ">SPRINT MIND 2019</a>. Meta‐analysis yielded a standardised mean difference change in cognition of ‐0.049 (95% CI ‐0.078 to ‐0.019) associated with antihypertensive treatment. </p> <p>Several authors have conducted systematic reviews comparing different classes of antihypertensive agents with no firm conclusions drawn (<a href="./references#CD004034-bbs2-0091" title="Levi MarpillatN , Macquin-MavierI , TropeanoAI , Bachoud-LeviAC , MaisonP . Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis. Journal of Hypertension2013;31(6):1073-82.">Levi Marpillat 2013</a>; <a href="./references#CD004034-bbs2-0102" title="PetersR , BoothA , PetersJ . A systematic review of calcium channel blocker use and cognitive decline/dementia in the elderly. Journal of Hypertension 2014 Oct;32(10):1945-57.">Peters 2014</a>; <a href="./references#CD004034-bbs2-0132" title="ZhuangS , WangHF , WangX , LiJ , XingCM . The association of renin-angiotensin system blockade use with the risks of cognitive impairment of aging and Alzheimer's disease: A meta-analysis. Journal of Clinical Neuroscience2016;33:32-8.">Zhuang 2016</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD004034-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004034.pub4/media/CDSR/CD004034/urn:x-wiley:14651858:media:CD004034:CD004034-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram for searches December 2014 (212), November 2015 (309), October 2016 (145), August 2017 (220), June 2018 (279), June 2019 (177), July 2020 (259)" data-id="CD004034-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004034.pub4/media/CDSR/CD004034/image_n/nCD004034-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004034.pub4/media/CDSR/CD004034/image_t/tCD004034-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram for searches December 2014 (212), November 2015 (309), October 2016 (145), August 2017 (220), June 2018 (279), June 2019 (177), July 2020 (259) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004034.pub4/full#CD004034-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004034.pub4/media/CDSR/CD004034/image_n/nCD004034-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004034-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004034.pub4/media/CDSR/CD004034/urn:x-wiley:14651858:media:CD004034:CD004034-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Incidence of dementia, Outcome 1: Number of cases of dementia placebo studies" data-id="CD004034-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004034.pub4/media/CDSR/CD004034/image_n/nCD004034-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004034.pub4/media/CDSR/CD004034/image_t/tCD004034-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Incidence of dementia, Outcome 1: Number of cases of dementia placebo studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004034.pub4/references#CD004034-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004034.pub4/media/CDSR/CD004034/image_n/nCD004034-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004034-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004034.pub4/media/CDSR/CD004034/urn:x-wiley:14651858:media:CD004034:CD004034-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Cognitive change from baseline, Outcome 1: Change in MMSE placebo studies" data-id="CD004034-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004034.pub4/media/CDSR/CD004034/image_n/nCD004034-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004034.pub4/media/CDSR/CD004034/image_t/tCD004034-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Cognitive change from baseline, Outcome 1: Change in MMSE placebo studies</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004034.pub4/references#CD004034-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004034.pub4/media/CDSR/CD004034/image_n/nCD004034-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004034-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004034.pub4/media/CDSR/CD004034/urn:x-wiley:14651858:media:CD004034:CD004034-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Change in blood pressure from baseline, Outcome 1: Change in systolic blood pressure level (mmHg) placebo studies" data-id="CD004034-fig-0004" src="/cdsr/doi/10.1002/14651858.CD004034.pub4/media/CDSR/CD004034/image_n/nCD004034-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004034.pub4/media/CDSR/CD004034/image_t/tCD004034-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Change in blood pressure from baseline, Outcome 1: Change in systolic blood pressure level (mmHg) placebo studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004034.pub4/references#CD004034-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004034.pub4/media/CDSR/CD004034/image_n/nCD004034-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004034-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004034.pub4/media/CDSR/CD004034/urn:x-wiley:14651858:media:CD004034:CD004034-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Change in blood pressure from baseline, Outcome 2: Change in diastolic blood pressure level (mmHg) placebo studies" data-id="CD004034-fig-0005" src="/cdsr/doi/10.1002/14651858.CD004034.pub4/media/CDSR/CD004034/image_n/nCD004034-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004034.pub4/media/CDSR/CD004034/image_t/tCD004034-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Change in blood pressure from baseline, Outcome 2: Change in diastolic blood pressure level (mmHg) placebo studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004034.pub4/references#CD004034-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004034.pub4/media/CDSR/CD004034/image_n/nCD004034-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD004034-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Antihypertensive therapy compared to placebo for patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antihypertensive therapy compared to placebo for people without prior cerebrovascular disease for prevention of cognitive impairment and dementia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants without prior cerebrovascular disease for prevention of cognitive impairment and dementia<br/><b>Setting:</b> community<br/><b>Intervention:</b> antihypertensive therapy<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="middle"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with antihypertensive therapy</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of cases of dementia</p> <p>Range of follow‐up 2 to 5 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.89<br/>(0.72 to 1.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>15,427<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30 per 1000<br/>(25 to 36) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in cognitive score (MMSE)</p> <p>Range of follow‐up 2 to 5 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in MMSE ranged from ‐0.15 to ‐0.08</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in MMSE was 0.20 points higher (0.10 points higher to 0.29 points higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9435<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>VERY LOW<sup>a‐d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in systolic blood pressure level (mmHg)</p> <p>Range of follow‐up 2 to 5 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in systolic blood pressure</p> <p>level (mmHg) ranged from ‐33.5 to ‐15.77</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in systolic blood pressure level (mmHg) was 9.25 points lower (9.73 points lower to 8.78 points lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17,793<br/>(6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>LOW<sup>c,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in diastolic blood pressure level (mmHg)</p> <p>Range of follow‐up 2 to 5 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in diastolic blood pressure level (mmHg) ranged from ‐13.1 to ‐4.21</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in diastolic blood pressure level (mmHg) was</p> <p>2.47 points lower (2.70 points lower to 2.24 points lower)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15,209<br/>(5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>LOW<sup>c,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> <p>Range of follow‐up 2 to 5 years</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign=""> <p>Results varied across studies, with some reporting evidence of more withdrawals due to adverse effects in the antihypertensive therapy group (<a href="./references#CD004034-bbs2-0009" title="ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the Treatment of Isolated Systolic Hypertension on Behavioral Variables. Results From the Systolic Hypertension in the Elderly Program. Arch Intern Med1994;154:2154-2160. Di BariM , PahorM , FranseLV , ShorrRI , WanJY , FerrucciL , et al. Dementia and Disability Outcomes in Large Hypertension Trials: Lessons Learned from the Systolic Hypertension in the Elderly Program (SHEP) Trial. American Journal of Epidemiology2001;153:72-8. SHEP Cooperative Research Group. Prevention of Stroke by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic Hypertension. Final Results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265:3255-64. The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and Design of a Randomized Clinical Trial on Prevention of Stroke in Isolated Systolic Hypertension. Journal of Clinical Epidemiology1988;41:1197-1208. ">SHEP 1991</a>, <a href="./references#CD004034-bbs2-0005" title="YodfatY , Bar-OnD , AmirM , Cristal N. Quality of life in normotensives compared to hypertensive men treated with isradipine or methyldopa as monotherapy or in combination with captopril: the LOMIR-MCT-IL study.. Journal of Human Hypertension 1996 Feb;10(2):117-22. YodfatY , Cristal N. A multicenter, double-blind, randomized, placebo-controlled study of isradipine and methyldopa as monotherapy or in combination with captopril in the treatment of hypertension. The LOMIR-MCT-IH Research Group.. American Journal of Hypertension 1993 Mar;6(3 Pt 2):57S-61S. ">LOMIR MCT IL 1996</a>, <a href="./references#CD004034-bbs2-0006" title="MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. British Medical Journal1992;304(6824):405-12. PrinceMJ , BirdAS , BlizardRA , MannAH . Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. British Medical Journal1996;312(7034):801-5. ">MRC 1996</a>), some reporting evidence of fewer withdrawals in the antihypertensive therapy group (<a href="./references#CD004034-bbs2-0011" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , De LeeuwP , DolleryCT , et al. Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: Objectives, protocol, and organization. Aging Clin Exp Res1991;3:287-302. FletcherAE , BulpittCJ , ThijsL , ToumilehtoJ , AntikainenR , BossiniA , et al. Quality of life on randomised treatment for isolated hypertension: results from the Syst-Eur Trial. Journal of Hypertension2002;20:2069-2079. FletcherAE , BulpittCJ , TuomilehtoJ , BrowneJ , BossiniA , Kawecka-JaszczK , et al. Quality of life of elderly patients with isolated systolic hypertension: baseline data from the Syst-Eur Trial. Journal of Hypertension1988;16:1117-1124. ForetteF , Seux M-L, StaessenJA , ThijsL , Babarskiene M-R, BabeanuS , et al. The Prevention of Dementia With Antihypertensive Treatment. New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study. Archives of Internal Medicine2002;162:2046-2052. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH , BabarskieneMR , et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet1998;352:1347-51. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH . Reduction of dementia by calcium-antagonist-based antihypertensive treatment. European Heart Journal Supplements2000;2:D17-D19. StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Lancet1997;350:757-764. ">Syst Eur 1998</a>, <a href="./references#CD004034-bbs2-0004" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumiterscuD , et al, for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. NEJM2008;358:1887-1898. BulpittC , FletcherA , BeckettN , CoopeJ , Gil-ExtremeraB , ForetteF , et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs &amp; Aging2001;18:151-164. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al, for the HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurology2008;7:683-689. PetersR , BeckettN , McCormackT , FagardR , FletcherA , BulpittC . Treating hypertension in the very elderly-benefits, risks, and future directions, a focus on the hypertension in the very elderly trial. European Heart Journal 2014 Jul;35(26):1712-8. PetersR , BeckettN , NunesM , FletcherA , ForetteF , BulpittC . A substudy protocol of the Hypertension in the Very Elderly Trial assessing cognitive decline and dementia incidence (HYVET-COG): an ongoing randomised, double-blind, placebo-controlled trial. Drugs Aging2006;23:83-92. ">HYVET 2008</a>), and one reporting no evidence of a difference between groups (<a href="./references#CD004034-bbs2-0008" title="Degl'InnocentiA , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , ZanchettiA , WiklundI . Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). Journal of Human Hypertension2004;18(4):239-45. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study of COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. Journal of Hypertension2004;22(8):1605-12. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. Journal of Hypertension2003;21:875-886. PapademetriouV , FarsangC , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , Zanchetti A for the SCOPE Study Group. Stroke Prevention With the Angiotension II Type-1 Receptor Blocker Candesartan in Elderly Patients With Isolated Systolic Hypertension. The Study on Cognition and Prognosis in the Elderly (SCOPE). Journal of the American College of Cardiology2004;44(6):1175-80. SkoogI , LithellH , HanssonL , ElmfeldtD , HofmanA , OlofssonB , et al, for the SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). American Journal of Hypertension2005;18:1052-1059. ">SCOPE 2003</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16,830</p> <p>(6 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>b,c,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heterogeneity precluded meta‐analysis</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> <p>measured via Sickness Impact Profile, PGWB Positive well‐being, and EuroQoL Current Health </p> <p>Range of follow‐up 2 to 5 years</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Two studies reported evidence of a difference between the active treatment and placebo groups (<a href="./references#CD004034-bbs2-0005" title="YodfatY , Bar-OnD , AmirM , Cristal N. Quality of life in normotensives compared to hypertensive men treated with isradipine or methyldopa as monotherapy or in combination with captopril: the LOMIR-MCT-IL study.. Journal of Human Hypertension 1996 Feb;10(2):117-22. YodfatY , Cristal N. A multicenter, double-blind, randomized, placebo-controlled study of isradipine and methyldopa as monotherapy or in combination with captopril in the treatment of hypertension. The LOMIR-MCT-IH Research Group.. American Journal of Hypertension 1993 Mar;6(3 Pt 2):57S-61S. ">LOMIR MCT IL 1996</a>: P = 0.03; <a href="./references#CD004034-bbs2-0008" title="Degl'InnocentiA , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , ZanchettiA , WiklundI . Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). Journal of Human Hypertension2004;18(4):239-45. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study of COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. Journal of Hypertension2004;22(8):1605-12. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. Journal of Hypertension2003;21:875-886. PapademetriouV , FarsangC , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , Zanchetti A for the SCOPE Study Group. Stroke Prevention With the Angiotension II Type-1 Receptor Blocker Candesartan in Elderly Patients With Isolated Systolic Hypertension. The Study on Cognition and Prognosis in the Elderly (SCOPE). Journal of the American College of Cardiology2004;44(6):1175-80. SkoogI , LithellH , HanssonL , ElmfeldtD , HofmanA , OlofssonB , et al, for the SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). American Journal of Hypertension2005;18:1052-1059. ">SCOPE 2003</a>: PGWB Positive well‐being = ‐0.8 vs ‐1.1, P = 0.04, and EuroQoL Current Health = ‐3.1 vs ‐5.3, P = 0.008). </p> <p>Three studies reported no evidence of a difference between groups (<a href="./references#CD004034-bbs2-0009" title="ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the Treatment of Isolated Systolic Hypertension on Behavioral Variables. Results From the Systolic Hypertension in the Elderly Program. Arch Intern Med1994;154:2154-2160. Di BariM , PahorM , FranseLV , ShorrRI , WanJY , FerrucciL , et al. Dementia and Disability Outcomes in Large Hypertension Trials: Lessons Learned from the Systolic Hypertension in the Elderly Program (SHEP) Trial. American Journal of Epidemiology2001;153:72-8. SHEP Cooperative Research Group. Prevention of Stroke by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic Hypertension. Final Results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265:3255-64. The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and Design of a Randomized Clinical Trial on Prevention of Stroke in Isolated Systolic Hypertension. Journal of Clinical Epidemiology1988;41:1197-1208. ">SHEP 1991</a>, <a href="./references#CD004034-bbs2-0011" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , De LeeuwP , DolleryCT , et al. Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: Objectives, protocol, and organization. Aging Clin Exp Res1991;3:287-302. FletcherAE , BulpittCJ , ThijsL , ToumilehtoJ , AntikainenR , BossiniA , et al. Quality of life on randomised treatment for isolated hypertension: results from the Syst-Eur Trial. Journal of Hypertension2002;20:2069-2079. FletcherAE , BulpittCJ , TuomilehtoJ , BrowneJ , BossiniA , Kawecka-JaszczK , et al. Quality of life of elderly patients with isolated systolic hypertension: baseline data from the Syst-Eur Trial. Journal of Hypertension1988;16:1117-1124. ForetteF , Seux M-L, StaessenJA , ThijsL , Babarskiene M-R, BabeanuS , et al. The Prevention of Dementia With Antihypertensive Treatment. New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study. Archives of Internal Medicine2002;162:2046-2052. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH , BabarskieneMR , et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet1998;352:1347-51. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH . Reduction of dementia by calcium-antagonist-based antihypertensive treatment. European Heart Journal Supplements2000;2:D17-D19. StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Lancet1997;350:757-764. ">Syst Eur 1998</a>, <a href="./references#CD004034-bbs2-0004" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumiterscuD , et al, for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. NEJM2008;358:1887-1898. BulpittC , FletcherA , BeckettN , CoopeJ , Gil-ExtremeraB , ForetteF , et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs &amp; Aging2001;18:151-164. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al, for the HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurology2008;7:683-689. PetersR , BeckettN , McCormackT , FagardR , FletcherA , BulpittC . Treating hypertension in the very elderly-benefits, risks, and future directions, a focus on the hypertension in the very elderly trial. European Heart Journal 2014 Jul;35(26):1712-8. PetersR , BeckettN , NunesM , FletcherA , ForetteF , BulpittC . A substudy protocol of the Hypertension in the Very Elderly Trial assessing cognitive decline and dementia incidence (HYVET-COG): an ongoing randomised, double-blind, placebo-controlled trial. Drugs Aging2006;23:83-92. ">HYVET 2008</a>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15,795</p> <p>(5 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>b,c,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heterogeneity precluded meta‐analysis</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded 1 level due to indirectness – studies not powered to detect significant differences in dementia rates or rate of cognitive decline as measured using MMSE between groups. Duration of studies likely too short to detect enough cognitive impairment and dementia in participants of the age studied. Conversely, younger participants may be more likely to benefit long‐term cognitively from prolonged antihypertensive treatment.<br/><sup>b</sup>Downgraded 1 level due to study limitations – likely attrition bias as cognitively impaired and frailer participants more likely to be lost to follow‐up.<br/><sup>c</sup>Downgraded 1 level due to study limitations – proportions of participants in placebo group receiving active treatment, particularly in <a href="./references#CD004034-bbs2-0008" title="Degl'InnocentiA , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , ZanchettiA , WiklundI . Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). Journal of Human Hypertension2004;18(4):239-45. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study of COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. Journal of Hypertension2004;22(8):1605-12. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. Journal of Hypertension2003;21:875-886. PapademetriouV , FarsangC , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , Zanchetti A for the SCOPE Study Group. Stroke Prevention With the Angiotension II Type-1 Receptor Blocker Candesartan in Elderly Patients With Isolated Systolic Hypertension. The Study on Cognition and Prognosis in the Elderly (SCOPE). Journal of the American College of Cardiology2004;44(6):1175-80. SkoogI , LithellH , HanssonL , ElmfeldtD , HofmanA , OlofssonB , et al, for the SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). American Journal of Hypertension2005;18:1052-1059. ">SCOPE 2003</a> and <a href="./references#CD004034-bbs2-0012" title="JiT , ZhaoY , WangJ , CuiY , DuanD , ChaiQ , et al. Effect of low dose statins and apolipoprotein E genotype on cerebral small vessel disease in older hypertensive patients: a subgroup analysis of a randomized clinical trial. J Am Med Dir Assoc2018;19:995-1002. ZhangH , CuiY , ZhaoY , DongY , DuanD , WangJ , ShengL , JiT , ZhouT , HuW , ChenY , SunS , GongG , ChaiQ , LiuZ . Effects of sartans and low-dose statins on cerebral white matter hyperintensities and cognitive function in older patients with hypertension: a randomized, double-blind and placebo-controlled clinical trial. Hypertension research2018;42(5):717-729. ">Zhang 2018</a>, means there is a high risk of contamination bias.<br/><sup>d</sup>Downgraded 1 level due to imprecision – this is below the statistically significant threshold suggested by <a href="./references#CD004034-bbs2-0105" title="PrinceM , AlbaneseE , GuerchetM , PrinaM . World Alzheimer Report 2014. Dementia and Risk Reduction: An Analysis Of Protective And Modifiable Factors. London: Alzheimer's Disease International, September 2014.">Prince 2014</a> and the clinically significant threshold suggested by <a href="./references#CD004034-bbs2-0093" title="LopezOL , BeckerJT , SaxtonJ , SweetRA , KlunkW , DeKoskyST . Alteration of a Clinically Meaningful Outcome in the Natural History of Alzheimer's Disease by Cholinesterase Inhibition. Journal of the American Geriatrics Society2005;53(1):83-7.">Lopez 2005</a> and <a href="./references#CD004034-bbs2-0084" title="JonesR , SheehanB , PhillipsP , JuszczakE , AdamsJ , BaldwinA , et al, DOMINO-AD team. DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT. Trials2009;10:57.">Jones 2009</a>.<br/><sup>e</sup>Downgraded 1 level due to inconsistency ‐ significant heterogeneity. Number of possible reasons, baseline BP varied between studies, different antihypertensive drugs were used, large proportions of participants in placebo groups, especially in <a href="./references#CD004034-bbs2-0008" title="Degl'InnocentiA , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , ZanchettiA , WiklundI . Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). Journal of Human Hypertension2004;18(4):239-45. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study of COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. Journal of Hypertension2004;22(8):1605-12. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. Journal of Hypertension2003;21:875-886. PapademetriouV , FarsangC , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , Zanchetti A for the SCOPE Study Group. Stroke Prevention With the Angiotension II Type-1 Receptor Blocker Candesartan in Elderly Patients With Isolated Systolic Hypertension. The Study on Cognition and Prognosis in the Elderly (SCOPE). Journal of the American College of Cardiology2004;44(6):1175-80. SkoogI , LithellH , HanssonL , ElmfeldtD , HofmanA , OlofssonB , et al, for the SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). American Journal of Hypertension2005;18:1052-1059. ">SCOPE 2003</a> and <a href="./references#CD004034-bbs2-0012" title="JiT , ZhaoY , WangJ , CuiY , DuanD , ChaiQ , et al. Effect of low dose statins and apolipoprotein E genotype on cerebral small vessel disease in older hypertensive patients: a subgroup analysis of a randomized clinical trial. J Am Med Dir Assoc2018;19:995-1002. ZhangH , CuiY , ZhaoY , DongY , DuanD , WangJ , ShengL , JiT , ZhouT , HuW , ChenY , SunS , GongG , ChaiQ , LiuZ . Effects of sartans and low-dose statins on cerebral white matter hyperintensities and cognitive function in older patients with hypertension: a randomized, double-blind and placebo-controlled clinical trial. Hypertension research2018;42(5):717-729. ">Zhang 2018</a>, received active treatment. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Antihypertensive therapy compared to placebo for patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004034.pub4/full#CD004034-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004034-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Study properties</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BP Entry Criteria (mmHg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Baseline BP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Comparison</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study Duration</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Placebo‐controlled RCTs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004034-bbs2-0004" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumiterscuD , et al, for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. NEJM2008;358:1887-1898. BulpittC , FletcherA , BeckettN , CoopeJ , Gil-ExtremeraB , ForetteF , et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs &amp; Aging2001;18:151-164. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al, for the HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurology2008;7:683-689. PetersR , BeckettN , McCormackT , FagardR , FletcherA , BulpittC . Treating hypertension in the very elderly-benefits, risks, and future directions, a focus on the hypertension in the very elderly trial. European Heart Journal 2014 Jul;35(26):1712-8. PetersR , BeckettN , NunesM , FletcherA , ForetteF , BulpittC . A substudy protocol of the Hypertension in the Very Elderly Trial assessing cognitive decline and dementia incidence (HYVET-COG): an ongoing randomised, double-blind, placebo-controlled trial. Drugs Aging2006;23:83-92. ">HYVET 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n=3336</b>, n=1687 Rx group; n=1649 placebo </p> <p>n=1469 completed 2 yr MMSE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SBP 160‐200, DBP &lt; 110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean SBP 173.1 Rx group; 172.9 placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>stepped (diuretic then ACE inhibitor) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 years, 2 year results reported for HYVET‐COG</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004034-bbs2-0007" title="Pérez-StableEJ , HallidayR , GardinerPS , BaronRB , HauckWW , AcreeM , CoatesTJ . The effects of propranolol on cognitive function and quality of life: a randomized trial among patients with diastolic hypertension.. The American Journal Of Medicine 2000 Apr 1;108(5):359-65. ">Perez Stable 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n=312</b>, n=156 each Rx and placebo groups </p> <p>dementia incidence reported for n=102 and n=101 respectively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DBP 90‐104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean BP 140/96 Rx group; 141/96 placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>placebo vs BB also lifestyle intervention factorial design (not included here)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004034-bbs2-0008" title="Degl'InnocentiA , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , ZanchettiA , WiklundI . Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). Journal of Human Hypertension2004;18(4):239-45. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study of COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. Journal of Hypertension2004;22(8):1605-12. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. Journal of Hypertension2003;21:875-886. PapademetriouV , FarsangC , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , Zanchetti A for the SCOPE Study Group. Stroke Prevention With the Angiotension II Type-1 Receptor Blocker Candesartan in Elderly Patients With Isolated Systolic Hypertension. The Study on Cognition and Prognosis in the Elderly (SCOPE). Journal of the American College of Cardiology2004;44(6):1175-80. SkoogI , LithellH , HanssonL , ElmfeldtD , HofmanA , OlofssonB , et al, for the SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). American Journal of Hypertension2005;18:1052-1059. ">SCOPE 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n=4937</b>, n=2477 Rx group; n=2460 placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BP 160‐179/90‐99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean BP 166.0/90.3 Rx group; 166.5/90.4 placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>stepped (ARB then diuretic) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44.6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004034-bbs2-0009" title="ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the Treatment of Isolated Systolic Hypertension on Behavioral Variables. Results From the Systolic Hypertension in the Elderly Program. Arch Intern Med1994;154:2154-2160. Di BariM , PahorM , FranseLV , ShorrRI , WanJY , FerrucciL , et al. Dementia and Disability Outcomes in Large Hypertension Trials: Lessons Learned from the Systolic Hypertension in the Elderly Program (SHEP) Trial. American Journal of Epidemiology2001;153:72-8. SHEP Cooperative Research Group. Prevention of Stroke by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic Hypertension. Final Results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265:3255-64. The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and Design of a Randomized Clinical Trial on Prevention of Stroke in Isolated Systolic Hypertension. Journal of Clinical Epidemiology1988;41:1197-1208. ">SHEP 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n=4736</b>, n=2365 Rx group; n=2371 placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SBP &gt; 160, DBP &lt; 90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean BP 170.5/76.7 Rx group; 170.1/76.4 placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>stepped (diuretic then BB then centrally acting agent) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean follow‐up 4.5 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004034-bbs2-0011" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , De LeeuwP , DolleryCT , et al. Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: Objectives, protocol, and organization. Aging Clin Exp Res1991;3:287-302. FletcherAE , BulpittCJ , ThijsL , ToumilehtoJ , AntikainenR , BossiniA , et al. Quality of life on randomised treatment for isolated hypertension: results from the Syst-Eur Trial. Journal of Hypertension2002;20:2069-2079. FletcherAE , BulpittCJ , TuomilehtoJ , BrowneJ , BossiniA , Kawecka-JaszczK , et al. Quality of life of elderly patients with isolated systolic hypertension: baseline data from the Syst-Eur Trial. Journal of Hypertension1988;16:1117-1124. ForetteF , Seux M-L, StaessenJA , ThijsL , Babarskiene M-R, BabeanuS , et al. The Prevention of Dementia With Antihypertensive Treatment. New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study. Archives of Internal Medicine2002;162:2046-2052. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH , BabarskieneMR , et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet1998;352:1347-51. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH . Reduction of dementia by calcium-antagonist-based antihypertensive treatment. European Heart Journal Supplements2000;2:D17-D19. StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Lancet1997;350:757-764. ">Syst Eur 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n=2418</b>, n=1238 Rx group; n=1180 placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SBP 160‐219, DBP &lt; 95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean BP 173.4/86.0 Rx group; 173.5/86.1 placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>stepped (CCB then ACE inhibitor then diuretic) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median follow‐up 2.0 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004034-bbs2-0005" title="YodfatY , Bar-OnD , AmirM , Cristal N. Quality of life in normotensives compared to hypertensive men treated with isradipine or methyldopa as monotherapy or in combination with captopril: the LOMIR-MCT-IL study.. Journal of Human Hypertension 1996 Feb;10(2):117-22. YodfatY , Cristal N. A multicenter, double-blind, randomized, placebo-controlled study of isradipine and methyldopa as monotherapy or in combination with captopril in the treatment of hypertension. The LOMIR-MCT-IH Research Group.. American Journal of Hypertension 1993 Mar;6(3 Pt 2):57S-61S. ">LOMIR MCT IL 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n=368</b> (n=124; n=120; n=124) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DBP 95‐105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean BP 154.5/99.7; 152.0/99.3; 150.7/99.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>stepped, isradipine vs methyldopa vs placebo, dose doubled then ACE inhibitor added</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004034-bbs2-0006" title="MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. British Medical Journal1992;304(6824):405-12. PrinceMJ , BirdAS , BlizardRA , MannAH . Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. British Medical Journal1996;312(7034):801-5. ">MRC 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n=2651 with n=2567 and <b>n=2584</b> completing PALT and TMT assessments, n=633 diuretic n=640 BB n=1311 placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SBP 160‐209, DBP &lt; 115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean BP diuretic 184.9/90.3; BB 184.2/90.7; placebo 183.5/90.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>stepped, BB vs diuretic vs placebo, then BB dose doubled, other study drug added then CCB added; additional drugs permitted </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004034-bbs2-0012" title="JiT , ZhaoY , WangJ , CuiY , DuanD , ChaiQ , et al. Effect of low dose statins and apolipoprotein E genotype on cerebral small vessel disease in older hypertensive patients: a subgroup analysis of a randomized clinical trial. J Am Med Dir Assoc2018;19:995-1002. ZhangH , CuiY , ZhaoY , DongY , DuanD , WangJ , ShengL , JiT , ZhouT , HuW , ChenY , SunS , GongG , ChaiQ , LiuZ . Effects of sartans and low-dose statins on cerebral white matter hyperintensities and cognitive function in older patients with hypertension: a randomized, double-blind and placebo-controlled clinical trial. Hypertension research2018;42(5):717-729. ">Zhang 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n=732</b> (n=366 both groups) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SBP ≥140 and/or DBP ≥ 90 or self‐reported use of BP lowering meds in previous 2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean 156.1/71.3 ARB; 156.5/71.2 placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>telmisartan vs placebo but all participants also Rx hydrochlorothiazide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean follow‐up 59.8 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Intensive versus standard BP reduction</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004034-bbs2-0001" title="BuseJB , BiggerJT , ByingtonRP , CooperLS , CushmanWC , FriedewaldWT , et al, ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. American Journal of Cardiology2007;99(12A):21i-33i. CushmanWC , Grimm RH Jr, CutlerJA , EvansGW , CapesS , CorsonMA , et al, ACCORD Study Group. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):44i-55i. LaunerLJ , MillerME , WilliamsonJD , LazarRM , GersteinHC , MurrayAM , et al, ACCORD MIND investigators. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurology2011;10(11):969-77. MargolisKL , O'ConnorPJ , MorganTM , BuseJB , CohenRM , CushmanWC , et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care2014;37(6):1721-8. O'ConnorPJ , NarayanKM , AndersonR , FeeneyP , FineL , AliMK , et al. Effect of intensive versus standard blood pressure control on depression and health-related quality of life in type 2 diabetes: the ACCORD trial. Diabetes Care2012;35(7):1479-81. WilliamsonJD , LaunerLJ , BryanRN , CokerLH , LazarRM , GersteinHC , et al, Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Investigators. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Internal Medicine2014;174(3):324-33. WilliamsonJD , MillerME , BryanRN , LazarRM , CokerLH , JohnsonJ , et al, ACCORD Study Group. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. American Journal of Cardiology2007;99(12A):112i-122i. ">ACCORD MIND 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n=1439</b>, n=745 intensive group, n=694 standard group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SBP ≥ 130 on ≥ 2 occasions on no meds, SBP 130‐160 on 0‐3 meds, 161‐170 on 0‐2 meds, 171‐180 on 0‐1 meds </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean 138.8/76.0 intensive group; 139.2/76.3 standard</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 120 vs &lt; 140 mmHg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004034-bbs2-0010" title="AmbrosiusWT , SinkKM , FoyCG , BerlowitzDR , CheungAK , CushmanWC , FineLJ , Goff DC Jr, JohnsonKC , KilleenAA , LewisCE , OparilS , ReboussinDM , RoccoMV , SnyderJK , WilliamsonJD , Wright JT Jr, WheltonPK , SPRINT Study Research Group. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).. Clinical Trials 2014 Oct;11(5):532-46. BerlowitzDR , FoyCG , KazisLE , BolinLP , ConroyMB , FitzpatrickP , GureTR , KimmelPL , KirchnerK , MoriskyDE , NewmanJ , OlneyC , OparilS , PajewskiNM , PowellJ , RamseyT , SimmonsDL , SnyderJ , SupianoMA , WeinerDE , WhittleJ , SPRINT Research Group. Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes.. The New England Journal of Medicine 2017 Aug 24;377(8):733-744. SPRINT Research Group, Wright JT Jr, WilliamsonJD , WheltonPK , SnyderJK , SinkKM , RoccoMV , ReboussinDM , RahmanM , OparilS , LewisCE , KimmelPL , JohnsonKC , Goff DC Jr, FineLJ , CutlerJA , CushmanWC , CheungAK , Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control.. The New England Journal of Medicine 2015 Nov 26;373(22):2103-16. The SPRINT MIND Investigators for the SPRINT Research Group. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA2019;321(6):553-561. WilliamsonJD , SupianoMA , ApplegateWB , BerlowitzDR , CampbellRC , ChertowGM , FineLJ , HaleyWE , HawfieldAT , IxJH , KitzmanDW , KostisJB , Krousel-WoodMA , LaunerLJ , OparilS , RodriguezCJ , RoumieCL , ShorrRI , SinkKM , WadleyVG , WheltonPK , WhittleJ , WoolardNF , Wright JT Jr, PajewskiNM , SPRINT Research Group. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.. JAMA 2016 Jun 28;315(24):2673-82. ">SPRINT MIND 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n=9,361</b>, n=4678 intensive group, n=4683 standard group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SBP 130 ‐ 180 on ≥ 2 occasions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean 139.7/78.2 intensive group; 139.7/78.0 standard</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 120 vs &lt; 140 mmHg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median intervention period 3.34 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Other included studies</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004034-bbs2-0002" title="HajjarI , HartM , ChenYL , MackW , MilbergW , ChuiH , et al. Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: a double-blind randomized clinical trial. Archives of Internal Medicine2012;172(5):442-4. HajjarI , HartM , ChenYL , MackW , NovakV , ChuiH , et al. Antihypertensive therapy and cerebral hemodynamics in executive mild cognitive impairment: results of a pilot randomized clinical trial. Journal of the American Geriatrics Society2013;61(2):194-201. HajjarI , HartM , MackW , LipsitzLA . Aldosterone, cognitive function, and cerebral hemodynamics in hypertension and antihypertensive therapy. American Journal of Hypertension2015;28(3):319-25. HajjarI , HartM , MilbergW , NovakV , LipsitzL . The rationale and design of the antihypertensives and vascular, endothelial, and cognitive function (AVEC) trial in elderly hypertensives with early cognitive impairment: role of the renin angiotensin system inhibition. BMC Geriatrics2009;9:48. ">AVEC 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n=47</b> (n=17; n=17; n=13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 140/90 or on antihypertensives</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean 153/85 ACE inhibitor; 149/81 ARB; 155/83 diuretic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>stepped, ARB vs diuretic vs ACE inhibitor, dose increased then CCB added then BB added</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004034-bbs2-0003" title="SatoN , SaijoY , HasebeN , CAMUI investigators. Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial. International Heart Journal2012;53(4):244-8. SatoN , SaijoY , SasagawaY , MorimotoH , TakeuchiT , SanoH , KoyamaS , TakeharaN , MoritaK , SumitomoK , MaruyamaJ , KikuchiK , HasebeN , CAMUI investigators. Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial: results after 1 year. Journal of Hypertension2013;31(6):1245-55. ">CAMUI 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n=142</b> (n=74 and n=68) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 140/90 or &gt; 130/80 if diabetic or renal disease and already on an ARB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean 156/83 ARB+C; 155/83 ARB+D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>stepped, ARB + CCB vs ARB + diuretic, further ARB added then alpha blocker then BB then antisympathetic agent added </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>RCTs: randomised controlled trials; MMSE: mini mental state examination; SBP: systolic blood pressure; DBP: diastolic blood pressure; Rx: hypertensive treatment group; ACE inhibitor: angiotensin converting enzyme inhibitor; BB: beta‐blocker; ARB: angiotensin receptor blocker; CCB: calcium channel blocker; PALT: paired associate learning test; TMT: trail making test. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Study properties</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004034.pub4/full#CD004034-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004034-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Study demographics</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gender</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Age criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Age</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Geographical area</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Race and ethnicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Educational background</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Baseline cognition</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Placebo‐controlled RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004034-bbs2-0004" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumiterscuD , et al, for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. NEJM2008;358:1887-1898. BulpittC , FletcherA , BeckettN , CoopeJ , Gil-ExtremeraB , ForetteF , et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs &amp; Aging2001;18:151-164. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al, for the HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurology2008;7:683-689. PetersR , BeckettN , McCormackT , FagardR , FletcherA , BulpittC . Treating hypertension in the very elderly-benefits, risks, and future directions, a focus on the hypertension in the very elderly trial. European Heart Journal 2014 Jul;35(26):1712-8. PetersR , BeckettN , NunesM , FletcherA , ForetteF , BulpittC . A substudy protocol of the Hypertension in the Very Elderly Trial assessing cognitive decline and dementia incidence (HYVET-COG): an ongoing randomised, double-blind, placebo-controlled trial. Drugs Aging2006;23:83-92. ">HYVET 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60% female</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 80 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean age 83.5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Eastern Europe (56%),</p> <p>China (40%),</p> <p>Western Europe, Australasia and Tunisia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27% no education</p> <p>28% primary</p> <p>29% secondary</p> <p>12% higher</p> <p>3% further</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median MMSE 26</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004034-bbs2-0007" title="Pérez-StableEJ , HallidayR , GardinerPS , BaronRB , HauckWW , AcreeM , CoatesTJ . The effects of propranolol on cognitive function and quality of life: a randomized trial among patients with diastolic hypertension.. The American Journal Of Medicine 2000 Apr 1;108(5):359-65. ">Perez Stable 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34% female</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18‐59 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean age 46/45 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>California, USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76%/71% white</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean 16 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean (SD) DSST 61 (10)</p> <p>See <a href="./references#CD004034-sec-0116" title="">Characteristics of included studies</a> for other tests </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004034-bbs2-0008" title="Degl'InnocentiA , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , ZanchettiA , WiklundI . Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). Journal of Human Hypertension2004;18(4):239-45. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study of COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. Journal of Hypertension2004;22(8):1605-12. LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , TrenkwalderP , Zanchetti A for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. Journal of Hypertension2003;21:875-886. PapademetriouV , FarsangC , ElmfeldtD , HofmanA , LithellH , OlofssonB , SkoogI , TrenkwalderP , Zanchetti A for the SCOPE Study Group. Stroke Prevention With the Angiotension II Type-1 Receptor Blocker Candesartan in Elderly Patients With Isolated Systolic Hypertension. The Study on Cognition and Prognosis in the Elderly (SCOPE). Journal of the American College of Cardiology2004;44(6):1175-80. SkoogI , LithellH , HanssonL , ElmfeldtD , HofmanA , OlofssonB , et al, for the SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). American Journal of Hypertension2005;18:1052-1059. ">SCOPE 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65% female</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70‐89 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean age 76.4 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primarily Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10% &lt;primary</p> <p>44% primary</p> <p>40% &gt;primary</p> <p>6% university</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean MMSE 28.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004034-bbs2-0009" title="ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the Treatment of Isolated Systolic Hypertension on Behavioral Variables. Results From the Systolic Hypertension in the Elderly Program. Arch Intern Med1994;154:2154-2160. Di BariM , PahorM , FranseLV , ShorrRI , WanJY , FerrucciL , et al. Dementia and Disability Outcomes in Large Hypertension Trials: Lessons Learned from the Systolic Hypertension in the Elderly Program (SHEP) Trial. American Journal of Epidemiology2001;153:72-8. SHEP Cooperative Research Group. Prevention of Stroke by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic Hypertension. Final Results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265:3255-64. The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and Design of a Randomized Clinical Trial on Prevention of Stroke in Isolated Systolic Hypertension. Journal of Clinical Epidemiology1988;41:1197-1208. ">SHEP 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57% female</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 60 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean age 71.6 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exclusively USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86.1% white, 13.9% black, 5% oriental,</p> <p>2% Hispanic, 1% other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean 11.7 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.3% active Rx 0.5% placebo groups 'cognitive impairment scale score of 4 or greater', based on the short‐CARE assessment tool </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004034-bbs2-0011" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , De LeeuwP , DolleryCT , et al. Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: Objectives, protocol, and organization. Aging Clin Exp Res1991;3:287-302. FletcherAE , BulpittCJ , ThijsL , ToumilehtoJ , AntikainenR , BossiniA , et al. Quality of life on randomised treatment for isolated hypertension: results from the Syst-Eur Trial. Journal of Hypertension2002;20:2069-2079. FletcherAE , BulpittCJ , TuomilehtoJ , BrowneJ , BossiniA , Kawecka-JaszczK , et al. Quality of life of elderly patients with isolated systolic hypertension: baseline data from the Syst-Eur Trial. Journal of Hypertension1988;16:1117-1124. ForetteF , Seux M-L, StaessenJA , ThijsL , Babarskiene M-R, BabeanuS , et al. The Prevention of Dementia With Antihypertensive Treatment. New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study. Archives of Internal Medicine2002;162:2046-2052. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH , BabarskieneMR , et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet1998;352:1347-51. ForetteF , SeuxML , StaessenJA , ThijsL , BirkenhagerWH . Reduction of dementia by calcium-antagonist-based antihypertensive treatment. European Heart Journal Supplements2000;2:D17-D19. StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Lancet1997;350:757-764. ">Syst Eur 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66% female</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 60 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean age 69.9 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exclusively Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean 12.3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median MMSE 29</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004034-bbs2-0005" title="YodfatY , Bar-OnD , AmirM , Cristal N. Quality of life in normotensives compared to hypertensive men treated with isradipine or methyldopa as monotherapy or in combination with captopril: the LOMIR-MCT-IL study.. Journal of Human Hypertension 1996 Feb;10(2):117-22. YodfatY , Cristal N. A multicenter, double-blind, randomized, placebo-controlled study of isradipine and methyldopa as monotherapy or in combination with captopril in the treatment of hypertension. The LOMIR-MCT-IH Research Group.. American Journal of Hypertension 1993 Mar;6(3 Pt 2):57S-61S. ">LOMIR MCT IL 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Solely male</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40‐65 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean age 52 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Israel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean semantic memory score 21.4, 20.8 and 22.3 across groups</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004034-bbs2-0006" title="MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. British Medical Journal1992;304(6824):405-12. PrinceMJ , BirdAS , BlizardRA , MannAH . Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. British Medical Journal1996;312(7034):801-5. ">MRC 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58% female</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65‐74 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean age 70.3/70.4 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean PALT score 17.0 all 3 groups; mean TMT score 59.9, 59.9 and 61.0 across 3 groups</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004034-bbs2-0012" title="JiT , ZhaoY , WangJ , CuiY , DuanD , ChaiQ , et al. Effect of low dose statins and apolipoprotein E genotype on cerebral small vessel disease in older hypertensive patients: a subgroup analysis of a randomized clinical trial. J Am Med Dir Assoc2018;19:995-1002. ZhangH , CuiY , ZhaoY , DongY , DuanD , WangJ , ShengL , JiT , ZhouT , HuW , ChenY , SunS , GongG , ChaiQ , LiuZ . Effects of sartans and low-dose statins on cerebral white matter hyperintensities and cognitive function in older patients with hypertension: a randomized, double-blind and placebo-controlled clinical trial. Hypertension research2018;42(5):717-729. ">Zhang 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48% female</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 60 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean age 70.7 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100% Han Chinese</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean 7 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean (IQR) MMSE 26 (25,28); mean (IQR) DRS 134 (129, 139)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Intensive versus standard BP reduction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004034-bbs2-0001" title="BuseJB , BiggerJT , ByingtonRP , CooperLS , CushmanWC , FriedewaldWT , et al, ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. American Journal of Cardiology2007;99(12A):21i-33i. CushmanWC , Grimm RH Jr, CutlerJA , EvansGW , CapesS , CorsonMA , et al, ACCORD Study Group. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):44i-55i. LaunerLJ , MillerME , WilliamsonJD , LazarRM , GersteinHC , MurrayAM , et al, ACCORD MIND investigators. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurology2011;10(11):969-77. MargolisKL , O'ConnorPJ , MorganTM , BuseJB , CohenRM , CushmanWC , et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care2014;37(6):1721-8. O'ConnorPJ , NarayanKM , AndersonR , FeeneyP , FineL , AliMK , et al. Effect of intensive versus standard blood pressure control on depression and health-related quality of life in type 2 diabetes: the ACCORD trial. Diabetes Care2012;35(7):1479-81. WilliamsonJD , LaunerLJ , BryanRN , CokerLH , LazarRM , GersteinHC , et al, Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Investigators. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Internal Medicine2014;174(3):324-33. WilliamsonJD , MillerME , BryanRN , LazarRM , CokerLH , JohnsonJ , et al, ACCORD Study Group. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. American Journal of Cardiology2007;99(12A):112i-122i. ">ACCORD MIND 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55% female</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 55 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean age 62.3/62.5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>North America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66% white, 22% black, 6% Hispanic, 6% other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14/12% &lt; high school</p> <p>24/28% high school</p> <p>37/35% some college</p> <p>25% ≥ college</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean MMSE 28</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004034-bbs2-0010" title="AmbrosiusWT , SinkKM , FoyCG , BerlowitzDR , CheungAK , CushmanWC , FineLJ , Goff DC Jr, JohnsonKC , KilleenAA , LewisCE , OparilS , ReboussinDM , RoccoMV , SnyderJK , WilliamsonJD , Wright JT Jr, WheltonPK , SPRINT Study Research Group. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).. Clinical Trials 2014 Oct;11(5):532-46. BerlowitzDR , FoyCG , KazisLE , BolinLP , ConroyMB , FitzpatrickP , GureTR , KimmelPL , KirchnerK , MoriskyDE , NewmanJ , OlneyC , OparilS , PajewskiNM , PowellJ , RamseyT , SimmonsDL , SnyderJ , SupianoMA , WeinerDE , WhittleJ , SPRINT Research Group. Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes.. The New England Journal of Medicine 2017 Aug 24;377(8):733-744. SPRINT Research Group, Wright JT Jr, WilliamsonJD , WheltonPK , SnyderJK , SinkKM , RoccoMV , ReboussinDM , RahmanM , OparilS , LewisCE , KimmelPL , JohnsonKC , Goff DC Jr, FineLJ , CutlerJA , CushmanWC , CheungAK , Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control.. The New England Journal of Medicine 2015 Nov 26;373(22):2103-16. The SPRINT MIND Investigators for the SPRINT Research Group. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA2019;321(6):553-561. WilliamsonJD , SupianoMA , ApplegateWB , BerlowitzDR , CampbellRC , ChertowGM , FineLJ , HaleyWE , HawfieldAT , IxJH , KitzmanDW , KostisJB , Krousel-WoodMA , LaunerLJ , OparilS , RodriguezCJ , RoumieCL , ShorrRI , SinkKM , WadleyVG , WheltonPK , WhittleJ , WoolardNF , Wright JT Jr, PajewskiNM , SPRINT Research Group. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.. JAMA 2016 Jun 28;315(24):2673-82. ">SPRINT MIND 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36% female</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 50 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean age 67.9 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58% white,30% black, 10% Hispanic, 2% other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median MoCA 23, range 20‐26; Median logical memory 8; Median digit symbol coding test 51 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Other included studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004034-bbs2-0002" title="HajjarI , HartM , ChenYL , MackW , MilbergW , ChuiH , et al. Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: a double-blind randomized clinical trial. Archives of Internal Medicine2012;172(5):442-4. HajjarI , HartM , ChenYL , MackW , NovakV , ChuiH , et al. Antihypertensive therapy and cerebral hemodynamics in executive mild cognitive impairment: results of a pilot randomized clinical trial. Journal of the American Geriatrics Society2013;61(2):194-201. HajjarI , HartM , MackW , LipsitzLA . Aldosterone, cognitive function, and cerebral hemodynamics in hypertension and antihypertensive therapy. American Journal of Hypertension2015;28(3):319-25. HajjarI , HartM , MilbergW , NovakV , LipsitzL . The rationale and design of the antihypertensives and vascular, endothelial, and cognitive function (AVEC) trial in elderly hypertensives with early cognitive impairment: role of the renin angiotensin system inhibition. BMC Geriatrics2009;9:48. ">AVEC 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57% female</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 60 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean age 72/72/71 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Boston, USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70% White, 23% African American</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19% up to high school, 81% college or more</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean (SD) MMSE 26(2), 26(2), 25(2) across groups</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004034-bbs2-0003" title="SatoN , SaijoY , HasebeN , CAMUI investigators. Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial. International Heart Journal2012;53(4):244-8. SatoN , SaijoY , SasagawaY , MorimotoH , TakeuchiT , SanoH , KoyamaS , TakeharaN , MoritaK , SumitomoK , MaruyamaJ , KikuchiK , HasebeN , CAMUI investigators. Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial: results after 1 year. Journal of Hypertension2013;31(6):1245-55. ">CAMUI 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52% female</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 65 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean age 74.1/74.5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Japan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean (SD) MMSE 27(3) and 26.5(3.2) across groups</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>RCTs: randomised controlled trials; MMSE: mini mental state examination; Rx: hypertensive treatment group; DSST: digit symbol substitution test; short‐CARE: short‐Comprehensive Assessment and Referral Evaluation; PALT: Paired Associate Learning Test; TMT: Trail Making Test; MoCA: Montreal Cognitive Assessment </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Study demographics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004034.pub4/full#CD004034-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004034-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Incidence of dementia</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Number of cases of dementia placebo studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15427</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.72, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Incidence of dementia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004034.pub4/references#CD004034-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004034-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Cognitive change from baseline</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Change in MMSE placebo studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9435</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.10, 0.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Cognitive change from baseline</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004034.pub4/references#CD004034-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004034-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Change in blood pressure from baseline</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Change in systolic blood pressure level (mmHg) placebo studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17793</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.25 [‐9.73, ‐8.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Change in diastolic blood pressure level (mmHg) placebo studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.47 [‐2.70, ‐2.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Change in blood pressure from baseline</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004034.pub4/references#CD004034-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD004034.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD004034-note-0013">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD004034-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD004034-note-0011">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD004034-note-0009">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD004034-note-0007">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD004034-note-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD004034-note-0012">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD004034-note-0006">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD004034-note-0005">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004034\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004034\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004034\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004034\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004034\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004034\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004034\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004034\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004034\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004034\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004034\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004034\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004034\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004034\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004034\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004034\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004034\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004034\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=IYhCEbRn&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004034.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004034.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD004034.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD004034.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004034.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715066369"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004034.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715066373"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004034.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d7e007d9a1bde',t:'MTc0MDcxNTA2Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 